{
 "cells": [
  {
   "cell_type": "code",
   "execution_count": 779,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Request successful!\n",
      "\n",
      "\n",
      "\"APIVrs: 1.01.05\"\n",
      "\"DataVrs: 2023:05:08 23:53:26.475\"\n",
      "\"Expression: multiple+myeloma\"\n",
      "\"NStudiesAvail: 451538\"\n",
      "\"NStudiesFound: 2701\"\n",
      "\"MinRank: 1\"\n",
      "\"MaxRank: 999\"\n",
      "\"NStudiesReturned: 999\"\n",
      "\"Field Names: BriefTitle,PrimaryOutcomeMeasure,PrimaryOutcomeTimeFrame,SecondaryOutcomeMeasure,OverallStatus,Phase\"\n",
      "\n",
      "\"Rank\",\"BriefTitle\",\"PrimaryOutcomeMeasure\",\"PrimaryOutcomeTimeFrame\",\"SecondaryOutcomeMeasure\",\"OverallStatus\",\"Phase\"\n",
      "1,\"Early Detection of Multiple Myeloma to Fight Cancer Disparities: A Screening and Patient Navigation Program\",\"To conduct and evaluate a study that incorporates patient navigation programs to recruit and screen participants for Multiple Myeloma and its disease precursors, MGUS or smoldering MM|To conduct and evaluate a study that incorporates patient navigation programs to recruit and screen participants for Multiple Myeloma and its disease precursors, MGUS or smoldering MM|To study participant knowledge of Multiple Myeloma\",\"12 months|12 months|12 months\",,\"Not yet recruiting\",\"Not Applicable\"\n",
      "2,\"Multiple Myeloma (MM) Profile in Brazil: A Retrospective Observational Analysis\",\"Number of Multiple Myeloma (MM) Participants Categorized by Clinical Characteristics|Number of Multiple Myeloma (MM) Participants Categorized by Treatment Patterns\",\"From initial diagnosis up to end of follow up treatment or to the retrospective cut-off date within the time of interest (between January 1, 2008, and December 31, 2016) [approximately 11.7 years]|From initial diagnosis up to end of follow up treatment or to the retrospective cut-off date within the time of interest (between January 1, 2008, and December 31, 2016) [approximately 11.7 years]\",\"Overall Survival (OS)|Duration of Treatment\",\"Completed\",\n",
      "3,\"CAR-T Cells Therapy in Relapsed/Refractory Multiple Myeloma\",\"Adverse events that Are related to treatment\",\"2 years\",\"Estimate 2 year overall survival(OS) after infusion of BCMA/CD138/CD38/CD56-CART and sequential treatment|Estimate 2 year relapse rate after infusion of BCMA/CD138/CD38/CD56-CART and sequential treatment|Estimate 2 year progression free survival after infusion of BCMA/CD138/CD38/CD56-CART and sequential treatment\",\"Terminated\",\"Not Applicable\"\n",
      "4,\"The Aim is to Identify Recurrent Genomic Mutations and/or Predisposing Polymorphisms in Patients With Sporadic Cases of Multiple Myeloma\",\"DNA mutations associated with the existence of multiple myeloma|DNA mutations associated with the existence of multiple myeloma|DNA mutations associated with the existence of multiple myeloma|DNA mutations associated with the existence of multiple myeloma|DNA mutations associated with the existence of multiple myeloma|DNA mutations associated with the existence of multiple myeloma\",\"baseline, pre-intervention/procedure/surgery|during the intervention/procedure/surgery|immediately after the intervention/procedure/surgery|at 1 year|up to 24 weeks|through study completion, an average of 1 year\",,\"Not yet recruiting\",\n",
      "5,\"Relating Clinical Outcomes in Multiple Myeloma to Personal Assessment of Genetic Profile\",\"Molecular profiles and clinical characteristics that define subsets of myeloma patients at initial diagnosis and at relapse of disease.\",\"Baseline to 8 years.\",\"Response rates|Survival rates|Bone disease assessed radiographically|Health-related quality of life|Resource utilization|Severe adverse events\",\"Active, not recruiting\",\n",
      "6,\"Assessment of Early Detection and Prognosis Based on cfDNA Methylation in Multiple Myeloma\",\"The sensitivity and specificity of a cfDNA methylation-based early detection modelfor multiple myeloma.\",\"12 months\",\"The sensitivity and specificity of a cfDNA methylation-based early detection model for multiple myeloma at different clinical stages.|The performance of a cfDNA methylation-based prognostic model for multiple myeloma.|The specific cfDNA methylation landscape of multiple myeloma in China\",\"Recruiting\",\n",
      "7,\"Impact of Paramedical Consultations in Oncological Supportive Care in Outpatients With Multiple Myeloma\",\"Comparison of quality of life evolution in outpatients with multiple myeloma between the two groups\",\"6 months\",\"Qualitative evaluation of quality of life|Comparison of quality of life in outpatients with multiple myeloma between the two groups|Comparison of quality of life in outpatients with multiple myeloma between the two groups|Comparison of autonomy evolution in outpatients with multiple myeloma between the two groups\",\"Recruiting\",\"Not Applicable\"\n",
      "8,\"Rationale for Cytogenetic Risk Stratification by Imaging Flow Cytometry in Multiple Myeloma\",\"Detection of plasmocytes by imaging flow cytometry techniques in plasmocytes cell line.|Detection of plasmocytes by imaging flow cytometry techniques in multiple myeloma bone marrow (MM BM).\",\"during the first six months of the study|from 6 months after the beginning of the study to two years after the beginning of the study\",,\"Withdrawn\",\n",
      "9,\"Comparison of F-18 FDG and C-11 Acetate PET in Multiple Myeloma\",\"Mean Multiple Myeloma Lesions Detected\",\"Day 1, Day 2\",\"Visual Image Analysis of Detected Multiple Myeloma Lesions\",\"Completed\",\"Phase 2\"\n",
      "10,\"Phase II Study of Dexamethasone, Thalidomide and Lenalidomide for Subjects With Relapsed or Refractory Multiple Myeloma\",\"Effect of Drug Combination on Multiple Myeloma\",\"The best response for all patients at any point were assessed for patients that were treated on study, from start of treatment up to 20 weeks\",,\"Terminated\",\"Phase 2\"\n",
      "11,\"A Study of Siltuximab (Anti- IL 6 Monoclonal Antibody) in Patients With High-risk Smoldering Multiple Myeloma\",\"One-Year Progression-Free Survival (PFS) Rate\",\"Up to 1 Year\",\"Progressive Disease Indicator Rate (PDIR) at 6 Months|Progression-Free Survival|Percentage of Participants With Serum M-protein Response|Time to Worsening in European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire-Core 30 (EORTC-QLQ-C30) Scale Score|Time to Worsening in the Brief Pain Inventory (BPI) Worst Item Scores|Number of Participants With Symptomatic Multiple Myeloma With Adverse Prognostic Features|Number of Participants With Best Response to First Subsequent Multiple Myeloma Treatment|Overall Survival (OS)\",\"Completed\",\"Phase 2\"\n",
      "12,\"Prognostic Potential of Cell Surface Markers and Pim Kinases in Multiple Myeloma\",\"Measure the expression levels of CXCR4, CD47, and pS6 by flow cytometry in myeloma patient's marrow aspirate\",\"3 years\",\"Determine if Pim kinase inhibitors or sphingosine kinase 2 inhibitors will inhibit patients' myeloma cells\",\"Completed\",\n",
      "13,\"Phase II Study of Thalidomide, Clarithromycin, Lenalidomide, and Dexamethasone for Newly Diagnosed Multiple Myeloma\",\"Effect of Drug Combination on Multiple Myeloma\",\"This was collected from patients for their duration on study treatment. Only the best response was recorded. Best responses were reported at any point of the study, from start of treatment up until removal of study, which occurred up to 57.4 cycles\",\"Median Time to Maximum Response|Event Free Survival|Progression Free Survival\",\"Completed\",\"Phase 2\"\n",
      "14,\"High Dose Sequential Therapy and Autologous Stem Cell Rescue for Multiple Myeloma\",\"To evaluate the progression free survival at one year in multiple myeloma patients who receive sequentially administered high dose cyclophosphamide and VP-16 followed by high-dose BCNU (Carmustine) plus Melphalan\",\"4 years\",\"To evaluate the response rates of multiple myeloma patients to this sequentially administered high dose chemotherapy.|To evaluate the safety and toxicity of this sequential high dose chemotherapy program in multiple myeloma patients.\",\"Completed\",\"Phase 2\"\n",
      "15,\"Stem Cell Transplant and Zoledronic Acid Improve Outcome in Previously Untreated Patients With Multiple Myeloma\",\"progression-free disease and overall toxicity in myeloma multiple\",\"3 years\",\"skeletal event\",\"Completed\",\n",
      "16,\"A Study of WVT078 in Patients With Multiple Myeloma (MM)\",\"Incidence of dose limiting toxicity (DLTs) in Cycle 1|Frequency of dose interruptions|Frequency of discontinuations|Frequency of dose reductions|Incidence and severity of AEs and SAEs, including changes in laboratory values, vital signs, ECGs, and CRS/immune-mediated reactions\",\"28 days (first cycle)|Up to 28 months|up to 28 months|up to 28 months|Up to 31 months\",\"Best Overall Response (BOR)|Duration of Response (DOR)|Progresson Free Survival (PFS)|AUC of WVT078 derived from serum concentrations|Cmax of WVT078 derived from serum concentrations|Cmin of WVT078 derived from serum concentrations|Tmax of WVT078 derived from serum concentrations|T1/2 of WVT078 derived from serum concentrations|Concentration of WVT078 Anti Drug Antibodies (ADA) as measured in serum|AUC of WHG626 derived from plasma concentrations|Cmax of WHG626 derived from plasma concentrations|Cmin of WHG626 derived from plasma concentrations|Tmax of WHG626 derived from plasma concentrations|T1/2 of WHG626 derived from plasma concentrations|AUC of GWQ573 (the active metabolite of WHG626) derived from plasma concentrations|Cmax of GWQ573 (the active metabolite of WHG626) derived from plasma concentrations|Cmin of GWQ573 (the active metabolite of WHG626) devived from plasma concentrations|Tmax of GWQ573 (the active metabolite of WHG626) derived from plasma concentrations|T1/2 of GWQ573 (the active metabolite of WHG626) derived from plasma concentrations\",\"Active, not recruiting\",\"Phase 1\"\n",
      "17,\"A Open-label Study of Ultra-High Dose Dexamethasone for Relapsed Multiple Myeloma\",\"Determine antitumor activity of ultrahigh dose dexamethasone (UHDD) as monotherapy in relapsed multiple myeloma.\",\"1 year\",\"Characterize the safety and tolerability by assessing the number of related adverse events of UHDD as monotherapy in patients with relapsed multiple myeloma.|Determine the progression free survival amongst responders.|Determine the subset of patients in whom UHDD can be used as monotherapy for treatment of relapsed multiple myeloma\",\"Withdrawn\",\"Phase 2\"\n",
      "18,\"Efficacy Study of CYT997 in Multiple Myeloma\",\"Overall response rate to CYT997 when used to treat patients with relapsed or refractory multiple myeloma\",\"Baseline to study completion\",\"Number of cycles required to achieve maximum response|Overall survival|Safety and tolerability|Time to disease progression\",\"Terminated\",\"Phase 2\"\n",
      "19,\"Thrombosis in Patients With Multiple Myeloma in an University Medical Center\",\"Venous thromboembolism incidence\",\"1 year\",\"Arterial thromboembolism\",\"Completed\",\n",
      "20,\"Etiology of Multiple Myeloma: A Case-Control Study\",\"The goal of this epidemiological research study is to identify biological and lifestyle factors that may be associated with the development of Multiple Myeloma (MM).\",\"2 Years\",,\"Unknown status\",\n",
      "21,\"A Study to Evaluate the My Hematology Oncology Patient Experience (MyHOPE™) For Multiple Myeloma (MM) Digital Care Network in Patients With MM\",\"Monthly eligibility and recruitment rates per month of patients with multiple myeloma|User average weekly log-in rates over the duration of follow-up from patients with MM and HCPs|Duration of follow-up|Patient-reported outcome completion rates|Frequency of user access by feature and by month, relative to the enrollment date of each participant|Percentage of patients for whom the HCPs complete the 6-month assessments|Patient empowerment and self-efficacy measured by CASE-Cancer\",\"Up to 12 months|Up to 6 months|Up to 6 months|Up to 6 months|Up to 6 months|up to 18 months|Up to 6 months\",\"Proportion of respondents scoring 4 or 5 on the Patient Platform Usability Survey or Healthcare Provider Platform Survey|Quality of life measured by Functional Assessment of Cancer Therapy-Multiple Myeloma (FACT-MM) total score\",\"Terminated\",\"Phase 1\"\n",
      "22,\"89Zr-bevacizumab PET Scan in Patients With Relapsing Multiple Myeloma\",\"Focal lesion of 89Zr-bevacizumab PET scanning in patients with relapsing multiple myeloma\",\"during scanning\",,\"Unknown status\",\"Not Applicable\"\n",
      "23,\"Efficacy of Perifosine Alone and in Combination With Dexamethasone for Patients With Multiple Myeloma\",\"Response rate (the combined CR + PR + MR) with treatment perifosine\",\"Every 3 weeks\",\"Response rate (CR + PR + MR) with combination therapy|Assess the safety and tolerability of perifosine alone and in combination|Obtain correlative data in patients with multiple myeloma treated with perifosine and in combination\",\"Completed\",\"Phase 2\"\n",
      "24,\"Busulfan, Melphalan, Fludarabine and T-Cell Depleted Allogeneic Hematopoietic Stem Cell Transplantation Followed by Post Transplantation Donor Lymphocyte Infusions\",\"Proportion of Participants With Relapsed Multiple Myeloma With Progression-free (PFS)\",\"2 years\",\"Proportion of Participants With Relapsed Multiple Myeloma Alive at 2 Years|Number of Participants Who Relapse That Are Restored to Remission (CR)\",\"Completed\",\"Phase 2\"\n",
      "25,\"Prospective Evaluation of Taste Function In Multiple Myeloma Patients Undergoing Autologous Hematopoietic Cell Transplantation\",\"Feasibility of comprehensive chemical gustometry in participants with multiple myeloma undergoing autologous HCT\",\"Change from baseline assessment up to 100 days\",,\"Active, not recruiting\",\n",
      "26,\"Patient and Care Partner Experiences Living With Multiple Myeloma (PaCE-MM)\",\"Trajectories of cognitive functions NIHTB-CB|Trajectories of cognitive functions PROMIS|Trajectories of HRQoL cognitive functions|Trajectories of physical function measured by ADLs|Trajectories of physical function measured by IADLS|Trajectories of physical function measured by Gait speed\",\"Up to 6 months|Up to 6 months|Up to 6 months|Up to 6 months|Up to 6 months|Up to 6 months\",\"Predictors of changes in cognitive function|Predictors of changes in physical function|Predictors of changes in quality of life|Gain a complete understanding of the challenges patients and care partners living with multiple myeloma face\",\"Recruiting\",\n",
      "27,\"Denosumab for Smoldering Multiple Myeloma\",\"Proportion of Subjects With a Downgraded Risk of Progression of Smoldering Multiple Myeloma if the Risk Category Decreases.\",\"1 year\",\"Proportion of Subjects With Skeletal Related Events|Proportion of Subjects With Disease Progression to Multiple Myeloma|Proportion of Subjects With Progression Free Survival|Proportion of Subjects With Change in Bone Mineral Density\",\"Active, not recruiting\",\"Phase 2\"\n",
      "28,\"Study to Evaluate t(11;14) Status and BCL2 Expression in Adult Participants With Multiple Myeloma (MM)\",\"Percentage of Participants With t(11;14) Status by Fluorescence In Situ Hybridization (FISH) Analysis of Bone Marrow Plasma Cells|Percentage of Participants With BCL2 Status by Quantitative Polymerase Chain Reaction (qPCR) Analysis of Bone Marrow Plasma Cells\",\"Up to approximately 2.5 months following last subject last visit|Up to approximately 2.5 months following last subject last visit\",\"Percentage of Participants Achieving Stability of t(11;14) Status|Percentage of Participants Achieving Stability of BCL2 Status|Percentage of Participants With t(11;14) Status Determined by Bone Marrow (BM) Biopsy|Percentage of Participants With BCL2 Status Determined by Bone Marrow Biopsy|Percentage of Participants With t(11;14) Status of MM Samples|Percentage of Participants With BCL2 Status of MM Samples|Percentage of Participants With t(11;14) Status of MM Samples at Different Treatment Lines Stages|Percentage of Participants With BCL2 Status of MM Samples at Different Treatment Lines Stages|Percentage of Participants With t(1;14) Status and BCL2 Status|Percentage of Participants With FISH Fusion (F) Categories as Determined by BM Biopsy|Percentage of Participants With FISH Fusion (F) Categories Across Lines of Therapies as Determined by BM Biopsy\",\"Recruiting\",\n",
      "29,\"A Post Authorisation Registry of IMNOVID (Pomalidomide) for Patients With Relapsed and Refractory Multiple Myeloma.\",\"Determine incidence of risks as outlined in the Risk Management Plan\",\"Up to 3 years\",\"Pregnancy Prevention Programme Effectiveness|Previous Treatments\",\"Completed\",\n",
      "30,\"Observational Study in Participants With Chronic Lymphocytic Leukemia (CLL), Multiple Myeloma (MM) and Non-Hodgkin's Lymphoma (NHL) in Latin America\",\"Number of Participants with Previous Comorbidities|Number of Participants as per treatment therapy received|Overall survival|Number of Participants with Response to Treatment\",\"1 year|1 year|1 year|1 year\",\"Incidence Percentage of Participants with Chronic Lymphocytic Leukemia (CLL), Multiple Myeloma (MM) and non-Hodgkin lymphoma (NHL)|Prevalence Percentage of Participants with CLL, MM and NHL\",\"Completed\",\n",
      "31,\"Ixazomib, ONC201, and Dexamethasone in Relapsed/Refractory Multiple Myeloma\",\"Recommended phase II dose (RPTD)\",\"9 Months\",\"Disease control rate|Progression free survival (PFS)|Duration of response (DOR)|Clinical benefit rate (CBR)\",\"Terminated\",\"Phase 1|Phase 2\"\n",
      "32,\"Selinexor for the Treatment of Intermediate and High-Risk Smoldering Multiple Myeloma\",\"Rate of progression to Multiple Myeloma\",\"2 years after end of treament\",\"Change in monoclonal protein (M-spike) or serum free light chains (sFLC)|Progression free survival|Rate of skeletal related events|rate of adverse events\",\"Not yet recruiting\",\"Phase 2\"\n",
      "33,\"Amplification of Zinc Finger Protein 217 Gene in Multiple Myeloma\",\"zinc-finger protein gene 217 in myeloma patients\",\"2 years\",,\"Unknown status\",\"Not Applicable\"\n",
      "34,\"Safety Study of Lenalidomide/Dexamethasone to Treat Patients With Relapsed or Refractory Multiple Myeloma\",\"Number of Adverse events of special interest during Len/Dex therapy\",\"Up to approximately 72 months\",\"Incidence (number) of thromboembolism|Duration of Len/Dex treatment over the course of the study|Number of patients with good and poor compliance to lenalidomide and dexamethasone|Type and frequency of prophylaxis treatment for prevention of thromboembolism\",\"Completed\",\n",
      "35,\"Anti-Angiogenesis Therapy Using Thalidomide in Multiple Myeloma\",\"To determine tumor response, overall and progression free survival following thalidomide therapy in patients with multiple myeloma\",,\"To determine toxicities associated with thalidomide in patients with multiple myeloma\",\"Completed\",\"Phase 2\"\n",
      "36,\"Celgene High Risk Multiple Myeloma (MM) Revlimid Induction and Maintenance Therapy\",\"Progression Free Survival\",\"2 years\",\"Time to Response|Overall Survival|Time to Progression|Duration of Response\",\"Completed\",\"Phase 2\"\n",
      "37,\"A Phase I Study Of Thymoglobulin In Patients With Relapsed Or Refractory Multiple Myeloma\",\"To determine the maximum tolerated dose and dose limiting toxicity of thymoglobulin in multiple myeloma patients.\",\"End of cycle 1 (DLT) and approximately 16 months after start of treatment (MTD)\",\"Determine the overall response rate (CR+PR) of patients with relapsed or refractory multiple myeloma treated with thymoglobulin|To determine the time to response, duration of response, and time to progression and overall survival|To determine the safety and tolerability of thymoglobulin|Assess the changes in lymphocyte apoptosis signaling in treated patients\",\"Completed\",\"Phase 1\"\n",
      "38,\"A Head-to-head Comparative Study of 18F-PSMA-1007 PET/CT and 18F-FDG PET/CT Imaging in Multiple Myeloma\",\"number of myeloma lesions\",\"through study completion, an average of 1 year\",\"standardized uptake value (SUV) of myeloma lesions\",\"Recruiting\",\"Not Applicable\"\n",
      "39,\"Multiple Myeloma Patient Registry\",\"Overall Response Rate|Time to Next Treatment (TTNT)|Overall Survival (OS)|Survival Time|European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30) Score|Katz Index of Independence for Activities of Daily Living|Lawton Instrumental Activities of Daily Living\",\"Up to 3 years|Up to 3 years|Up to 3 years|Up to 3 years|Up to 3 years|Up to 3 years|Up to 3 years\",,\"Terminated\",\n",
      "40,\"A Study to Determine the Effect and Safety of an Oral Janus Kinase 2 (JAK2)-Inhibitor (Ruxolitinib; INBC018424) in Patients With Multiple Myeloma\",\"Number of Responders According to the International Uniform Response Criteria for Multiple Myeloma\",\"Day 1 of Cycles 2, 3, and 4 and then every 3 months thereafter (up to 25 months).\",\"Time to Disease Progression According to the International Uniform Response Criteria for Multiple Myeloma\",\"Completed\",\"Phase 2\"\n",
      "41,\"Tandem Auto Stem Cell Transplant With Melphalan Followed by Melphalan and Bortezomib in Patients With Multiple Myeloma\",\"To determine the progression-free survival of patients with multiple myeloma treated with tandem cycles of high-dose melphalan followed by high-dose melphalan in combination with bortezomib with autologous HSC transplantation.\",\"3 years\",\"To determine the response rate, overall survival, and regimen-related toxicities of patients with multiple myeloma treated with high-dose melphalan or high-dose melphalan in combination with bortezomib given in tandem transplants.\",\"Active, not recruiting\",\"Phase 3\"\n",
      "42,\"Phase II Study to Evaluate Fenofibrate Therapy in Patients With Smoldering or Symptomatic Multiple Myeloma\",\"Rate of Response in Participants Receiving Fenofibrate Therapy\",\"After two cycles, about 2 months\",\"Number of Subjects Experiencing Adverse Events|Proportion of Participants Achieving Progression-Free Survival\",\"Terminated\",\"Phase 2\"\n",
      "43,\"Genomic and Phenotypic Determinants of Resistance to Immunotherapies in Multiple Myeloma\",\"Sensitivity vs resistance to new immunotherapies|Cell extrinsic mechanisms of response|Biomarkers of response|Biomarkers of response\",\"5 years|5 years|5 years|5 years\",,\"Recruiting\",\n",
      "44,\"A Study of Elotuzumab With Pomalidomide, Bortezomib, and Dexamethasone in Relapsed Multiple Myeloma\",\"Overall response rate by International Myeloma Working Group criteria.|Number of participants with treatment-related adverse events as assessed by CTCAE v4.0\",\"2 years|2 years\",\"Progression Free Survival\",\"Active, not recruiting\",\"Phase 2\"\n",
      "45,\"Optical Genome Mapping in Characterization of Multiple Myeloma\",\"Validate the use of Optical Genome Mapping in Multiple Myeloma characterization\",\"At MM diagnosis\",\"Evaluate Optical Genome Mapping for identification of genetic abnormalities that are not detected with FISH in Multiple Myeloma\",\"Not yet recruiting\",\n",
      "46,\"Predicting Progression of Developing Myeloma in a High-Risk Screened Population (PROMISE)\",\"Time to progression (TTP) from MGUS/SMM to overt multiple myeloma.\",\"15 years\",,\"Recruiting\",\n",
      "47,\"A Study of Fully Human BCMA CAR-T (CT103A) in Patients With Newly Diagnosed High-risk Multiple Myeloma (FUMANBA-2)\",\"Proportion of Minimal Residual Disease (MRD)-negative subjects|Median progression-free survival (mPFS)\",\"Up to 2 years after CT103A infusion|Up to 2 years after CT103A infusion\",\"Best overall response (BOR)|Median survival (mOS)|Event-free survival (EFS)|Duration of response (DOR)|Safety endpoint|Pharmacokinetic(PK) endpoint|PK endpoint - Tmax|PK endpoint - AUC 0 to 28d and AUC 0 to 90d|Levels of Soluable BCMA|PD endpoint\",\"Not yet recruiting\",\"Phase 1\"\n",
      "48,\"Dendritic Cell (DC)/Myeloma Fusions in Combination With Nivolumab in Patients With Relapsed Multiple Myeloma\",\"Number of Patients Who Develop Immunologic Response to Nivolumab and the DC/MM Fusion Vaccine\",\"2 years\",\"Number of Patients Who Achieve a Clinical Response (SD, PR, VGPR, CR)|Number of Participants With Treatment-related Adverse Events as Assessed by CTCAE v4.0|Number of Patients Who Are Alive Without Progression at 2 Years\",\"Terminated\",\"Phase 2\"\n",
      "49,\"A Study to Assess the Adverse Events and Change in Disease Activity in Adult Participants With Relapsed or Refractory Multiple Myeloma Receiving Oral ABBV-453 Tablets\",\"Overall Response Rate (ORR) per Adapted International Myeloma Working Group (IMWG) criteria\",\"Up to Approximately 12 Months\",\"Duration of Response (DOR)|Depth of Response Minimal Residual Disease (MRD)|Progression Free Survival (PFS)|Overall Survival (OS)\",\"Recruiting\",\"Phase 1\"\n",
      "50,\"Study To Evaluate Safety and Efficacy of P276-00 in Subjects With Refractory Multiple Myeloma\",\"To determine the maximum tolerated dose of P276-00 in subjects with relapsed and/or relapsed/refractory Multiple Myeloma\",\"18 months\",,\"Completed\",\"Phase 1|Phase 2\"\n",
      "51,\"Treatment of Chemotherapy Refractory Multiple Myeloma by CART-138\",\"Occurrence of study related adverse events\",\"Until week 24\",\"Anti-myeloma responses to CART-138 cell infusions\",\"Unknown status\",\"Phase 1|Phase 2\"\n",
      "52,\"UARK 2005-05, Coagulation-Related Effects of Velcade Treatment in Patients With Relapsed or Refractory Multiple Myeloma\",\"Antithrombotic Effect of VELCADE in a Malignancy Associated With a Hypercoagulable State in Patients With Relapsed/Refractory Multiple Myeloma.\",\"60 days\",,\"Completed\",\"Not Applicable\"\n",
      "53,\"Detecting Early Myocardial Infiltration w/Amyloid & Light Chain Deposition Disease in Multiple Myeloma Subjects\",\"This study is to see if MRI techniques can be used for early evaluation of cardiac amyloidosis which is sometimes seen in individuals with multiple myeloma.\",\"The time frame is five additional minutes & three additional images during and MRI.\",,\"Terminated\",\n",
      "54,\"Hemostatic Effects of VELCADE®* Treatment in Multiple Myeloma Patients\",\"Efficacy of Velcade\",\"48 hours\",,\"Terminated\",\"Phase 2\"\n",
      "55,\"Non -Interventional Study-Palliative Therapy of Multiple Myeloma With a Combination of Lenalidomide and Dexamethasone\",\"Time to progression (TTP)\",\"maximum 3 years per Patient\",\"Overall Response Rate|Time to Treatment Discontinuation (TTD)|Overall Survival (OS)|Safety Profile|Dosage of Lenalidomide and Dexamethasone|Kidney Function|Neutropenia / Infection (Concomitant Medication)|Thrombosis Prophylaxis\",\"Completed\",\n",
      "56,\"PAD Combination Therapy Followed by Thal/Dex for Relapsed or Refractory Multiple Myeloma\",\"Response rate of PAD induction Therapy\",,\"Response rate of PAD followed by Thal/Dex maintenance|Progression free survival and Overall survival of PAD/Thal-Dex.|To evaluate toxicities of PAD/Thal-Dex\",\"Unknown status\",\"Phase 2\"\n",
      "57,\"LCAR-B38M Cells in Treating Relapsed/Refractory (R/R) Multiple Myeloma\",\"Occurrence of treatment related adverse events as assessed by CTCAE v4.0\",\"Day 1-30 days after injection\",\"Anti-myeloma responses to LCAR-B38M cell treatment|Anti-myeloma responses to LCAR-B38M cell treatment\",\"Unknown status\",\"Phase 1|Phase 2\"\n",
      "58,\"Safety and Efficiency Study of BCMA-PD1-CART Cells in Relapsed/Refractory Multiple Myeloma\",\"Incidence of Treatment-related Adverse Events\",\"3 years\",\"Overall Remission Rate(ORR) of BCMA-PD1-CART cells in Lymphoma|Overall survival(OS) of BCMA-PD1-CART cells in Lymphoma|Progress-free survival(PFS) of BCMA-PD1-CART cells in Lymphoma|Rate of BCMA-PD1-CARTcells in peripheral blood cells|Quantity of BCMA-PD1-CART cells copies in peripheral blood cells.\",\"Unknown status\",\"Phase 2\"\n",
      "59,\"Safety and Efficacy Study of a Triplet Combination of MLN9708, Lenalidomide and Dexamethasone in the Initial Management of Multiple Myeloma (IFM2013-06)\",\"To evaluate the stringent Complete Response (sCR) rate of the combination of MLN9708, Lenalidomide and Dexamethasone in newly diagnosed multiple myeloma (MM) patients after extended consolidation therapy\",\"sixteen months\",\"To evaluate the overall response rate after induction therapy|To evaluate the safety Evaluate the safety|To evaluate the quality of stem cell harvest|To evaluate the overall response rate after high-dose therapy (prior to consolidation)|To evaluate the overall response rate after consolidation therapy|To evaluate the feasibility of maintenance with MLN9708|To evaluate duration of response, progression-free and overall survival\",\"Unknown status\",\"Phase 2\"\n",
      "60,\"A Clinical Trial of Oral Suberoylanilide Hydroxamic Acid (SAHA) in Patients With Advanced Multiple Myeloma (0683-004)\",\"PHASE I: Maximum tolerated dose (MTD) of vorinostat in patients with advanced multiple myeloma.|PHASE II: Safety and overall response rate to SAHA in patients with advanced multiple myeloma.\",,\"1) Anti-tumor activity in patients with advanced multiple myeloma; 2) Biological effects of SAHA in peripheral mononuclear cells and bone marrow plasma cells; 3) Correlation of biological effects of SAHA with serum drug concentration.\",\"Terminated\",\"Phase 1\"\n",
      "61,\"Tumor-Associated Antigen-Specific Cytotoxic T-Lymphocytes for Multiple Myeloma\",\"Number of Patients with Adverse events\",\"8 weeks\",\"Expansion of the CTLs|Persistence of the CTLs|Reduction of the Multiple Myeloma\",\"Recruiting\",\"Phase 1\"\n",
      "62,\"Ixazomib -Daratumumab Without Dexamethasone (IDara) in Elderly Relapse Refractory Multiple Myeloma\",\"Very Good Partial Response (VGPR) + Complete Response (CR) Rate using the IMWG response criteria\",\"12 months\",,\"Recruiting\",\"Phase 2\"\n",
      "63,\"Study of Thrombin Generation During the 3 First Cycles of Chemotherapy in Patients With Newly Diagnosed Multiple Myeloma\",\"change from baseline in Thrombin generation measure|change from baseline in Thrombin generation measure|change from baseline in Thrombin generation measure|change from baseline in Thrombin generation measure\",\"day 21|day 42|day 63|day 0\",\"image-confirmed venous thromboembolic events|change from baseline in TFPI resistance measure|change from baseline in acquired protein S deficiency measure|change from baseline in TFPI resistance measure|change from baseline in TFPI resistance measure|change from baseline in acquired protein S deficiency measure|change from baseline in acquired protein S deficiency measure|change from baseline in TFPI resistance measure|change from baseline in acquired protein S deficiency measure\",\"Completed\",\n",
      "64,\"Elotuzumab, Selinexor, and Dexamethasone for Relapsed Refractory Multiple Myeloma\",\"Response of relapsed refractory multiple myeloma (RRMM) patient to elotuzumab, selinexor, and dexamethasone (ESd).\",\"18-24 months.\",\"Incidence of adverse events in RRMM patients treated with ESd.|Duration of Response (DOR) of RRMM patients to ESd.|Overall Survival (OS) of RRMM patients treated with ESd.\",\"Withdrawn\",\"Phase 2\"\n",
      "65,\"Safety and Efficacy Study of Single Weekly Bortezomib in Newly Diagnosed Multiple Myeloma\",\"Number of Participants at Each Response Category (Stable Disease, Minimal Response, Partial Response, Very Good Partial Response, Near Complete Response/Complete Resonse)\",\"Data was collected for each subject for the duration of the participation in the study, which was an average of 4.8 cycles.\",\"Number of Participants With Dose Reductions in Bortezomib, Dexamethasone or Both\",\"Completed\",\"Phase 2\"\n",
      "66,\"Bortezomib in Combination With CC-5013 in Patients With Relapsed/Refractory Multiple Myeloma\",\"To evaluate the safety of bortezomib when given in combination with CC-5013 in subjects with relapsed and relapsed/refractory multiple myeloma, to identify the MTD as well as a RP2D.\",\"2 years\",\"To evaluate the response of the combination of bortezomib and CC-5013|To determine the pharmacokinetics of bortezomib and CC5013 in patients with multiple myeloma.\",\"Completed\",\"Phase 1\"\n",
      "67,\"Ultra-low-dose Whole-body CT Using AI-based CT Reconstruction in Patients With Multiple Myeloma\",\"Contrast-to-noise ratio\",\"3 months after the CT scan\",,\"Recruiting\",\n",
      "68,\"A Study of Real-life Current Standards of Care in Patients With Relapsed and/or Refractory Multiple Myeloma Who Received at Least 3 Prior Lines of Therapy Including Proteasome Inhibitor (PI), Immunomodulatory Drug (IMID), and Cluster of Differentiation 38 (CD38) Monoclonal Antibody Treatment\",\"Overall Response Rate (ORR)\",\"Up to 24 months\",\"Very Good Partial Response (VGPR) Rate|Complete Response (CR) Rate|Stringent Complete Response (sCR) Rate|Minimal Residual Disease (MRD) Negative Rate|Clinical Benefit Rate (CBR)|Duration of Response|Time to Response|Time to Next Treatment [TTNT]|Progression-free Survival (PFS)|Time to Progression on the Next Line of Subsequent Antimyeloma Therapy or Death (PFS2)|Overall Survival (OS)|Change from Baseline in Health-related Quality of Life (HRQoL) using European Organization for Research and Treatment of Cancer (EORTC) QLQ-C30 Scale Score|Change from Baseline in Health-related Quality of Life (HRQoL) using European Organization for Research and Treatment of Cancer (EORTC) QLQ-MY20 Scale Score|Change from Baseline in Health-related Quality of Life (HRQoL) using EQ-5D-5L Questionnaire Score|Number of Patients with Adverse Events (AEs)|Severity of Adverse Events as Assessed by National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE)\",\"Completed\",\n",
      "69,\"Carfilzomib Multiple Myeloma Expanded Access Protocol for Patients With Relapsed and Refractory Disease\",,,,\"Approved for marketing\",\n",
      "70,\"Study of Tecemotide (L-BLP25) in Subjects With Slowly Progressive Multiple Myeloma With no Symptoms and Who Have Had no Chemotherapy\",\"Number of Participants With Overall Induced Mucinous Glycoprotein-1 (MUC-1)-Specific Immune Response\",\"From the date of randomization up to Week 104\",\"Number of Participants With Baseline Immune Response and Initial Increase of MUC1 Specific Immune Response|Number of Participants With Overall Induced Immune Response by Human Leukocyte-associated Antigen (HLA) Type|Percentage of Participants With Objective Clinical Response (Complete Response [CR], or Partial Response [PR], or Minimal Response [MR]|Time to Progression (TTP)|Time to Anti-tumor Therapy|Number of Participants With Treatment Emergent Adverse Events (TEAEs),Serious TEAEs, TEAEs of Grade 3 or 4 According to NCI-CTCAE v3.0, TEAEs Leading to Discontinuation and Injection Site Reactions (ISRs)\",\"Completed\",\"Phase 2\"\n",
      "71,\"Study of ACY-1215 Alone and in Combination With Bortezomib and Dexamethasone in Multiple Myeloma\",\"Phase 1 (a & b): To determine the maximum tolerated dose of ACY-1215 as monotherapy or in combination with bortezomib and dexamethasone in patients with relapsed or relapsed/refractory multiple myeloma.|Phase 2a: To determine the objective response rate to ACY-1215 in combination with bortezomib and dexamethasone in patients with relapsed or relapsed/refractory multiple myeloma.\",\"Upon completion of 21-day treatment cycle|Assessed every other treatment cycle (cycles 2, 4 and 6)\",\"Characterize the safety of ACY-1215 alone or in combination with bortezomib and dexamethasone in patients with relapsed or relapsed/refractory multiple myeloma|Determine the single- and multiple-dose PK of ACY-1215 alone and in combination with bortezomib and dexamethasone in patients with relapsed or relapsed/refractory multiple myeloma|Evaluate the pharmacodynamics of ACY-1215 alone or in combination with bortezomib and dexamethasone in patients with relapsed or relapsed/refractory multiple myeloma.\",\"Completed\",\"Phase 1|Phase 2\"\n",
      "72,\"Quality of Life the Danish Multiple Myeloma Patients\",\"A longitudinal description of quality of life (QoL) using patient-reported outcomes measurement (PROM) for the general population of multiple myeloma patients.\",\"24 months\",\"Description of changes in QoL over time, based on PROM for the general population of multiple myeloma patients.|Description of the impact of peripheral neuropathy on QoL in the general population of multiple myeloma patients over time, based on PROM.|Description of the impact of recalibration response shift for interpretation of data from longitudinal QoL studies using PROM for QoL measurement in the general population of previously untreated multiple myeloma patients.\",\"Active, not recruiting\",\n",
      "73,\"Study of Natalizumab in Relapsed/Refractory Multiple Myeloma\",\"Number of Participants With Dose Limiting Toxicities (DLTs)|Objective Response Rate (ORR)|Number of Participants With Adverse Events (AEs)\",\"Day 1 up to Day 28|Day 1 up to Month 6|Day 1 up to Month 6\",\"Number Of Participants Who Achieve A Complete Response|Kaplan-Meier Estimates for Duration Of Response For Participants With A Response|Pharmacokinetic (PK) Profile Of Natalizumab|Natalizumab Binding Saturation Of α4 Integrin Sites On Peripheral Blood Mononuclear Cells (PBMC)\",\"Terminated\",\"Phase 1|Phase 2\"\n",
      "74,\"A Study of NINLARO® in Chinese Adults With Multiple Myeloma\",\"Progression Free Survival (PFS)\",\"From the date of first administration of ixazomib therapy to the date of first documentation of progressive disease (PD) or death, lost to follow-up, whichever occurs first (up to 24 months)\",\"Time to Next Treatment (TTNT)|Percentage of Participants Achieving Very Good Partial Response (VGPR)|Percentage of Participants Achieving Complete Response (CR)|Percentage of Participants Achieving Stringent Complete Response (sCR)|Duration of Ixazomib Therapy (DOT)|Duration of CR|Overall Survival (OS)|Health-related Quality of Life (HRQOL) Based on European Organization for Research and Treatment of Cancer Multiple Myeloma Module (EORTC QLQ-MY20)|HRQOL Based on EORTC QLQ-C30|HRQOL Based on EuroQoL Group 5-Dimension 5-Level (EQ-5D-5L)|Treatment Satisfaction Questionnaire for Medication (TSQM-9)|Number of Participants Categorized Based on Healthcare Resource Utilization|Number of Participants Categorized Based on Reason for Dose Reduction of Ixazomib Therapy|Number of Participants Categorized Based on Reason for Interruption of Ixazomib Therapy|Number of Participants Categorized Based on Reason for Discontinuation of Ixazomib Therapy|Relative Dose Intensity (RDI)|Number of Participants who Experience at Least one Adverse Event (AE)|Number of Participants Categorized Based on Occurrence of Second Primary Malignancies (SPM)\",\"Recruiting\",\n",
      "75,\"Selinexor, Pomalidomide, and Dexamethasone For Multiple Myeloma With CNS Involvement\",\"Progression free survival\",\"From date of enrollment until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 24 months.\",\"Overall survival|Overall response rate|Adverse Events\",\"Recruiting\",\"Phase 2\"\n",
      "76,\"A Phase 2 Study With Panzem in Patients With Relapsed or Plateau Phase Multiple Myeloma\",\"To determine tumor response of 2ME2 administered orally by evaluation of objective responses in patients with plateau phase or relapsed multiple myeloma\",\"At least yearly\",\"To assess the safety and tolerability of 2ME2 administered orally by evaluation of the frequency, severity, and duration of treatment-emergent adverse events in patients with plateau phase or relapsed multiple myeloma|To determine the minimum 2ME2 levels achieved in plasma following daily oral administration in patients with plateau phase or relapsed multiple myeloma\",\"Completed\",\"Phase 2\"\n",
      "77,\"An Efficacy and Safety Study of bb2121 in Subjects With Relapsed and Refractory Multiple Myeloma and in Subjects With High-Risk Multiple Myeloma\",\"Overall response rate (ORR)- Cohort 1|Complete response (CR) rate - Cohort 2a , b, c and Cohort 3\",\"Up to approximately 5 years|Up to approximately 5 years\",\"Complete response (CR) rate - Cohort 1|Overall response rate (ORR) - Cohort 2a, b, c and Cohort 3|Very good partial response (VGPR) rate - Cohort 2c|Time to response (TTR)|Duration of response (DoR)|Progression-free survival (PFS)|Time to progression (TTP)|Overall survival (OS)|Adverse Events (AEs)|Percentage of participants who received lenalidomide maintenance for the first 3 cycles following bb2121 infusion with at least 75% dose compliance - Cohort 3|Pharmacokinetics - Cmax|Pharmacokinetics - tmax|Pharmacokinetics - AUC|Pharmacokinetics - tlast|Pharmacokinetics - AUC0-28days|Immunogenicity|Subject-reported outcomes as measured by European Organization for Research and Treatment of Cancer Quality-of-Life questionnaire (EORTC-QLQ-C30)|Subject-reported outcomes as measured by EuroQoL Group EQ-5D-5L Health Questionnaire|Subject-reported outcomes as measured by EORTC-QLQ-MY20\",\"Recruiting\",\"Phase 2\"\n",
      "78,\"Retrospective Viability Study of the PETHEMA-POMCIDEX Clinical Practice Guidelines for the Treatment of Patients With Relapsed and Refractory Multiple Myeloma (RRMM)\",\"Level of compliance at PETHEMA centres in Spain with the clinical practice guidelines proposed by the Spanish Myeloma Group for the treatment of relapsed and refractory MM with POMCIDEX.\",\"3 months\",,\"Completed\",\n",
      "79,\"VMP Regimen - Safety, Efficacy, and Optimal Dose Finding Study for Patients With Multiple Myeloma\",\"PFS (progression-free survival)\",\"18 Month after VMP therapy administration\",\"ORR (Overall Response Rate)|CR (Complete Response)|Time to Response (TTR)|Time to Progression (TTP)|Time to Next Treatment (TTNT)|OS (Overall Survival)|Percentage of IMWG frailty scores at Cycle 5 and Cycle 9|Prognosis prediction factors\",\"Unknown status\",\n",
      "80,\"Vaccines and COVID-19 in Multiple Myeloma\",\"Feasibility of obtaining baseline clinical and PRO data capture from 200 consented patients.|Feasibility of obtaining 30-day clinical and PRO data capture from 200 consented patients.|Feasibility of obtaining 6-month clinical and PRO data capture from 200 consented patients.\",\"At Baseline|30 days after enrollment|6 months after enrollment\",\"COVID Vaccine Prevalence|COVID Booster Incidence|PRO Review|COVID-19 Infection baseline|COVID-19 Infection on study|Patient reported COVID 19 adverse events baseline|Patient reported COVID 19 adverse events on study|EHR COVID 19 adverse events baseline|EHR COVID 19 adverse events on study\",\"Not yet recruiting\",\n",
      "81,\"Lenalidomide & Adriamycin & Dexamethasone (RAD) in Newly Diagnosed, Multiple Myeloma Patients\",\"Overall response rate\",\"142 days\",\"Progression-free survival (PFS)|Time to progression (TTP)|Time to Next Therapy (TtNT)|Number and severity of Adverse events as a measure of safety and toxicity profile\",\"Completed\",\"Phase 2\"\n",
      "82,\"Assessment of Efficacy and Safety of Perifosine, Bortezomib and Dexamethasone in Multiple Myeloma Patients\",\"Determine the PFS (progression free survival) in patients with multiple myeloma, treated with perifosine, bortezomib and dexamethasone compared to patients treated with placebo, bortezomib and dexamethasone\",\"6 - 24 months\",\"Overall survival (OS)|Overall response rate (ORR)|Adverse Events\",\"Terminated\",\"Phase 3\"\n",
      "83,\"Bortezomib With Melphalan and Prednisone for Multiple Myeloma\",\"Response\",\"6 weeks following completion of treatment\",\"Number of Patients With Any Grade or Severe Adverse Event|Median Duration of Response\",\"Completed\",\"Phase 2\"\n",
      "84,\"A Trial Evaluating Efficacy & Safety of RVD +/- Panobinostat in Transplant Eligible, Newly Diagnosed Multiple Myeloma (NDMM)\",\"Near Complete Response (nCR)/CR Rate of the Combination of Panobinostat With Bortezomib, Lenalidomide and Dexamethasone (P-RVD) vs RVD in Newly Diagnosed Multiple Myeloma Patients\",\"84 days\",\"Minimal Residual Disease (MRD) Negativity (mCR) After 4 Cycles of Induction by Next Gen Sequencing|Best Overall Response Rate (ORR) and MRD Negativity After ASCT and Maintenance|Depth of Response by International Myeloma Working Group (IMWG) Criteria|Duration of Response|Overall Survival|Progression Free Survival\",\"Terminated\",\"Phase 2\"\n",
      "85,\"Antineoplaston Therapy in Treating Patients With Multiple Myeloma\",\"Number of Participants With Objective Response, Stable Disease, Progressive Disease or Not Evaluable\",\"36 months\",,\"Terminated\",\"Phase 2\"\n",
      "86,\"Assessment of Allogeneic Hematopoietic Cell Transplantation in Medicare Beneficiaries With Multiple Myeloma\",\"Compare five-year survival\",\"5 years post transplant\",\"Progression-free survival (PFS)|Relapse or progression|Transplant related mortality|Incidence of acute GVHD|Incidence of chronic GVHD\",\"Recruiting\",\n",
      "87,\"Prospective Comparison of 18F-choline PET/CT and 18F-FDG PET/CT in the Initial Work-up of Multiple Myeloma\",\"Number of whole-body bone lesions|Number of whole-body bone lesions|Number of bone lesions within defined skeletal areas|Number of bone lesions within defined skeletal areas\",\"Day 0|Day 7|Day 0|Day 7\",\"Diagnostic performance for the detection of focal bone lesions|Diagnostic performance for the detection of focal bone lesions|Diagnostic performances for the detection of diffuse infiltrative disease of the spine|Diagnostic performances for the detection of diffuse infiltrative disease of the spine|Number of extra-medullary lesions|Number of extra-medullary lesions\",\"Recruiting\",\"Phase 3\"\n",
      "88,\"Study of Daratumumab in Multiple Myeloma (MM) Patients in >VGPR/MRD-positive\",\"Overall Responde Rate (ORR)\",\"every 6 months\",\"Progression free survival (PFS)|Complete Remission Rate (CR)|Duration of Response (DoR)\",\"Unknown status\",\"Phase 2\"\n",
      "89,\"Survival Outcomes of Multiple Myeloma Patients Admitted on Assiut Clinical Hematology Unit\",\"Determine the survival outcomes of multiple myeloma patients admitted on Assiut clinical Hematology unit\",\"2 years\",,\"Not yet recruiting\",\n",
      "90,\"Isatuximab, Pomalidomide, Elotuzumab and Dexamethasone in Relapsed and/or Refractory Multiple Myeloma\",\"The number of subjects in each status category of the International Myeloma Working Group (stringent complete response, complete response, very good partial response, partial response, minimal response, stable disease, progressive disease).|The number of subjects in each status category of the International Myeloma Working Group (stringent complete response, complete response, very good partial response, partial response, minimal response, stable disease, progressive disease).|The number of subjects in each status category of the International Myeloma Working Group (stringent complete response, complete response, very good partial response, partial response, minimal response, stable disease, progressive disease).\",\"Year 1|Year 2|Year 3\",,\"Recruiting\",\"Phase 2\"\n",
      "91,\"Value of Macrophage-Colony Stimulating Factor as a New Marker of Bone Lesions in Multiple Myeloma\",\"Serum Macrophage-Colony Stimulating Factor (M-CSF) levels\",\"Day 1\",\"Tumour osteolysis\",\"Completed\",\"Not Applicable\"\n",
      "92,\"Phase 1/2 Study of ISB 1442 in Relapsed/Refractory Multiple Myeloma\",\"Phase 1: Frequency and Severity Of Treatment-Emergent Adverse Events (TEAEs)|Phase 1: Number of Dose-Limiting Toxicities (DLTS) During the First 28 Days After the First Administration of ISB 1442 (Cycle 1)|Phase 2: Multiple Myeloma: Overall Response Rate (ORR) Based on International Myeloma Working Group (IMWG)\",\"Up to 18 months|Up to 28 days|18 months\",\"Maximum Concentration (Cmax) of ISB 1442 in Serum|Time to Reach Maximum Concentration (Tmax) of ISB 1442 in Serum|Area Under the Concentration Time Curve From Zero to Time t (AUC0-t) of ISB 1442 in Serum|Area Under the Concentration Time Curve in Dosing Intervals (AUC0-tau) of ISB1442 in Serum|Percent Incidence of Anti-Drug Antibody (ADA) and Neutralizing Antibody (nAb) From Baseline Until End-of-Treatment (EOT)|Phase 1 and Phase 2: Time to Progression (TTP)|Phase 1 and Phase 2: Time to Next Treatment (TTNT)|Phase 1 and Phase 2: Time to Response (TTR)|Phase 1 and Phase 2: Progression free survival (PFS)|Phase 1 and Phase 2: Overall survival (OS)|Phase 1: Overall Response Rate (ORR) Based on International Myeloma Working Group (IMWG)|Phase 1 and Phase 2: Complete Response Rate (CRR) Based on International Myeloma Working Group (IMWG)|Phase 1 and Phase 2: Duration of Response (DOR) Based on International Myeloma Working Group (IMWG)|Phase 2: Frequency and Severity of Treatment Emergent Adverse Events (TEAEs)\",\"Recruiting\",\"Phase 1|Phase 2\"\n",
      "93,\"A Phase I Study Of Panobinostat/Lenalidomide/Bortezomib/Dex for Relapsed And Relapsed/Refractory Multiple Myeloma\",\"MTD (Maximum Tolerated Dose) of panobinostat in combination with RVD|Recommended dose of the combination for Phase 2 studies in participants with relapsed and relapsed/refractory multiple myeloma (MM) with SC bortezomib.\",\"2 Years|2 Years\",\"Response to pan-RVD (minimal response or better|Progression-free survival (PFS)|Duration of response\",\"Completed\",\"Phase 1\"\n",
      "94,\"Study of Single Agent Lenalidomide in Older Adults With Newly Diagnosed Multiple Myeloma\",\"Combined Therapy - Median Progression Free Survival\",\"up to 36 months\",\"Response Rate|Number of Participants With Serious Adverse Events|Single Agent - Median Progressive Free Survival (PFS)|Number of Participants With 1 Year Overall Survival (OS)\",\"Completed\",\"Phase 2\"\n",
      "95,\"Safety and Dose Determining Multi-dose Study of BT062 in Patients With Relapsed or Refractory Multiple Myeloma\",\"Dose Limiting Toxicities (DLT) - Number of Participants With at Least 1 DLT|Maximum Tolerated Dose (MTD)\",\"Starting with first study drug administration until 30-day follow-up visit (average 4.99 months)|First 28-day cycle\",\"Qualitative and Quantitative Toxicities of BT062|Multi-dose Pharmacokinetics Properties of BT062 - Cmax|Anti-tumor Activity of BT062 in Subjects With Relapsed or Relapsed/Refractory Multiple Myeloma by Number of Participants With Objective Response(ORR) and/or Clinial Benefit(CBR) Based on the International Myeloma Working Group Uniform Response Criteria|Time to Progression (TTP), Progression Free Survival (PFS) and Overall Survival (OS)\",\"Completed\",\"Phase 1|Phase 2\"\n",
      "96,\"Combined Bone Marrow Transplantation (BMT) and Renal Transplant for Multiple Myeloma (MM) With End Stage Renal Disease (ESRD)\",\"Remission status of multiple myeloma|Renal allograft acceptance and ability to discontinue immunosuppressive therapy\",\"3 years|3 years\",\"Graft versus host disease (GVHD)|Opportunistic infections|T cell recovery and immune reconstitution\",\"Completed\",\"Phase 1\"\n",
      "97,\"Bendamustine, Prednisone and Velcade® for First-line Treatment of Patients With Symptomatic Multiple Myeloma\",\"Overall Response Rate (ORR) of BPV\",\"2 years\",\"Number and percentage of patients achieving a complete response|Progression-free survival (PFS)|Overall survival (OS)|Time-to-progression (TTP)|Disease-free survival (DFS)|Duration of response (DOR)|Renal response according to IMWG (CRrenal, PRrenal, MRrenal)|Toxicity (with respect to adverse events of CTCAE grade ≧3 and SAEs)|Time to objective Response (TOR)|Time to treatment failure (TTF)\",\"Completed\",\"Phase 2\"\n",
      "98,\"Vulnerability and Therapeutic Changes in Older Patients With Multiple Myeloma.\",\"The occurrence of the events\",\"6 MONTHS\",\"Type of Vulnerability|Therapeutic changes|Toxicity during treatment|Progression to 1 and 2 years|Complete response at 1 and 2 years\",\"Unknown status\",\"Not Applicable\"\n",
      "99,\"High Dose Chemotherapy Using BeEAM for Autologous Transplant in Multiple Myeloma\",\"To estimate the response at day 100 following transplant (rate of CR)\",\"Day 100\",\"Number of patients with overall survival post-transplant|Number of patients with event-free survival|Number of patients with non-relapse mortality\",\"Completed\",\"Phase 2\"\n",
      "100,\"Safety and Efficacy of ABI-009 (Nab-rapamycin) in Combination With Pomalidomide and Dexamethasone for Relapsed and Refractory Multiple Myeloma\",\"Maximum tolerated dose.\",\"1 Cycle (28-Days)\",\"Overall response rate.|Progression free survival.|Treatment-emergent adverse events.\",\"Withdrawn\",\"Phase 1\"\n",
      "101,\"Efficacy and Safety Study of bb2121 Versus Standard Regimens in Subjects With Relapsed and Refractory Multiple Myeloma (RRMM)\",\"Progression-free Survival (PFS)\",\"Minimum of 5 years from randomization\",\"Overall Survival (OS)|Event-free Survival (EFS)|Overall Response Rate (ORR)|Minimal Residual Disease (MRD)|Complete Response (CR) Rate|Duration of Response (DOR)|Time to Response (TTR)|Adverse Events (AEs)|Pharmacokinetics- Cmax|Pharmacokinetics- tmax|Pharmacokinetics- AUC|Pharmacokinetics- t-last|Pharmacokinetics- AUC0-28days|Subject-reported outcomes as measured by European Organization for Research and Treatment of Cancer Quality-of-Life questionnaire (EORTC-QLQ-C30)|Subject-reported outcomes as measured by EuroQoL Group European Quality of Life-5 Dimensions health state classifier to 5 Levels (EQ-5D-5L) Health Questionnaire|Subject-reported outcomes as measured by European Quality of Life Multiple Myeloma Module (EORTC-QLQ-MY20)|Time to next antimyeloma treatment|Progression-free survival after next line therapy (PFS2)\",\"Active, not recruiting\",\"Phase 3\"\n",
      "102,\"VELCADE as Maintenance Treatment in Patients With Multiple Myeloma Following Autologous Peripheral Blood Stem Cell Transplantation (PBSCT)\",\"Primary endpoints are to study the safety of four cycles of VELCADE in patients with multiple myeloma following high-dose chemotherapy and autologous PBSCT.\",,\"The secondary objectives of this study are to assess the efficacy of four cycles of VELCADE at two different dose levels as maintenance treatment in patients with multiple myeloma|and detectable residual disease following high-dose chemotherapy and autologous PBSCT|to assess the 2 year progression-free survival|and to assess the 2 year overall survival.\",\"Unknown status\",\"Phase 2\"\n",
      "103,\"A Study of Real-Life Current Standards of Care in Participants With Relapsed and/or Refractory Multiple Myeloma\",\"Overall Response Rate (ORR)\",\"Up to 35 months\",\"Very Good Partial Response (VGPR) Rate|Complete Response (CR) Rate|Stringent Complete Response (sCR) Rate|Minimal Residual Disease (MRD) Negative Rate|Clinical Benefit Rate (CBR)|Duration of Response (DOR)|Time to Response (TTR)|Time to Best Response|Time to Next Treatment (TTNT)|Progression-free Survival (PFS)|Time to Progression on the Next Line of Subsequent Antimyeloma Therapy or Death, Whichever Occurs First (PFS2)|Overall Survival (OS)|Change from Baseline in Health-related Quality of Life (HRQoL) (Symptoms, Functioning, and Well-being) Assessed by European Organization for Research and Treatment of Cancer Quality-of-life Questionnaire Core 30 (EORTC-QLQ-C30) Scale Score|Change from Baseline in Health-related Quality of Life (HRQoL) (Symptoms, Functioning, and Well-being) Assessed by EuroQol Five Dimension Questionnaire 5-Level (EQ-5D-5L)|Change from Baseline in Health-related Quality of Life (HRQoL) (Symptoms, Functioning, and Well-being) Assessed by EORTC QLQ-IL39|Number of Participants with Adverse Events (AEs)|Severity of Adverse Events as Assessed by National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE)\",\"Active, not recruiting\",\n",
      "104,\"A Study of HG146 Capsule in Chinese Subjects With Relapsed and Refractory Multiple Myeloma\",\"Maximum tolerated dose of HG146\",\"Up to 3 months\",\"Peak Plasma Concentration (Cmax)|Area under the plasma concentration versus time curve (AUC)|Time of Peak Concentration (Tmax)|Half life (T1/2)|Incidence of adverse events related to treatments|Incidence of laboratory abnormalities related to treatments\",\"Recruiting\",\"Phase 1\"\n",
      "105,\"Rivaroxaban or Aspirin As Thromboprophylaxis in Multiple Myeloma\",\"Incidence of venous thromboembolic (VTE) and/or arterial thromboembolic (ATE) events in patients with Multiple Myeloma placed on the Rivaroxaban vs Aspirin after starting with Len-Dex therapy|Number of participants with treatment-related adverse events as assessed by CTCAE v6.0\",\"6 months|6 months\",\"External validation of the IMWG criteria for risk assessment of thromboembolic events in multiple myeloma patients|Assessment of correlation of between levels of biomarkers of myeloma and thrombosis with the risk of ATE or VTE\",\"Recruiting\",\"Phase 2|Phase 3\"\n",
      "106,\"Study on the Anti-tumor Activity, Safety and Pharmacology of IPH2101 in Patients With Smoldering Multiple Myeloma\",\"Rate of Patients Achieving an Objective Response\",\"from start to end of study (14 months)\",\"Safety Assessment|Pharmacodynamics of IPH2101|Secondary Anti-tumor Activity\",\"Completed\",\"Phase 2\"\n",
      "107,\"Efficacy and Safety Study of SyB L-0501 for Patients With Multiple Myeloma\",\"Complete Response (CR) Rate [Based on the Modified Southwest Oncology Group (SWOG) Criteria]\",\"Up to 36 weeks\",\"CR Rate [Based on the International Myeloma Working Group (IMWG) Criteria]|Response Rate (Based on the IMWG Criteria)|CR Rate Based on the (Bladé) Criteria|Response Rate (Based on the Bladé Criteria)|Response Rate (Based on the Modified SWOG Criteria)|Progression-Free Survival (PFS)|Time to Treatment Failure (TTF)|Duration of Response (DOR)|Overall Survival (OS)|Number of Subjects With Adverse Event, Related Adverse Event, Serious Adverse Event, and Related Serious Adverse Event|Number of Adverse Events, Related Adverse Events, Serious Adverse Events, and Related Serious Adverse Events|Number of Subjects With Abnormality (Grade ≥3) in Laboratory Test Values|Number of Abnormalities (Grade ≥3) in Laboratory Test Values|Pharmacokinetic Parameters (Cmax)|Pharmacokinetic Parameters (Tmax)|Pharmacokinetic Parameters (AUC)|Pharmacokinetic Parameters (t1/2)\",\"Terminated\",\"Phase 2\"\n",
      "108,\"Role of Osteocytes in Myeloma Bone Disease\",\"Molecular interactions between multiple myeloma and osteocytes\",\"Up to 4 years\",\"Multiple Myeloma osteocytes and tumor staging|Multiple Myeloma osteocytes and Type I collagen fragments on bone resorption\",\"Recruiting\",\n",
      "109,\"Phase II Study of Revlimid®, Oral Cyclophosphamide and Prednisone for Patients With Newly Diagnosed Multiple Myeloma\",\"Response Rate (RR) After 6 Cycles of Therapy Using the Proposed International Myeloma Working Group Uniform Response Criteria\",\"After 6 cycles\",\"Treatment Related Adverse Events Grade 3 or Higher|Quality of Life Using the FACT-G Data\",\"Completed\",\"Phase 2\"\n",
      "110,\"A Study of ION251 Administered to Patients With Relapsed/Refractory Multiple Myeloma\",\"Maximum-Tolerated Dose (MTD)|Recommended Phase 2 Dose (PR2D)\",\"Up to 28 days from the last dose of study drug in Cycle 1 (each cycle is 28 days)|Up to 28 days from the last dose of study drug\",\"Safety and Tolerability as Measured by the Incidence of TEAEs|Incidence of Abnormal Laboratory Values and Vital Signs|Cmax: Maximum Observed Concentration ION251|AUC[0-t]: Area Under the Plasma Concentration-Time Curve from Hour zero to t of ION251|t1/2: Distribution Half-life of ION251|Trough Concentration of ION251|Urine 0-24 Hour (hr) Excretion of ION251\",\"Recruiting\",\"Phase 1\"\n",
      "111,\"A Study of KRN125 in Patients With Multiple Myeloma and Malignant Lymphoma\",\"Achievement of a target of ≥ 2*10^6 CD34+ cells/kg collected during apheresis period in patients with multiple myeloma.\",\"Day 5, 6, 7\",\"Achievement of a target of ≥ 2*10^6 CD34+ cells/kg collected during apheresis period in patients with malignant lymphoma.\",\"Completed\",\"Phase 2\"\n",
      "112,\"An Efficacy and Safety Study of Bortezomib in Participants Previously Treated for Multiple Myeloma With Limited Kidney Function\",\"Percentage of Participants With Renal Compromised Multiple Myeloma by International Myeloma Working Group (IMWG) Uniform Response Criteria\",\"Week 24 or Early termination visit (30-45 days after last dose)\",\"Best Response to Treatment|Time to Progression (TTP) of Disease|Duration of Response|Eastern Cooperative Oncology Group Performance Status (ECOG PS) Score|Karnofsky Performance Status (KPS) Score|Quality of Life Assessment by QLQ C-30|Quality of Life Assessed by Euro Quality of Life (EQ-5D)|Renal Function\",\"Terminated\",\"Phase 2\"\n",
      "113,\"Dysregulation of Glutamine Activity in the Pathogenesis of Multiple Myeloma\",\"Percent enrichment of 13-Carbon in the tricarboxylic acid (TCA) cycle intermediates within bone marrow plasma cells from patients with monoclonal gammopathy of undetermined significance (MGUS) and multiple myeloma\",\"Up to 1 day\",\"Percent enrichment of 13-Carbon in the TCA cycle intermediates within bone marrow plasma from patients with MGUS and multiple myeloma|Percent enrichment of 13-Carbon in the TCA cycle intermediates within the peripheral blood plasma from patients with MGUS and multiple myeloma\",\"Recruiting\",\"Not Applicable\"\n",
      "114,\"Humanized CAR-T Cells of Anti-BCAM and Anti-CD19 Against Relapsed and Refractory Multiple Myeloma\",\"Overall response rate (ORR)|minimal residual disease（MRD）|Progression-free survival (PFS)|Overall survival (OS)\",\"2 year|2 year|2 year|2 year\",\"Safety (incidence of adverse events defined as dose-limited toxicity)|Expression of CD19 CART cells\",\"Unknown status\",\"Phase 1\"\n",
      "115,\"Two Biologically and Clinically Distinct Entities: Progressive Versus Stable Multiple Myeloma (MM) Precursor Conditions\",\"Rate of progression to active Multiple Myeloma (MM)\",\"Up to 5 years\",\"Frequency of participant conversion from MGUS/SMM to Myeloma defining genomic events|Frequency of participant conversion from MGUS/SMM to associated progressive phenotype|Rate of participant conversion from MGUS/SMM to Myeloma defining genomic events|Rate of participant conversion from MGUS/SMM to associated progressive phenotype\",\"Recruiting\",\n",
      "116,\"Functional Imaging in Multiple Myeloma -PET/CT and Diffusion Weighted Imaging in Multiple Myeloma\",\"Multiple myeloma identified as bone disease, myeloma or plasmacytoma\",\"\"\"baseline\"\"\",\"Disease heterogeneity|Early signs of bone remodeling\",\"Unknown status\",\n",
      "117,\"Zevalin for Patients With Incomplete Response to Chemo Prior to Autologous Stem Cell Transplant for Multiple Myeloma\",\"Safety and Efficacy\",\"Through day +104 following immunotherapy\",\"Time to Engraftment in Patients Who Proceed to Myeloablative Chemotherapy After Receiving 90Y Zevalin® (Ibritumomab Tiuxetan).|Degree of CD20 Expression on Plasma Cells and/or Targeting of Post-germinal Center B Cells Correlation With Toxicity, Response and Biodistribution\",\"Terminated\",\"Phase 2\"\n",
      "118,\"Antibiotic Therapy in Preventing Early Infection in Patients With Multiple Myeloma Who Are Receiving Chemotherapy\",\"Proportion of Patients Experiencing a Serious Bacterial Infection\",\"First three months of chemotherapy\",,\"Completed\",\"Phase 3\"\n",
      "119,\"Melphalan+Bortezomib as a Conditioning Regimen for Autologous and Allogeneic Stem Cell Transplants in Multiple Myeloma\",\"Progression Free Survival (PFS)\",\"End of 2 year, post transplant follow-up\",\"Overall Survival (OS) Rate|Molecular Complete Response (CR) Rates in Patients With Multiple Myeloma\",\"Completed\",\"Phase 2\"\n",
      "120,\"A Study to Assess Renal Function Response to Treatment in Patients With Relapsed Multiple Myeloma and Creatinine Clearance\",\"Creatinine levels to determinates Renal function response|Age of participants at baseline to determinates Renal function response|Weight of participants at baseline to determinates Renal function response|Gender of participants at baseline to determinates Renal function response\",\"Up to 12 months|Baseline visit|Baseline visit|Baseline visit\",\"Race of participants at Baseline|Clinical Outcome of participants with Multiple Myeloma (MM) clinical description|Renal response rate assessment in clinical practice.|Time dependent Renal response rate assessment in clinical practice.|Type of Anti-myeloma therapeutic regimens.|Multiple Myeloma (MM) response to anti-myeloma treatment|MM response to Time to Progression|MM response to Time to first response|MM response to Progression Free Survival|Adverse events (AEs)|Cost of visit to hospital/primary health care associated with anti-myeloma therapy|Number of participants with relapsed kidney function\",\"Completed\",\n",
      "121,\"RAD001 and Lenalidomide in the Treatment of Subjects With Relapsed and Relapsed/Refractory Multiple Myeloma\",\"To evaluate the safety of RAD001 when given in combination with lenalidomide and to identify the maximum tolerated dose (MTD) as well as a recommended Phase 2 dose for the combination in this patient population.\",\"2 years\",\"To evaluate the response to the combination of RAD001 and lenalidomide in subjects with multiple myeloma.|To determine the pharmacokinetics of RAD001 and lenalidomide.|To identify possible surrogate markers to better define mechanisms of action for the combination of the two drugs.\",\"Completed\",\"Phase 1\"\n",
      "122,\"Busulfan and Melphalan Conditioning in Multiple Myeloma\",\"Treatment response up to 2 months after ASCT|Safety and toxicity (frequency of grade 3 or worse toxicities) of the conditioning regimen\",\"2 months later after last patent received ASCT|2 months later after last patent received ASCT\",\"Progression free survival(PFS)|Overall survival (OS)\",\"Unknown status\",\"Phase 2\"\n",
      "123,\"Vertebral Fat Quantitative MRI as a Marker of Bone Fragility in Multiple Myeloma (MYELOMEFRAGIQUANTI)\",\"Percentage of bone marrow fat in vertebral bone marrow|Vertebral fracture severity score\",\"At the moment of the diagnosis of the vertebral fracture before treatment by vertebroplasty|At the moment of the diagnosis of the vertebral fracture before treatment by vertebroplasty\",\"Sex|Age at the diagnosis of multiple myeloma|Weight/body mass index (BMI)|Age at the moment of the vertebral fracture|Type of the monoclonal component|Serum rate of the monoclonal component|Medullary plasmacytosis|Presence of anaemia|Presence of hypercalcemia|Presence of renal failure related to myeloma|Presence of amyloidosis|Multiple myeloma stage according to the Salmon-Durie staging System|Multiple myeloma stage according to the International Staging System (ISS)|Serum rate of Lactate dehydrogenase|Salmon-Durie Plus classification|Type of bone damage on CT scan|Vertebral radiodensity\",\"Unknown status\",\n",
      "124,\"RMPT for Relapsed/Refractory Multiple Myeloma\",\"Myeloma response rate in terms of partial remission (PR) and very good partial remission (VGPR)\",\"4 years\",\"progression free survival and overall survival\",\"Completed\",\"Phase 2\"\n",
      "125,\"RAPA-201 T Cell Therapy for Relapsed, Refractory Multiple Myeloma\",\"Overall response rate\",\"One (1) year after last dose of RAPA-201 cells.\",\"Effect of therapy on disease control|Effect in Quality of Life\",\"Recruiting\",\"Phase 2\"\n",
      "126,\"Study of Bendamustine and IXAZOMIB (MLN9708) Plus Dexamethasone in Relapsed/Refractory Multiple Myeloma\",\"Maximum Tolerated Dose of Bendamustine|Objective Response Rate\",\"Six months for each dosing cohort|18 months\",\"Overall Survival (OS)|Progression Free Survival (PFS)|Cumulative Response Rates in Patients After Eight Cycles.|Duration of Response (DoR)|Number of Participants Experiencing Dose-Limiting Toxicity (DLT)\",\"Completed\",\"Phase 1|Phase 2\"\n",
      "127,\"Efficacy of Panobinostat in Patients With Relapsed and Bortezomib-refractory Multiple Myeloma\",\"Overall Response Rate (PR+nCR+CR)\",\"after eight cycyles of treatment (24 weeks)\",\"Responders to Treatment|Time to Response (Greater Than or Equal to PR) Based on Investigator Assessment|Progression-free Survival|Time to Progression|Over All Survival\",\"Completed\",\"Phase 2\"\n",
      "128,\"To Compare Conservative Management Vs. Balloon Kyphoplasty in the Treatment of VCFs in Patients With Multiple Myeloma\",\"the effect of sham procedure & conservative management alone (arm 1) versus balloon kyphoplasty (arm 2) on patient reported pain scores as assessed by VAS (at week 4)\",\"At week 4\",\"the effect of conservative management alone versus balloon kyphoplasty on patient reported pain scores as assessed by VAS (at weeks 1, 8, 12, 16, 26, year 1 and year 2)|the pain relief requirements of conservative management alone versus balloon kyphoplasty using a daily pain diary (capturing usage of pain relief by type)|the effect of conservative management alone versus balloon kyphoplasty on patient reported Quality Of Life outcomes|procedure related complications of conservative management alone versus balloon kyphoplasty|the cost utility of the conservative management alone versus the balloon kyphoplasty\",\"Terminated\",\"Not Applicable\"\n",
      "129,\"Dyspnea and Cardiotoxicity in Multiple Myeloma Patients Who Receive Carfilzomib\",\"Endothelial Function and Dyspnea Associations in Multiple Myeloma Patients\",\"2 months\",\"Cardiovascular Toxicities Associated with Changes in Carfilzomib-Induced Endothelial Function|The Affects of Carfilzomib Dose/Dosing Schedule on the Incidence of Dyspnea|Changes in Cardiovascular Physiology and Risk Factors Associated with Endothelial Function\",\"Recruiting\",\n",
      "130,\"Neurocognitive and Neuroimaging Outcomes in Older Patients With Multiple Myeloma Treated With Autologous Stem Cell Transplantation\",\"Changes in neurocognitive functions in older participants with Multiple Myeloma following high-dose (HD) chemotherapy and autologous stem cell transplantation (ASCT) assessed by initial and follow-up neurocognitive evaluation|Changes in regional brain volume and functional connectivity when baseline and follow-up MRIs are compared.\",\"up to 4 months following chemotherapy and ASCT|up to 4 months following chemotherapy and ASCT\",,\"Active, not recruiting\",\"Not Applicable\"\n",
      "131,\"Inflammatory Cytokines in Symptom Production in Multiple Myeloma\",\"Multiple myeloma module of MDASI (MDASI-MM) Questionnaire\",\"Baseline with 12 Month Longitudinal Assessment\",,\"Completed\",\n",
      "132,\"Rituximab and Cyclophosphamide in Treating Patients With High Risk, Refractory, or Relapsed Multiple Myeloma\",\"Event-free Survival|Safety of Maintenance Rituximab Following High Dose Cyclophosphamide\",\"1 year|2, 3, 6, 9, and 12 months\",\"Safety and Toxicity|Complete Response (CR) Rate and Partial Response (PR) Rate|Effect of Rituximab by Clonogenic Growth of Multiple Myeloma (MM) Progenitors and the Mechanisms by Which MM Stem Cells Are Inhibited|Overall Survival\",\"Completed\",\"Phase 2\"\n",
      "133,\"Protocol to Obtain Blood and Bone Marrow Samples for Myeloma Research\",\"Cancer cell response to molecular testing of killing cell parts.\",\"2 Years\",,\"Terminated\",\n",
      "134,\"A Study of Dabrafenib and/or Trametinib in Patients With Relapsed and/or Refractory Multiple Myeloma\",\"Overall Response Rate\",\"100 weeks\",\"Number of Participants with Severe Adverse Events\",\"Unknown status\",\"Phase 1\"\n",
      "135,\"Biomarkers in Multiple Myeloma\",\"Level of thrombin generation in newly diagnosed and untreated MM|Level of factor VIII in newly diagnosed and untreated MM|Level of D-Dimers in newly diagnosed and untreated MM|Level of pro-coagulant phospholipids in newly diagnosed and untreated MM\",\"24 months|24 months|24 months|24 months\",\"Association between biomarkers (thrombin, factor VIII, D-Dimers, pro-coagulant phospholipids) and VTE onset|Association between biomarkers (thrombin, factor VIII, D-Dimers, pro-coagulant phospholipids) and MM outcome|Evolution of biomarkers (thrombin, factor VIII, D-Dimers, pro-coagulant phospholipids) at 3 months post-treatment|Evaluation of the exposition of Apixaban (Eliquis®)\",\"Recruiting\",\"Not Applicable\"\n",
      "136,\"A Registry Study of Participants With Multiple Myeloma in Latin America\",\"Demographic Characteristics of Multiple Myeloma (MM) Participants|Number of Participants with Comorbid Conditions|General Health Status Based on Frailty Score|Eastern Cooperative Oncology Group (ECOG) Performance Status Score|Sequence of Treatments in Participants with Multiple Myeloma (MM)|Number of Participants in Each Stage of Multiple Myeloma (MM) Disease\",\"Baseline|Baseline|Approximately up to 2.7 years|Approximately up to 2.7 years|Approximately up to 2.7 years|Approximately up to 2.7 years\",\"Overall Survival (OS)|Progression-Free Survival (PFS)|Percentage of Participants with Complete Response (CR)|Percentage of Participants with Stringent Complete Response (sCR)|Duration of Response|Time to Next Treatment|Percentage of Participants who Adopted Treatment Regimens|Number of Participants with Adverse Events|Number of Participants who Underwent Different Types of Minimal Residual Disease (MRD) Tests\",\"Completed\",\n",
      "137,\"Integrating Touchscreen-based Geriatric Assessment and Frailty Screening for Adults With Multiple Myeloma\",\"Feasibility, usability, and acceptability of a tablet-based modified geriatric assessment using online questionnaires.|Physician use and perceived utility of the modified geriatric assessment\",\"Years 1-2|Years 1-2\",\"Description of treatment decision making patterns chosen by hematologists managing older patients with multiple myeloma|Description of rates of CTCAE Grade 3-5 toxicities in older adults with MM who receive treatment following a treatment decision making visit at which an mCGA is completed|Description of the relationship between the mCGA and toxicity in older adults with MM over 3 months of chemotherapy|Description of the relationship between the mCGA and dose modification and/or treatment discontinuation in older adults with MM over 3 months of chemotherapy.\",\"Completed\",\"Not Applicable\"\n",
      "138,\"A Phase II Trial of Anti-KIR in Smoldering Multiple Myeloma\",\"Response Rate\",\"1 year\",\"Count of Participants With Serious and Non-Serious Adverse Events\",\"Terminated\",\"Phase 2\"\n",
      "139,\"Study Comparing Carfilzomib, Lenalidomide, and Dexamethasone (CRd) vs Lenalidomide and Dexamethasone (Rd) in Subjects With Relapsed Multiple Myeloma\",\"Progression-free Survival (PFS)\",\"From randomization through the data cutoff date of 16 June 2014. Median follow-up time was approximately 31 months.\",\"Overall Survival|Overall Response Rate|Disease Control Rate|Duration of Response|Duration of Disease Control|Quality of Life Core Module (QLQ-C30) Global Health Status/Quality of Life Scores\",\"Completed\",\"Phase 3\"\n",
      "140,\"Clinical and Sociodemographic Characterization of Multiple Myeloma Participants With Symptomatic Relapse and/or Refractory Disease in Spain (CharisMMa Study)\",\"Percentage of MM Participants Categorized by Sociodemographic Variables at Diagnosis|Percentage of MM Participants Categorized by Clinical Variables at Diagnosis|Percentage of MM Participants Categorized by Clinical Variables at Latest Symptomatic Relapse and/or Refractory Episode\",\"Day 1|Day 1|Day 1\",\"Percentage of MM Participants With Clinical and Sociodemographic Characteristics Categorized by Treatment Selection at the Latest Symptomatic Relapse and/or Refractory Episode|Number of New Relevant Variables That Are Not Currently Collected in Clinical Records and That Could Influence in the Disease Management at Relapse|Health-Related Quality of Life (HRQOL) Based on European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire- Core 30|HRQOL Based on EORTC Multiple Myeloma Module (EORTC QLQ-MY20) Subscale Score|HRQOL Based on the Spanish Translated Version of EORTC Multiple Myeloma Module (EORTC QLQ-MY20)|Percentage of Participants With Health Care Resource Utilization (HU)\",\"Completed\",\n",
      "141,\"Induction Therapy for Multiple Myeloma With Carfilzomib, Lenalidomide,Dexamethasone,Panobinostat\",\"Phase I: Maximum Tolerated Dose (MTD)\",\"Up to 8 months\",\"Stringent Complete Remission (sCR) Rate after 4 and 8 Cycles of Treatment|Phase II: Overall Response Rate (ORR)\",\"Withdrawn\",\"Phase 1|Phase 2\"\n",
      "142,\"Lenalidomide + Azacitidine for Adaptive Immunotherapy -> Auto SCT in Multiple Myeloma\",\"Feasibility to Mobilize and Infuse Autologous Lymphocytes (ALI) After Immunomodulatory Therapy and After Stem Cell Transplant Engraftment\",\"6 months\",\"Complete Response Rate at 6 Months|Toxicity as Assessed by NCI CTCAE v3.0|Time to Progression Post Transplant|Progression-free and Overall Survival|Pre- and Post-ALI Immune Response to Cancer Testis Antigens (CTA)|CTA Expression Before and After Azacitidine Therapy\",\"Completed\",\"Not Applicable\"\n",
      "143,\"O6-benzylguanine And Carmustine in Treating Patients With Multiple Myeloma\",\"Evaluate the efficacy of O6-benzylguanine combined with carmustine in patients with previously untreated or refractory multiple myeloma.\",\"Every 6 weeks in the absence of disease progression or unacceptable toxicity. Patients receive 2 additional courses beyond attainment of best response. Patients are followed every 2 months.\",,\"Completed\",\"Phase 2\"\n",
      "144,\"Study on the Effect of Ibrutinib on High Risk Smoldering Multiple Myeloma Patients\",\"Number of Patients Without Symptomatic Myeloma\",\"up to 1 year\",\"Overall Response Rate|Bone Density Changes|PET-MRI Changes|Change in Serum Interleukin-6 (IL-6)|Change in Serum Stromal Cell-derived Factor-1 (SDF-1)|Change in Serum Receptor Activator of Nuclear-factor Kappa B Ligand (RANKL)|Change in Serum Macrophage Inflammatory Protein-1α (MIP-1α)|Change in Serum Dickkopf-1 (DKK-1)|Change in Serum C-terminal Telopeptide (CTX)|Change in Urine N-terminal Telopeptide (NTx)\",\"Terminated\",\"Phase 2\"\n",
      "145,\"Revlimid® Capsules Special Drug Use-results Survey (in Patients With Newly-diagnosed Multiple Myeloma [NDMM])\",\"Adverse Events (AEs)\",\"Up to approximately 6 months\",,\"Completed\",\n",
      "146,\"Connect® MM- The Multiple Myeloma Disease Registry\",\"Identify and summarize patterns in therapeutic regimens|Identify and summarize patterns in therapeutic regimens and patient outcomes\",\"Minimum 8 years|Minimum 8 years\",\"Summarize Effectiveness of Treatment Regimens|Summarize health-related quality of life (HRQoL) relation to treatment regimens/sequence and clinical outcomes\",\"Active, not recruiting\",\n",
      "147,\"CART-19 for Multiple Myeloma\",\"Number of Adverse Events\",\"2 years\",,\"Completed\",\"Phase 1\"\n",
      "148,\"Clinical Activity of Metformin With High-dose of Dexamethasone in Relapse Multiple Myeloma\",\"Response Rate (RR)\",\"From the date of randomization to the date of the first major documented response (CR, PR or MR) that occurs, evaluated up to 35 days after the completion of 6th treatment cycles or if the response occurs earlier.\",\"Time to progression (TTP) during treatment with metformin and HDdexa according to criteria for defining response of the International Myeloma Working Group (IMWG)|Duration of response (DOR) during treatment with metformin and HDdexa according to criteria for defining response of the International Myeloma Working Group (IMWG)|Event free survival (EFS) during treatment with metformin and HDdexa according to criteria for defining response of the International Myeloma Working Group (IMWG)\",\"Unknown status\",\"Phase 2\"\n",
      "149,\"A Study to Evaluate 3 Dose Schedules of Daratumumab in Participants With Smoldering Multiple Myeloma\",\"The percentage of participants who achieve a complete response (CR)|The percentage of participants that have an event (disease progression or death) per patient-year\",\"Up to 7 years|Up to 7 years\",\"The percentage of participants who are minimal residual disease (MRD) negative|Time to next treatment (TNT)|The percentage of participants who achieve a Complete Response (CR) or a Partial Response (PR)|The median time of progression free survival (PFS)|The percentage of participants with symptomatic multiple myeloma|Response to first subsequent multiple myeloma treatment|Overall survival rate\",\"Active, not recruiting\",\"Phase 2\"\n",
      "150,\"Evaluation Study on Performance of Guided Clinical Pharmacy Consultation in Patients With Multiple Myeloma on First Oral Anticancer Treatment\",\"Observance of treatment by patients following Revlimid - Velcade - Dexamethasone protocol who had the benefit of a Guided Clinical Pharmacy Consultation|Observance of treatment by patients following Revlimid - Dexamethazone protocol who had the benefit of the Guided Clinical Pharmacy Consultation|Observance of treatment by patients following Revlimid - Velcade - Dexamethasone protocol who did not not have the benefit of a Guided Clinical Pharmacy Consultation|Observance of treatment by patients following Revlimid - Dexamethazone protocol who did not have the benefit of the Guided Clinical Pharmacy Consultation\",\"End of treatment. Day 21 +/- 5 days|End of treatment. Day 28 +/- 5 days|End of treatment. Day 21 +/- 5 days|End of treatment. Day 28 +/- 5 days\",\"Results of the self-questionnaire for patients following the Revlimid - Velcade - Dexamethasone protocol who benefitted from the guided clinical pharmacy consultation.|Results of the self-questionnaire for patients following the Revlimid - Velcade - Dexamethasone protocol who did not have the benefit of the guided clinical pharmacy consultation|Results of the self-questionnaire for patients following the Revlimid - Dexamethazone protocol who benefitted from the guided clinical pharmacy consultation|Results of the self-questionnaire for patients following the Revlimid - Dexamethazone protocol who did not have the benefit of the guided clinical pharmacy consultation|System Usability Score for patients following Revlimid - Velcade - Dexamethasone protocol who benefitted from the guided clinical pharmacy consultation.|System Usability Score for patients following Revlimid - Velcade - Dexamethasone protocol who did not have the benefit of the guided clinical pharmacy consultation.|System Usability Score for patients following Revlimid - Dexamethazone protocol who benefitted from the guided clinical pharmacy consultation.|System Usability Score for patients following Revlimid - Dexamethazone protocol who did not have the benefit of the guided clinical pharmacy consultation.|Semi-directive interview for patients following Revlimid - Velcade - Dexamethasone protocol who benefitted from the guided clinical pharmacy consultation.|Semi-directive interview for patients following Revlimid - Velcade - Dexamethasone protocol who did not have the benefit of the guided clinical pharmacy consultation.|Semi-directive interview for patients following Revlimid - Dexamethazone protocol who benefitted from the guided clinical pharmacy consultation.|Semi-directive interview for patients following Revlimid - Dexamethazone protocol who did not have the benefit of the guided clinical pharmacy consultation.|Pill-count for patients following Revlimid - Velcade - Dexamethasone protocol who benefitted from the guided clinical pharmacy consultation.|Pill-count for patients following Revlimid - Velcade - Dexamethasone protocol who did not benefit from the guided clinical pharmacy consultation.|Pill-count for patients following Revlimid - Dexamethazone protocol who benefitted from the guided clinical pharmacy consultation.|Pill-count for patients following Revlimid - Dexamethazone protocol who did not benefit from the guided clinical pharmacy consultation.|Rate of discrepancies per item in patients on Revlimid - Velcade - Dexamethasone protocol who benefitted from the Guided Clinical Pharmacy Consultation|Rate of discrepancies per item in patients on Revlimid - Velcade - Dexamethasone protocol who did not benefit from the Guided Clinical Pharmacy Consultation|Rate of discrepancies per item in patients on Revlimid - Dexamethazone protocol who benefitted from the Guided Clinical Pharmacy Consultation|Rate of discrepancies per item in patients on Revlimid - Dexamethazone protocol who did not benefit from the Guided Clinical Pharmacy Consultation\",\"Recruiting\",\"Not Applicable\"\n",
      "151,\"Study of Belantamab Mafodotin With Carfilzomib, Pomalidomide, and Dexamethasone in Relapsed Multiple Myeloma\",\"Rate of Very Good Partial Response (No Prior CAR T-Cell Therapy Cohort)|Rate of Overall Response (Prior CAR T-Cell Therapy Cohort)\",\"6-24 months|6-24 months\",\"Overall Response Rate|Minimal Residual Disease Negativity Rate|Progression-Free Survival|Overall Survival Among Participants|Frequency and Severity of Adverse Events (AEs)/ Serious Adverse Events\",\"Not yet recruiting\",\"Phase 2\"\n",
      "152,\"Phase 3 Study With Carfilzomib and Dexamethasone Versus Bortezomib and Dexamethasone for Relapsed Multiple Myeloma Patients\",\"Progression-free Survival\",\"From randomization until the data cut-off date of 10 November 2014; median follow-up time for PFS was 11.1.and 11.9 months in the bortezomib and carfilzomib arms respectively\",\"Overall Survival|Overall Response|Duration of Response|Percentage of Participants With ≥ Grade 2 Peripheral Neuropathy|Percentage of Participants With a Significant Reduction in Left Ventricular Ejection Fraction (LVEF)|Change From Baseline in Right Ventricular Fractional Area Change (FAC)|Change From Baseline in Pulmonary Artery Systolic Pressure (PASP)\",\"Completed\",\"Phase 3\"\n",
      "153,\"Multiple Myeloma and Environmental Exposure to Pesticides in the French West Indies: A Population Based Case-control Study.\",\"Measure of association between exposure to chlordecone and risk of multiple myeloma.\",\"Pesticide samples will be sent to the Reference Laboratory of Animal Ecology and Ecotoxicology in Liège once or twice a year. For a given patient, the time frame (questionnaire + and blood analyses) will be 12 months after inclusion.\",\"proportion of MM cases attributable to pesticide exposure\",\"Unknown status\",\n",
      "154,\"Multiple Myeloma Trial of Orally Administered Salmonella Based Survivin Vaccine\",\"Number of patients with dose limiting toxicity (DLT) by CTCAE, v5.0\",\"8 weeks\",\"Overall response rate according to the modified International Myeloma Working Group (IMWG) Uniform Response criteria.\",\"Active, not recruiting\",\"Phase 1\"\n",
      "155,\"Study in Patients With Untreated Multiple Myeloma and Renal Insufficiency\",\"effect of BHQ880 compared with placebo on time to first Skeletal Related Event (SRE) in patients with untreated multiple myeloma and renal insufficiency in combination with bortezomib and dexamethasone\",\"18-month median time to first SRE assumed for the placebo arm\",\"safety and tolerability of BHQ880 in combination with bortezomib and dexamethasone|Characterize the PharmacoKinetics (PK) profiles of BHQ880 and bortezomib|Evaluate the effect of BHQ880 on bone metabolism|Determine the antimyeloma effect of BHQ880 compared to placebo when used in combination with bortezomib and dexamethasone.\",\"Completed\",\"Phase 2\"\n",
      "156,\"Feasibility Study of an ePRO Monitoring for Patients With Multiple Myeloma and Development of Item Lists\",\"Patient rated feasibility and adequacy of the item lists and symptom monitoring program|Assessment completion rate\",\"6 weeks after inclusion of the patient or after the patient used the portal 3 times, whichever came first|From the inclusion of the patient until the end of the study (ie, at maximum 12 months) or until the patient withdraws, whichever came first\",\"Completeness of questionnaires|Frequency of clinical alerts in the system\",\"Completed\",\n",
      "157,\"Palbociclib in Combination With Lenalidomide and Dexamethasone for Multiple Myeloma\",\"Establish a maximum-tolerated dose of Palbociclib, lenalidomide, and dexamethasone for patients with relapsed or refractory multiple myeloma\",\"3 years\",\"Number of subjects who demonstrate a response to Palbociclib, Lenalidomide, and dexamethasone|Survival duration without disease progression of relapsed/refractory study subjects treated with palbociclib, lenalidomide, and dexamethasone|Toxicity profile associated with the study regimen (palbociclib, lenalidomide, and dexamethasone)\",\"Terminated\",\"Phase 1\"\n",
      "158,\"CAR-T Cells in Treating Patients With Relapsed or Refractory Multiple Myeloma\",\"Number of Participants with Severe/Adverse Events as a Measure of Safety|CAR-T Cell expansion level\",\"28 days|24 months\",\"Objective response rate of complete remission and partial remission|Overall survival time\",\"Unknown status\",\"Early Phase 1\"\n",
      "159,\"Prospective Research Assessment in Multiple Myeloma: An Observational Evaluation (PREAMBLE)\",\"Overall Survival (OS) for participants with relapsed/refractory multiple myeloma (RRMM)|Overall Survival (OS) for participants with newly-diagnosed multiple myeloma (NDMM)|Progression-Free Survival (PFS) for participants with RRMM|Progression-Free Survival (PFS) for participants with NDMM\",\"Up to 5 years|Up to 8 years|Up to 5 years|Up to 8 years\",\"Treatment patterns of approved MM therapies as measured by the Response Rate for participants with RRMM|Treatment patterns of approved MM therapies as measured by the Response Rate for participants with NDMM|Healthcare resource utilization (HCRU) for participants with RRMM|Healthcare resource utilization (HCRU) for participants with NDMM|Healthcare resource utilization (HCRU) for participants with RRMM|Healthcare resource utilization (HCRU) for participants with NDMM|Patient reported outcomes as measured by EQ-5D summary index for participants with RRMM|Patient reported outcomes as measured by EQ-5D summary index for participants with NDMM|Patient reported outcomes as measured by EORTC-QLQ-C30 for participants with RRMM|Patient reported outcomes as measured by EORTC-QLQ-C30 for participants with NDMM|Patient reported outcomes as measured by EORTC-QLQ-MY20 for participants with RRMM|Patient reported outcomes as measured by EORTC-QLQ-MY20 for participants with NDMM|Incidence of Adverse Events (AEs) for participants with RRMM|Incidence of Adverse Events (AEs) for participants with NDMM\",\"Recruiting\",\n",
      "160,\"A Study of Combination Thalidomide Plus Dexamethasone Therapy vs. Dexamethasone Therapy Alone in Previously Untreated Subjects With Multiple Myeloma\",\"Time to tumor progression (TTP)\",\"Up to 3 years\",\"Number of patients who survived|Time to first symptomatic skeletal-related event (SRE)(clinical need for radiation therapy or surgery to bone)|Myeloma response rate|Number of participants with adverse events\",\"Completed\",\"Phase 3\"\n",
      "161,\"Study of Teclistamab in Combination in Elderly Patients With Multiple Myeloma\",\"Rate of very good partial response (VGPR) or better according to the IMWG criteria in patients with newly diagnosed multiple myeloma after 4 cycles of treatment with Tec-Dara or Tec-Len\",\"At the end of 4 th cycle (each cycle is 28 days), an average 4 months\",\"Treatment-emergent adverse events according to the National Cancer Institute's Common Terminology Criteria for Adverse Events (NCI CTCAE, Version 5.0).|overall response rate(PR or better) as defined by the IMWG response criteria|Very good partial response or better, defined as VGPR or CR according to the IMWG criteria at the time of data cutoff|Compleat response or better, defined as negative immunofixation of serum and urine, and disappearance of any soft tissue plasmacytomas, and <5% plasma cells in bone marrow*|Time to response|Duration of response|Time from randomization to discontinuation of therapy for any reason including death, progression or toxicity|Overall survival time|TTTF, defined as the time from the date of the first dose of study treatment to discontinuation of therapy for any reason including death, progression, toxicity|TTNT, defined as the time from date of the first dose of study treatment to the start of the next-line treatmentTime-to-next treatment|Rate of minimal residual disease (MRD)-negativity (at level of 10-5 and 10-6 by NGS) at 6 months|Rate of Sustained MRD-negativity-(at level of 10-5 and 10-6 by NGS)\",\"Not yet recruiting\",\"Phase 2\"\n",
      "162,\"Brostallicin in Treating Patients With Recurrent or Refractory Multiple Myeloma\",\"Objective Tumor Response Rate\",\"1 year\",\"Maximum Tolerated Dose of brostallicin|Time to response|Duration of Response|Time to treatment failure|Time to tumor progression|Overall Survival\",\"Completed\",\"Phase 1|Phase 2\"\n",
      "163,\"Up-front CART-BCMA With or Without huCART19 in High-risk Multiple Myeloma\",\"Adverse event reporting\",\"90 Days\",\"Adverse event reporting|Clinical outcomes after each CAR T cell regimen|Duration of Response|Progression-free Survival (PFS)|Overall Survival (OS)|Evaluate effects of huCART19 on correlative parameters of CART BCMA resistance and clonogenic multiple myeloma cells, such as the following:|Composition of investigative products|Maintenance therapy effects on persistence|In vivo CAR T cell expansion as measured by flow cytometry|In vivo CAR T cell expansion as measured by qPCR|Duration of in vivo persistence of CAR T cells.|Effects of maintenance therapy on CAR T cell pharmacokinetic parameters.|Bioactivity by multiplex cytokine analysis|Cellular composition of CAR T cell products|Immune cell phenotyping|Impact of T Cells on systemic soluble immune factors in patients\",\"Active, not recruiting\",\"Phase 1\"\n",
      "164,\"Stage I Multiple Myeloma Treatment\",\"Survival without progress\",\"every month during 6 years\",\"predictive factors of a fast evolution of multiple myeloma|Secondary effects of zolédronate\",\"Unknown status\",\"Phase 4\"\n",
      "165,\"Study of Combination PS-341 and Thalidomide in Multiple Myeloma\",\"Assess the toxicity of PS-341 combined with one of four doses of thalidomide in patients with refractory multiple myeloma\",\"until pt progresses or unexceptible toxicity\",,\"Completed\",\"Phase 1\"\n",
      "166,\"LCAR-B4822M-02 Cells in Treating Relapsed/Refractory (R/R) Multiple Myeloma\",\"Occurrence of treatment related adverse events\",\"Day 1-30 days after injection\",\"Anti-myeloma responses to LCAR-B4822M cell treatment|Anti-myeloma responses to LCAR-B38M cell treatment\",\"Unknown status\",\"Phase 1\"\n",
      "167,\"Study of the Combination of Panobinostat & Carfilzomib in Patients With Relapsed &/or Refractory Multiple Myeloma\",\"Maximum tolerated dose (MTD) of the combination of panobinostat and carfilzomib\",\"28 day cycle\",,\"Completed\",\"Phase 1\"\n",
      "168,\"Study to Assess Anti-CD38 Antibody Drug Conjugate in Relapsed or Refractory Multiple Myeloma\",\"Safety of STI-6129\",\"Baseline through study completion at up to approximately 24 months\",\"Measuring Pharmacokinetic [PK] Profile|Overall response and duration|Assess preliminary efficacy\",\"Active, not recruiting\",\"Phase 1|Phase 2\"\n",
      "169,\"Busulfan, Melphalan, Escalating Carfilzomib Conditioning Auto Stem Cell Transplantation for Multiple Myeloma (MM)\",\"36 participants evaluated for safety with treatment-related adverse events and grading by using CTCAE v4.0.|36 participants evaluated for tolerability with treatment-related adverse events and grading by using CTCAE v4.0.\",\"3 years|3 years\",\"36 participants evaluated for response to treatment by testing blood for multiple myeloma levels.|36 participants evaluated for progression by testing blood for multiple myeloma levels.|36 participants evaluated for overall survival by clinical visit or contact by phone.|36 participants evaluated for absolute neutrophil count by testing white blood cells levels.|36 participants evaluated for platelet engraftment by testing platelet count in blood cells.|36 participants evaluated by oral exam to assess mucositis events and grading levels by using CTCAE v4.0.|36 participants evaluated by the liver to assess Veno-occlusive disease and grading levels by using CTCAE v4.0.|36 participants evaluated by a physical exam to assess peripheral neuropathy and grading by using CTCAE v4.0.|36 participants evaluated for response to treatment by testing urine for multiple myeloma levels.|36 participants evaluated for progression by testing urine for multiple myeloma levels.\",\"Recruiting\",\"Phase 1|Phase 2\"\n",
      "170,\"BCMA-Targeted CAR-T Cell Therapy for Relapsed/Refractory Multiple Myeloma\",\"Adverse events that related to treatment|The response rate of BCMA CAR-T treatment in patients with relapse/refractory Multiple Myeloma that treatment by BCMA CAR-T cells therapy\",\"2 years|2 years\",\"Rate of BCMA CAR-T cells in bone marrow and peripheral blood|Quantity of BCMA CAR copies in bone marrow and peripheral blood|Quantity of clonal plasma cells in bone marrow|Levels of Cytokines in Serum|Duration of Response (DOR) of BCMA CAR-T treatment in patients with refractory/relapsed multiple myeloma|Progress-free survival(PFS) of BCMA CAR-T treatment in patients with refractory/relapsed multiple myeloma|Overall survival(OS) of BCMA CAR-T treatment in patients with refractory/relapsed multiple myeloma\",\"Recruiting\",\"Phase 1|Phase 2\"\n",
      "171,\"A Diagnostic Study of CD38-Targeted ImmunoPET of Myeloma\",\"89Zr-daratumumab PET/CT for pre-treatment multiple myeloma imaging|89Zr-daratumumab PET/CT for post-treatment multiple myeloma imaging|Prediction of response to therapy\",\"up to 3 years|up to 3 years|up to 3 years\",,\"Recruiting\",\"Phase 2\"\n",
      "172,\"Study to Assess Adverse Events and Change in Disease Activity of Intravenous (IV) Lemzoparlimab With or Without Oral/IV Dexamethasone and in Combination With Oral/IV/Subcutaneous Anti-Myeloma Regimens in Adult Participants With Multiple Myeloma\",\"Dose Limiting Toxicities (DLTs) of Lemzoparlimab With or Without Dexamethasone and in Combination With Anti-myeloma Regimens in Participants With Relapsed/Refractory (R/R) Multiple Myeloma (MM)\",\"Up to 28 days after study drug administration\",\"Percentage of Participants Achieving Best Overall Response of Documented Partial Response (PR) or Better|Progression Free Survival (PFS)|Duration of Response (DOR)|Time to Progression (TTP)\",\"Terminated\",\"Phase 1\"\n",
      "173,\"Observational Registry Study of Chinese Patients Treated With Revlimid (Lenalidomide)\",\"Progression Free Survival (PFS)|Response Rates\",\"2 years after enrollment of last patient|2 years after enrollment of last patient\",\"Overall Survival (OS)|Time to Response (TTR) and Duration of Response (DOR)|Duration of Treatment with Revlimid|Safety Profile of Revlimid\",\"Terminated\",\n",
      "174,\"VTD Followed By MPT Maintenance As a First Line Treatment For The Patients With MM Who Are Non-Transplant Candidates\",\"Response rate of VTD induction Therapy\",\"2008-02-01\",\"Response rate of VTD/MPT maintenance therapy|Progression free survival Overall survival of VTD/MPT|To evaluate toxicities of VTD/MPT\",\"Completed\",\"Phase 2\"\n",
      "175,\"A Multicenter, Open-label, Phase 1b Study of Carfilzomib, Cyclophosphamide and Dexamethasone in Newly Diagnosed Multiple Myeloma Subjects\",\"Number of Participants With Dose-limiting Toxicities (DLTs)\",\"First cycle treatment over 28-days\",\"Overall Response Rate (ORR)|Time To Response (TTR)|Number of Participants With Adverse Events\",\"Completed\",\"Phase 1\"\n",
      "176,\"Zoledronic Acid in Patients With Multiple Myeloma and Asymptomatic Biochemical Relapse\",\"Time to next need treatment\",\"6 months\",\"Time to symptom relapse|disease progression|prognostic factors|antitumour effect of ZOL|Overall survival\",\"Completed\",\"Phase 4\"\n",
      "177,\"Safety and Efficacy of BCMA-Targeted CAR-T Therapy for Relapsed/Refractory Multiple Myeloma\",\"Adverse events that related to treatment|The response rate of BCMA CAR-T treatment in patients with relapse/refractory Multiple Myeloma that treatment by BCMA CAR-T cells therapy\",\"2 years|6 months\",\"Rate of BCMA CAR-T cells in bone marrow and peripheral blood|Quantity of BCMA CAR copies in bone marrow and peripheral blood|Quantity of clonal plasma cells in bone marrow|Levels of IL-6 in Serum|Duration of Response (DOR) of BCMA CAR-T treatment in patients with refractory/relapsed Multiple Myeloma|Progress-free survival(PFS) of BCMA CAR-T treatment in patients with refractory/relapsed multiple myeloma|Overall survival(OS) of BCMA CAR-T treatment in patients with refractory/relapsed multiple myeloma\",\"Recruiting\",\"Phase 1|Phase 2\"\n",
      "178,\"A Companion Study for Studies THAL-MM-003, CC-5013-MM-009, and CC-5013-MM-010 for Subjects With Multiple Myeloma\",\"Number of Participants With Adverse Events (AE) During the Treatment Phase|Number of Participants With Adverse Events (AE) During the Extension Phase\",\"Until data cut-off of 22 Oct 2009; AEs/SAEs were recorded from informed consent to 30 days post treatment discontinuation visit. Maximum exposure to Lenalidomide treatment was 1260 days.|From 22 Oct 2009 to November 2013; AEs/SAEs were recorded from informed consent to 30 days post treatment discontinuation visit.\",\"Time to Progression|Myeloma Response Rate|Duration of Response\",\"Completed\",\"Phase 3\"\n",
      "179,\"Study of bb2121 in Multiple Myeloma\",\"Incidence of adverse events (AEs) and abnormal laboratory test results, including dose limiting toxicities (DLTs)\",\"Day 1 through Month 60\",\"Disease-specific response criteria including: overall response rate (ORR), complete response (CR), very good partial response (VGPR), and partial response (PR) according to the International Myeloma Working Group (IMWG) Uniform Response Criteria for MM.\",\"Completed\",\"Phase 1\"\n",
      "180,\"PH III Study of Lenalidomide and Dexamethasone With or Without Elotuzumab to Treat Previously Untreated Multiple Myeloma (ELO 1 Substudy)\",\"Change From Baseline to Progression of the Cell Surface Expression of CS1 From Bone Marrow-Derived Multiple Myeloma (MM) Cells\",\"From baseline (screening) to time of progression (up to approximately 54 months)\",\"Percent of Bone Marrow-Derived Multiple Myeloma (MM) Cells Expressing Cell Surface CS1 at Time of Progression|Levels of CS1 Soluble Form (sCS1) in Serum|Change From Baseline in the Levels of CS1 Soluble Form (sCS1) in Serum During Therapy and At Progression|Change From Baseline in the Number of Circulating Multiple Myeloma (MM) Cells|Change From Baseline in Cell Surface CS1 Expression Levels in Circulating Multiple Myeloma (MM) Cells|CS1 Expression Levels in Matched Samples of Bone Marrow-Derived Multiple Myeloma (MM) Cells and Circulating MM Cells\",\"Terminated\",\"Phase 3\"\n",
      "181,\"S0417 Bortezomib, Thalidomide, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma\",\"Overall Response Rate Complete Remission (CR), Remission (R), and Partial Remission (PR).\",\"1 year\",\"Toxicity Evaluation|Progression-Free Survival\",\"Terminated\",\"Phase 2\"\n",
      "182,\"Th1/Tc1 Immunotherapy Following Stem Cell Transplantation in Multiple Myeloma\",\"Number of Patients With an Adverse Event Attributable to the Investigational Therapy|Number of Participants With Progression Free Survival in Cohort A Th1 (Type 1 T Helper Cells)/Tc1 (T Cytotoxic Cells, Type 1) Rapa Prevention of Relapse|Number of Patients Who Developed a Partial Response (PR)+Complete Response (CR) in Cohort B at Any Time Point Post Therapy With PR/CR Being Maintained Until Study Completed\",\"2 months|Study completion at 22 months|Study completion at 22 months\",\"Immune Reconstitution in Recipients of Th1.(T Helper Cell) Rapa Cells.|Count of Participants With Serious and Non-serious Adverse Events Assessed by the Common Terminology Criteria in Adverse Events (CTCAE v4.0)\",\"Terminated\",\"Phase 1|Phase 2\"\n",
      "183,\"Lenalidomide and Dexamethasone With/Without Stem Cell Transplant in Patients With Multiple Myeloma\",\"Complete Response Rate\",\"3 years\",\"Overall Survival Rate (OS)|Overall Survival Rate (OS)|Progression Free Survival (PFS)|Progression Free Survival (PFS)\",\"Completed\",\"Phase 4\"\n",
      "184,\"A Study of Melphalan Flufenamide (Melflufen) Plus Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma\",\"Overall Response Rate (ORR)\",\"Patients were followed until documented progression, unacceptable toxicity, patient/physician decision to withdraw or date of death, whichever came first. Longest time to response in study recorded as 15.3 months. Longest time on treatment 35 months.\",\"Progression Free Survival (PFS)|Duration of Response|Overall Survival|Functional Status and Well-being: EORTC QLQ-C30|Functional Status and Well-being: EQ-5D-3L|Clinical Benefit Rate|Time to Response|Time to Progression\",\"Completed\",\"Phase 2\"\n",
      "185,\"Bortezomib and Thalidomide in Treating Patients With Newly Diagnosed Stage II or Stage III Multiple Myeloma\",\"Clinical Response to Treatment\",\"1-6 months\",\"Peripheral Motor and Sensory Neuropathy (Grade 2 and Higher)|Mobilization of Stem Cells in Patients Proceeding to Autologous Peripheral Stem Transplantation|The Time to Response|Quality of Life\",\"Completed\",\"Phase 2\"\n",
      "186,\"The Molecular Characterization of Multiple Myeloma at Relapse\",\"Molecular characteristics (by FISH, SNP, GEP, miRNA)\",\"0-3 years\",\"Event free survival (EFS)|Overall survival (OS)\",\"Completed\",\n",
      "187,\"Serum NGAL IN Patients With Multiple Myeloma\",\"serum Neutrophil Gelatinase-associated Lipocalin in patients with multiple myeloma\",\"baseline to 3 months\",,\"Not yet recruiting\",\n",
      "188,\"Noninvasive Detection and Assessment of Therapy Response in Multiple Myeloma Using Whole-Body MRI\",\"Detection of lesions|Assessment of therapy response|Progression Free Survival (PFS)|Overall Survival (OS)\",\"Up to 4 years|Up to 4 years|Up to 4 years|Up to 4 years\",,\"Recruiting\",\"Not Applicable\"\n",
      "189,\"Clarithromycin Plus CTd Regimen for Patients With Newly Diagnosed Multiple Myeloma\",\"Percentage of Participants With Very Good Partial Remission (VGPR) or Better\",\"up to 4 months\",\"Median Progression Free Survival (PFS) in months|2 Year Overall Survival (OS) Rate|Number of participants with adverse events\",\"Unknown status\",\"Phase 3\"\n",
      "190,\"a Clinical Research of BCMA-Targeted Prime CAR-T Cell Therapy in Relapsed/Refractory Multiple Myeloma\",\"Adverse events that related to treatment|The response rate of BCMA targeted prime CAR-T treatment in patients with relapse/refractory Multiple Myeloma that treatment by BCMA targeted prime CAR-T cells therapy\",\"2 years|2 years\",\"Rate of BCMA targeted prime CAR-T cells in bone marrow and peripheral blood|Quantity of BCMA targeted prime CAR copies in bone marrow and peripheral blood|Quantity of clonal plasma cells in bone marrow|Levels of IL-6 in Serum|Duration of Response (DOR) of BCMA targeted prime CAR-T treatment in patients with refractory/relapsed multiple myeloma|Progress-free survival(PFS) of BCMA targeted prime CAR-T treatment in patients with refractory/relapsed multiple myeloma|Overall survival(OS) of BCMA targeted prime CAR-T treatment in patients with refractory/relapsed multiple myeloma\",\"Recruiting\",\"Phase 1|Phase 2\"\n",
      "191,\"Retrospective Study to Describe Carfilzomib Use on Patients With Relapsed Multiple Myeloma in France in the Context of Carfilzomib Nominative Expanded Access and Compassionate Use\",\"Duration of carfilzomib treatment\",\"31 august 2021\",\"Time to next treatment|Progression Free survival (PFS)\",\"Completed\",\n",
      "192,\"Study of Lenalidomide/Dexamethasone With Nivolumab and Ipilimumab in Patients With Newly Diagnosed Multiple Myeloma\",\"Maximum Tolerated Dose (MTD) of Nivolumab and Ipilimumab with Dexamethasone and Lenalidomide (NILd) in Participants with Newly Diagnosed Multiple Myeloma|Adverse Events (AE) of Nivolumab and Ipilimumab with Dexamethasone and Lenalidomide (NILd) in Participants with Newly Diagnosed Multiple Myeloma\",\"28 days|Start of study drug combination up to 30 days after the last dose of drug\",\"Rate of Response of Nivolumab and Ipilimumab with Dexamethasone and Lenalidomide (NILd) in Participants with Newly Diagnosed Multiple Myeloma|Progression Free Survival (PFS) of Nivolumab and Ipilimumab with Dexamethasone and Lenalidomide (NILd) in Participants with Newly Diagnosed Multiple Myeloma|Overall Survival of Nivolumab and Ipilimumab with Dexamethasone and Lenalidomide (NILd) in Participants with Newly Diagnosed Multiple Myeloma|Duration of Response (DOR) of Nivolumab and Ipilimumab with Dexamethasone and Lenalidomide (NILd) in Participants with Newly Diagnosed Multiple Myeloma|Clinical Benefit Rate (CBR) of Nivolumab and Ipilimumab with Dexamethasone and Lenalidomide (NILd) in Participants with Newly Diagnosed Multiple Myeloma\",\"Withdrawn\",\"Phase 1\"\n",
      "193,\"A Phase II Study of Clofarabine in Patients With Relapsed or Refractory Multiple Myeloma\",\"Overall response rate (CR+PR)\",\"Every 3 months\",\"Time to response|Safety and tolerability of clofarabine|Duration of response|Time to progression\",\"Terminated\",\"Phase 2\"\n",
      "194,\"Auto Transplant High Dose Melphalan vs High Dose Melphalan+Bortezomib in Pts With Multiple Myeloma Age 65 Years or Older\",\"To compare the progression free survival of elderly patients with multiple myeloma treated with either high-dose melphalan versus high-dose melphalan and bortezomib.\",\"Participants will be followed post transplant for a minimum of 2 years, and after that may be monitored as part of the study indefinitely\",\"To compare the response rate, overall survival and toxicity of high-dose melphalan versus high-dose melphalan and bortezomib\",\"Active, not recruiting\",\"Phase 2\"\n",
      "195,\"Determining the Feasibility of MLN9708 as Maintenance After Allogeneic Stem Cell Transplant for Multiple Myeloma\",\"Number of Phase I Patients Receiving 2.3mg, 3mg, or 4mg MLN9708 Experiencing a Dose-Limiting Toxicity (DLT) to Determine the Maximum Tolerated Dose|Number of Participants With Grade 3/4/5 Serious Adverse Events and Adverse Events as a Measure of Safety of MLN9708 When Used as Maintenance After Allogeneic Stem Cell Transplant for Multiple Myeloma Multiple Myeloma\",\"Collected from day of first dose to the end of the first treatment cycle, up to 28 days|Defined as the time from Day 1 of study drug administration until 30 days after treatment completion for up to 2 years.\",\"Median Progression-Free Survival (PFS) at 2 Years Post-maintenance Therapy|Median Overall Survival (OS) at 2 Years Post-allogeneic Stem Cell Transplant (ASCT)|Number of Participants With Incidence of Chronic Graft-versus-host Disease (cGVHD) After Receiving Allogeneic Stem Cell Transplant and Maintenance With MLN9708|Number of Participants With Incidence of Acute Graft-versus-host Disease (aGVHD) After Receiving Allogeneic Stem Cell Transplant and Maintenance With MLN9708\",\"Completed\",\"Phase 2\"\n",
      "196,\"A Phase I/II Study of BI-505 in Conjunction With Autologous Stem Cell Transplant in Multiple Myeloma\",\"Phase I: Determine the safety and feasibility of administering BI-505 in conjunction with HDM+ASCT in multiple myeloma patients|Phase II: Determine the effect of BI-505 on rate of stringent complete response for multiple myeloma patients with measurable disease pre-ASCT.\",\"Adverse events will be assessed within 30 days of ASCT in the safety part of the study.|At Day 100 after ASCT\",\"Determine the effect of BI-505 on rate of stringent complete response (sCR) at day 100 in subgroups stratified according to response to initial therapy (+/- VGPR).|Determine the effect of BI-505 administered in conjunction with HDM + ASCT on IMWG response category (PR, VGPR, CR, sCR) at one year post-ASCT and progression-free survival.|Evaluate the effect of BI-505 on MRD-negative rate at day 100 and change in MRD status at day 100 compared to baseline.|Evaluate anti-myeloma effect of BI-505 monotherapy, prior to HDM + ASCT|Evaluate bone marrow immune cell composition and phenotype, including macrophage infiltration and expression of intracellular adhesion molecule (ICAM)-1 expression on multiple myeloma plasma cells, as potential biomarkers of response to BI-505|Evaluate the pharmacokinetic profile of BI-505 in this clinical setting by analysing Cmax|Evaluate the pharmacokinetic profile of BI-505 in this clinical setting by analysing Tmax|Evaluate the pharmacokinetic profile of BI-505 in this clinical setting by analysing AUC|Evaluate the pharmacokinetic profile of BI-505 in this clinical setting by analysing CL|Evaluate the pharmacokinetic profile of BI-505 in this clinical setting by analysing Vss|Evaluate the pharmacokinetic profile of BI-505 in this clinical setting by analysing t1/2\",\"Terminated\",\"Phase 1|Phase 2\"\n",
      "197,\"A Multicenter Cross-sectional Study on Mental Health of Patients With Multiple Myeloma\",\"morbidity of psychological distress in patients with multiple myeloma.\",\"Baseline (the time when the patient is enrolled to the study)\",\"morbidity of anxiety in patients with multiple myeloma.|morbidity of insomnia in patients with multiple myeloma.\",\"Recruiting\",\n",
      "198,\"Safety, Efficacy, Dose-finding Study of a Monoclonal Antibody in Patients With Multiple Myeloma\",\"Safety, pharmacokinetics and pharmacodynamics at multiple doses\",\"At the completion of each dose escalation cohort\",\"Clinical response after various doses\",\"Completed\",\"Phase 1\"\n",
      "199,\"Phase 2 Study to Evaluate the Oral Combination of Ixazomib (MLN9708) With Cyclophosphamide and Dexamethasone in Patients With Newly Diagnosed or Relapsed and/or Refractory Multiple Myeloma\",\"Combined Response Rate During the Induction Phase in Newly Diagnosed Multiple Myeloma (NDMM) Participants|Overall Response Rate (ORR) in Relapsed and/or Refractory Multiple Myeloma (RRMM) Participants\",\"Day 1 of Cycles 1-13, 28-day cycles (Up to 1 year)|Day 1 of each 28 day cycle (Up to 45 months)\",\"Number of Participants With Adverse Events (AEs), Grade 3 or Higher AEs, AEs Resulting in Treatment Discontinuation, AEs Resulting in Dose Reduction and Serious Adverse Events (SAEs) in NDMM Participants|Percentage of Participants With CR + VGPR + PR (ORR), CR, VGPR, PR and Stable Disease (SD), Progressive Disease (PD) During the Induction Phase|Percentage of Participants With CR + VGPR + PR (ORR), CR + VGPR, CR, VGPR, PR, SD and PD Throughout the Entire Treatment Period in NDMM Participants|Time to Response (TTR) in NDMM Participants During the Induction Phase|Duration of Response (DOR) in NDMM Participants|Time to Progression (TTP) in NDMM Participants|Progression Free Survival (PFS) in NDMM Participants|Number of Participants With AEs, SAEs, AEs Resulting in Discontinuation and AEs Resulting in Dose Reduction in NDMM Participants Remaining on Treatment After 13 Cycles|Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire (QLQ-C30) During the Induction Phase in NDMM Participants|Percentage of Participants With CR + VGR + PR (ORR), CR, VGPR, and PR in NDMM Participants Remaining on Treatment After 13 Cycles|Cmax: Maximum Observed Plasma Concentration for Ixazomib in NDMM Participants|Tmax: Time to First Occurrence of Cmax for Ixazomib in NDMM Participants|AUCtau: Area Under the Concentration-time Curve During a Dosing Interval for Ixazomib in NDMM Participants|Number of Participants With AEs, Grade 3 or Higher AEs, AEs Resulting in Treatment Discontinuation, AEs Resulting in Dose Reduction, SAEs in RRMM Participants|Cmax: Maximum Observed Plasma Concentration for Ixazomib in RRMM Participants|Tmax: Time to First Occurrence of Cmax for Ixazomib in RRMM Participants|AUCtau: Area Under the Concentration-time Curve During a Dosing Interval for Ixazomib in RRMM Participants|Percentage of Participants With (CR + VGPR), CR, VGPR, PR, SD and PD in RRMM Participants|Time to Response (TTR) in RRMM Participants|Duration of Response (DOR) in RRMM Participants|Time to Progression (TTP) in RRMM Participants|Progression Free Survival (PFS) in RRMM Participants|Change From Baseline in EORTC Quality of Life Questionnaire (QLQ-C30) in RRMM Participants\",\"Completed\",\"Phase 2\"\n",
      "200,\"A Study of BCMA-directed CAR-T Cells Treatment in Subjects With r/r Multiple Myeloma\",\"The Incidence of adverse events (TEAEs) within 30 days after intravenous infusion of C-CAR088\",\"30 days\",\"Overall response rate (ORR)|Progression free survival (PFS)\",\"Unknown status\",\"Phase 1\"\n",
      "201,\"D.T. PACE Versus High Dose Melphalan and Autologous Transplant in Patients With Previously Treated Multiple Myeloma\",\"1.1 To evaluate, in a randomized phase III clinical trial in previously treated multiple myeloma patients whether angio-chemotherapy with D.T. PACE may be equivalent or superior to tandem transplant.\",,,\"Completed\",\"Phase 3\"\n",
      "202,\"Safety and Efficacy of Atiprimod for Patients With Refractory Multiple Myeloma\",\"The primary objective of this study is to identify the maximum tolerated dose\",\"1 year\",\"The secondary objective of this study is to measure the pharmacokinetics of\",\"Completed\",\"Phase 1|Phase 2\"\n",
      "203,\"A Study of BCMA-directed CAR-T Cells Treatment in Subjects With r/r Multiple Myeloma\",\"Safety: The incidence of treatment-emergent adverse events (TEAEs)\",\"30 days\",\"Overall response rate (ORR)|Progression free survival (PFS)|The CART cell duration in vivo|The soluble BCMA changes in peripheral blood\",\"Unknown status\",\"Phase 1\"\n",
      "204,\"BCMA Chimeric Antigen Receptor Expressing T Cells Therapy for Relapsed/Refractory Multiple Myeloma\",\"Safety measured by occurrence of study related adverse effects defined by NCI CTCAE 5.0\",\"6 months\",\"Overall complete remission rate defined by the standard response criteria for malignant lymphoma for each arm|Duration of CAR-positive T cells in circulation\",\"Recruiting\",\"Early Phase 1\"\n",
      "205,\"Vaccination in the Peripheral Stem Cell Transplant Setting for Multiple Myeloma\",\"Multiple myeloma\",,,\"Completed\",\"Phase 1|Phase 2\"\n",
      "206,\"Protocol of the Combination of Bortezomib and Tipifarnib for Relapsed or Refractory Multiple Myeloma\",\"Adverse events based on the NCI Common Terminology Criteria (CTC) version 3.0\",\"Ongoing from start of treatment until 30 days post\",\"Laboratory tests to include: serum protein electrophoresis, quantitative immunoglobulins assay and immunofixation, 24 hour urine collection for Bence Jones protein, total proteins, and creatinine, bone marrow aspiration and analysis for plasma cells\",\"Completed\",\"Phase 1\"\n",
      "207,\"Autologous Stem Cell Transplantation and Maintenance Therapy for Multiple Myeloma\",\"Event Free Survival\",\"3 years\",\"Disease Response|Overall survival|Grade > 2 toxicities|Incidence of infections|Treatment related Mortality\",\"Terminated\",\"Phase 2\"\n",
      "208,\"A Phase 1 Study in Subjects With Relapsed or Refractory Multiple Myeloma\",\"Number of Participants Who Experienced a Dose-Limiting Toxicity (DLT)|Number of Participants With a Treatment-emergent Adverse Event (TEAE)\",\"Day 1 to Day 28|Day 1 of Cycle 1 to up to the end of Cycle 4, where each cycle is 3 weeks; up to 12 weeks.\",\"Maximum Observed Concentration (Cmax) of AMG 224|Minimum Observed Concentration (Cmin) of AMG 224|Area Under the Concentration-time Curve (AUC) of AMG 224|Clearance (CL) of AMG 224|Half-life (t1/2) of AMG 224|Best Overall Response (BOR) According to International Myeloma Working Group Uniform Response Criteria (IMWG-URC)|Time To Progression (TTP) According to International Myeloma Working Group Uniform Response Criteria (IMWG-URC)|Duration of Response (DOR) According to International Myeloma Working Group Uniform Response Criteria (IMWG-URC)|Percentage of Participants With Conversion to Minimal Residual Disease (MRD)-Negativity|Number of Participants With an Anti-AMG 224 Antibody Formation\",\"Completed\",\"Phase 1\"\n",
      "209,\"Trial of Activated Marrow Infiltrating Lymphocytes Alone or in Conjunction With an Allogeneic Granulocyte Macrophage Colony-stimulating Factor (GM-CSF)-Based Myeloma Cellular Vaccine in the Autologous Transplant Setting in Multiple Myeloma\",\"Response Rates by Blade Criteria\",\"Up to 1 year\",\"Progression-free Survival|Overall Survival|Feasibility as Measured by Participant Withdrawal or Removal|Safety as Measured by Grade 3-5 Adverse Events|Anti-tumor Immune Response|The Effect of aMILs on Osteoclastogenesis as Measured by Bone Turnover (RANKL/OPG Ratio)|The Effect of aMILs on Osteoclastogenesis as Measured by Bone Turnover (Serum C Telopeptide Levels)|The Effect of aMILs on Osteoclastogenesis as Measured by Bone Turnover (bAlkaline Phosphatase Levels)|The Effect of aMILs on Osteoclastogenesis as Measured by Bone Turnover (Osteocalcin Levels)|Effect of aMILs on Clonogenic Myeloma Precursors\",\"Completed\",\"Phase 2\"\n",
      "210,\"Evaluation of Clinical Treatment of Multiple Myeloma Based on Multi-omics\",\"Treatment toxicities:neuritis|Confirmed responses: Strictly Complete response, sCR|Confirmed responses: Complete response, CR|Confirmed responses: Very good partial response, VGPR|Confirmed responses: Partial response, PR|Confirmed responses: Minimal remission, MR|Confirmed responses: Stable disease, SD|Progressive disease, PD\",\"From registration to December,2022|From registration to December,2022|From registration to December,2022|From registration to December,2022|From registration to December,2022|From registration to December,2022|From registration to December,2022|From registration to December,2022\",\"Progression-free survival|Overall survival\",\"Enrolling by invitation\",\n",
      "211,\"A Study of KW-2478 in Combination With Bortezomib in Subjects With Relapsed and/or Refractory Multiple Myeloma\",\"To Establish the Safety, Tolerability, and RP2D (Phase 1); To Assess the Overall Response Rate in Subjects With Advanced Multiple Myeloma (Phase 2).\",\"21 day cycle, up to 52 weeks\",\"Phase 1: PK Absorption Tmax hr Day 11|Phase 1: PK Exposure Cmax ng/mL Day 11|Phase 1: PK Exposure AUC0-t hr*ng/mL Day 11|Phase 1: PK Elimination t½ hr Day 11\",\"Completed\",\"Phase 1|Phase 2\"\n",
      "212,\"ACVDL Treatment for Patients With Newly Diagnosed Multiple Myeloma\",\"Response rate\",\"4 weeks after completion of 8 treatment cycles\",\"Complete response rate|Very good partial response rate|Time to progression|Progression free survival\",\"Completed\",\"Phase 2\"\n",
      "213,\"Clinical Trial to Evaluate the Safety and Efficacy of IM21 CAR-T Cells in Patients With Relapsed and Refractory (R/R) Multiple Myeloma\",\"Incidence of adverse events (AEs)|Persistence of CAR-T cells (cell counts and cell percentage in peripheral blood and bone marrow )\",\"Up to 28 days after CAR-T cell infusion|Up to 24 weeks after CAR-T cell infusion\",\"Objective response rate (ORR)|Overall survival (OS)|Minimal residual disease（MRD）|Duration of Response (DOR)\",\"Recruiting\",\"Early Phase 1\"\n",
      "214,\"Safety and Efficacy Assessments of Osalmid in Multiple Myeloma\",\"overall response rate\",\"at week16\",\"time to progression|duration of response|progression-free survival|overall survival\",\"Unknown status\",\"Phase 1|Phase 2\"\n",
      "215,\"Sotatercept (ACE-011) With Lenalidomide or Pomalidomide and Dexamethasone in Relapsed/Refractory Multiple Myeloma\",\"Maximum Tolerated Dose of ACE-011\",\"2 years\",\"Efficacy of ACE-011|Safety of ACE-011|Pharmacodynamic measures|Pharmacodynamic markers\",\"Active, not recruiting\",\"Phase 1\"\n",
      "216,\"Study of Fluphenazine in Relapsed or Relapsed-and-Refractory Multiple Myeloma\",\"Tolerability of fluphenazine.\",\"21 day treatment cycle(s)\",\"Changes in serum and urine M-protein or free light chain concentrations determined using protein electrophoresis.\",\"Unknown status\",\"Phase 1\"\n",
      "217,\"Efficacy Study of ZD6474 to Treat Multiple Myeloma Cancer\",,,,\"Completed\",\"Phase 2\"\n",
      "218,\"Filgrastim in Treating Patients With Bortezomib-, Carfilzomib-, or IMID-Refractory Multiple Myeloma\",\"Safety of the combination of G-CSF and bortezomib-, carfilzomib-, or IMID-based treatment regimens in patients with refractory multiple myeloma.\",\"Up to 30 days after last treatment\",\"Effects of G-CSF on bone marrow and bone marrow cytokine and chemokine levels. Including: Quantification of marrow osteoblasts and CAR cells, measurement of SDF-1 (CXCL12), IL-6, BAFF, assessment of myeloma cell proliferation and survival in bone marrow|Response rate as defined by the International Myeloma Working Group (IMWG) criteria|Overall survival duration of patients treated on study|Progression-free survival of patients treated on study|Duration of response of patients treated on study\",\"Terminated\",\"Early Phase 1\"\n",
      "219,\"Lenalidomide and Pidilizumab in Treating Patients With Relapsed or Refractory Multiple Myeloma\",\"MTD of pidilizumab combined with lenalidomide defined as the dose level at which no more than one of 6 patients experiences a dose-limiting toxicity (Phase I)|Overall response rate in responding patients according to the IMWG response criteria (Phase II)\",\"28 days|Up to 30 days\",\"Time to progression|Overall survival (Phase II)|Pharmacokinetic parameters of pidilizumab in combination with lenalidomide\",\"Terminated\",\"Phase 1\"\n",
      "220,\"Clinical Study to Evaluate the Safety and Efficacy of IM21 CAR-T Cells in the Treatment of Elderly Patients With Relapsed or Refractory Multiple Myeloma\",\"Incidence of adverse events within 1 month after CAR-T cell infusion\",\"30days\",\"Objective Response Rate(ORR) at 90 days\",\"Unknown status\",\"Phase 1\"\n",
      "221,\"Cyclophosphamide, VELCADE, DOXIL, and Dexamethasone, (CVDD) in Newly Diagnosed Patients With Multiple Myeloma (MM)\",\"Phase I - Maximum Planned Dose (MPD) Level|Phase II: Overall Response Rate (ORR)\",\"9 months|Up to 6 months\",\"Phase II: Progression-Free Survival (PFS)|Phase II: Two Year Overall Survival (OS)\",\"Completed\",\"Phase 1|Phase 2\"\n",
      "222,\"Study of Iberdomide in People With Multiple Myeloma Who Have Had an Autologous Hematopoietic Stem Cell Transplant (AHCT)\",\"Complete response (CR) rate\",\"6 months\",,\"Recruiting\",\"Phase 2\"\n",
      "223,\"Multiple Myeloma Minimal Residual Disease\",\"Quantification of residual disease\",\"Residual disease is assessed up to 18 months after inclusion\",\"kinetic of variation of the residual tumor cells detected by flow cytometry method|kinetic of variation of the residual tumor cells detected by new generation sequencing method|kinetic of variation of the circulating tumor cells\",\"Completed\",\n",
      "224,\"Phase II Study of Efficacy and Safety of Lenalidomide, Subcutaneous Bortezomib and Dexamethasone Therapy for Newly Diagnosed Multiple Myeloma\",\"Overall Response Rate|Rate and Severity of Peripheral Neuropathy\",\"12 Weeks|12 Weeks\",\"Time to Progression|Progression Free Survival|Duration of Response|Overall Response\",\"Active, not recruiting\",\"Phase 2\"\n",
      "225,\"CP-751,871 Treatment For Patients With Multiple Myeloma\",\"Maximum Tolerated Dose (MTD)\",\"Baseline up to Cycle 1 (Week 4 or Week 8)\",\"Single Dose End-of-infusion Concentration (Cinf) for CP-751,871|Single Dose Area Under the Curve From Time Zero to Last Quantifiable Concentration (AUClast) for CP-751,871|Single Dose Volume of Distribution (Vz) for CP-751,871|Single Dose Plasma Decay Half-life (t1/2) for CP-751,871|Single Dose Area Under the Curve From Time Zero to Extrapolated Infinite Time [AUC (0 - ∞)] for CP-751,871|Single Dose Volume of Distribution at Steady State (Vss) for CP-751,871|Single Dose Systemic Clearance (CL) for CP-751,871|Multiple Dose Cinf for CP-751,871|Multiple Dose Minimum Observed Plasma Trough Concentration (Cmin) for CP-751,871|Pharmacodynamic-based Dose|Human Anti-human Antibody (HAHA) Response to CP-751,871|Percentage of Participants With Objective Response (OR)|Time to Disease Progression\",\"Completed\",\"Phase 1\"\n",
      "226,\"Detection of Amyloidosis in Multiple Myeloma Patients by [18F]Florbetaben Positron Emission Tomography\",\"sensitivity and specificity per patient analysis\",\"Up to 6 months after [18F]Florbetaben PET/CT scanning\",\"sensitivity and specificity per organ analysis|Correlation with severity|Adverse events\",\"Completed\",\"Not Applicable\"\n",
      "227,\"Overcoming Chemotherapy Resistance In Refractory Multiple Myeloma With Simvastatin and Zoledronic Acid\",\"Change in Paraprotein Level and Free Light Chain (FLC) Ratio From Baseline Measurement\",\"4 weeks after treatment begins\",\"Overall Survival|Duration of Response|Progression Free Survival (PFS)|Duration of Response|Duration of Response|Incidence Rate of Toxicity|Comparison of Quality of Life Scores\",\"Terminated\",\"Not Applicable\"\n",
      "228,\"Institut Paoli Calmettes Multiple Myeloma Database\",\"Survival of patients\",\"10 years\",\"Collection of patients characteristics\",\"Recruiting\",\n",
      "229,\"A Study of Denosumab in Multiple Myeloma Patients With Renal Insufficiency\",\"Percent Change Of sCTX Levels\",\"2 years\",\"Percent Change In Bone Mineral Density|Percent Change In uNTX Levels|Subject Incidence Of Hypocalcemia|Subject Incidence Of Occurrence Of Documented SRE At 12 Months|Subject Incidence Of Adverse Events|Percent Change In Bone Turnover Markers\",\"Unknown status\",\"Phase 2\"\n",
      "230,\"TKI258 in Subjects With Refractory or Relapsed Multiple Myeloma\",\"Maximum tolerated dose|Dose limiting toxicity|Safety profile\",,\"Evaluation of pharmacokinetics and pharmacodynamics\",\"Terminated\",\"Phase 1\"\n",
      "231,\"Study of Plitidepsin (Aplidin®) in Combination With Bortezomib and Dexamethasone in Patients With Multiple Myeloma\",\"Recommended Dose of Plitidepsin in Combination With Bortezomib and Dexamethasone|Recommended Dose of Bortezomib in Combination With Plitidepsin and Dexamethasone|Recommended Dose of Dexamethasone in Combination With Plitidepsin and Bortezomib|Number of Participants Who Experienced Dose-Limiting Toxicities (DLTs)\",\"After 28-day cycle|After 28-day cycle|After 28-day cycle|After 28-day cycle\",\"Response According to International Myeloma Working Group Criteria|Overall Response Rate|Duration of Response|Time to Progression|Time to Progression Rates|Progression-free Survival|Progression-free Survival Rates|Event-free Survival|Event-free Survival Rates\",\"Completed\",\"Phase 1\"\n",
      "232,\"Carfilzomib and Lenalidomide With Dexamethasone Combination in Newly Diagnosed, Previously Untreated Multiple Myeloma\",\"The Maximum Tolerated Dose (MTD) of Carfilzomib|The Percentage of Patients That Achieve a Response to Treatment\",\"6 Months|4 Months After Treatment Start\",\"The Percentage of Patients Alive Without Progression\",\"Completed\",\"Phase 1|Phase 2\"\n",
      "233,\"Safety and Efficacy of Anti-BCMA/GPRC5D CAR-T Cell Therapy in Treating Relapsed and Refractory Multiple Myeloma(rr/MM)\",\"Number of participants with Adverse Events, with abnormal vital signs, abnormal physical examination findings, abnormal laboratory test results, abnormal ECGs and abnormal echocardiograms.\",\"12 months\",\"overall response rate (ORR) according to the International Myeloma Working Group (IMWG) Uniform Response Criteria for MM|complete response (CR) according to the International Myeloma Working Group (IMWG) Uniform Response Criteria for MM|very good partial response (VGPR) according to the International Myeloma Working Group (IMWG) Uniform Response Criteria for MM|partial response (PR) according to the International Myeloma Working Group (IMWG) Uniform Response Criteria for MM\",\"Recruiting\",\"Phase 2\"\n",
      "234,\"Dose Escalation Study of I-131-CLR1404 in Patients With Relapsed or Refractory Multiple Myeloma\",\"Number of participants with dose limiting toxicities (DLT)\",\"up to 85 days\",\"Identification of recommended phase 2 dose of I-131-CLR1404 with concurrent weekly dexamethasone|Identification of recommended phase 2 dose of I-131-CLR1404 without dexamethasone|Identify the recommended dosing schedule of I-131-CLR1404, in relapsed or refractory MM\",\"Completed\",\"Phase 1\"\n",
      "235,\"Phase I/II Study of hLL1 in Multiple Myeloma\",\"safety and tolerability of hLL1 administered twice weekly for 4 consecutive weeks\",\"first 12 weeks, then over 2 years\",\"The secondary objectives are to obtain information on efficacy, pharmacodynamics, pharmacokinetics, and immunogenicity, and to determine the optimal dose for subsequent studies.\",\"Completed\",\"Phase 1|Phase 2\"\n",
      "236,\"Study of Ciforadenant in Combination With Daratumumab in Patients With Relapsed or Refractory Multiple Myeloma\",\"Safety and tolerability of ciforadenant in combination with daratumumab relapsed / refractory multiple myeloma.|Safety and tolerability of ciforadenant in combination with daratumumab relapsed / refractory multiple myeloma.\",\"From start of treatment to end of treatment, up to 24 months|28 days following first administration of ciforadnenat in combination with daratumumab\",\"Overall response rate.|Duration of response.|Disease control rate.|Time to next therapy.|Progression free survival.|Minimal Residual Disease.\",\"Completed\",\"Phase 1\"\n",
      "237,\"Total Marrow Irradiation With High Dose Melphalan Prior to Autologous Transplant for Relapsed or Refractory Multiple Myeloma (BMT-03)\",\"Maximum tolerated dose of TMI\",\"Up to 60 days post-transplant.\",\"Progression Free Survival\",\"Completed\",\"Phase 1\"\n",
      "238,\"Carfilzomib, Clarithromycin (Biaxin®), Lenalidomide (Revlimid®), and Dexamethasone (Decadron®) [Car-BiRD] Therapy for Subjects With Multiple Myeloma\",\"Response to Car-BiRD Treatment.\",\"From baseline to best response, up to 116 weeks.\",\"Event Free Survival|MRD Negativity Following CarBiRD Regimen|Progression Free Survival|Stem Cells Collection\",\"Active, not recruiting\",\"Phase 2\"\n",
      "239,\"Lenalidomide Maintenance Therapy for Multiple Myeloma\",\"Longitudinal Assessment of T Cell (Cluster of Differentiation 4 (CD4), Cluster of Differentiation 8 (CD8), Natural Killer T-cell (NKT) and Natural Killer (NK) Cell Counts\",\"participants were followed for the duration of their treatment, an average of 2 years\",\"Number of Participants With Serious and Non-serious Adverse Events|Duration of Response|Progression Free Survival (PFS)|Natural Killer (NK) Cell Function and Activity|Changes in B Cell Subsets, Myeloid Derived Suppressor Cells and T Regulatory Cells by Phenotypic Analysis During the Course of Therapy|Expression of Cereblon (CRBN) and How it Relates to Natural Killer (NK) Cell Number and Activity\",\"Terminated\",\"Phase 2\"\n",
      "240,\"A Study of Carfilzomib, Lenalidomide, Vorinostat, and Dexamethasone in Relapsed and/or Refractory Multiple Myeloma\",\"Safety and dose of carfilzomib, lenalidomide, vorinostat and dexamethasone for MM\",\"12 months\",\"Overall response rate (ORR) Time to next treatment (TTNT) Time to progression (TTP) Duration of response (DOR\",\"Active, not recruiting\",\"Phase 1|Phase 2\"\n",
      "241,\"Vorinostat,Lenalinomide and Dexamethasone in Multiple Myeloma Refractory to Previous Lenalinomide Containing Regimens\",\"Overall Response Rate (PR or Better) of Vorinostat in Combination With Lenalidomide and Dexamethasone in Patients With Relapsed/Refractory MM Refractory to a Previous Lenalidomide Containing Regimen\",\"On treatment portion of study is completed after 12 cycles (each cycle is 28 days in duration) and one month of follow up. Patients may be followed for up to two years after last dose of lenalidomide and vorinostat for disease status and survival.\",,\"Completed\",\"Phase 1|Phase 2\"\n",
      "242,\"Study of Velcade® and Bone Formation in Patients With Relapsed/Refractory Multiple Myeloma\",\"Number of Participants With a Positive Response to Bortezomib Measured by the Bone Marker Parathyroid Hormone|Number of Participants With a Positive Response to Bortezomib Measured by Bone Markers Like Calcium|Number of Participants With a Positive Response to Bortezomib Measured by Bone Marker Alkaline Phosphatase|Number of Participants With a Positive Response to Bortezomib Measured by Bone Markers Like Magnesium|Number of Participants With a Positive Response to Bortezomib Measured by Bone Markers Like Phosphate.\",\"6 months|6 months|6 months|6 months|6 months\",\"Number of Participants With a Positive Response to Bortezomib Measured by Bone Marker Osteocalcin\",\"Terminated\",\"Phase 2\"\n",
      "243,\"Auto-Allo Tandem Stem Cell Transplantation for Patients With Multiple Myeloma\",\"Event-free survival 4 years after auto-allo/ auto-auto Tandem-SCT. Any of the following will be considered an endpoint event: recurrence or progression of primary disease, disease related mortality, or treatment related mortality.\",\"four years after Tandem stem cell transplantation\",\"Incidence of acute GvHD|Incidence of chronic GvHD|Toxicity of conditioning regimen and of maintenance therapy|cumulative incidence of relapse|Disease related mortality|Treatment related mortality|overall survival\",\"Unknown status\",\"Phase 2\"\n",
      "244,\"Effect of AT7519M Alone and AT7519M Plus Bortezomib in Patients With Previously Treated Multiple Myeloma\",\"To evaluate the clinical efficacy of AT7519M alone or in combination with bortezomib\",\"Subjects with be followed until disease progression (an average of 4 cycles per subject. i.e an average of 84 days)\",\"Assess the type, incidence and severity of clinically significant treatment emergent adverse events as assessed by National Cancer Institute - Common Terminology Criteria for Adverse Events (NCI-CTCAE) V 4.03|To define the pharmacokinetic profile of AT7519M and bortezomib when administered alone or in combination with bortezomib|To identify the maximum tolerated dose (MTD) of AT7519M in combination with bortezomib\",\"Completed\",\"Phase 1|Phase 2\"\n",
      "245,\"Whole Body MRI Imaging in Multiple Myeloma at 3 Tesla MRI : Added Value of Diffusion Weighted Imaging\",\"Validation\",\"2 years\",\"Therapy assessment\",\"Unknown status\",\n",
      "246,\"Phase II Clinical Trial of ITF2357 In Patients With Relapsed/Refractory Multiple Myeloma\",\"Number of patients with relapsing/refractory multiple myeloma with TEAE, included serious AE\",\"30 weeks\",\"Decrease in M protein and clinical response rate (PR plus CR according to the European Group for Blood & Marrow Transplantation - EBMT- criteria).\",\"Terminated\",\"Phase 2\"\n",
      "247,\"Engraftment Syndrome After Autologous Stem Cell Transplant: Retrospective Review in Patients With Multiple Myeloma\",\"number of patients developing Engraftment syndrome following stem cell transplant\",\"6 months post-transplant\",,\"Completed\",\n",
      "248,\"An Exploratory Study to Evaluate the Combination of Elotuzumab and Nivolumab With and Without Pomalidomide in Relapsed Refractory Multiple Myeloma\",\"Response Rate|Number of participants with treatment-related adverse events as assessed by CTCAE v4.0\",\"2 years|6 months\",\"The Rate of Clinical Benefit Response (CBR)|Time to Response|Duration of Response|Progression Free Survival|Overall Survival|Time to Treatment Failure\",\"Withdrawn\",\"Phase 2\"\n",
      "249,\"PHA-739358 for the Treatment of Multiple Myeloma\",\"Response Rate according to International Myeloma Working Group uniform response criteria for multiple myeloma.\",\"At end of each cycle\",\"Overall safety profile\",\"Terminated\",\"Phase 2\"\n",
      "250,\"Study of CX-4945 in Patients With Relapsed or Refractory Multiple Myeloma\",\"Safety\",\"One year (assessed at Cycle 1).\",\"Pharmacokinetic and pharmacodynamic assessments.|Assess for efficacy response|Establish the recommended Phase 2 dose\",\"Unknown status\",\"Phase 1\"\n",
      "251,\"Study of Vorinostat With Doxil and Bortezomib for Patients With Relapsed/Refractory Multiple Myeloma\",\"Estimate the overall response rate.\",\"18 months\",\"Evaluate the quality of life measures in patients.|Assess the safety and tolerability.|Estimate the overall survival.|Estimate Progression-free survival\",\"Withdrawn\",\"Phase 2\"\n",
      "252,\"Delanzomib (CEP-18770) in Combination With Lenalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma\",\"The patient's best response to treatment with CEP-18770 in combination with lenalidomide and dexamethasone|Determination of the maximum tolerated dose (MTD) of CEP-18770 in combination with lenalidomide and dexamethasone in patients with refractory or relapsed multiple myeloma\",\"Baseline to endpoint (defined as a maximum of 1 year after first administration of CEP-18770 or until disease progression)|Days 1 to 28 of cycle 1\",\"Time interval from the date of first response to the date of disease progression|Time interval from the date of first dose to the date of disease progression|Evaluation of the safety and tolerability of CEP-18770 in combination with lenalidomide and dexamethasone|Cmax pharmacokinetic parameter|tmax pharmacokinetic parameter|AUC pharmacokinetic parameter\",\"Terminated\",\"Phase 1|Phase 2\"\n",
      "253,\"Bortezomib, Doxorubicin Hydrochloride Liposome, and Dexamethasone Followed by Thalidomide and Dexamethasone With or Without Bortezomib in Treating Patients With Multiple Myeloma\",\"Disease Response\",\"2 years\",,\"Completed\",\"Phase 2\"\n",
      "254,\"Phase I/II Study of SLAMF7 FPBMC/CS-1 FPBMC in Relapsed/Refractory Multiple Myeloma\",\"Dose-limiting toxicities (DLTs)|Adverse event profile\",\"From time of informed consent through one week following 8th FPBMC infusion|From time of informed consent through 30 days following last FPBMC infusion\",\"Overall response rate (ORR)|Minimal Residual Disease (MRD) status|Overall Survival (OS)|Cellular anti-myeloma responses|Progression-free survival (PFS)|Humoral anti-myeloma responses|Lymphocyte response following infusions of SLAMF7 FPBMC\",\"Recruiting\",\"Phase 1|Phase 2\"\n",
      "255,\"Vaccination With Dendritic Cell/Tumor Fusions With Autologous Stem Cell Transplants in Patients With Multiple Myeloma\",\"To assess the toxicity associated with vaccination of multiple myeloma patients with dendritic cell/myeloma fusions and GM-CSF prior to stem cell mobilization and following high dose chemotherapy with stem cell rescue.\",\"5 years\",\"To determine whether tumor specific cellular and humoral immunity can be induced by serial vaccination with DC/tumor cell fusions in conjunction with high dose chemotherapy with stem cell rescue|To determine if vaccination with DC/tumor cell fusions results in clinical disease response in patients with evidence of residual disease post-transplant|To determine the time to disease progression in this participant population.\",\"Completed\",\"Phase 1\"\n",
      "256,\"Safety, Pharmacokinetics and Efficacy Study of Bisthianostat in Refractory or Recurrent Multiple Myeloma Patients\",\"Maximum tolerated dose of Bisthianostat|Treatment-related adverse events considered as dose-limiting toxicity\",\"Up to 24 months|During the first cycle (4 weeks)\",\"Peak Plasma Concentration (Cmax)|Area under the plasma concentration versus time curve (AUC)|Time of Peak Concentration (Tmax)|Half life (T1/2)|Objective Response Rate|Incidence of adverse events related to treatments|Incidence of laboratory abnormalities related to treatments\",\"Unknown status\",\"Phase 1\"\n",
      "257,\"Efficacy Study Comparing Velcade Dexamethasone Thalidomide Versus Velcade Cyclophosphamide Dexamethasone as Induction Treatment in the Initial Management of Multiple Myeloma (IFM2013-04)\",\"Response assessment according to the criteria IMWG\",\"15-17 month\",\"Response assessment according to the criteria IMWG|Number of Adverse Events|Number of collected stem cell|Number of death|Response assessment according to the criteria IMWG|Number of relapse according to the criteria IMWG\",\"Completed\",\"Phase 3\"\n",
      "258,\"A Study of Oral LGH447 in Patients With Relapsed and/or Refractory Multiple Myeloma\",\"Estimate the MTD and/or RDE\",\"12 months\",\"Number of participants with adverse events and serious adverse events.|Pharmacokinetic (PK) effects of LGH447|Pharmacodynamic (PD) effects of LGH447|Anti-Myeloma activity associated with LGH447|Effect of multiple-doses of LGH447 on the PK of midazolam\",\"Completed\",\"Phase 1\"\n",
      "259,\"A Study of AT9283 in Patients With Relapsed or Refractory Multiple Myeloma\",\"Overall Response Rate\",\"3 years\",\"Adverse effects of AT9283|Evaluation of potential predictive and prognostic biomarkers (marrow, blood)|Evaluation of disease-related symptoms including pain, fatigue, mucositis\",\"Completed\",\"Phase 2\"\n",
      "260,\"Level of Physical Activity and Its Associations With Fatigue and Quality of Life in Multiple Myeloma Survivors\",\"Change in the level of physical activity, occurrence of fatigue and quality of life amongst multiple myeloma survivors in the local setting\",\"1 year\",,\"Unknown status\",\n",
      "261,\"Myeloma-Developing Regimens Using Genomics (MyDRUG)\",\"Overall Response Rate - Actionable Genetic Alteration|Overall Response Rate - Non-Actionable Genetic Alteration\",\"Patients will be evaluated monthly for response from the start of the study until the date of documented disease progression, assessed up to 2 years|Patients will be evaluated monthly for response from the start of the study until the date of documented disease progression, assessed up to 2 years\",,\"Recruiting\",\"Phase 1|Phase 2\"\n",
      "262,\"Elotuzumab in Patients With Multiple Myeloma Before and After Peripheral Stem Cell Autologous Graft\",\"Maximal response rate Assesment of the International Myeloma Working Group uniform response criteria\",\"1 month after the last consolidation cure\",\"survival and progression-free survival|evaluation of the answer to the treatment to improve or maintain the response|Role of the consolidation phase in the improvement or maintenance of the response to the treatment Time before progression|Conversion from negative residual disease to positive residual disease or maintenance of a negative residual disease during all therapeutical phases|correlation between residual disease and duration of the response to the treatment|Tolerance to each phase of treatment (the induction phase, the intensive treatment, the consolidation phase)\",\"Withdrawn\",\"Phase 2\"\n",
      "263,\"Study to Compare VMP With HDM Followed by VRD Consolidation and Lenalidomide Maintenance in Patients With Newly Diagnosed Multiple Myeloma\",\"For all registered patients: progression free survival (PFS) as defined by time from registration to progression or death from any cause (whichever occurs first).|For all patients included in R1; PFS as defined by time from randomization R1 to progression or death from any cause whichever comes first|For all patients included in R2; PFS as defined by time from randomization R2 to progression or death from any cause whichever comes first\",\"end of trial (last patient last visit)|end of trial (last patient last visit)|end of trial (last patient last visit)\",\"Overall survival measured from the time of registration /randomization R1/ randomization R2. Patients still alive or lost to follow up are censored at the date they were last known to be alive.|Toxicity|Response (PR, VGPR, CR and stringent CR), and improvement of response during the various stages of the treatment.\",\"Unknown status\",\"Phase 3\"\n",
      "264,\"The Effects of Huang-Lian-Jie-Du-Tang（HLJDT) on the Survival of Patients With Multiple Myeloma in Maintain Therapy\",\"Overall survival of patients with multiple myeloma treated with Huang-Lian-Jie-Du-Tang（HLJDT) in maintain therapy\",\"6 months\",,\"Unknown status\",\"Phase 1\"\n",
      "265,\"Combination Study of Revlimid®, Velcade® Dexamethasone and Doxil® (RVDD)for Newly Diagnosed Multiple Myeloma\",\"Maximum Tolerated Dose (MTD) of Combination Therapy With VELCADE, Dexamethasone, and Doxil, (RVDD)\",\"1 month post treatment\",\"The Percentage of Patients That Achieved Partial or Complete Response to Treatment.\",\"Completed\",\"Phase 1|Phase 2\"\n",
      "266,\"Efficacy and Safety Study of 3 Thalidomide Doses for the Treatment of Relapsed Refractory Multiple Myeloma\",\"The evaluation of Independent Review Committee-documented time to progression (TTP).\",\">160 \"\"IRC confirmed\"\" disease progression in the Dexamethasone or Thalidomide 400 mg/day arms\",\"Response rate (CR + PR), according to the EBMT criteria|Response duration|Clinical benefit as measured by ECOG performance status, transfusion requirement and Grade ≥3 infections (assessed by the National Cancer Institute Common Toxicity Criteria)|Progression-free survival (PFS)|Overall survival (OS)|Composite of disease progression and death (recurrent time(s) from randomisation to disease progression and/or death)|Quality of life as determined by the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC QLQ-C30)|Adverse events (AEs)|Assessment of peripheral neuropathy|Vital signs and physical examination|Clinical laboratory tests\",\"Completed\",\"Phase 3\"\n",
      "267,\"Trial of Combination of Ixazomib and Lenalidomide and Dexamethasone in Smoldering Multiple Myeloma\",\"Proportion Of High Risk SMM Patients Who Are Progression Free 2 Years After Receiving IRD Combination Therapy\",\"2 years\",\"Progression Free Survival|Time To Progression|Duration of Response|Objective Response Rate|Overall Survival\",\"Active, not recruiting\",\"Phase 2\"\n",
      "268,\"Non-interventional Study on Time to Response and Quality of Life in Relapsed/Refractory Multiple Myeloma When Treated With Lenalidomide in Second Line\",,,,\"Completed\",\n",
      "269,\"Bortezomib, Lenalidomide, and Dexamethasone Combination Therapy for Patients With Relapsed or Relapsed and Refractory Multiple Myeloma\",\"The Proportion of Patients Alive and Without Progressive Disease (PD) for ≥6 Months\",\"6 months after therapy\",\"Objective Response Rate|Duration of Response|Progression Free Survival|Overall Survival\",\"Completed\",\"Phase 2\"\n",
      "270,\"Multi-CAR T Cell Therapy in the Treatment of Multiple Myeloma\",\"Percentage of patients with treatment related adverse effect\",\"1 month\",\"Anti-tumor activity of fourth generation multiple CAR-T cells after infusion|Anti-tumor activity of fourth generation multiple CAR-T cells in patients with relapsed or refractory MM\",\"Unknown status\",\"Phase 1|Phase 2\"\n",
      "271,\"Allogeneic Hematopoietic Stem Cell Transplantation With Ixazomib for High Risk Multiple Myeloma (BMT CTN 1302)\",\"Percentage of Participants With Progression-Free Survival\",\"12 months and 21 months post-randomization\",\"Percentage of Participants With Acute GVHD (Grades III-IV)|Percentage of Participants With Chronic GVHD|Percentage of Participants With Best Response to Treatment After Randomization|Percentage of Participants With Response to Treatment|Percentage of Participants With Disease Progression|Percentage of Participants With Overall Survival (OS)|Percentage of Participants With Treatment-Related Mortality (TRM)|Percentage of Participants With Toxicities Post-randomization by Toxicity Type|Percentage of Participants With Toxicities Post-randomization by Time Point|Percentage of Participants With Infections Post-randomization by Infection Type|Percentage of Participants With Infections Post-randomization by Time Point|Functional Assessment of Cancer Therapy (FACT) - Bone Marrow Transplant (BMT) Total Score|Medical Outcomes Study (MOS) - Short Form 36 (SF-36) Score\",\"Completed\",\"Phase 2\"\n",
      "272,\"Pomalidomide in Combination With Low-dose Dexamethasone or Pomalidomide in Combination With Low-dose Dexamethasone and Daratumumab in Subjects With Relapsed or Refractory Multiple Myeloma Following Lenalidomide-based Therapy in the First or Second Line Setting\",\"Overall response rate (ORR)\",\"Approximately 2 years\",\"Overall survival (OS)|Progression-free survival (PFS)|Duration of Response (DoR)|Time to Response (TTR)|Time to progression (TTP)|Adverse Events\",\"Active, not recruiting\",\"Phase 2\"\n",
      "273,\"Study of T Cells Targeting B-Cell Maturation Antigen for Previously Treated Multiple Myeloma\",\"Number of Participants With Dose Limiting Toxicities|Number of Participants With Serious and Non-serious Adverse Events Assessed by the Common Terminology Criteria in Adverse Events (CTCAE v4.0)\",\"After the start of treatment and up to 60 days|Date treatment consent signed to date off study, approx. 3 mos and 7 days for DL 0.3 x 10^6 CAR + T cells, 4 mos and 4 days for 1.0 x 10^6 CAR + T cells, 9 mos and 13 days for 3.0 x 10^6 CAR + T cells, and 48 mos and 12 days for 9.0 x 10^6 CAR + T cells.\",\"Number of Participants With Best Response\",\"Completed\",\"Phase 1\"\n",
      "274,\"A Phase 1/2a Dose-Finding Study of PT-112 in Patients With Relapsed or Refractory Multiple Myeloma\",\"Recommended dose (RD) of PT-112 for further studies in patients with relapsed or refractory multiple myeloma (MM)\",\"18 months\",\"Peak Plasma Concentration (Cmax)|Area under the plasma concentration versus time curve (AUC)|Dose-limiting toxicities (DLTs)|Number of patients with Adverse Events (AEs)|Tumor response, including assessment of minimal residual disease, according to the International Myeloma Working Group (IMWG) response criteria|Duration of response|Progression free survival|Relationship between sensitivity/response to treatment and disease status including cytogenetic biomarkers\",\"Completed\",\"Phase 1\"\n",
      "275,\"ACY-1215 (Ricolinostat) in Combination With Pomalidomide and Low-dose Dex in Relapsed-and-Refractory Multiple Myeloma\",\"Phase 1b: MTD and dosing schedule of ACY-1215 administered in combination with pomalidomide and low-dose dexamethasone in patients with MM|Phase 2: Overall response rate of ACY-1215 in combination with pomalidomide and dexamethasone in patients with relapsed-and-refractory multiple myeloma\",\"28 days|Every 56 days for the duration on treatment, an estimated average of 4 months\",\"Phase 1b & 2: Safety assessed by type, frequency and severity of AEs and relationship of AEs to study drug|Phase 1b and 2: Efficacy assessed by time to response, duration of response, time to progression, progression free survival, and objective response as assessed by a central adjudication committee|Phase 1b: Plasma levels of ACY-1215 and plasma levels of pomalidomide|Phase 1b: Exposure response of treatment including biomarkers relating to intracellular protein acetylation, protein levels, mRNA and microRA expression profiles.\",\"Active, not recruiting\",\"Phase 1|Phase 2\"\n",
      "276,\"A Study to Investigate the Safety and Efficacy of Belantamab for the Treatment of Multiple Myeloma When Used as Monotherapy and in Combination Treatments\",\"Part 1, 2 and 3: Number of Participants with any Adverse Event|Part 1: Number of Participants with Dose Limiting Toxicities (DLTs)|Part 1, 2 and 3: Number of Participants with Worst Case Grade Change from Baseline in Laboratory and Vital Sign Parameters|Part 2 and 3: Number of Participants with Corneal Adverse Events (CAEs)\",\"Up to 52 months|Cycle 1 (Each cycle is of 28 days)|Up to 52 months|Up to 52 months\",\"Part 1, 2 and 3: Observed Plasma Concentration of Bela|Part 1, 2 and 3: Area Under the Curve (AUC) of Bela|Part 1, 2 and 3: Maximum Concentration (Cmax) of Bela|Part 1, 2 and 3: Number of Participants with Anti-Drug Antibodies (ADA) against Bela|Part 1, 2 and 3: Titers of ADA against Bela|Part 2 and 3: Number of Participants with ADAs against Belamaf|Part 2 and 3: Titers of ADAs against Belamaf|Part 1, 2 and 3: Objective Response Rate (ORR)|Part 2 and 3: Stringent Complete Response (sCR) Rate|Part 2 and 3: Complete Response (CR) Rate|Part 2 and 3: Very Good Partial Response (VGPR) Rate|Part 2 and 3: Observed Plasma Concentration of Belamaf\",\"Not yet recruiting\",\"Phase 1|Phase 2\"\n",
      "277,\"Bone Pain in Multiple Myeloma- a Translational Study\",\"Change in bone innervation by immunohistological assessment (presence)|Change in bone innervation by immunohistological assessment (location)|Change in bone innervation by immunohistological assessment (density)|Characterization of pain in patients with firstly-diagnosed myeloma through standardized questionnaires (Brief Pain Inventory (BPI), FACT-BP(FACT-Bone Pain), PCS (Pain catastrophizing scale), painDETECT)|Characterization of quality of life in patients with firstly-diagnosed myeloma through standardized questionnaires (EORTC QLQ-C30 (core 30) , EORT QLQ-MY20 (myeloma module 20), EORTC QLQ-CIPN20 (chemotherapy-induced peripheral neuropathy module 20) )|Change in quality of life in myeloma after first-line treatment through standardized questionnaires (EORTC QLQ-C30, EORT QLQ-MY20, EORTC QLQ-CIPN20)|Change in pain in myeloma after first-line treatment through standardized questionnaires (BPI, FACT-BP, PCS, painDETECT)\",\"Change from baseline to completion of first line treatment (expected to be measured at 8 months after baseline; expected to be reported within 2 years from baseline) for patients with a positive myeloma diagnosis.|Change from baseline to completion of first line treatment (expected to be measured at 8 months after baseline; expected to be reported within 2 years from baseline) for patients with a positive myeloma diagnosis.|Change from baseline to completion of first line treatment (expected to be measured at 8 months after baseline; expected to be reported within 2 years from baseline) for patients with a positive myeloma diagnosis.|Baseline|Baseline|Change from baseline to completion of first line treatment (expected to be measured at 8 months after baseline; expected to be reported within 2 years from baseline) for patients with a positive myeloma diagnosis.|Change from baseline to completion of first line treatment (expected to be measured at 8 months after baseline; expected to be reported within 2 years from baseline) for patients with a positive myeloma diagnosis.\",\"Change in serum bone biomarkers (CTX1, P1NP) measured by ELISA|Change in inflammatory serum biomarkers measured by multiplex array.\",\"Active, not recruiting\",\n",
      "278,\"Clinical Trial of PXD101 in Patients With Advanced Multiple Myeloma\",,,,\"Completed\",\"Phase 2\"\n",
      "279,\"sdAb-based TRNT of Multiple Myeloma: a Feasibility Study\",\"Fraction of Patients (n=3) for Whom a sdAb Could be Generated That Binds to the Idiotype of the Paraprotein.|Amount of Paraprotein-targeting sdAbs Generated Per Patient\",\"Within 2 years after study completion|Within 2 years after study completion\",,\"Completed\",\"Not Applicable\"\n",
      "280,\"68Ga-pentixather and 68Ga-pentixafor PET/CT in Multiple Myeloma\",\"Metabolic parameter|PET-positive diffuse bone marrow involvement|PET-positive focal bone marrow lesions|PET-positive extramedullary lesions\",\"through study completion, an average of 2 years|through study completion, an average of 2 years|through study completion, an average of 2 years|through study completion, an average of 2 years\",\"Adverse effects|Tumor burden assessment|Follow-up assessment|CXCR4 expression in biopsies and metabolic parameters in PET\",\"Recruiting\",\"Early Phase 1\"\n",
      "281,\"Dose-Escalation Study of ABBV-838, an Antibody Drug Conjugate, in Subjects With Relapsed and Refractory Multiple Myeloma\",\"Maximum plasma concentration (Cmax) of ABBV-838|Maximum tolerated dose of ABBV-838\",\"Cycle 1 Day 1 (C1D1) and C3D1 pre- and post-dose; C1D4, C1D8, C1D15, C2D1, C2D15, C3D4, C3D8, C3D15, C4D1, and all subsequent ABBV-838 pre-dose dosing cycles|Up to 2 years from first dose of study\",\"Preliminary activity of ABBV-838 monotherapy\",\"Terminated\",\"Phase 1\"\n",
      "282,\"Post-authorisation Study of Biological Relapse in Patients With Multiple Myeloma\",\"Time to progression (TTP)\",\"Up to 38 months\",\"Race of participants at Baseline|Age of participants at Baseline|Gender of participants at Baseline|Stage of Multiple Myeloma (MM) before study entry based on the international staging system (ISS)|Time from first pathologic diagnosis|The number of Comorbidities|Concomitant treatments related to MM|ECOG performance status|Define the abnormal finding in complete blood count at base line|Define the abnormal findings within the Biochemistry panel|The time from biological progression until clinical relapse|Overall Response rate|Event-free survival (EFS)|Progression-free survival (PFS)|Overall survival (OS)|EORTC QLQ-C30 Questionnaire|QLQ-MY24 Questionnaire|Cost associated with participants visit to hospital/primary health care associated with anti-myeloma therapy|Adverse Events (AEs)\",\"Terminated\",\n",
      "283,\"PF-06863135 As Single Agent And In Combination With Immunomodulatory Agents In Relapse/Refractory Multiple Myeloma\",\"Dose Escalation: Number of participants with Dose-limiting toxicities (DLT)|To evaluate anti-myeloma activity by objective response rate (ORR) in dose expansion|To evaluate anti-myeloma activity by duration of response (DOR) in dose expansion\",\"At the end of Cycle 1 (each Cycle is 21 or 28 days)|From baseline through disease progression, patient refusal, unacceptable toxicity or study completion (approximately 2 years)|From baseline through disease progression, patient refusal, unacceptable toxicity or study completion (approximately 2 years)\",\"To evaluate incidence of treatment emergent adverse events and laboratory abnormalities|To evaluate anti-myeloma activity by objective response rate (ORR) in dose escalation|To evaluate anti-myeloma activity by time to event endpoints|To evaluate anti-myeloma activity by duration of event endpoints|Impact of treatment on systemic soluble immune factors|Maximum plasma concentration (Cmax) of PF-06863135|Trough serum concentrations of PF-06863135 and dexamethasone|Area under the concentration versus time curve from time zero to the last quantifiable time point prior to the next dose (AUClast) of PF-06863135|Incidence and titers of anti-drug antibodies and neutralizing antibodies against PF-06863135\",\"Active, not recruiting\",\"Phase 1\"\n",
      "284,\"Study Evaluating ABT-199 in Participants With Relapsed or Refractory Multiple Myeloma\",\"Number of Participants With Adverse Events|Phase 1: Maximum Observed Plasma Concentration (Cmax) of Venetoclax|Phase 1: Time to Maximum Observed Plasma Concentration (Tmax) of Venetoclax|Phase 1: Area Under the Plasma Concentration-Time Curve Over Time From 0 to 24 Hours (AUC0-24) of Venetoclax|Phase 2: Overall Response Rate|Phase 2: Very Good Partial Response Rate or Better\",\"From first dose of study drug until 30 days following last dose of study drug (up to 2482 days)|Cycle 2, Day 1 at predose, 2, 4, 6, 8, and 24 hours postdose|Cycle 2, Day 1 at predose, 2, 4, 6, 8, and 24 hours postdose|Cycle 2, Day 1 at predose, 2, 4, 6, 8, and 24 hours postdose (dose escalation cohort); (1200 mg dose): Cycle 2, Day 1 at predose (safety expansion cohort, 1200 mg dose)|Response was assessed at Cycle 2, Day 1, and on Day 1 of every cycle thereafter; estimated median time on follow-up was 31.7 months|Response was assessed at Cycle 2, Day 1, and on Day 1 of every cycle thereafter; estimated median time on follow-up was 31.7 months\",\"Phase 1: Overall Response Rate|Time to Response (TTR)|Time to Progression (TTP)|Duration of Response|Phase 2: Progression-Free Survival (PFS)|Phase 2: Overall Survival (OS)|Phase 2: Mean Change From Baseline in Brief Pain Inventory - Short Form (BPI-SF) Worst Pain|Phase 2: Mean Change From Baseline in Physical Functioning Scale of the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30)|Phase 2: Mean Change From Baseline in Global Health Status/Quality of Life Scale of the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30)|Phase 2: Mean Change From Baseline in Patient Reported Outcomes Measurement Information System [PROMIS] Cancer Fatigue Short Form [SF] Score\",\"Completed\",\"Phase 1|Phase 2\"\n",
      "285,\"A Study of Noscapine HCl (CB3304 ) in Patients With Relapsed or Refractory Multiple Myeloma\",\"To determine the maximum tolerated dose\",\"During the first 28 day treatment cycle\",\"To determine the safety and tolerability in the study population|To evaluate the pharmacokinetics of study drug|To assess anti-tumor effects as classified by International Uniform Response Criteria for Multiple Myeloma\",\"Terminated\",\"Phase 1\"\n",
      "286,\"MEDI2228 in Subjects With Relapsed/Refractory Multiple Myeloma\",\"Occurrence of adverse events (AEs)|Occurrence of SAE (serious adverse events)|Occurrence of DLTs (dose limiting toxicities)|Number of patients with changes in laboratory parameters from baseline|Number of patients with changes in vital signs from baseline|Number of patients with changes in elctrocardiogram (ECG) results from baseline\",\"From time of informed consent through 90 days post end of treatment|From time of informed consent through 90 days post end of treatment|From time of informed consent through 90 days post end of treatment|From time of informed consent and up to 21 days post end of treatment|From time of informed consent and up to 21 days post end of treatment|From time of informed consent and up to 21 days post end of treatment\",\"MEDI2228 maximum observed concentration for PK|MEDI2228 area under the concentration-time curve for PK|MEDI2228 clearance for PK|MEDI2228 terminal half-life for PK|Number of subjects who develop anti-drug antibodies (ADAs)|Objective response rate (ORR)|Clinical benefit rate|Duration of response (DoR)|Progression free survival (PFS)|Overall Survival (OS)\",\"Completed\",\"Phase 1\"\n",
      "287,\"Total Marrow Irradiation With High Dose Melphalan Prior to Autologous Transplant for Multiple Myeloma\",\"Progression Free Survival No Results Due to 1 Subject Came Off Treatment Within 7 Days and 1 Subject Came Off Treatment Within 5 Days. Not Enough Data to Analyze\",\"Up to 1 year post-transplant.\",,\"Terminated\",\"Phase 1\"\n",
      "288,\"BCMA and CD19 Targeted Fast Dual CAR-T for BCMA+ Refractory/Relapsed Multiple Myeloma\",\"Incidence and severity of adverse events after GC012F infusion\",\"up to 24 weeks after GC012F infusion\",\"Percentage of MRD negative patients after GC012F treatment|ORR (PR, VGPR, CR and sCR) of patients receive GC012F treatment|Progression free survival after GC012F treatment|Copies and cell counts of CAR in blood and bone marrow (if available) after GC012F treatment|Cytokines in serum after GC012F treatment|Subset of lymphocytes and ADA in blood after GC012F treatment|Replication competent lentivirus (RCL) in blood after GC012F treatment|Duration of response after GC012F treatment|Overall survival after GC012F treatment\",\"Recruiting\",\"Early Phase 1\"\n",
      "289,\"Bortezomib, Lenalidomide and Dexamethasone Combination Therapy in Patients With Newly Diagnosed Multiple Myeloma\",\"Objective Response Rate of the Drug Combination in This Patient Populations.\",\"Full response assessment was conducted at the end of cycle 8 (average of168 days) and after cycle 4 (84 days) for patients proceeding to transplant.\",\"Estimated 18-month Progression Free Survival (PFS) Rate|Percentage of Patients Who Remained in Response for More Than 18 Months|Estimated 18-month Overall Survival Rate\",\"Active, not recruiting\",\"Phase 1|Phase 2\"\n",
      "290,\"Cyclophosphamide With Biochemical Progression During Lenalidomide-Dexamethasone Treatment for Relapsed/Refractory Multiple Myeloma (MM)\",\"Efficacy in terms of response and survival\",\"2 years\",\"Safety in terms of hematological and non-hematological adverse events|The progression free survival (PFS)|The overall survival (OS)|Duration of time to progression (TTP)|Time to next therapy (TNT)|Identification of patient's subgroups according to specific prognostic factors\",\"Completed\",\"Phase 2\"\n",
      "291,\"BCMA-directed CAR-T Cell Therapy in Adult Patients With Multiple Myeloma\",\"Incidence of Dose limiting toxicities (DLT)|Nature of Dose limiting toxicities (DLT)|Incidence and severity of adverse events (AEs) and serious adverse events (SAEs)\",\"28 days|28 days|24 months\",\"Manufacture success rate (defined as number of subjects treated with planned target dose divided by total number of subjects treated)|Overall Response Rate (ORR)|Response rate at 3 and 6 months in Part A|Overall response rate at 3 and 6 months in Part B|Overall Complete Response Rate (CRR)|CRR at months 3 and 6 in Part A|CRR at months 3 and 6 in Part B|DOR (duration of response) in Part A|Cmax of BCMA CAR-T cells|Tmax of BCMA CAR-T cells|AUC of BCMA CAR-T cells|Clast of BCMA CAR-T cells|number of patients with pre-existing and treatment induced immunogenicity (cellular and humoral) of BCMA CAR-T cell therapy\",\"Recruiting\",\"Phase 1\"\n",
      "292,\"Clinical Decision-making, Prognosis, Quality of Life and Satisfaction in Relapsed/Refractory Multiple Myeloma\",\"The primary objective is overall survival (OS) as predicted by baseline self-reported EORTC QLQ-C30 fatigue scale ratings, independently from other prognostic factors for OS in MM, including the clinically-based prognostic frailty score.\",\"30 months from study entry\",\"To devise a patient-centered frailty score for RRMM patients.|To investigate the prognostic value of the frailty score in the setting of RRMM.|To investigate QoL over time (outcome measures: EORTC QLQ-C30 and QLQ-MY20) by type of treatment and examine factors that contribute the most in maintaining baseline QoL levels.|To investigate relationship between satisfaction with information provision (outcome measure: EORTC INFO-25) and QoL outcomes (outcome measures: EORTC QLQ-C30 and QLQ-MY20).|To assess patients' preferences for involvement in treatment decision-making and the relationships between preferences and patient characteristics.|To assess and compare the baseline self-reported EORTC QLQ-C30 fatigue scale ratings, between those RRMM patients who had received only one line of treatment (1 line) versus more than one line of treatment (>1 line) at study entry\",\"Recruiting\",\n",
      "293,\"A Study of Venetoclax and Dexamethasone Compared With Pomalidomide and Dexamethasone in Participants With Relapsed or Refractory Multiple Myeloma\",\"Progression-Free Survival (PFS)|US Specific: Overall Response Rate (ORR) per the Independent Review Committee (IRC)\",\"Up to approximately 43 months from first randomization|Up to approximately 43 months\",\"Overall Response Rate (ORR)|Very Good Partial Response or Better Response Rate (VGPR)|Overall survival (OS)|Minimal Residual Disease (MRD) Negativity Rate|Time to Deterioration in Disease Symptoms|Time to Deterioration in Physical Functioning|Change from Baseline in PROMIS Fatigue Score|Change from Baseline in BPI-SF Worst Pain Score|Change from Baseline in EuroQoL 5 Dimension 5 Level (EQ-5D-5L)|Change from Baseline in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30)|Change from Baseline in European Organization for Research and Treatment of Cancer Quality of Life Multiple Myeloma Module 20 (EORTC QLQ-MY20)|Duration of response (DOR)|Time to Disease Progression (TTP)|Time to Response (TTR)|Cmax of Venetoclax|Trough Concentration (Ctrough) of Venetoclax|Number of Participants With Adverse Events (AEs)|US Specific: Progress-Free Survival\",\"Recruiting\",\"Phase 3\"\n",
      "294,\"Protein Tyrosine Kinases (PTK) in Multiple Myeloma\",\"To determine the effectiveness of PTK in treating patients with relapsed or refractory myeloma\",,\"To evaluate the progression free survival of patients treated with PTK|to investigate the safety of PTK in patients with relapsed/refractory multiple myeloma\",\"Completed\",\"Phase 2\"\n",
      "295,\"Safety Study of Lenalidomide Maintenance Therapy Post Allogeneic HCT for High-risk Multiple Myeloma\",\"To determine tolerability and safety profile of a maximum of 12 cycles or 12 months from first dose (which ever comes first) of lenalidomide maintenance therapy post allogeneic hematopoietic cell transplantation for high risk multiple myeloma.\",\"12 months\",\"To estimate the incidences of ≥ grade 3 adverse events, graft failure, infections, treatment-related mortality (TRM) and incidence and severity of acute and chronic GVHD after initiation of lenalidomide.|To measure the overall response and best response rates to lenalidomide maintenance therapy following allogeneic HCT.|To determine time to disease progression and overall survival after lenalidomide.\",\"Completed\",\"Phase 2\"\n",
      "296,\"A Multiple Myeloma Trial in Patients With Bone Metastases\",\"The Number of Participants With a Significant Increase in Serum Creatinine at 12 Months|The Number of Participants With Disease Progression\",\"Baseline and 12 Months|24 Months\",\"The Number of Participants With a Significant Increase in Serum Creatinine at 24 Months|Time to First Significant Increase in Serum Creatinine|Zoledronic Acid Concentrations\",\"Completed\",\"Phase 4\"\n",
      "297,\"Pomalidomide in Gene Expression Profiling (GEP)-Defined High-risk Multiple Myeloma\",\"Progression-free Survival (PFS) After Initiation of Pomalidomide Therapy\",\"1 year following initiation of pomalidomide therapy\",,\"Completed\",\"Phase 2\"\n",
      "298,\"Efficacy and Safety of LBH589B in Adult Patients With Multiple Myeloma\",\"Response Rate (Complete Response(CR) / Partial Response (PR))\",\"From Start of the Study up to 57 Weeks approximately.\",\"Overall Response Rate|Clinical Benefit Rate|Duration of Response|Time to Response|Progression Free Survival (PFS)|Safety and Tolerability|Time to Peak Concentration (Tmax) of Panobinostat|Maximum Plasma Concentration (Cmax) of Panobinostat|Area Under the Plasma Concentration (AUC0-24) of Panobinostat|Last Observed Plasma Concentration (Clast) of Panobinostat|Time of Clast (Tlast) of Panobinostat\",\"Terminated\",\"Phase 2\"\n",
      "299,\"A Study Assessing the Health-Related Quality of Life (HRQoL) in Participants With Relapsed and/or Refractory Multiple Myeloma (RRMM) With Triple Class Exposure\",\"Health-Related Quality of Life (HRQoL) in specific domains: Fatigue, as measured by EORTC QLQ-C30|HRQoL in specific domains: Pain, as measured by the EORTC QLQ-C30|HRQoL in specific domains: Physical Functioning as measured by the EORTC QLQ-C30|HRQoL in specific domains: Cognitive Functioning, as measured by the EORTC QLQ-C30|HRQoL in specific domains: Global health, as measured by the EORTC QLQ-C30|HRQoL in specific domains: Disease Symptoms as measured by the EORTC QLQ-MY20|HRQoL in specific domains: Side effects as measured by the EORTC QLQ-MY20\",\"Up to 1 year|Up to 1 year|Up to 1 year|Up to 1 year|Up to 1 year|Up to 1 year|Up to 1 year\",\"HRQoL in specific domains: Functional Scale as measured by the EORTC QLQ-C30|HRQoL in specific domains: Symptoms Scale as measured by the EORTC QLQ-C30|HRQoL in specific domains: Global Health Status as measured by the EORTC QLQ-C30|HRQoL in specific domains: Future Perspective as measured by the EORTC QLQ-MY20|HRQoL in specific domains: Body Image as measured by the EORTC QLQ-MY20|HRQoL in specific domains: Generic HRQoL as measured by the EQ-5D-5L\",\"Active, not recruiting\",\n",
      "300,\"Response Adapted Therapy With Bortezomib/Dexamethasone Followed by Addition of Lenalidomide in Non Responders as Initial Treatment for Patients With Multiple Myeloma\",\"overall response rate\",\"2 years\",\"overall response rate|response|toxicity|quality of life (QOL)|progression-free survival (PFS)|Characterization of genomic mutations of targetable genes|Characterization of immunomodulatory checkpoint pathways in multiple myeloma\",\"Active, not recruiting\",\"Phase 2\"\n",
      "301,\"A Phase II Study of Belinostat in Combination With Bortezomib in Patients With Relapsed, Refractory Multiple Myeloma\",\"Objective response rate of belinostat administered in combination with bortezomib in multiple myeloma subjects who are refractory to or have relapsed from at least one prior bortezomib-containing regimen.|Safety of belinostat plus bortezomib.\",,\"Duration of response, time to response (TTR), and time to progression (TTP).|Effect on biomarkers of bone metabolism. Effect on disease-related bone pain.\",\"Terminated\",\"Phase 2\"\n",
      "302,\"SST0001 (Roneparstat) in Advanced Multiple Myeloma\",\"Maximum tolerated dose (MTD).\",\"28 days of first cycle of therapy.\",\"Adverse events, physical examination and laboratory tests.|Maximum plasma concentration (Cmax)|Time to achieve Cmax (Tmax)|Area under the concentration curve from administration to the last observed concentration time (AUClast)|Half-life (T1/2)|aPTT (Activated Partial Thromboplastin Time)|TT (Thrombin Time)|INR (International Normalized Ratio)|Tumor response.\",\"Completed\",\"Phase 1\"\n",
      "303,\"Phase 1b Study Evaluating OPomD in Relapsed or Refractory Multiple Myeloma\",\"Determine the maximum tolerated dose for each formulation of oprozomib in combination with pomalidomide and dexamethasone|Incidence of treatment-related adverse events for all subjects on continued oprozomib treatment|Incidence of treatment-emergent adverse events|Number of patients with changes in laboratory test results\",\"The primary analysis will be based on subject data collected up to 2 months from the date of last subject enrollment|Data collected up to 2 months from the date of last subject enrollment.|Data collected up to 2 months from the date of last subject enrollment.|The primary analysis will be based on subject data collected up to 2 months from the date of last subject enrollment\",\"Maximum observed concentration (Cmax)|Time to Cmax (tmax)|Area under the concentration-time curve|Overall response|Best overall response|Progression free survival|Duration of response\",\"Completed\",\"Phase 1\"\n",
      "304,\"Dendritic Cell/Myeloma Fusion Vaccine for Multiple Myeloma (BMT CTN 1401)\",\"Percentage of Participants With 1-year Response Rate of CR/sCR\",\"1 year\",\"Participants Response to Treatment|Percentage of Participants With Myeloma Progression of Vaccine and Non-vaccine Arms|Percentage of Participants With Myeloma Progression in Pairwise Analysis|Percentage of Participants With Treatment-related Mortality (TRM)|Percentage of Participants With Progression-Free Survival|Percentage of Participants With Progression-Free Survival in Pairwise Analysis|Percentage of Participants With Overall Survival|Percentage of Participants With Overall Survival in Pairwise Analysis|Number of Grade ≥ 3 Toxicities|Participants With Grade ≥ 3 Toxicities|Number of Grade 2 and 3 Infections|Percentage of Participants With Grade 2 and 3 Infections|Percentage of Participants With Grade 2 and 3 Infections in Pairwise Analysis|Number of Participants With Minimal Residual Disease (MRD)\",\"Completed\",\"Phase 2\"\n",
      "305,\"APRIL CAR T Cells (AUTO2) Targeting BCMA and TACI for the Treatment of Multiple Myeloma\",\"Phase I - Number of Subjects With Grade 3 to 5 Toxicity During the Dose Limiting Toxicity (DLT) Period|Phase I - Number of Subjects With a Dose Limiting Toxicity (DLT)|Number of Infused Patients With Best Overall Response\",\"Up to 28 days post-infusion|Up to 28 days post-infusion|Up to 2 years\",\"Proportion of Patients for Whom an AUTO2 Product Can be Generated|Clinical Benefit Rate|Duration of Response|Time to Disease Progression|Progression-free Survival|Overall Survival|Number of Patients With Expansion Followed by Persistence of RQR8/APRIL CAR Positive T Cells in the Peripheral Blood\",\"Terminated\",\"Phase 1|Phase 2\"\n",
      "306,\"Prevalence of Ocular Disorders in Multiple Myeloma (MM-OO-16)\",\"To assess prevalence of reduced visual acuity (>/= 20/40), cataract (graded according to LOCS III grading scale), dry eye, retinopathy, elevated intraocular pressure (> 21 mmHg) in patients on treatment for Multiple Myeloma\",\"12 months\",,\"Completed\",\n",
      "307,\"A Study to Assess Adverse Events and Change in Disease State of Intravenously (IV) Infused ABBV-383 of Adult Participants With Relapsed or Refractory Multiple Myeloma in Japan\",\"Number of Dose-Limiting Toxicities (DLT)|Number of Participants with Adverse Events (AE)\",\"Up to Approximately 12 Months|Up to Approximately 24 Months\",\"Objective Response Rate (ORR)|Progression Free Survival (PFS)|Time to Response (TTR)|Duration of Response (DOR)|Minimal Residual Disease (MRD) Negativity Rate\",\"Active, not recruiting\",\"Phase 1\"\n",
      "308,\"Ph I Study in Adult Patients With Relapsed or Refractory Multiple Myeloma\",\"Number of Participants with first-cycle dose limiting toxicity\",\"Time interval between the date of the first dose administration in Cycle 1 (each cycle is 28 days) and the date of the first dose administration in Cycle 2 which is expected to be 28 days or up to 42 days in case of dose delay due to toxicity\",\"Number of participants with Adverse Events (AEs)|Number of Participants by Best Tumor response|Number of Participants with Overall Response|Number of Participants with Clinical Benefit|Duration of Response|Progression Free Survival (PFS)|Maximum concentration (Cmax) of NMS-03597812 after single and multiple doses of drug|Time to maximum plasma concentration (Tmax) of NMS-03597812 after single and multiple doses of drug|Area under the plasma concentration versus time curve up to the last detectable plasma concentration (AUClast) of NMS-03597812 after single and multiple doses of drug|Minimum plasma concentration (Cmin) of NMS-03597812 after single and multiple doses of drug.|Average plasma concentration (Cave) of NMS-03597812 after multiple doses of drug|Area under the plasma concentration versus time curve to infinity (AUCinf) of NMS-03597812 after multiple doses of drug|Terminal elimination half-life (t1/2) of NMS-03597812 after multiple doses of drug|Oral plasma clearance (CL/F) of NMS-03597812 after multiple doses of drug|Apparent volume of distribution (Vd/F) of NMS-03597812 after multiple doses of drug|Accumulation ratio (Rac) of NMS-03597812 after multiple doses of drug|Renal clearance of NMS-03597812 after multiple doses of drug.|Cumulative amount recovered unchanged in the urine (Ae) of NMS-03597812 after multiple doses of drug|Cumulative amount recovered unchanged in the urine expressed as a fraction of administered dose (Ae%) of NMS-03597812 after multiple doses of drug.\",\"Recruiting\",\"Phase 1\"\n",
      "309,\"Bortezomib, Isatuximab, Cyclophosphamide and Dexamethasone Induction in Transplant-Eligible Multiple Myeloma Patients\",\"The number of subjects who achieve very good partial response.\",\"100 days following autologous stem cell transplant\",\"The number of subjects who achieve complete response.|The number of subjects who achieve partial response.\",\"Recruiting\",\"Phase 2\"\n",
      "310,\"Activated White Blood Cells With ASCT for Newly Diagnosed Multiple Myeloma\",\"Hematopoietic Engraftment|Disease Response|Feasibility of MILs Generation as Assessed by Percentage of Participants With Successful MIL Generation\",\"Up to 1 year|Up to 2 years|Up to 1 year\",\"T-cell Reconstitution as Determined by Absolute Lymphocyte Count (ALC)|Survival|Pneumococcal-specific Vaccine Responses|Anti-tumor Immune Responses\",\"Completed\",\"Phase 1|Phase 2\"\n",
      "311,\"Phase II Study of Biaxin, Revlimid, and Dexamethasone for Untreated Multiple Myeloma\",\"Response rate, time to maximum response, toxicities\",\"3 years\",,\"Completed\",\"Phase 2\"\n",
      "312,\"Thalidomide 100 mg/Day Versus Thalidomide 400 mg/Day in Relapse Refractory Multiple Myeloma\",\"all cause mortality\",\"one year\",\"response rate\",\"Completed\",\"Phase 2|Phase 3\"\n",
      "313,\"Open-label Study Comparing Iberdomide, Daratumumab and Dexamethasone (IberDd) Versus Daratumumab, Bortezomib, and Dexamethasone (DVd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM)\",\"Progression-free Survival (PFS)\",\"Up to approximately 5 years\",\"Overall Survival (OS)|Minimal Residual Disease (MRD) negativity rate|Overall Response Rate (ORR)|Time to response (TTR)|Duration of Response (DoR)|Time to Progression (TTP)|Time to Next Treatment (TTNT)|Progression-free Survival 2 (PFS2)|Safety|European Organization for Research and Treatment of Cancer - Quality of Life C30 Questionnaire (EORTC QLQ-C30)|European Quality of Life Multiple Myeloma Module (EORTC QLQ-MY20)|Recommended iberdomide dose for Stage 2|Area under the plasma concentration-time curve from time zero to tau (AUC(TAU))|Maximum plasma concentration (Cmax)|Time to maximum plasma concentration (Tmax)\",\"Recruiting\",\"Phase 3\"\n",
      "314,\"Novel Drugs After Allo-HSCT in Patients With Multiple Myeloma\",\"Overall Survival (OS)\",\"these outcome measures will be assessed at 2 year from transplant\",\"Progression Free Survival 1 (PFS1)|Progression Free Survival 2 (PFS2)|Acute Graft-versus-Host Disease (aGVHD)|Chronic Graft-versus-Host Disease (cGVHD)|Non-Relapse Mortality (NRM)\",\"Completed\",\n",
      "315,\"Study of Carfilzomib, Cyclophosphamide and Dexamethasone in Newly Diagnosed Multiple Myeloma Patients\",\"Dose Limiting Toxicity (DLT)\",\"1 year\",\"Response rate (RR)|Progression-free survival (PFS)|Time to progression (TTP)|Duration of response (DOR)|Overall survival (OS)|Time to next therapy (TTNT)|Responses|Response and survival|Maintenance|Adverse event\",\"Active, not recruiting\",\"Phase 1|Phase 2\"\n",
      "316,\"Pre-emptive Daratumumab Therapy of Minimal Residual Disease Reappearance or Biochemical Relapse in Multiple Myeloma\",\"Event Free Survival (ESF)\",\"from randomization till the date of development clinical relapse or death from any cause; up to 129 weeks\",\"Overall Response Rate|Overall Survival\",\"Recruiting\",\"Phase 2\"\n",
      "317,\"Cost-Utility Analysis of Home-based Versus Hospital-based Chemotherapy in Multiple Myeloma: Case of Carfilzomib\",\"Incremental cost-utility ratio (ICUR) expressed in euros per QALY.|Differences of quality of life in cancer patients between each group|Differences of quality of life in myeloma patients between each group|Cost of care\",\"Up to 20 months|Up to 20 months|Up to 20 months|Up to 20 month\",\"Healthcare resource utilization|Adverse events related to myeloma treatment|Patients and caregivers' satisfaction\",\"Not yet recruiting\",\"Not Applicable\"\n",
      "318,\"AE-941 in Treating Patients With Relapsed or Refractory Multiple Myeloma\",,,,\"Completed\",\"Phase 2\"\n",
      "319,\"Japanese Phase 2 Study to Evaluate the Efficacy and Safety of Pomalidomide in Subjects With Relapsed and Refractory Multiple Myeloma\",\"Myeloma Response Rate Based on the International Myeloma Working Group (IMWG) Uniform Response Criteria|Myeloma Response Rate Based on the International Myeloma Working Group (IMWG) Uniform Response Criteria (Later Cut-off Date)\",\"From the first dose until the data cut-off date of 03 Sept 2014; Maximum time in follow-up was 36.0 weeks.|From the first dose until the final data cut-off date of 25 September 2015; maximum duration on treatment was 80.9 weeks\",\"Myeloma Response Rate Based on European Group for Blood and Marrow Transplantation (EBMT) Criteria|Time to Response|Myeloma Response Rate Based on European Group for Blood and Marrow Transplantation (EBMT) Criteria (Later Cut-off Date)|Time to Response (Later Cut-off Date)|Kaplan-Meier Estimates of Duration of Response|Kaplan-Meier Estimates of Duration of Response (Later Cut-off Date)|Kaplan-Meier Estimates of Progression-free Survival (PFS)|Kaplan-Meier Estimates of PFS (Later Cut-off Date)|Number of Participants With Adverse Events\",\"Completed\",\"Phase 2\"\n",
      "320,\"Ixazomib Plus Low-dose Lenalidomide Versus Ixazomib Alone for Maintenance Treatment of High Risk Multiple Myeloma\",\"Progression-Free Survival (PFS)\",\"through study completion, a average of 1 year\",\"Very Good Partial Response (VGPR) + Complete Response (CR) Rate|Overall Survival (OS)|Percentage of Participants with Adverse Events (AEs)\",\"Recruiting\",\"Phase 4\"\n",
      "321,\"Open Label Study With Imetelstat to Determine Effect of Imetelstat in Patients w/ Previously Treated Multiple Myeloma\",\"Rate of Improvement in Response\",\"From time of first dose (Cycle 1 day 1) through end of study period (12 mos. after last participant is enrolled)\",\"Progression-free Survival (PFS)|Safety and Tolerability\",\"Completed\",\"Phase 2\"\n",
      "322,\"Study to Assess Allogeneic Anti-CD38 A2 Dimeric Antigen Receptor T Cells in Relapsed or Refractory Multiple Myeloma\",\"Safety of STI-1492\",\"Baseline through study completion at up to approximately 54 months\",\"Overall response and duration|Assessment of improvements in hypercalcemia, renal function, anemia and lytic bone lesions (CRAB criteria)|Assessment of serum immunoglobulin levels\",\"Recruiting\",\"Phase 1\"\n",
      "323,\"SU5416 in Treating Patients With Refractory or Relapsed Multiple Myeloma\",,,,\"Completed\",\"Phase 2\"\n",
      "324,\"An Efficacy Study of Pomalidomide in Patient With Multiple Myeloma in Routine Clinical Practice\",\"Progression Free Survival (PFS)\",\"Up to approximately 6 months\",\"Overall Response Rate (ORR)|Duration of Response (DOR)|Overall Survival (OS)|Time to Progression (TTP)|Time to Treatment Failure (TTF)|Adverse Events (AEs)\",\"Completed\",\n",
      "325,\"Peripheral Stem Cell Transplant in Treating Patients With Multiple Myeloma\",\"Treatment-related mortality\",\"6 months\",\"Treatment Completion Rate|Respone Rate|Chimerism Rate|GVHD Incidence|Survival|Correlation of cytogenetics and response\",\"Completed\",\"Phase 2\"\n",
      "326,\"Real-World Use of Selinexor, Daratumumab and Dexamethasone in Chinese Patients With Multiple Myeloma at First Relapse\",\"Overall Response Rate (ORR)\",\"28 days after the last therapy\",,\"Not yet recruiting\",\n",
      "327,\"MagnetisMM-4: Umbrella Study of Elranatamab (PF-06863135) in Combination With Anti-Cancer Treatments in Multiple Myeloma\",\"Sub-Study A Phase 1: Dose Limiting Toxicity|Sub-Study A Phase 2: Objective Response Rate|Sub-Study B Phase 1 Escalation: Dose Limiting Toxicity|Sub-Study B Phase 1 Expansion: Frequency of Treatment-Emergent Adverse Events|Sub-Study B Phase 1 Expansion: Frequency of Laboratory Abnormalities\",\"35 days|assessed every 4 weeks (for approximately 2 years)|42 days|assessed for approximately 2 years|assessed every cycle (each cycle approximately 28 days)\",\"Sub-Study A Phase 1: Objective Response Rate|Sub-Study A Phase 1 and Phase 2: Complete Response Rate|Sub-Study A Phase 1 and Phase 2: Time to Response|Sub-Study A Phase 1 and 2: Duration of Response|Sub-Study A Phase 1 and Phase 2: Duration of Complete Response|Sub-Study A Phase 1 and Phase 2: Progression Free Survival|Sub-Study A Phase 1 and Phase 2: Overall Survival|Sub-Study A Phase 1 and Phase 2: Minimal Residual Disease Negativity Rate|Sub-Study A Phase 1 and Phase 2: Frequency of Treatment-Emergent Adverse Events|Sub-Study A Phase 1 and Phase 2: Frequency of Laboratory Abnormalities|Sub-Study A Phase 1 and Phase 2: Immunogenicity of elranatamab in combination with nirogacestat|Sub-Study A Phase 1 and Phase 2: Concentrations of elranatamab and/or nirogacestat|Sub-Study A Phase 1: Maximum Observed Concentration (Cmax) for elranatamab|Sub-Study A Phase 1: Time to Maximum Concentration (Tmax) for elranatamab|Sub-Study A Phase 1: Area Under the Concentration versus Time Curve from Time 0 to the Last Measurable Concentration (AUClast) for elranatamab|Sub-Study B Phase 1 Escalation: Frequency of Treatment-Emergent Adverse Events|Sub-Study B Phase 1 Escalation: Frequency of Laboratory Abnormalities|Sub-Study B Phase 1 Escalation and Expansion: Objective Response Rate|Sub-Study B Phase 1 Escalation and Expansion: Complete Response Rate|Sub-Study B Phase 1 Escalation and Expansion: Time to Response|Sub-Study B Phase 1 Escalation and Expansion: Duration of Response|Sub-Study B Phase 1 Escalation and Expansion: Duration of Complete Response|Sub-Study B Phase 1 Escalation and Expansion: Progression Free Survival|Sub-Study B Phase 1 Escalation and Expansion: Overall Survival|Sub-Study B Phase 1 Escalation and Expansion: Minimal Residual Disease Negativity Rate|Sub-Study B Phase 1 Escalation and Expansion: Immunogenicity of elranatamab in combination with lenalidomide|Sub-Study B Phase 1 Escalation and Expansion: Concentrations of elranatamab and/or lenalidomide|Sub-Study B Phase 1 Escalation and Expansion: Maximum Observed Concentrations (Cmax) for elranatamab|Sub-Study B Phase 1 Escalation and Expansion: Time to Maximum Concentration (Tmax) for elranatamab|Sub-Study B Phase 1 Escalation and Expansion: Area Under the Concentration versus Time Curve from Time 0 to the Last Measurable Concentration (AUClast) for elranatamab\",\"Recruiting\",\"Phase 2\"\n",
      "328,\"Phase I/II Study of Carfilzomib, Pomalidomide and Dexamethasone in Relapsed And/Or Refractory Multiple Myeloma Patients (CPD)\",\"DLT|Partial response\",\"1 year|3 years\",\"Toxicities|PFS|TTP|DFS|DOR|TTNT|OS|Tumor response and survival\",\"Active, not recruiting\",\"Phase 1|Phase 2\"\n",
      "329,\"Mass Accumulation Rate (MAR) as a Predictive Biomarker in Multiple Myeloma\",\"Best Response 4 months\",\"0-4 months\",,\"Recruiting\",\n",
      "330,\"Rituximab, Yttrium Y 90 Ibritumomab Tiuxetan, Melphalan, and Autologous Peripheral Stem Cell Transplant in Treating Patients With Previously Treated Multiple Myeloma\",\"Toxicity as measured by CTCAE v 3.0|Clonotypic B cells\",\"19 Months|19 months\",\"Response (complete response, very good partial response, partial response)|Time to progression and duration of response|Impact of rituximab and yttrium Y 90 ibritumomab tiuxetan on the clonal plasma cells in the blood and marrow prior to high-dose melphalan\",\"Completed\",\"Phase 1\"\n",
      "331,\"Combination Study for High Risk Multiple Myeloma Patients\",\"Incidence of Treatment-Emergent Adverse Events (Safety and Tolerability)|Overall Rate of Response (Efficacy)\",\"34 Months|34 Months\",\"PFS|DOR|OS\",\"Terminated\",\"Phase 2\"\n",
      "332,\"Zoledronic Acid in the Management of Patients With Asymptomatic/Early Stage Multiple Myeloma\",\"· To examine the effect of intravenous zoledronic acid at the dose of 4 mg given every three months compared with observation, on percent change in bone mineral density of the spine at one year in patients with asymptomatic, smoldering and stage I MM.\",\"18 months\",\"· To examine the effect of intravenous zoledronic acid at the above schedule on percent change in bone mineral density of the total hip and femur.\",\"Terminated\",\"Phase 2\"\n",
      "333,\"Study of Bortezomib and Dexamethasone With or Without Elotuzumab to Treat Relapsed or Refractory Multiple Myeloma\",\"Median Investigator-Assessed Progression-free Survival (PFS) Time (Months) From Randomization to Date of First Tumor Progression or Death Due to Any Cause - Randomized Participants|Number of Investigator-Assessed Progression-free Survival Events From Randomization to Date of First Tumor Progression or Death Due to Any Cause - All Randomized Participants|1 Year Progression-Free Survival Rate - Randomized Participants\",\"Randomization until 111 events (disease progression or death), up to May 2014, approximately 2 years|Randomization until 111 events, up to May 2014, approximately 2 years|Year 1 after last participant was randomized\",\"Median Progression-free Survival Time (Months) From Randomization to Date of First Tumor Progression or Death Due to Any Cause, in Randomized Participants With at Least One FcγRIIIa V Allele|Investigator-Assessed Objective Response Rate (ORR) - All Randomized Participants|Investigator-Assessed Objective Response Rate in Randomized Participants With at Least One FcγRIIIa V Allele\",\"Completed\",\"Phase 2\"\n",
      "334,\"Fludarabine Added to Induction Treatment in Untreated Multiple Myeloma Patients\",\"The toxicity and safety of Fludarabine when added to induction therapy by registration of side effects and adverse events in accordance with the common toxicity criteria (CTC).\",,\"Quantification of clonal cells in bone marrow and blood by flow cytometry (MRD) and to study new potential prognostic markers identified by cytomic, genomic and proteomic analysis.|Estimation of the efficacy of Fludarabine when added to induction chemotherapy (CyDex) in patients with multiple myeloma by clinical end points: disease response and progression free survival\",\"Unknown status\",\"Phase 2\"\n",
      "335,\"An Open-label, Dose-escalation Safety and Tolerability Trial Assessing Anti-KIR (1-7F9) in Subjects With Multiple Myeloma\",\"Maximum Tolerated Dose (MTD) of IPH2101 as Determined by Number of Participants With Dose-Limiting Toxicities (DLTs) Related to IPH2101 Treatment\",\"From start of the treatment to end of study\",\"Maximum Plasma Concentration (Cmax) of IPH2101 After Cycle 1 Administration|Area Under the Plasma-concentration-time Curve [AUC (INF)] of IPH2101 After Cycle 1 Administration|Number of Evaluable Patients With Stable Disease. \"\"Evaluable\"\" is Defined as 2 Consecutive M Protein Assessments\",\"Completed\",\"Phase 1\"\n",
      "336,\"Relevance of [68Ga]Ga -PentixaFor-PET for Initial Staging and Therapeutic Evaluation of Multiple Myeloma in First Line Treatment\",\"To determine the sensitivity of [68Ga]Ga-PentixaFor-PET to detect Multiple Myeloma (MM) lesions [Bone marrow (BM) lesions and/or extra-medullary disease (EMD) ] at the time of initial diagnosis.\",\"1 Month\",\"To determine at the time of initial diagnosis, the specificity, the positive predictive value (PPV) and negative predictive value (NPV) of [68Ga]Ga-PentixaFor-PET|To determine at the time of initial diagnosis the prognostic impact of FDG PET and of [68Ga]Ga-PentixaFor-PET depending on the positivity, number and intensity of uptake detected by each imaging technique|To determine at the time of initial diagnosis the discrepancies rate between FDG PET and [68Ga]Ga-PentixaFor-PET|To determine at the time of initial diagnosis the factors associated with discrepancies between FDG PET and [68Ga]Ga-PentixaFor-PET|To determine at the time of initial diagnosis the correlation between PET-FDG and [68Ga]Ga-PentixaFor-PET uptakes evaluated by SUV and the cytogenetic data evaluated on the myelogram (particularly the measurement of the expression of the gene coding|To determine at the time of initial diagnosis the tolerance of [68Ga]Ga-PentixaFor-PET|To determine at the time of initial diagnosis the tolerance of [68Ga]Ga-PentixaFor-PET|To determine at the time of therapeutic evaluation the discrepancies rate between FDG PET and [68Ga]Ga-PentixaFor-PET and if available their link with histology.|To determine at the time of therapeutic evaluation the prognostic impact of FDG PET and [68Ga]Ga-PentixaFor-PET depending on the positivity, number and intensity of uptake detected by each imaging technique.|To determine at the time of therapeutic evaluation the prognostic impact of FDG PET and [68Ga]Ga-PentixaFor-PET depending on the positivity, number and intensity of uptake detected by each imaging technique.|To determine at the time of therapeutic evaluation the link between PET-FDG, [68Ga]Ga-PentixaFor-PET results and minimal residual disease evaluated by flow cytometry|To determine at the time of therapeutic evaluation the tolerance of [68Ga]Ga-PentixaFor-PET\",\"Recruiting\",\"Phase 2\"\n",
      "337,\"Long-term KRd in Relapsed and/or Refractory Multiple Myeloma\",\"Progression-free survival\",\"up to 54 months\",\"Overall survival|Overall response rate, clinical benefit rate|Duration of response|Toxicity profile\",\"Not yet recruiting\",\n",
      "338,\"Expanded Access Single Named Patient Program With Elotuzumab (BMS-901608) for the Treatment of Patient R-A With Relapsed/Refractory Multiple Myeloma\",,,,\"No longer available\",\n",
      "339,\"Oligosecretary Myeloma: Prevalence and Its Clinical Significance\",\"Number of patients with oligosecretary myeloma among multiple myeloma patients\",\"up to 1 year\",,\"Completed\",\n",
      "340,\"Safety and Efficacy of SDX-101 (R-Etodolac) in Patients With Relapsed or Refractory Multiple Myeloma (MM)\",,,,\"Terminated\",\"Phase 2\"\n",
      "341,\"Study of Pomalidomide and Low Dose Dexamethasone With or Without Pembrolizumab (MK-3475) in Refractory or Relapsed and Refractory Multiple Myeloma (rrMM) (MK-3475-183/KEYNOTE-183)\",\"Progression Free Survival (PFS) Assessed by Clinical Adjudication Committee (CAC) Blinded Central Review According to the International Myeloma Working Group (IMWG) Response Criteria|Overall Survival (OS)\",\"Up to approximately 30 months|Up to approximately 54 months\",\"Overall Response Rate (ORR) Evaluated According to the IMWG Response Criteria by CAC Blinded Central Review|Participants Experiencing One or More Adverse Events (AEs)|Participants Discontinuing Study Investigational Product Due to an AE|Disease Control Rate (DCR) Evaluated According to the IMWG Response Criteria by CAC Blinded Central Review|Second Progression Free Survival (PFS2)\",\"Terminated\",\"Phase 3\"\n",
      "342,\"S9922 Combination Chemo Plus Filgrastim With or Without Thalidomide in Refractory Multiple Myeloma\",\"PFS\",\"18 months\",,\"Terminated\",\"Phase 3\"\n",
      "343,\"Lenalidomide and Rituximab in Treating Patients With Recurrent and/or Refractory Multiple Myeloma\",\"Final Response Rate After 4 Courses of Treatment\",\"2 years\",,\"Terminated\",\"Phase 2\"\n",
      "344,\"A Safety Study of SGN-CD48A in Patients With Multiple Myeloma\",\"Type, incidence, severity, seriousness, and relatedness of adverse events|Incidence of laboratory abnormalities|Incidence of dose limiting toxicity\",\"Through 1 month following last dose|Through 1 month following last dose|Through 3 weeks following first dose\",\"Objective response rate|Complete response rate|Duration of objective response|Duration of complete response|Progression-free survival|Overall survival|Blood concentrations of SGN-CD48A and metabolites|Incidence of antitherapeutic antibodies\",\"Terminated\",\"Phase 1\"\n",
      "345,\"A Study to Learn How Patients With Triple Class Refractory Multiple Myeloma (TCR-MM) Are Treated in Italian Centers for Blood Related Diseases\",\"Real-World Overall Response Rate (ORR) for each TCR MM therapy|Real-World Progression Free Survival (PFS)|Real-World Overall Survival (OS)|Real-World Duration of response (DOR)\",\"3-18 months|3-18 months|3-18 months|3-18 months\",,\"Not yet recruiting\",\n",
      "346,\"A Study of PAD Followed by Autologous Stem Cell Transplantation (ASCT) to Treat Newly Diagnosed Multiple Myeloma\",\"Bone Formation Markers Measurement\",\"Up to Cycle 4 with 28 days per cycle\",\"Measurement of Bone Mineral Density|Skeletal Related Events' Evaluation\",\"Completed\",\"Phase 2\"\n",
      "347,\"A Trial of ASP7487 (OSI-906) in Combination With Bortezomib for the Treatment of Relapsed Multiple Myeloma\",\"Maximum Tolerated Dose of the Combination of ASP7487 (OSI-906) With Velcade and Dexamethasone\",\"45 months\",,\"Terminated\",\"Phase 1|Phase 2\"\n",
      "348,\"BCMA and CD19 Targeted Fast Dual CART for Chromosomal Abnomalities High-risk BCMA+ Multiple Myeloma\",\"Incidence and severity of adverse events after GC012F injection\",\"Minimum 2 years after GC012F infusion\",\"Percentage of MRD negative patients after GC012F infusion|ORR(PR, VGPR, CR and sCR) of patients after GC012F treatment|Progression free survival after GC012F treatment|Duration of response of subjects after GC012F treatment|Overall survivalof subjects after GC012F treatment|Cytokines in serum after GC012F infusion|Subset of lymphocytes in blood after GC012F infusion|Anti-GC012F antibodies in blood after GC012F infusion|Cell counts of GC012F in blood and bone marrow(if available) after GC012F infusion|Copies of GC012F in blood and bone marrow(if available) after GC012F infusion\",\"Unknown status\",\"Early Phase 1\"\n",
      "349,\"Anti-BCMA CAR-T Cell Therapy for the R/R Multiple Myeloma\",\"Incidence of dose limiting toxicity (DLTs)|Incidence and severity of AEs and SAEs\",\"within 4 weeks after infusion|Up to 24 months\",\"Best Overall Response|Duration of Response\",\"Recruiting\",\"Early Phase 1\"\n",
      "350,\"Paricalcitol and Zoledronate in Treating Patients With Relapsed or Refractory Multiple Myeloma or Other Plasma Cell Disorders\",,,,\"Terminated\",\"Phase 1\"\n",
      "351,\"Chemotherapy, Vaccine Therapy, and Stem Cell Transplantation in Patients With Newly Diagnosed Multiple Myeloma\",\"Tumor-specific immune response\",\"Up to 1 year\",\"Grade 3-4 toxicity\",\"Completed\",\"Phase 1|Phase 2\"\n",
      "352,\"Study of BHQ880 in Patients With High Risk Smoldering Multiple Myeloma\",\"Overall response rate (Complete Response + Partial Response + Minimal Response) of patients achieving an objective response (defined according to the IMWG uniform response criteria by the Frequency of response of serum or urine M-protein to BHQ880A\",\"at 6 month\",\"Safety and tolerability of BHQ880 in patients with smoldering multiple myeloma by assessing AEs, SAEs, clinical laboratory values|Characterize the PK profile of BHQ880 as a single agent administered monthly by assessing BHQ880 levels in plasma|Evaluate the effect of BHQ880 on bone metabolism by assessing serum and urine bone biomarkers|Evaluate the effect of BHQ880 on bone mineral density by DXA scan and QCT\",\"Completed\",\"Phase 2\"\n",
      "353,\"Combined Carfilzomib and Hydroxychloroquine in Patients With Relapsed/Refractory Multiple Myeloma\",\"maximum tolerated dose of hydroxychloroquine when added to standard-dose regimen of carfilzomib/dexamethasone\",\"3 months\",\"estimate of toxicity rate of hydroxychloroquine when added at a maximum tolerated dose to standard-dose regimen of carfilzomib/dexamethasone\",\"Completed\",\"Phase 1\"\n",
      "354,\"The Efficacy and Safety of Colchicine Combined With Conventional Therapy in Multiple Myeloma Patients\",\"Serum M protein|Proportion of bone marrow plasma cells|Serum protein electrophoresis (SPEP) and urine protein electrophoresis (UPEP）|Serum free light chain (FLC)\",\"[Time Frame:Baseline, at the end of each cycle (each cycle is 35 days). From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 60 months]|[Time Frame:Baseline, at the end of each cycle (each cycle is 35 days). From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 60 months]|[Time Frame:Baseline, at the end of each cycle (each cycle is 35 days). From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 60 months]|[Time Frame:Baseline, at the end of each cycle (each cycle is 35 days). From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 60 months]\",\"Imaging（X ray/CT/MRI）|Complete blood count (CBC)|Blood biochemistries|Eastern Cooperative Oncology Group (ECOG) Score\",\"Recruiting\",\"Phase 3\"\n",
      "355,\"A Study to Assess Disease Burden, in Terms of Health-related Quality of Life and Direct Healthcare Costs, in Patients With Newly Diagnosed Multiple Myeloma Who Are Not Candidates for Autologous Stem Cell Transplant (ASCT) in Spain\",\"Health-related quality of life (HRQoL)|EuroQoL 5-Dimension, 5-Level Questionnaire (EQ-5D-5L)|Quality of Life Questionnaire (QLQ-C30)|Quality of Life Questionnaire - Multiple Myeloma Module 20 (QLQ-MY20)|Health care cost for Multiple Myeloma (MM) patients\",\"4 years|4 years|4 years|4 years|4 years\",\"Time to progression (TTP)|Progression-free survival (PFS)|Overall survival (OS)|Overall response rate|Response duration|Treatment-free interval [TFI]\",\"Completed\",\n",
      "356,\"Efficacy and Safety Study of bb2121 in Subjects With Relapsed and Refractory Multiple Myeloma\",\"Overall Response Rate (ORR)\",\"Minimum of 24 months post-bb2121 infusion\",\"Complete Response (CR) Rate|Time to Response|Duration of Response|Progression-free Survival (PFS)|Time to Progression (TTP)|Overall Survival (OS)|Adverse Events (AEs)|Pharmacokinetics - Cmax|Pharmacokinetics - Tmax|Pharmacokinetics - AUC|Immunogenicity|Minimal Residual Disease (MRD)|Subject-reported outcomes as measured by European Organization for Research and Treatment of Cancer Quality-of-Life questionnaire (EORTC-QLQ-C30)|Subject-reported outcomes as measured by EuroQoL Group EQ-5D-5L Health Questionnaire|Subject-reported outcomes as measured by EORTC-QLQ-MY20\",\"Active, not recruiting\",\"Phase 2\"\n",
      "357,\"Anti-BCMA or/and Anti-CD19 CART Cells Treatment of Relapsed Multiple Myeloma\",\"No Dose-limiting toxicity\",\"up to 5 mouths after T cell infusion\",,\"Unknown status\",\"Phase 1\"\n",
      "358,\"Evaluation of Ultrasensitive Chromosomal Aneuploidy Detection for Detecting Minimal Residual Disease in Multiple Myeloma\",\"Comparison of the prognostic of the MRD negative and MRD positive defined by UCAD|The concordance rate analysis between UCAD and multiparameter flow cytometry(MFC)\",\"36month|36month\",\"The applicability analysis of UCAD|The MRD negative rate analysis among VGPR patients\",\"Unknown status\",\n",
      "359,\"Pembrolizumab, Belantamab and Dexamethasone in Refractory Multiple Myeloma.\",\"Overall Response Rate (ORR)\",\"2 years\",\"Progression-Free Survival (PFS)|Overall Survival (OS)|Time to next treatment|Tolerability and Safety\",\"Withdrawn\",\"Phase 1|Phase 2\"\n",
      "360,\"IV Busulfan Plus Bortezomib Conditioning Regimen for Second Autologous Stem Cell Transplant in Multiple Myeloma Patients\",\"Percentage of Participants With Overall Disease Response at Month 6\",\"6 Months\",\"Overall Survival|Percentage of Participants With Overall Survival Events|Progression-free Survival|Percentage of Participants With Progression-free Survival Events|Percent Change in IV Busulfan Dose|Ratio Area Under Curve (AUC)/Target AUC|Percent Difference Between Area Under Curve (AUC) and Target AUC|Percentage of Participants With Transplant-Related Mortality|Percentage of Participants With Hepatic Veno-Occlusive Disease Based on Baltimore Criteria\",\"Completed\",\"Phase 2\"\n",
      "361,\"EMMA-1 (Erbitux for Multiple Myeloma)\",\"Overall response rate (CR+PR+MR)at 16 weeks and during follow-up (every 3 months)\",\"After 16 weeks\",\"Safety profile of Cetuximab +/- Dexamethasone|Freedom from treatment failure|Progression-free survival|Overall survival|Pharmacogenomic evaluation of response to treatment\",\"Terminated\",\"Phase 2\"\n",
      "362,\"Study of the Combination of Panobinostat and Carfilzomib in Patients With Relapsed/Refractory Multiple Myeloma\",\"Number of Phase I Patients (Dose Level 1-6) Experiencing a Dose-Limiting Toxicity (DLT) to Determine the Optimal Dosage|Phase II: Overall Response Rate\",\"28 days from the start of study treatment|up to 6 years\",\"Time-to-progression (TTP)|Progression-free-survival (PFS)|Overall-survival (OS)\",\"Completed\",\"Phase 1|Phase 2\"\n",
      "363,\"Combination Chemotherapy in Treating Patients With Stage II or Stage III Multiple Myeloma\",\"Comparison of response rates\",,\"Time to achieve a maximal response|Duration of response\",\"Completed\",\"Phase 3\"\n",
      "364,\"Belantamab Mafodotin in Newly Diagnosed Transplant Eligible Multiple Myeloma Patients\",\"Incidence of deaths|Incidence of adverse events (AEs)|Incidence of analytical alterations|Incidence of ocular events\",\"Throughout the study period. Approximately 48 months|Throughout the study period. Approximately 48 months|Throughout the study period. Approximately 48 months|Throughout the study period. Approximately 48 months\",\"Overall Response Rate (ORR)|Complete Response Rate (CRR)|Minimal Residual Disease (MRD) negativity rate|Time to Response (TTR)|Duration of Response (DoR)|Progression-Free Survival (PFS)|Progression-Free Survival 2 (PFS2)|Overall Survival (OS)|Efficiency of hematopoietic stem cell collection\",\"Recruiting\",\"Phase 2\"\n",
      "365,\"Quality of Life in Patients With Multiple Myeloma-validation Study\",\"Psychometric properties of the culturally-adapted Swiss-German Myeloma Patient Outcome Scale (MyPOS)\",\"upon enrollment\",,\"Terminated\",\n",
      "366,\"Dose-finding of Lenalidomide as Maintenance in Multiple Myeloma\",\"Maximal tolerable dose of lenalidomide after allogeneic stem cell transplantation in patients with multiple myeloma\",\"2 years post-transplantation\",\"Determination of remission status after lenalidomide treatment|Effect on T-cell/ NK-cell recovery|Incidence of infectious complications and GvHD\",\"Completed\",\"Phase 1|Phase 2\"\n",
      "367,\"Study of the Bruton's Tyrosine Kinase Inhibitor in Subjects With Relapsed or Relapsed and Refractory Multiple Myeloma\",\"The Clinical Benefit Response (CBR)\",\"From the date of first study treatment until disease progression per IMWG, up to 60 months\",\"To Evaluate the Efficacy of PCI-32765 by Assessing ORR|Pharmacokinetics (PK). (Assessed by Sampling and Testing for Drug and Metabolite Levels at Designated Time Points). Mean Maximum Observed Plasma Concentration (Cmax)|Pharmacokinetics (PK) (Assessed by Sampling and Testing for Drug and Metabolite Levels at Designated Time Points). Mean Time to Maximum Observed Plasma Concentration (Tmax).|Pharmacokinetics (PK) (Assessed by Sampling and Testing for Drug and Metabolite Levels at Designated Time Points). Mean Area Under the Plasma Concentration-Time Curve From Time 0 to 24 Hours (AUC0-24h).|Pharmacokinetics (PK) (Assessed by Sampling and Testing for Drug and Metabolite Levels at Designated Time Points). Mean Terminal Elimination Half-life (t1/2,Term).|Pharmacokinetics (PK) (Assessed by Sampling and Testing for Drug and Metabolite Levels at Designated Time Points). Mean Accumulation Ratio for AUC0-24h (Acc. Ratio AUC0-24h)|Pharmacokinetics (PK) (Assessed by Sampling and Testing for Drug and Metabolite Levels at Designated Time Points). Mean Metabolite-to-Parent Ratio for Cmax (M/P Cmax)|Pharmacokinetics (PK) (Assessed by Sampling and Testing for Drug and Metabolite Levels at Designated Time Points). Mean Metabolite-to-Parent Ratio for AUC0-24h (M/P AUC0-24h)|Duration of Clinical Benefit Response (DCB)|Duration of Response (DOR)\",\"Completed\",\"Phase 2\"\n",
      "368,\"Thalidomide to Patients With Previously Untreated Multiple Myeloma\",\"overall survival\",\"october 2007\",\"Quality of life|Time to response|Frequency of response|Time to progression|Time to 2. response|Frequency of 2. response|Time to 2. progression|Toxicity|Time to definitive treatment failure\",\"Completed\",\"Phase 3\"\n",
      "369,\"Clinical Trial to Evaluate CT053 in Patients With Relapsed and/or Refractory Multiple Myeloma (LUMMICAR STUDY 1)\",\"Phase 1, Safety and tolerability: dose limiting toxicity|Phase 2, efficacy of CT053 CAR-BCMA T cells: overall response rate\",\"28days post administration of CAR-T-cells|3 months post administration of CAR-T-cells\",\"Additional efficacy evaluation after 12 weeks of CT053 CAR-BCMA T cells infusion|Additional efficacy evaluation after 12 weeks of CT053 CAR-BCMA T cells infusion|Additional efficacy evaluation after 12 weeks of CT053 CAR-BCMA T cells infusion|Additional efficacy evaluation after 12 weeks of CT053 CAR-BCMA T cells infusion|Additional efficacy evaluation after 12 weeks of CT053 CAR-BCMA T cells infusion|Additional efficacy evaluation after 12 weeks of CT053 CAR-BCMA T cells infusion|Safety and tolerability of CAR-BCMA T cell therapy|Pharmacokinetics (the cell persistence duration in peripheral blood)|Pharmacokinetics (the cell persistence duration in peripheral blood)|Safety and tolerability of CAR-BCMA T cell therapy|Efficacy endpoint of CAR-BCMA T cells after infusion|Efficacy endpoint of CAR-BCMA T cells after infusion|Efficacy endpoint of CAR-BCMA T cells after infusion|Efficacy endpoint of CAR-BCMA T cells after infusion|Efficacy endpoint of CAR-BCMA T cells after infusion|Efficacy endpoint of CAR-BCMA T cells after infusion|Efficacy endpoint of CAR-BCMA T cells after infusion|Efficacy endpoint of CAR-BCMA T cells after infusion|Efficacy endpoint of CAR-BCMA T cells after infusion\",\"Recruiting\",\"Phase 1|Phase 2\"\n",
      "370,\"Open-Label, Phase 2, Proof of Concept Study in Multiple Myeloma - Denosumab\",\"Complete Response or Partial Response Based on M-Protein Assessments Only\",\"Up to 18 months\",\"Complete Response, Partial Response or Minimal Response Based on M-Protein Assessments Only|Complete Response Based on M-Protein Assessments Only\",\"Completed\",\"Phase 2\"\n",
      "371,\"Multiple Myeloma Treated With Thalidomide Before Autotransplant or With Conventional Chemotherapy and as Consolidation/Maintenance Treatment in Young and Elderly Patients : 3 Randomized Studies.\",\"very good partial response rate (monclonal protein decrease of 90 % or more)at the end induction phase (MY-TAG and MY-DECT), progression free survival during consolidation/maintenance treatment (MY-PLAT)\",\"before autotransplant (MY-TAG), after 4 cycles (MY-DECT), every 6 months (MY-PLAT)\",\"partial response rate (> or = 50%), PFS and OS since diagnosis, safety thalidomide + chemotherapy\",\"Completed\",\"Phase 3\"\n",
      "372,\"BT062 in Combination With Lenalidomide or Pomalidomide and Dexamethasone in Patients With Multiple Myeloma\",\"Determination of optimal dose of BT062 (Phase I part)|Evaluation of response (Phase IIa part)\",\"6 months|18 months\",\"Qualitative toxicities of BT062 in combination with lenalidomide/dexamethasone or pomalidomide/dexamethasone|Pharmacokinetics of BT062 in combination with lenalidomide/dexamethasone or pomalidomide/dexamethasone|Assessment of Time To Event end points|Quantitative toxicities of BT062 in combination with lenalidomide/dexamethasone or pomalidomide/dexamethasone\",\"Completed\",\"Phase 1|Phase 2\"\n",
      "373,\"Allogeneic Hematopoietic Stem Cell Transplantation for Multiple Myeloma\",\"Progression Free Survival\",\"Subjects will be followed for progression-free survival for at least 36 months\",\"Overall Survival (OS)|Overall Response Rate\",\"Completed\",\"Phase 2\"\n",
      "374,\"Autologous Transplant for Multiple Myeloma\",\"Number of Participants Achieving a Complete Response|Number of Participants Achieving a Complete Response|Number of Participants Achieving a Complete Response\",\"100 Days post transplant|6 months post transplant|12 months post transplant\",\"Number of Patients With Extended Disease-free Survival|Number of Participants With Overall Survival|Number of Participants With Overall Survival|Number of Participants With Overall Survival|Count of Participants Experiencing Transplant Related Mortality|Number of Participants Experiencing Incidence of Relapse|Number of Participants With Disease Progression|Time to Progression|Time to Relapse|Number of Participants With Absolute Neutrophil Recovery|Time to Attainment of CR|Time to Attainment of CR+PR|Duration of Maintenance Treatment|Dropout Rate From Maintenance Therapy|Number of Participants With Toxicities|Number of Participants With Infections\",\"Completed\",\"Phase 2|Phase 3\"\n",
      "375,\"Carfilzomib, Cyclophosphamide and Dexamethasone In Newly Diagnosed Multiple Myeloma Patients\",\"Toxicity: Assessment of adverse events will be performed at the end of third cycle according to the National Cancer Institute Common Terminology Criteria of Adverse Events (CTCAE version 4.0)|Efficacy will be assessed by considering partial response (PR) following the proposed regimen. Assessment of Partial Response rate will be performed at the end of third cycle according to the criteria of the International Myeloma Working Group.\",\"4 years|4 years\",\"Response rate|Duration of Progression Free Survival|Time to progression (TTP)|Duration of Response (DOR)|Duration of Overall Survival|Time to next therapy|Progressio Free Survival|β2-microglobulin as prognostic factors|peripheral neuropathy|Progression Free Survival|C reactive protein as prognostic factors|cytogenetics as prognostic factors|microRNA|gene expression profile|Overall Survival\",\"Active, not recruiting\",\"Phase 2\"\n",
      "376,\"Early Patient Access Single Named Patient Program for the Use of Ulocuplumab for the Treatment of Multiple Myeloma\",,,,\"No longer available\",\n",
      "377,\"Therapeutic Research in Multiple Myeloma\",,,,\"Completed\",\n",
      "378,\"Biological Therapy in Treating Patients With Multiple Myeloma That Has Recurred Following Bone Marrow Transplantation\",,,,\"Completed\",\"Phase 2\"\n",
      "379,\"Expanded Treatment Prot of Panobinostat in Combo w/ Bortez and Dex in Pts w/ Relapsed and/or Refractory Multiple Myeloma\",,,,\"No longer available\",\n",
      "380,\"Safety and Efficacy Study of GCS-100LE in the Treatment of Multiple Myeloma\",\"To evaluate GCS-100 related dose-limiting toxicity and to identify the maximum tolerated dose and/or the recommended dose for further studies.\",\"Up to 12 consecutive 21-day treatment cycles\",\"To evaluate the safety of treatment with GCS-100 in combination with bortezomib (VelcadeTM) and dexamethasone in subjects whose disease has progressed on GCS-100 alone.\",\"Terminated\",\"Phase 1\"\n",
      "381,\"Chemotherapy With or Without Wobe-Mugos E in Treating Patients With Stage II or Stage III Multiple Myeloma\",,,,\"Unknown status\",\"Phase 3\"\n",
      "382,\"MINIALO-VELCADE2005: A Study of Bortezomib (Velcade) Treated Multiple Myeloma Patients Pre and Post Allogeneic Haematopoietic Progenitor Cell Transplant With no Myeloablative Conditioning\",\"Analyze the efficacy of allogeneic bone marrow transplantation in a reduced-intensity manner combined with bortezomib\",\"2 years\",,\"Completed\",\"Phase 2\"\n",
      "383,\"PRospective Multiple Myeloma Impact Study\",\"Change in treatment intention\",\"Treatment intention is measured before MMprofiler SKY92 and within 4 weeks after MMprofiler\",\"3 year Progression Free Survival|3 year Overall Survival|5 year Progression Free Survival|5 year Overall Survival\",\"Active, not recruiting\",\"Not Applicable\"\n",
      "384,\"Descartes-25 in Relapsed/Refractory Multiple Myeloma\",\"Maximum Tolerated Dose\",\"1 Year\",,\"Recruiting\",\"Phase 1|Phase 2\"\n",
      "385,\"Thalidomide, Doxorubicin, and Dexamethasone in Treating Patients With Untreated Stage II or Stage III Multiple Myeloma\",,,,\"Completed\",\"Phase 2\"\n",
      "386,\"Multiple Myeloma Outcomes Based on Maintenance Therapy Post Autologous Stem Cell Transplant\",\"MRD conversion rate\",\"At 1 year after transplant\",\"Progression Free Survival (PFS) at 1 Year|Progression Free Survival (PFS) at 2 Years|MRD by NGS Clonoseq testing\",\"Recruiting\",\n",
      "387,\"Dual-target CAR-T Cells (C-4-29) in the Treatment of Relapsed/Refractory Multiple Myeloma\",\"Incidence of Adverse events after C-4-29 infusion [Safety and Tolerability]|Obtain the maximum tolerated dose of C-4-29 cells[Safety and Tolerability]\",\"28 days|28 days\",\"Objective response rate after C-4-29 infusion [Effectiveness]|AUCS of C-4-29 cells [Cell dynamics]|CMAX of C-4-29 cells [Cell dynamics]|TMAX of C-4-29 cells [Cell dynamics]|Peripheral blood M protein contents after C-4-29 infusion [Cell dynamics]|Urine Bence-Jones protein contents after C-4-29 infusion [Cell dynamics]|Immunogenicity of C-4-29 cells\",\"Enrolling by invitation\",\"Phase 1\"\n",
      "388,\"Zoledronate With or Without Thalidomide in Treating Patients With Early Stage Multiple Myeloma\",\"Time to Disease Progression (TTP)\",\"randomization to progression (up to 5 years)\",\"12-month Progression-free Survival (PFS)|Number of Participants With a Confirmed Response (Complete Response [CR], Very Good Partial Response [VGPR] or Partial Response [PR]) on Two Consecutive Evaluations at Least 2 Weeks Apart in the First 12 Months of Treatment|Duration of Response (Complete Response, Partial Response, and Very Good Partial Response)|Time to Subsequent Treatment|Time to Treatment Failure|Number of Participants With Severe (Grade 3, 4 or 5) Adverse Events\",\"Completed\",\"Phase 3\"\n",
      "389,\"Preventive Treatment of VETD in Patients With Multiple Myeloma Receiving Chemotherapy With Thalidomide or Lenalinomide.\",\"Disease history and VETD risk factors. Chemotherapy protocol for multiple myeloma. Therapeutic used for VETD prevention (LWMH, anticoagulants, antiplatelets or none)\",\"4 months\",\"PE and DVT rate at 4 months and one year. Bleedings and all relevant SAE and AE at 4 months and one year.\",\"Completed\",\n",
      "390,\"Carfilzomib, Cyclophosphamide, Dexamethasone in Transplant Eligible Newly Diagnosed High-risk Multiple Myeloma\",\"Progression Free Survival\",\"2 years\",\"Minimal residual disease negativity|Overall Survival (OS)\",\"Completed\",\"Phase 2\"\n",
      "391,\"Minimal Residual Disease Guided Maintenance Therapy With Belantamab Mafodotin and Lenalidomide After Autologous Hematopoietic Cell Transplantation in Patients With Newly Diagnosed Multiple Myeloma\",\"Conversion rate from MRD-positive to MRD-negative CR in patients with newly diagnosed multiple myeloma (NDMM) receiving post-transplant maintenance therapy with belantamab mafodotin plus lenalidomide.\",\"through study completion, an average of 1 year\",,\"Recruiting\",\"Phase 2\"\n",
      "392,\"Maintenance Treatment of Multiple Myeloma (MM) After Autologous Peripheral Blood Transplant (PBSCT) Using Polyethylene Glycol alpha2B Interpheron (PEG-INTRON)\",\"Time to Progression (TTP) and WHO (World Health Organization) Toxicity scale\",\"three years\",\"Increase of Response (anti-tumoral effect) and Dose Tolerance\",\"Unknown status\",\"Phase 2\"\n",
      "393,\"S0232 Dexamethasone With or Without Lenalidomide in Treating Patients With Previously Untreated Stage I, Stage II, or Stage III Multiple Myeloma\",\"Progression-Free Survival\",\"From date of initial registration to date of progression/relapse of disease or death from any cause, whichever came first, up to 5 years\",\"Toxicity\",\"Completed\",\"Phase 3\"\n",
      "394,\"Combination Chemotherapy With or Without PSC 833 in Treating Patients With Relapsed or Refractory Multiple Myeloma\",,,,\"Completed\",\"Phase 3\"\n",
      "395,\"Selinexor Treatment for Multiple Myeloma Patients Who Are Refractory to Lenalidomide-containing Therapy.\",\"Overall Response|Clinical Benefit Rate\",\"30 months|30 months\",\"Adverse Events Occurrences|Time to progression (TTP)|Progression-free survival (PFS)|Time to first response|Duration of Response (DOR)|Overall survival (OS)\",\"Recruiting\",\"Phase 1\"\n",
      "396,\"A Safety Study of Lenalidomide in Previously Untreated Adult Multiple Myeloma Patients Who Are Not Eligible for Transplant\",\"Incidence of cardiovascular events\",\"Approximately 8 years\",\"Incidence of renal impairment in NDMM patients|Incidence of infections in NDMM patients|Incidence of Second primary malignancy (SPM) in TNE NDMM patients treated with any first line regimen\",\"Active, not recruiting\",\n",
      "397,\"Velcade-Melphalan-Prednisone in Older Untreated Multiple Myeloma Patients.\",\"Determinate the efficacy of combination velcade, melphalan, prednisone\",\"1 year\",\"Assess safety and tolerability|Assess potential superiority of this regimen versus historical controls with melphalan and prednisone alone|Evaluate efficacy in terms of progression-free survival and overall survival\",\"Completed\",\"Phase 1|Phase 2\"\n",
      "398,\"Matched Unrelated Donor Stem Cell Transplantation (MUD-SCT) After Dose-reduced Conditioning for Patients With Multiple Myeloma and Relapse After Autologous SCT\",\"Engraftment, chimerism, toxicity, non-relapse mortality\",\"Follow-up until day +1095\",\"Evaluation of response/GvHD/ infectious complications/ disease-free survival, Prognostic impact of cytogenetic, Evaluation of incidence and prognostic impact of molecular remission in patients with clinically complete remission.\",\"Completed\",\"Phase 2\"\n",
      "399,\"Study to Determine the Maximum Tolerated Dose for the Combination of Pomalidomide, Bortezomib and Low-Dose Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma\",\"Maximum Tolerated Dose\",\"Up to 2 years\",\"Adverse events|Overall Survival|Response Rate|Duration of response|Time to response\",\"Completed\",\"Phase 1\"\n",
      "400,\"E-PRISM: Phase II Trial of Elotuzumab Lenalidomide and Dexamethasone in High-Risk Smoldering Multiple Myeloma\",\"Proportion of patients who are progression free at 2 years\",\"2 Years\",\"Response rate|Safety of the combination therapy|Time to progression|Overall survival\",\"Active, not recruiting\",\"Phase 2\"\n",
      "401,\"A Study of Belantamab Mafodotin to Investigate Safety, Tolerability, Pharmacokinetics, Immunogenicity and Clinical Activity in Participants With Relapsed/Refractory Multiple Myeloma (RRMM)\",\"Number of participants with Adverse events (AEs)|Number of participants with serious adverse events (SAEs)|Number of participants with dose limited toxicities (DLTs)\",\"Up to 15 months|Up to 15 months|Day 1 to Day 21 (Cycle 1)\",\"Change from Baseline in systolic blood pressure (SBP) and diastolic blood pressure (DBP) (Millimeters of mercury)|Change from Baseline in temperature (degrees Celsius)|Change from Baseline in pulse rate (beats per minute)|Change from Baseline in hematology parameters: platelet count, absolute white blood cells (WBC), reticulocyte count, Neutrophils, Lymphocytes, Monocytes, Eosinophils, Basophils count (Giga cells per Liter)|Change from Baseline in hematology parameter: Red Blood Cell (RBC) Count (Trillion cells per liter)|Change from Baseline in hematology parameter: Hematocrit (Proportion of red blood cells in blood)|Change from Baseline in hematology parameter: Mean Corpuscular Hemoglobin (MCH) (Picograms)|Change from Baseline in hematology parameter: Mean Corpuscular Volume (MCV) (Femtoliters)|Change from Baseline in hematology parameter: Hemoglobin, Mean Corpuscular Hemoglobin concentration (MCHC) (Grams per Liter)|Change from Baseline in chemistry parameters: Blood urea nitrogen (BUN), Creatinine, Glucose, Calcium, Sodium, Potassium, Phosphorous, Chloride, Magnesium, Uric Acid, Carbon dioxide (CO2), Total and direct bilirubin (Millimoles per Liter)|Change from Baseline in chemistry parameter: estimated glomerular filtration rate (eGFR) (milliliter per minute per 1.73 meter square)|Change from Baseline in chemistry parameters: Alanine Amino Transferase (ALT), Alkaline Phosphatase (ALP), Aspartate Amino Transferase (AST), Creatine kinase, Gamma Glutamyl Transferase (GGT), Lactate dehydrogenase (LDH) (International units per Liter)|Change from Baseline in chemistry parameters: Albumin, Total Protein (grams per liter)|Change from Baseline in chemistry parameter: Albumin/creatinine ratio (ratio)|Change from Baseline in Urinalysis Parameter: Specific Gravity (Ratio)|Change from Baseline in Urinalysis Parameter: Urine potential of hydrogen (pH)|Change from Baseline in urinalysis parameter: Glucose and ketones (Millimole per liter)|Change from Baseline in urinalysis parameter: Protein (Grams per liter)|Change from Baseline in urinalysis parameter: blood (10^9 cells per liter)|Area under the plasma concentration-time curve from time zero to time t (AUC[0-t]) after single dose of belantamab mafodotin (antibody-drug conjugate (ADC))|AUC(0-t) after single dose of belantamab mafodotin (total antibody)|AUC(0-t) after single dose of belantamab mafodotin (cys- monomethyl auristatin-F [mcMMAF])|Area under the plasma concentration-time curve from time zero extrapolated to infinity (AUC[0-infinity]) after single dose of belantamab mafodotin (ADC)|AUC(0-infinity) after single dose of belantamab mafodotin (total antibody)|Maximum observed plasma concentration (Cmax) after single dose of belantamab mafodotin (ADC)|Cmax after single dose of belantamab mafodotin (total antibody)|Cmax after single dose of belantamab mafodotin (cys-mcMMAF)|Time to Cmax (tmax) after single dose of belantamab mafodotin (ADC)|tmax after single dose of belantamab mafodotin (total antibody)|tmax after single dose of belantamab mafodotin (cys-mcMMAF)|Last time point where the concentration is above the limit of quantification (tlast) after single dose of belantamab mafodotin (ADC)|tlast after single dose of belantamab mafodotin (total antibody)|Systemic clearance (CL) after single dose of belantamab mafodotin (ADC)|CL after single dose of belantamab mafodotin (total antibody)|Volume of distribution at steady state (Vss) after single dose of belantamab mafodotin (ADC)|Vss after single dose of belantamab mafodotin (total antibody)|Terminal phase elimination rate (Lambda Z) after single dose of belantamab mafodotin (ADC)|Lambda Z after single dose of belantamab mafodotin (total antibody)|Terminal phase half-life (t1/2) after single dose of belantamab mafodotin (ADC)|t1/2 after single dose of belantamab mafodotin (total antibody)|t1/2 after single dose of belantamab mafodotin (cys-mcMMAF)|Trough concentration (Ctrough) after repeat dose of belantamab mafodotin (ADC)|Ctrough after repeat dose of belantamab mafodotin (total antibody)|Ctrough after repeat dose of belantamab mafodotin (cys-mcMMAF)|Number of subjects with abnormal ocular findings|Percentage of participants with Objective Response Rate (ORR)|Number of participants with Anti-drug antibodies (ADAs) against belantamab mafodotin|Titers of ADAs against belantamab mafodotin\",\"Completed\",\"Phase 1\"\n",
      "402,\"Phase 2 Study of Carfilzomib in Relapsed and Refractory Multiple Myeloma\",\"Best Overall Response Rate (ORR)\",\"A0: Subjects evaluated for disease response on Day 24 of Cycles 2, 4, 6, 9, and 12. Onset of response measured on Day 15 of Cycle 1. A1: Subjects evaluated for disease response on Day 15 of Cycle 1, Day 1 of Cycles 2 through 12 and at End of Study.\",\"Clinical Benefit Response (CBR) (A0 Only)|Clinical Benefit Response (CBR) (A1 Only)|Duration of Response (A0 Only)|Duration of Response (A1 Only)|Time to Progression (A0 Only)|Time to Progression (A1 Only)|Progression-free Survival (A0 Only)|Progression-free Survival (A1 Only)|Overall Survival (A1 Only)\",\"Completed\",\"Phase 2\"\n",
      "403,\"A Study to Evaluate Daratumumab in Transplant Eligible Participants With Previously Untreated Multiple Myeloma\",\"stringent complete response (sCR) after consolidation therapy|Progression free survival after maintenance therapy\",\"Up to 9 months|up to 60 months\",\"PFS (Progression-Free Survival) (from first randomization)|Time to Progression (TTP)|proportion of Post ASCT (Autologous Stem Cell Transplantation) / consolidation CR rate|proportion of Post ASCT/consolidation MRD (Minimal Residual Disease) negativation|proportion of Post induction sCR|PFS 2 (from first randomization)|OS (overall survival) (from first randomization)\",\"Active, not recruiting\",\"Phase 3\"\n",
      "404,\"Combination Chemotherapy With or Without Thalidomide in Treating Patients With Multiple Myeloma\",\"Event-free survival\",,\"Partial response and complete response|Overall survival|Progression-free survival|Toxicity\",\"Unknown status\",\"Phase 3\"\n",
      "405,\"Study of Bortezomib and Dexamethasone With or Without Cyclophosphamide in Patients With Relapsed or Not Controllable Multiple Myeloma\",\"Time to Progression of Disease\",\"From the date of randomization until the disease progression or participant's death from any cause whichever occurred first, as assessed up to 72 weeks after end of treatment visit (ie, 46 days after last dose of study medication)\",\"Progression-Free Survival (PFS)|Overall Survival (OS)|Overall Response Rate (ORR) - International Myeloma Working Group (IMWG) Response Criteria\",\"Completed\",\"Phase 3\"\n",
      "406,\"A Study of hLL1-DOX (Milatuzumab-Doxorubicin Antibody-Drug Conjugate) in Patients With Multiple Myeloma\",\"All patients administered any dose of study drug will be included in the evaluation of safety\",\"Before infusion, 5 min after start, every 15 min until completion, then 30, 60, 90 and 120 min later of each dose of study drug\",\"Determine the therapeutic efficacy of hLL1-DOX in this patient population\",\"Terminated\",\"Phase 1|Phase 2\"\n",
      "407,\"A Study of PAD Versus Velcade, Cyclophosphamide and Dexamethasone (VCD) Treatment in Subjects With Multiple Myeloma\",\"Complete Response Rate\",\"Up to cycle 4 (with 28 days per cycle).\",\"Safety|Overall Response Rate|Time To Response|1-year Survival Rate|Overall Survival\",\"Unknown status\",\"Phase 4\"\n",
      "408,\"A Study of the Combination Vorinostat With Lenalidomide, Bortezomib and Dexamethasone for Patients With Newly Diagnosed Multiple Myeloma\",\"To determine the maximum tolerated dose (MTD) and recommended phase II doses (RP2D) of vorinostat in combination with lenalidomide, bortezomib, and dexamethasone.\",\"Every 3 weeks\",\"Efficacy by standard myeloma measurements (SPEP, UPEP [urine protein electrophoresis], bone marrow)\",\"Completed\",\"Phase 1\"\n",
      "409,\"Bryostatin 1 in Treating Patients With Relapsed Multiple Myeloma\",,,,\"Completed\",\"Phase 2\"\n",
      "410,\"Everolimus in Treating Patients With Relapsed or Refractory Multiple Myeloma\",\"Confirmed response (complete response, very good partial response, partial response, or minimal response) of serum and urine monoclonal protein\",,\"Toxicity\",\"Completed\",\"Phase 2\"\n",
      "411,\"A Phase 3, Multicenter, Randomized, Open-Label Study to Compare the Efficacy and Safety of Pomalidomide in Combination With Low-Dose Dexamethasone Versus High-Dose Dexamethasone in Subjects With Refractory Multiple Myeloma or Relapsed and Refractory Multiple Myeloma and Companion Study\",\"Progression-free Survival (PFS) - Primary Analysis|Progression-free Survival (PFS) With a Later Cut-off Date\",\"From randomization until the data cut-off date of 07 September 2012. Maximum duration of follow-up for PFS assessments was 57 weeks.|From randomization until the data cut-off date of 01 March 2013. Maximum duration of follow-up for PFS assessments was 74 weeks.\",\"Number of Participants With Adverse Events (AEs)|Overall Survival - Primary Analysis|Overall Survival With a Later Cut-off Date|Overall Survival Based on the Final Dataset|Percentage of Participants With an Objective Response According to International Myeloma Working Group (IMWG) Uniform Response Criteria|Percentage of Participants With Objective Response According to European Group for Blood and Marrow Transplantation (EBMT) Criteria|Time to Progression|Time to Response|Duration of Response|Time to the First Hemoglobin Improvement|Time to Improvement in Bone Pain|Time to Improvement in Renal Function|Time to Improvement in Eastern Cooperative Oncology Group (ECOG) Performance Status|Change From Baseline in the European Organization for Research and Treatment of Cancer Cancer Quality of Life Questionnaire for Patients With Cancer (EORTC QLQ-C30) Global Health Status Domain|Change From Baseline in the EORTC QLQ-C30 Physical Functioning Domain|Change From Baseline in the EORTC QLQ-C30 Emotional Functioning Domain|Change From Baseline in the EORTC QLQ-C30 Fatigue Domain|Change From Baseline in the EORTC QLQ-C30 Pain Domain|Change From Baseline in the European Organization for Research and Treatment of Cancer QoL Questionnaire for Patients With Multiple Myeloma (EORTC QLQ-MY20) Disease Symptoms|Change From Baseline in the EORTC QLQ-MY20 Side Effects Domain|Change From Baseline in the European Quality of Life-5 Dimensions (EQ-5D) Utility Index Score|Time to First Worsening of Quality of Life (QOL) Domains\",\"Completed\",\"Phase 3\"\n",
      "412,\"A Study of Aplidin (Plitidepsin) 3 h iv in Subjects With Relapsing or Refractory Multiple Myeloma\",\"Objective Response Rate (ORR), Defined as the Combined Rate of Complete Response, Partial Response and Minimal Response\",\"Every 2 weeks until progression or death occurs.\",\"Time to Progression (TTP)|Progression Free Survival (PFS)|Number of Patients With Overall Survival (OS)\",\"Completed\",\"Phase 2\"\n",
      "413,\"Safety and Efficacy of Pomalidomide, Bortezomib and Low-dose Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma\",\"Progression Free Survival\",\"Up to 1 year\",\"Overall Survival|Adverse Event|Overall Response Rate|Duration of Response\",\"Completed\",\"Phase 3\"\n",
      "414,\"Comparison of Melphalan-Prednisone (MP) to MP Plus Thalidomide in the Treatment of Newly Diagnosed Very Elderly Patients (> 75 Years) With Multiple Myeloma\",\"overall Survival\",\"May 2007\",\"Progression Free Survival|Response rates|Safety\",\"Terminated\",\"Phase 3\"\n",
      "415,\"Bendamustine, Lenalidomide (Revlimid®) and Dexamethasone (BRd) as 2nd-line Therapy for Patients With Relapsed or Refractory Multiple Myeloma\",\"Efficacy (combined CR-/VGPR-rate) achieved during the induction treatment phase or within four weeks after the last administration of six induction cycles of the BRd regimen\",\"Every 4 weeks up to 7 months\",\"Objective response rates (sCR, CR, VGPR, PR, MR)|Best response (sCR, CR, VGPR, PR, MR)|Time to progression (TTP)|Overall survival (OS)|Safety and tolerability\",\"Completed\",\"Phase 2\"\n",
      "416,\"Imaging Studies and the Development of Multiple Myeloma\",\"To explore the distribution of 18F-Fluciclatide PET/CT in bone marrow microenvironment in patients with multiple myeloma and its precursor disease (MGUS and SMM)\",\"1 year\",\"Distribution of agent\",\"Withdrawn\",\"Phase 2\"\n",
      "417,\"A Study to Investigate the Efficacy and Safety of Two Doses of GSK2857916 in Participants With Multiple Myeloma Who Have Failed Prior Treatment With an Anti-CD38 Antibody\",\"Overall Response Rate (ORR) by Independent Review Committee (IRC) (Full Analysis Population)|Overall Response Rate by Independent Review Committee (Efficacy Population)\",\"Up to 48 weeks|Up to 48 weeks\",\"Overall Response Rate by Investigator Assessment (IA) (Full Analysis Population)|Overall Response Rate by Investigator Assessment (Efficacy Population)|Clinical Benefit Rate (CBR) by Investigator Assessment (Full Analysis Population)|Clinical Benefit Rate by Investigator Assessment (Efficacy Population)|Clinical Benefit Rate by Independent Review Committee (Full Analysis Population)|Clinical Benefit Rate by Independent Review Committee (Efficacy Population)|Duration of Response (DoR) by Investigator Assessment (Full Analysis Population)|Duration of Response by Investigator Assessment (Efficacy Population)|Duration of Response by Independent Review Committee (Full Analysis Population)|Duration of Response by Independent Review Committee (Efficacy Population)|Time to Response by Investigator Assessment (Full Analysis Population)|Time to Response by Investigator Assessment (Efficacy Population)|Time to Response by Independent Review Committee (Full Analysis Population)|Time to Response by Independent Review Committee (Efficacy Population)|Progression Free Survival by Investigator Assessment|Progression Free Survival by Independent Review Committee|Time to Progression by Investigator Assessment|Time to Progression by Independent Review Committee|Overall Survival|Number of Participants With Change From Baseline in Hematology Parameters With Respect to the Normal Range|Number of Participants With Grade Change From Baseline in Hematology Parameters|Number of Participants With Change From Baseline in Clinical Chemistry Parameters With Respect to the Normal Range|Number of Participants With Grade Change From Baseline in Clinical Chemistry Parameters|Number of Participants With Abnormal Findings During Physical Examination|Number of Participants With Change From Baseline in Pulse Rate|Number of Participants With Change From Baseline in Body Temperature|Number of Participants With Grade Change From Baseline in Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP)|Number of Participants With Serious Adverse Events (SAEs), Common (>=5%) Non-serious Adverse Events and Adverse Events of Special Interest (AESI)|Number of Participants With Change From Baseline in Best Corrected Visual Acuity (BCVA) Test Scores|Number of Participants With Intraocular Pressure (IOP) >=22 mmHg Anytime Post-Baseline|Number of Participants With Shift in Pupillary Examination Findings From Normal (Baseline) to Abnormal (Worst Post-Baseline)|Number of Participants With Shift in Extraocular Muscle Movement From Yes (Baseline) to no (Worst Post-Baseline)|Number of Participants With Shift in Corneal Epithelium Findings From Normal (Baseline) to Abnormal (Worst Post-Baseline) for Corneal Epithelium (CE) and Corneal Stroma (CS)|Number of Participants With Shift in Corneal Epithelium Findings From no (Baseline) to Yes (Worst Post-Baseline)|Number of Participants With Shift in Tear Break-up Time From >10 Seconds (Baseline) to <=5 Seconds (Worst Post-Baseline)|Area Under the Concentration-time Curve From Time Zero Extrapolated to Infinite Time (AUC[0-infinity]) of GSK2857916 Following IV Dose in Participants With RRMM|Area Under the Concentration-time Curve Over the Dosing Interval (AUC[0-tau]) of GSK2857916 Following IV Dose in Participants With RRMM|Area Under the Concentration-time Curve From Zero to Time of Last Quantifiable Concentration (AUC[0-tlast]) of GSK2857916 Following IV Dose in Participants With RRMM|Maximum Observed Concentration (Cmax) of GSK2857916 Following IV Dose in Participants With RRMM|Time to Reach Maximum Observed Concentration (Tmax) of GSK2857916 Following IV Dose in Participants With RRMM|Terminal Half-life (t1/2) of GSK2857916 Following IV Dose in Participants With RRMM|AUC(0-infinity) of GSK2857916 Total Antibody Following IV Dose in Participants With RRMM|AUC(0-tau) of GSK2857916 Total Antibody Following IV Dose in Participants With RRMM|AUC(0-tlast) of GSK2857916 Total Antibody Following IV Dose in Participants With RRMM|Cmax of GSK2857916 Total Antibody Following IV Dose in Participants With RRMM|Tmax of GSK2857916 Total Antibody Following IV Dose in Participants With RRMM|t1/2 of GSK2857916 Total Antibody Following IV Dose in Participants With RRMM|AUC(0-infinity) of Cysteine-maleimidocaproyl Monomethyl Auristatin F (Cys-mcMMAF) Following IV Dose of GSK2857916 in Participants With RRMM|AUC(0-tau) of Cys-mcMMAF Following IV Dose of GSK2857916 in Participants With RRMM|AUC(0-tlast) of Cysteine-maleimidocaproyl Monomethyl Auristatin F (Cys-mcMMAF) Following IV Dose of GSK2857916 in Participants With RRMM|Cmax of Cys-mcMMAF Following IV Dose of GSK2857916 in Participants With RRMM|Tmax of Cys-mcMMAF Following IV Dose of GSK2857916 in Participants With RRMM|t1/2 of Cys-mcMMAF Following IV Dose of GSK2857916 in Participants With RRMM|Number of Participants With at Least One Confirmed Positive Post-Baseline Anti-drug Antibody (ADA) Result|Titers of Anti-drug Antibodies Against GSK2857916|Number of Participants With Symptomatic AEs Measured by Patient-reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE)|Worst Change From Baseline in National Eye Institute Visual Function Questionnaire-25 (NEI-VFQ-25) Overall Composite Score|Worst Change From Baseline in Ocular Surface Disease Index (OSDI) Total Score|Change From Baseline in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire 30-item Core Module (EORTC QLQ-C30) Score|Change From Baseline in EORTC QLQ 20-item Multiple Myeloma Module (MY20) Score\",\"Active, not recruiting\",\"Phase 2\"\n",
      "418,\"Clarithromycin, Sulfamethoxazole/Trimethoprim or Observation in Newly Diagnosed Multiple Myeloma\",\"Comparison of frequency of infections in patients treated with clarithromycin, sulfamethoxazole/trimethoprim or observed without prophylactic antibiotic\",\"One year\",\"Response rates in the group of patients treated with clarithromycin compared to the other patients in the study|Comparison of adverse events assessed by CTCAE v4.0 in patients treated with clarithromycin, sulfamethoxazole/trimethoprim or observed without prophylactic antibiotic|Comparison of overall survival between patients treated with clarithromycin, sulfamethoxazole/trimethoprim or observed without prophylactic antibiotic|Quality of life assessed by EORTC QLQ-MY20|Quality of life assessed by EORTC QLQ-C30\",\"Unknown status\",\"Phase 2\"\n",
      "419,\"A Phase 2 Study of Lenalidomide to Evaluate the Efficacy in Japanese Patients With Newly Diagnosed Multiple Myeloma\",\"Overall Response Rate\",\"From first dose until the data cut-off date of 15 July 2014. Median time on follow-up was 61.6 weeks.\",\"Time to Response|Duration of Response|Progression Free Survival (PFS)|Overall Survival (OS)|Number of Participants With Adverse Events\",\"Completed\",\"Phase 2\"\n",
      "420,\"Safety & Efficacy Study of Perifosine + Bortezomib +/- Dexamethasone for Multiple Myeloma Patients\",\"Phase I: Maximum Tolerated Dose (MTD). Phase II: To determine response rate.\",\"Every 3 weeks\",\"Phase II: Tolerability and Safety|Phase II: Correlative data\",\"Completed\",\"Phase 1|Phase 2\"\n",
      "421,\"Post Marketing Surveillance on Safety Evaluation of POMALYST® (Pomalidomide) Treatment of Multiple Myeloma in Korea\",\"Adverse events\",\"From enrollment until at least 28 days after completion of study treatment\",\"Overall response rate\",\"Recruiting\",\n",
      "422,\"Study Evaluating the Safety and Tolerability of Weekly Dosing of Oral IXAZOMIB in Adult Patients With Relapsed and Refractory Multiple Myeloma\",\"Number of Participants Reporting One or More Treatment-Emergent Adverse Events and Serious Adverse Events|Neurotoxicity Grading\",\"From the first dose through 30 days after last dose of ixazomib citrate or until the start of subsequent antineoplastic therapy (Up to 354 days)|Cycle 1 Day 1 and End of Study (Up to 354 days)\",\"Cmax: Maximum Observed Plasma Concentration for MLN2238|Tmax: Time to Reach the Maximum Observed Plasma Concentration (Cmax) for MLN2238|AUC(0-168): Area Under the Plasma Concentration-Time Curve From Time 0 to 168 Hours Postdose for MLN2238|Accumulation Ratio: Day 15 AUC0-168 / Day 1 AUC0-168 for MLN2238|Terminal Elimination Rate Constant (λz) for MLN2238|Terminal Phase Elimination Half-life (T1/2) for MLN2238|Emax: Maximum Inhibition|TEmax: Time of Occurrence of Emax|Overall Response to Treatment With Ixazomib Citrate Based on Investigator's Evaluation Over Time\",\"Completed\",\"Phase 1\"\n",
      "423,\"\"\"WB-DCE-MRI\"\" in Multiple Myeloma as an Independent Prognostic Factor for Disease-free Survival\",\"Maximal percentage of bone marrow measurement on last WB DCE MRI\",\"Measurements will be performed on initialWB DCE MRI Examination. Follow-up = Five year\",\"Maximal percentage of bone marrow measurement on initial WB DCE MRI\",\"Completed\",\"Not Applicable\"\n",
      "424,\"A Study of CC-5013 Plus Dexamethasone Versus Dexamethasone Alone in Previously Treated Subjects With Multiple Myeloma\",\"Kaplan-Meier Estimate of Time to Tumor Progression (TTP)|Kaplan-Meier Estimate of Time to Tumor Progression (TTP) (Later Cut-off Date of 02 Mar 2008)\",\"From randomization up to cut-off date of 03 August 2005; up to 24 months|From randomization up to cut-off date of 02 March 2008; up to 51 months\",\"Kaplan-Meier Estimate of Overall Survival (OS)|Kaplan-Meier Estimate of Overall Survival (OS) (Later Cut-off Date of 02 March 2008)|Summary of Myeloma Response Rates Based on Best Response Assessment|Myeloma Response Rates Based on the Reviewers Best Response Assessment (Later Cut-off Date of 02 March 2008)|Number of Participants With Adverse Events (AE)|Time to First Symptomatic Skeletal-related Event (SRE) (Clinical Need for Radiation or Surgery to Bone)|Time to First Worsening on the Eastern Cooperative Oncology Group (ECOG) Performance Scale|Time to First Worsening on the Eastern Cooperative Oncology Group (ECOG) Performance Scale (Later Cut-off Date of 02 March 2008)\",\"Completed\",\"Phase 3\"\n",
      "425,\"Study of Weekly Carfilzomib, Cyclophosphamide and Dexamethasone In Newly Diagnosed Multiple Myeloma Patients (wCCyd)\",\"Identification of Dose-limiting toxicity (DLT)|Partial Response (PR)\",\"1 year|1 year\",\"Response rate (RR)|Progression free-survival (PFS)|Time to progression (TTP)|Duration of response (DOR)|Overall survival (OS)|Time to next therapy (TTNT)|Responses|Response and survival|Maintenance\",\"Active, not recruiting\",\"Phase 1|Phase 2\"\n",
      "426,\"Master Protocol for the Phase 1 Study of Cell Therapies in Multiple Myeloma\",\"Incidence of treatment-emergent adverse events (TEAEs), including DLT(s)|Establish the RP2D of the investigational agent\",\"24 months|24 months\",\"Best overall response (BOR) by IMWG Consensus Criteria|ORR by IMWG Consensus Criteria|In vivo pharmacokinetics\",\"Recruiting\",\"Phase 1\"\n",
      "427,\"Expanded Access Protocol (EAP) to Provide Bortezomib to Patients With Multiple Myeloma Who Have Received at Least 2 Previous Lines of Therapy and Are Refractory to or Have Relapsed After Their Last Therapy for Multiple Myeloma\",,,,\"Completed\",\n",
      "428,\"BB-10901 in Treating Patients With Relapsed and/or Refractory Multiple Myeloma\",\"Dose-limiting toxicity|Maximum tolerated dose\",\"through cycle 1|for the duration of the study\",\"Qualitative and quantitative toxicities|Pharmacokinetics|Anti-tumor activity including overall response rate, time to progression and survival\",\"Completed\",\"Phase 1\"\n",
      "429,\"Bortezomib (Velcade) in Patients With Untreated Multiple Myeloma\",\"Objective Response (OR) Rate\",\"Response was assessed every two cycles on treatment. Treatment duration in months was a median (range) of 5.1 (0.8-6.1).\",\"Very Good Partial Response (VGPR) Rate|Time to Progression (TTP)|Progression-Free Survival (PFS)|Number of Participants With Treatment-Emergent Sensory Neuropathy|Number of Participants With Treatment-Emergent Neuropathic Pain\",\"Completed\",\"Phase 2\"\n",
      "430,\"Bortezomib Before Donor Stem Cell Transplant in Treating Patients With Multiple Myeloma\",\"Tolerability as assessed by CTCAE v3.0 (Phase I)|Assessment of toxicity (Phase I)|Proportion of successes|Transplant-related mortality (TRM) (Phase II)|Rate acute graft-vs-host disease (GVHD) (Phase I)\",\"100 days\",\"Rate of grades II-IV and grades III-IV acute graft-vs-host disease (GVHD)|Cumulative rate of chronic GVHD|Overall response|Overall survival|Progression-free survival\",\"Withdrawn\",\"Phase 1|Phase 2\"\n",
      "431,\"A Safety Study of Human Cord Blood Derived, Culture-expanded, Natural Killer Cell (PNK-007) Infusion With or Without Subcutaneous Recombinant Human Interleukin-2 (rhIL-2) Following Autologous Stem Cell Transplant for Multiple Myeloma (MM)\",\"Dose-Limiting Toxicity (DLT)|Maximum Tolerated Dose (MTD)|Dose Timing After Autologous Stem Cell Transplant|Adverse Events (AEs)\",\"Up to 28 days|Up to 28 days|Up to 28 days|Up to 12 months\",\"Response Rate\",\"Completed\",\"Phase 1\"\n",
      "432,\"The Effect of High Dose Simvastatine on Multiple Myeloma\",\"Response estimated by internationally approved criteria after 8 weeks of intermittend treatment with simvastatine\",\"8 weeks after treatment start\",\"Changes in markers of bone metabolisme after 8 weeks of intermittend treatment with simvastatine|Toxicity according to CTC after 8 weeks of intermittend treatment with simvastatine\",\"Completed\",\"Phase 1|Phase 2\"\n",
      "433,\"Carfilzomib, Lenalidomide, and Dexamethasone for Smoldering Multiple Myeloma\",\"Percentage of Participants With Minimal Residual Disease (MRD)Negative Complete Response (CR) Per International Myeloma Working Group (IMWG) Criteria\",\"8 months\",\"Percentage of Participants That Have Minimal Residual Disease (MRD)-Negative Complete Response (CR) for a Minimum of 1 Year|Number of Participants With Serious and/or Non-serious Adverse Events Assessed by the Common Terminology Criteria for Adverse Events (CTCAE v4.0)|Clinical Progression Free Survival|Biochemical Progression Free Survival|Duration of Response|Overall Response Rate\",\"Active, not recruiting\",\"Phase 2\"\n",
      "434,\"A Study of Belantamab Mafodotin and Nirogacestat in People With Multiple Myeloma That Has Not Responded to Treatment or Has Come Back After Treatment\",\"Number of Participants who Experienced Dose-Limiting Toxicities (DLTs)\",\"up to six weeks\",\"Clinical Response\",\"Recruiting\",\"Phase 1\"\n",
      "435,\"ctDNA Methylation Sequencing for Myeloma\",\"Sample Collection Completed\",\"From Aug 31 2022 to Jun 30 2025\",,\"Recruiting\",\n",
      "436,\"A Phase I Study of Ganetespib +/- Bortezomib in Patients With Relapsed and/or Refractory Multiple Myeloma\",\"Maximum tolerated dose (MTD) of ganetespib in combination with bortezomib and dexamethasone.\",\"30 days after final cycle\",,\"Completed\",\"Phase 1\"\n",
      "437,\"BCMA Chimeric Antigen Receptor Expressing T Cells in Multiple Myeloma\",\"Safety measured by occurrence of study related adverse effects defined by NCI CTCAE 4.0\",\"6 months\",\"Overall complete remission rate defined by the standard response criteria for malignant lymphoma for each arm|Duration of CAR-positive T cells in circulation|Total number of CAR-positive T cells infiltrated into lymphoma tissue\",\"Unknown status\",\"Phase 1\"\n",
      "438,\"APRIL CAR-T Cell Therapy for Patients With BCMA/TACI Positive Relapsed and/or Refractory Multiple Myeloma\",\"Dose-limiting toxicity (DLT)|Incidence of treatment-emergent adverse events (TEAEs)\",\"Baseline up to 28 days after APRIL targeted CAR T-cells infusion|Time Frame: Up to 2 years after APRIL targeted CAR T-cells infusion\",\"Multiple Myeloma (MM), Overall response rate (ORR)|MM, Overall survival (OS)|MM, Event-free survival (EFS)|Quality of life including sports activity|Activities of Daily Living (ADL) score|Instrumental Activities of Daily Living (IADL) score|Hospital Anxiety and Depression Scale (HADS) score\",\"Recruiting\",\"Early Phase 1\"\n",
      "439,\"AHSCT Combined With CAR-T Cells in the Treatment of Refractory and Relapsed Multiple Myeloma\",\"Dose-limiting toxicity (DLT)|Incidence of treatment-emergent adverse events (TEAEs)\",\"Baseline up to 28 days after BCMA CAR T-cells infusion|24 months after cell infusion\",\"overall response rate|Complete response rate(CRR)|Overall survival (OS)|Duration of response(DOR)|Progression-free survival (PFS)\",\"Recruiting\",\"Phase 1\"\n",
      "440,\"Phase 1-2 Amrubicin in Combo With Lenalidomide + Weekly Dexamethasone in Relapsed/Refractory Multiple Myeloma\",\"Response Rates After Amrubicin + Lenalidomide + Dexamethasone, Per International Myeloma Working Group Uniform Response Criteria\",\"12 weeks\",\"Duration of Response (DOR)|Progression-free Survival (PFS)|Time-to-next Treatment\",\"Completed\",\"Phase 1|Phase 2\"\n",
      "441,\"Safety, Efficacy and Pharmacokinetic Study of PRLX 93936 in Patients With Multiple Myeloma\",\"Maximum Tolerated Dose\",\"Cycle 1 (28 days from first dose)\",\"Response to treatment|Time to response|Duration of response|Time to progression\",\"Unknown status\",\"Phase 1|Phase 2\"\n",
      "442,\"Study of Dual Targeted CD19/BCMA FASTCART GC012F in Relapsed/ Refractory Multiple Myeloma\",\"Dose limitinged toxicity（DLT）after GC012F infusion|Adverse Events (AE) after infusion\",\"Up to 21 days after patients infused with GC012F injectiom|Up to 48 weeks after patients infused with GC012F injectiom\",\"Overall Response Rate(ORR)|Progression-free survival (PFS), Overall Survival (OS), Duration Of Response (DOR)|CAR-T cell counts and number of CAR gene copies\",\"Recruiting\",\"Phase 1\"\n",
      "443,\"Interleukin-12 in Treating Patients With Multiple Myeloma\",,,,\"Completed\",\"Phase 2\"\n",
      "444,\"Phase 2 Clinical Trial of NPI-0052 in Patients With Relapsed or Relapsed/Refractory Multiple Myeloma\",\"Number of Patients Exhibiting a Given Overall Response as Determined by Investigator\",\"Through study completion, an average of 6.09 weeks.\",\"Duration of MRZ Treatment|Number of Cycles of Marizomib (MRZ)|Number of Patients Receiving Marizomib (MRZ) in Each Cycle|Number of Patients With Treatment Emergent Adverse Events (TEAEs)|Number of Treatment Emergent Adverse Events (TEAEs)|Maximum Observed Blood Drug Concentration (Cmax)\",\"Completed\",\"Phase 2\"\n",
      "445,\"Oblimersen, Thalidomide, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma\",\"Complete and partial remission\",,\"Relationship between molecular and clinical outcomes\",\"Completed\",\"Phase 2\"\n",
      "446,\"Study of Venetoclax in Combination With Carfilzomib and Dexamethasone in Participants With Relapsed or Refractory Multiple Myeloma (MM)\",\"Number of Participants with Adverse Events|Very Good Partial Response (VGPR) or Better Response Rate of VenKd in Participants with Relapsed or Refractory Multiple Myeloma (RRMM) as well as Those with t(11;14)-positive RRMM|Objective Response Rate (ORR) of VenKd in Participants with Relapsed or Refractory Multiple Myeloma (RRMM) as well as Those with t(11;14)-positive RRMM|Complete Response (CR) or Better Rate of VenKd in Participants with Relapsed or Refractory Multiple Myeloma (RRMM) as well as Those with t(11;14)-positive RRMM\",\"First dose of study drug through at least 30 days after end of treatment (approximately 2 years)|First dose of study drug through at least 30 days after end of treatment (approximately 2 years)|First dose of study drug through at least 30 days after end of treatment (approximately 2 years)|First dose of study drug through at least 30 days after end of treatment (approximately 2 years)\",\"Very Good Partial Response (VGPR) or Better Response Rate in Participants with Relapsed or Refractory Multiple Myeloma and in a Subset of Participants with High B-cell lymphocyte-2 (BCL-2) Expression|Progression-free survival (PFS) in Participants with Relapsed or Refractory Multiple Myeloma and in a Subset of Participants with High B-cell lymphocyte-2 (BCL-2) Expression|Minimal residual disease (MRD)|Duration of Overall Response (DOR) in Participants with Relapsed or Refractory Multiple Myeloma and in a Subset of Participants with High B-cell lymphocyte-2 (BCL-2) Expression|Time to progression (TTP) in Participants with Relapsed or Refractory Multiple Myeloma and in a Subset of Participants with High B-cell lymphocyte-2 (BCL-2) Expression|Objective response rate (ORR) in Participants with Relapsed or Refractory Multiple Myeloma and in a Subset of Participants with High B-cell lymphocyte-2 (BCL-2) Expression|Time to Response (TTR) in Participants with Relapsed or Refractory Multiple Myeloma and in a Subset of Participants with High B-cell lymphocyte-2 (BCL-2) Expression|Area under the plasma concentration-time curve from 0 to 24 hours (AUC0-24) post-dose of Venetoclax|Clearance (CL) of Carfilzomib|Terminal Phase Elimination Rate Constant (β) of Carfilzomib|AUC from 0 to Infinity (AUC∞) of Carfilzomib|AUC from Time 0 to the Time of the Last Measurable Concentration (AUCt) of Carfilzomib|Maximum Plasma Concentration (Cmax) of Venetoclax|Cmax of Carfilzomib|Terminal Elimination Half-life (t1/2) of Carfilzomib|Time to Maximum Plasma Concentration (Peak Time, Tmax) of Venetoclax\",\"Recruiting\",\"Phase 2\"\n",
      "447,\"A Study Evaluating Venetoclax (ABT-199) in Multiple Myeloma Subjects Who Are Receiving Bortezomib and Dexamethasone as Standard Therapy\",\"Progression-free survival (PFS).\",\"Measured at subject's baseline (prior to subject's first dose) and at Day 1 of every Cycle thereafter for up to 3 years following the last subject first dose.\",\"Brief Pain Inventory - Short Form [BPI-SF] - Worst Pain|Duration of Response (DOR).|Progression-Free Survival (PFS) in subjects with high B-cell lymphoma 2 (BCL-2) expression.|Minimal Residual Disease (MRD) status.|Objective Response Rate (ORR).|Patient Reported Outcomes Measurement Information System - (PROMIS)|European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core (EORTC QLQ-C30) - Physical Functioning|Overall survival (OS).|European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core (EORTC QLQ-C30) - Global Health Status|Very Good Partial Response (VGPR) or better response rate.|Time to disease progression (TTP).\",\"Completed\",\"Phase 3\"\n",
      "448,\"Lenalidomide and High Dose Melphalan Followed by Autologous Stem Cell Transplant in Multiple Myeloma\",\"Phase I: Number of Patients With Dose Limiting Toxicity|Phase II: Overall Response Rate\",\"up to 1 month|up to 5 years\",\"Phase II: Treatment-Related Adverse Events Grade 3 or Higher\",\"Completed\",\"Phase 1|Phase 2\"\n",
      "449,\"INCB001158 Combined With Subcutaneous (SC) Daratumumab, Compared to Daratumumab SC, in Relapsed or Refractory Multiple Myeloma\",\"Phase 1: Number of Participants With Any Treatment-emergent Adverse Event (TEAE)|Phase 2: Overall Response Rate (ORR): Number of Participants With a Documented Response of Complete Response (CR), Very Good Partial Response (VGPR), or PR, as Per International Myeloma Working Group (IMWG) Criteria\",\"up to 454 days|up to Day 386\",\"Phase 1: ORR: Number of Participants With a Documented Response of CR, VGPR, or PR, as Per IMWG Criteria|Phase 2: Number of Participants With Any TEAE|Phase 1: Time to Response, Defined as the Time From the First Dose of Study Drug to the First Documented Response of PR or Better (CR, VGPR, or PR), as Per IMWG Criteria|Phase 2: Time to Response, Defined as the Time From the First Dose of Study Drug to the First Documented Response of PR or Better (CR, VGPR, or PR), as Per IMWG Criteria|Phase 1: Duration of Response, Defined as Time From First Documented Response of PR or Better (CR, VGPR, PR), as Per IMWG Criteria, Until Date of Disease Progression or Death, Whichever Occurred First|Phase 2: Duration of Response, Defined as Time From First Documented Response of PR or Better (CR, VGPR, PR), as Per IMWG Criteria, Until Date of Disease Progression or Death, Whichever Occurred First|Progression-free Survival (PFS), Defined as the Duration From the Date of the First Dose of Study Drug Until Either Progressive Disease, as Per IMWG Criteria, or Death, Whichever Occurred First|Phase 1: Minimal Residual Disease (MRD), Defined as the Percentage of MRD-negative Participants|Phase 2: MRD, Defined as the Percentage of MRD-negative Participants|Overall Survival\",\"Terminated\",\"Phase 1|Phase 2\"\n",
      "450,\"Safety and Efficacy Study of Imexon for Treatment of Multiple Myeloma Patients\",\"Determine the maximally tolerated dose of imexon in multiple myeloma patients|evaluate the toxicity of imexon|Preliminarily evaluate efficacy in terms of response and progression free survival.\",,\"Evaluate biomarker responses.\",\"Completed\",\"Phase 1|Phase 2\"\n",
      "451,\"Urinary Protein/Creatinine Ratio in a Single Urine Sample Versus 24-hour Proteinuria in Patients With Multiple Myeloma\",\"change in urinary protein/creatinine ratio\",\"Change from baseline in urinary protein/creatinine ratio at 8 AM, 12 AM, 4 PM\",\"changes in urinary excretion of FLC|methods for estimating the urinary concentration of FLC\",\"Completed\",\n",
      "452,\"Conditioning Regimen of Bendamustine and Melphalan Followed by Transplant in Patients With Multiple Myeloma\",\"Maximum Tolerated Dose (Phase 1)|Overall Response Rate (Phase 2) - Number of Participants Achieving at Least a Partial Response or Better in Disease Status at Day 100 Post-transplant\",\"35 days post-transplant|100 days post-transplant\",\"Progression-Free Survival (Phase 1)|Progression-Free Survival (Phase 2)|Overall Survival at 2 Years (Phase 1)|Overall Survival at 3 Years (Phase 2)\",\"Completed\",\"Phase 1|Phase 2\"\n",
      "453,\"Study of the Safety and Effectiveness of LGH447 and BYL719 in Patients With Relapsed and Refractory Multiple Myeloma\",\"Phase Ib: Number of Total Dose-limiting Toxicities (DLT)|Phase II: Overall Response Rate (ORR) as assessed by Investigators\",\"Cycle 1 (28 days)|29 months (End of Study)\",\"Phase II: Percent change of ORR (Overall Response Rate) between the two arms|Number of participants with adverse events, serious adverse events, changes in laboratory values, and electrocardiograms (ECGs), as a measure of safety and tolerability.|Determine single and multiple dose Pharmacokinetics (PK) profiles|Changes between pre- and post-treatment levels of pS6RP and 4EBP1 levels in bone marrow aspirates and 4EBP1 in peripheral blood|Phase II: Absolute difference in ORR|Disease Control Rate|Progression Free Survival|Time to response|Duration of Response\",\"Completed\",\"Phase 1\"\n",
      "454,\"Sorafenib, Lenalidomide, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma\",\"Number of Participants With a Grade 3 and 4 Adverse Event (Phase I)|Number of Participants Who Achieve a Confirmed Response (Partial Response [PR], Very Good PR [VGPR], Complete Response [CR], or Stringent CR [sCR]) (Phase II)\",\"up to 3 years|Duration on Treatment (up to 3 years)\",\"Overall Survival (Phase II)|Time to Disease Progression (Phase II)|Changes in Microvessel Density From Baseline to Post-treatment and Correlation With > Clinical Outcomes (Phase II)|Change in Apoptosis Rate From Baseline to Post-treatment and Correlation With > Clinical Outcomes (Phase II)|Plasma Cell Gene Expression Profiles and Correlation With > Clinical Outcomes|Percentage of Stained Circulating Endothelial Cells and Endothelial Progenitor Cells and Correlation With Clinical Outcomes (Phase II|Change in VEGF Expression Levels and Correlation With Clinical Outcomes (Phase II)\",\"Terminated\",\"Phase 1\"\n",
      "455,\"B Cell Maturation Antigen（BMCA）-Targeted CAR-T for Refractory/Relapsed Multiple Myeloma\",\"complete remission rate|incidence and severity of adverse events\",\"at the time point 3 months after CAR-T cell transfusion|from the date of the start of treatment to 36 months after last patient's enrollment\",\"progression free survival|overall survival|duration of the CAR-T cells in the patients\",\"Unknown status\",\"Phase 2\"\n",
      "456,\"Carfilzomib, Lenalidomide, and Dexamethasone in New Multiple Myeloma Patients\",\"Number of Participants With Serious and Non-serious Adverse Events\",\"4 years and 9 months and 2 days\",\"Overall Response Rate|Progression Free Survival (PFS) at 48 Months|Percentage of Responders With Duration of Response (DOR) at 48 Months|Overall Survival (OS) Rate|Cluster of Differentiation 138 (CD138) + Plasma Cells Gene Expression Profiling on Pre and Post Carfilzomib Exposure Bone Marrow Samples|Rate of Minimal Residual Disease (MRD) by Flow Cytometry|Complete Response (CR) and Minimal Residual Disease Neg (MRDneg) CR Rates at Treatment Intervals With Carfilzomib, Lenalidomide & Dexamethasone (CRd) in New Multiple Myeloma Patients After 8 Cycles of Induction, 1 Year Maintenance, and 2 Years Maintenance\",\"Completed\",\"Phase 2\"\n",
      "457,\"Mobilization of Stem Cells With AMD3100 (Plerixafor) and G-CSF in Non-Hodgkin's Lymphoma and Multiple Myeloma Patients\",\"Number of Participants in Overall Safety Summary of Treatment Emergent Adverse Events (TEAE)\",\"Day 1 to approximately Day 38 (before start of chemotherapy)\",\"Number of Participants Achieving a Two-Fold (Relative) Increase in Peripheral Blood (PB) CD34+ Cells/µL Following the First Dose of Plerixafor|Number of Transplants in Which Participants Achieved Polymorphonuclear Leukocyte (PMN) Engraftment by Day 12 But No Later Than Day 21 Post Peripheral Blood Stem Cell (PBSC) Transplant\",\"Completed\",\"Phase 2\"\n",
      "458,\"Trial of Carfilzomib, Lenalidomide, Dexamethasone Versus Lenalidomide Alone After Stem-cell Transplant for Multiple Myeloma\",\"Progression free survival rates in participants receiving drug combination\",\"4 years\",\"Rate of minimal residual negative disease (MRD) in participants receiving drug combination|Response rate in participants receiving drug combination|Treatment-related side effects\",\"Active, not recruiting\",\"Phase 3\"\n",
      "459,\"Thalidomide for Multiple Myeloma\",\"Maximum Tolerated Dose of Thalidomide\",\"14 day cycles\",,\"Completed\",\"Phase 3\"\n",
      "460,\"Bendamustine + Pomalidomide + Dex in R/R Multiple Myeloma\",\"Maximum Tolerated Dose of Pomalidomide and Bendamustine|Initial Response Rate\",\"2 cycles (approximately 2 months)|2 cycles (approximately 2 months)\",\"Overall Response Rate|Time to Progression|Time to Next Therapy|Progression Free Survival\",\"Unknown status\",\"Phase 1|Phase 2\"\n",
      "461,\"A Study of Motexafin Gadolinium for the Treatment of Relapsed or Refractory Multiple Myeloma\",\"Rate of complete response, partial response and stable disease (clinical benefit rate)\",,\"Progression-free survival|Safety and tolerability\",\"Completed\",\"Phase 2\"\n",
      "462,\"Clarithromycin in Multiple Myeloma Induction Therapy\",\"Comparison of number of participants with very good partial response or better response after three courses of VCD combined with clarithromycin or placebo\",\"10 weeks\",\"Comparison of number of participants with very good partial response or better response after HDT in patients treated with three courses of VCD combined with clarithromycin or placebo|Comparison of number of participants with sCR, CR, PR, PD or SD in the treatment groups after induction therapy and HDT, respectively|Comparison of frequency of infections in patients treated VCD combined with clarithromycin or placebo|Comparison of number of stem cells harvested in patients treated with clarithromycin and placebo in combination with VCD|Neurotoxicity assessed by FACT/GOG-Ntx, Version 4.0|Quality of life assessed by EORTC QLQ-MY20|Quality of life assessed by EORTC QLQ-C30|Comparison of adverse events in patients treated VCD combined with clarithromycin or placebo assessed by CTCAE v4.0\",\"Terminated\",\"Phase 2\"\n",
      "463,\"Study of Oral Ixazomib in Adult Participants With Relapsed and/or Refractory (RR) Multiple Myeloma\",\"Number of Participants With One or More Treatment-emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)|Number of Participants With Clinically Significant Abnormalities Reported as TEAEs|Number of Participants With a TEAE of Peripheral Neuropathy|Number of Participants With Clinically Significant Changes in Vital Signs Reported as TEAEs|Maximum Tolerated Dose (MTD) of Ixazomib|Recommended Phase 2 Dose (RP2D) of Ixazomib\",\"From first dose of the study drug through 30 days after the last dose of study drug or start of subsequent antineoplastic therapy (Up to 81.1 months)|From first dose of the study drug through 30 days after the last dose of study drug or start of subsequent antineoplastic therapy (Up to 81.1 months)|From first dose of the study drug through 30 days after the last dose of study drug or start of subsequent antineoplastic therapy (Up to 81.1 months)|From first dose of the study drug through 30 days after the last dose of study drug or start of subsequent antineoplastic therapy (Up to 81.1 months)|Cycle 1 (21 days)|Cycle 1 through Cycle 39 (Up to 28.3 months)\",\"Cmax: Maximum Observed Plasma Concentration for Ixazomib|Tmax: Time to Reach the Maximum Plasma Concentration (Cmax) for Ixazomib|AUC(0-last): Area Under the Plasma Concentration-Time Curve From Time 0 to the Time of the Last Quantifiable Concentration for Ixazomib|AUC(0-72): Area Under the Plasma Concentration-Time Curve From Time 0 to 72 Hours Postdose for Ixazomib|λz: Terminal Disposition Phase Rate Constant for Ixazomib|T1/2: Terminal Disposition Phase Elimination Half-life for Ixazomib|CL/F: Blood Clearance Calculated Using the Observed Value of the Last Quantifiable Concentration for Ixazomib|Emax: Maximum Observed Effect for Ixazomib|TEmax: Time to Maximum Observed Effect (Emax) for Ixazomib|Overall Response Rate (ORR)\",\"Completed\",\"Phase 1\"\n",
      "464,\"Economic Evaluation of the Use of Plerixafor for Autologous HSC Transplantation for Multiple Myeloma\",\"Cost-effectiveness analysis\",\"1 year\",,\"Completed\",\n",
      "465,\"MAGE-A3 Protein + AS15 as Consolidation for Multiple Myeloma Patients Undergoing Autologous Stem Cell Transplantation\",\"Assessment of Safety of recMAGE-A3 + AS15\",\"Continuously for up to 14 months\",\"Induction or Augmentation of MAGE-A3-Specific Humoral Immunity|Induction or Augmentation of MAGE-A3-Specific Cellular Immunity|Assessment of Tumor Response|Assessment of Survival and Time to Subsequent Therapy\",\"Completed\",\"Phase 1\"\n",
      "466,\"Interferon Alfa Following Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Stage III or Stage IV Multiple Myeloma\",,,,\"Completed\",\"Phase 2\"\n",
      "467,\"Telo Genomics Technology to Detect & Profile Multiple Myeloma MRD\",\"To validate the sensitivity of Telo Genomics assay (measurement tool) to detect MRD (measurement expressed in the number of plasma cells per 100000 cells) and establish the clinical utility of TELO - DMRD for MRD enumeration|To assess the utility of TeloView® technology genomic profiling (measurement tool) to stratify post-transplant MM patients into relapse risk groups (dichotomous measure of high or low) by analyzing the residual MRD plasma cells\",\"Approximately 5 years|Approximately 5 years\",,\"Not yet recruiting\",\n",
      "468,\"Combination Chemo, Peripheral Stem Cell Transplant, Biological Therapy, Pamidronate and Thalidomide for Multiple Myeloma\",\"Best Response Prior to Tandem Autologous Stem Cell Transplant|Response After Tandem Autologous Stem Cell Transplant|Three-year Overall Survival|Progression-free Survival|Best Response at 6 Months Post Tandem Autologous Stem Cell Transplant|Best Response After Tandem Autologous Stem Cell Transplant and Maintenance\",\"From enrollment in the study until day -8: before dilantin given pre-first high-dose chemo preceeding first cycle of tandem autologous cell transplant|After second cycle of tandem autologous stem cell transplant: Day 0 of second transplant to 12 weeks post-cycle 2 cell infusion of the tandem transplant.|Estimate reported at three years after day 0 of the first cycle of infusion of cells of the tandem transplant.|Estimate reported at three years after day 0 of the first cycle of infusion of cells of the tandem transplant.|Six months after day 0 of the first cycle of the tandem autologous stem cell transplant. This will be used to determine administration of thalidomide.|Response after six months after day 0 of the first cycle of the tandem transplant, after administration of maintenance thalidomide if necessary, until three years post-day 0 of the first cycle of the tandem transplant.\",,\"Completed\",\"Phase 2\"\n",
      "469,\"A Non-interventional,Observational Post Authorization Study of Patients With Multiple Myeloma Treated With Lenalidomide TR\",\"Adverse Events (AEs)\",\"Up to 5 years\",,\"Unknown status\",\n",
      "470,\"MEDI-551 as Maintenance Therapy After Allogeneic Stem Cell Transplant in Multiple Myeloma\",\"Progression Free Survival\",\"5 years\",,\"Terminated\",\"Phase 2\"\n",
      "471,\"Cyclophosphamide, Bortezomib, and Dexamethasone in Treating Patients With Newly Diagnosed Multiple Myeloma\",\"Number of Participants Who Achieved a Confirmed Responses Defined as a Complete Response (CR), Near CR or Very Good Partial Response (VGPR) After the First 4 Months of Treatment\",\"After 4 months of treatment\",\"Progression Free Survival (PFS)|Overall Survival (OS)|Number of Participants Who Responded to Treatment (Complete Response,CR; Near Complete Response, nCR; Very Good Partial Response, VGPR; or Partial Response, PR) After 4 Cycles|Duration of Response|Number of Participants Who Responded to Treatment (CR, nCR, VGPR or PR) After 8 Cycles|Number of Participants Who Responded to Treatment (CR, nCR, VGPR or PR) After 12 Cycles|Number of Participants With Severe Adverse Events|Participants Who Successfully Completed Collection of Peripheral Blood Stem Cells for Transplant\",\"Completed\",\"Phase 2\"\n",
      "472,\"A Study of BCMA CAR-T Cell Therapy for Newly Diagnosed Multiple Myeloma\",\"Dose-limiting toxicity (DLT)|Incidence of treatment-emergent adverse events (TEAEs)\",\"Baseline up to 28 days after BCMA CAR T-cells infusion|Baseline up to 2 years after BCMA CAR T-cells infusion\",\"Multiple Myeloma (MM), Overall response rate (ORR)|Complete response rate(CRR)|Partial response Rate (PRR)|Overall survival\",\"Recruiting\",\"Phase 2\"\n",
      "473,\"Relapse Myeloma; Cyclofosfamide; Bortezomib; Maintenance\",\"Toxicity of induction chemotherapy according to CTCAE version 3.0\",\"5 years\",\"Progression Free Survival|Overall Survival\",\"Completed\",\"Phase 2\"\n",
      "474,\"A Phase 3 Study Comparing Oral Ixazomib Plus Lenalidomide and Dexamethasone Versus Placebo Plus Lenalidomide and Dexamethasone in Adult Participants With Relapsed and/or Refractory Multiple Myeloma\",\"Progression Free Survival (PFS) as Assessed by the Independent Review Committee (IRC)\",\"From date of randomization until disease progression or death up to approximately 27 months (approximate median follow-up 15 months)\",\"Overall Survival (OS)|Overall Survival in High-Risk Participants Carrying Deletion 17 [Del(17)]|Overall Response Rate (ORR) as Assessed by the IRC|Percentage of Participants With Complete Response (CR) and Very Good Partial Response (VGPR) as Assessed by the IRC|Duration of Response (DOR)|Time to Progression (TTP) as Assessed by the IRC|Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)|Number of Participants With Change From Baseline in Pain Response|Change From Baseline in the European Organization for Research and Treatment of Cancer (EORTC) Core Quality of Life (QOL) Questionnaire (EORTC-QLQ-C30)|Change From Baseline in the European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire Multiple Myeloma Module (QLQ-MY-20)|OS in High-Risk Participants|PFS in High-Risk Participants|Plasma Concentration Over Time for Ixazomib|Overall Response Rate in Participants Defined by Polymorphism\",\"Completed\",\"Phase 3\"\n",
      "475,\"Higher Frequency Zoledronic Acid in the Treatment of Multiple Myeloma\",\"1. To determine response rates (RR) and disease progression rates in all MM patients treated with dtZ regimen.\",\"4 months\",\"To assess overall survival (OS) in all patients treated with dtZ regimen.|Assessment of incidence of skeletal related events (SREs).|Assessment of percent change in renal function in all patients.\",\"Completed\",\"Phase 2\"\n",
      "476,\"Anakinra With or Without Dexamethasone in Treating Patients With Smoldering or Indolent Multiple Myeloma\",\"Patients With Confirmed Response (Complete Response, Very Good Partial Response, Partial Response, or Minimal Response) on 2 Consecutive Months During the First 6 Months of Treatment With Anakinra Alone\",\"6 months\",\"Number of Patients With Response to Treatment With Dexamethasone and Anakinra|Number of Patients Who Are Progression-free and Alive at 6 Months|Number of Patients With Severe Non-hematological Adverse Events in Patients Receiving Anakinra Alone or in Combination With Dexamethasone.|Progression Free Survival (PFS) in Patients Treated With Anakinra Alone or in Combination With Dexamethasone|Number of Patients With Severe Non-hematological Adverse Events in Participants Receiving Anakinra in Combination With Dexamethasone|Duration of Response\",\"Completed\",\"Phase 2\"\n",
      "477,\"Aurora A Kinase Inhibitor MLN8237 and Bortezomib in Treating Patients With Relapsed or Refractory Multiple Myeloma\",\"Dose-limiting Toxicity (DLT) (Phase I)|Overall Response Rate to the Combination of MLN8237 and Bortezomib in Patients With Relapsed or Refractory Multiple Myeloma.\",\"28 days|Every 28 day cycle(up to 10 cycles)\",\"Progression-free Survival|Overall Survival\",\"Completed\",\"Phase 1|Phase 2\"\n",
      "478,\"Combination CCI-779 (Temsirolimus) and Bortezomib (Velcade) in Relapsed and/or Relapsed/Refractory Multiple Myeloma\",\"Toxicity. Number of Patients With Specific Toxicities Are Reported.|Best Response to Combination Treatment\",\"10 months|10 months\",\"Progression-Free Survival\",\"Completed\",\"Phase 1|Phase 2\"\n",
      "479,\"Exploratory Trial to Estimate Proportion of Patients With Tumor Cell Contaminated Leukapheresis Products With and Without Bortezomib With In-vivo Purging - Multiple Myeloma (MM)\",\"Multiparametric Flow Cytometry - Minimum Residual Disease\",\"Day 0 for all subjects (Day 0 is the day of stem cell collection)\",\"Multiparametric Flow Cytometry - Cluster of Differentiation 34 (CD34)Assessment|Cluster of Differentiation 34 (CD34) Enumeration\",\"Completed\",\"Phase 2\"\n",
      "480,\"Role of BCL-B in Multiple Myeloma\",\"To determine whether BCL-B is a survival factor in malignant plasmocytes, we will analyse the level of expression of Bcl-B at the both mRNA and protein levels in a cohort of MGUS and MM patients.\",\"6 months\",\"To determine whether deregulation of BCL-B expression is associated to chimioresistances commonly observed in Multiple Myeloma, We will compare Bcl-B expression in MM patients either sensitive or resistant to conventional therapies.\",\"Unknown status\",\n",
      "481,\"Melphalan, Prednisone, and CC-5013 (Revlimid) as Induction Therapy in Multiple Myeloma\",\"SAFETY AND EFFICACY\",,\"PROGRESSION FREE SURVIVAL AND OVERALL SURVIVAL\",\"Completed\",\"Phase 1|Phase 2\"\n",
      "482,\"Study to Evaluate the Combination of Bendamustine, Bortezomib and Dexamethasone (BBD) in the First-Line Treatment of Patients With Multiple Myeloma Who Are Not Candidates for High Dose Chemotherapy\",\"Complete Response Rate|Number of Patients Who Experienced Serious and Non-serious Adverse Events\",\"every 8 weeks for approximately 48 months|approximately 36 weeks\",\"Progression Free Survival|Overall Survival|Overall Response Rate\",\"Completed\",\"Phase 2\"\n",
      "483,\"Thalidomide and Prednisone After Autologous Stem Cell Transplantation Multiple Myeloma\",\"Overall Survival\",\"11 years\",\"Disease Progression-free Survival\",\"Completed\",\"Phase 3\"\n",
      "484,\"Pegylated Liposomal Doxorubicin, Bortezomib, Dexamethasone and Lenalidomide for Relapsed/Refractory Multiple Myeloma\",\"International Myeloma Working Group (IMWG) Response Criteria\",\"Up to 7.5 months (eight 28-day cycles)\",\"Time to First Response|Time to Best Response|Duration of Response|Time to Progression|Progression-free Survival|Follow-up Time\",\"Completed\",\"Phase 2\"\n",
      "485,\"Phase 1/2 Study of VELCADE® in Combination With Other Drugs to Treat Previously Untreated Multiple Myeloma Patients\",\"Number of Patients With Combined Complete Response and Very Good Partial Response\",\"Up to 48 weeks or until disease progression\",\"Number of Patients With Adverse Events (AEs)|Number of Patients With Overall Response|Number of Patients With Stringent Complete Response Rate|Number of Patients With Complete Response Rate + Near Complete Response Rate|Duration of Response|Time to Disease Progression|Time to Response|Progression-free Survival|Probability of 1-year Survival|Overall Survival\",\"Completed\",\"Phase 1|Phase 2\"\n",
      "486,\"Pharmacokinetic Study of Thalidomide in Subjects With Multiple Myeloma\",\"Pharmacokinetic parameters for plasma thalidomide: Tmax Cmax AUC t1/2 CL/F V/F\",\"predose, 1, 2, 3, 4, 5, 6, 8, 10, 12, 16 and 24 hours postdose\",,\"Completed\",\"Phase 1\"\n",
      "487,\"Chemotherapy, Stem Cell Transplantation and Donor and Patient Vaccination for Treatment of Multiple Myeloma\",\"Immune Response|Number of Participants With Adverse Events\",\"105 days|9 years\",,\"Completed\",\"Phase 2\"\n",
      "488,\"Isotretinoin Plus Dexamethasone in Treating Patients With Multiple Myeloma\",,,,\"Completed\",\"Phase 2\"\n",
      "489,\"A Study of Venetoclax in Combination With Pomalidomide and Dexamethasone in Participants With Relapsed or Refractory Multiple Myeloma\",\"Number of Participants With Adverse Events|Overall Response Rate (ORR)\",\"From first dose of study drug until 30 days following last dose of study drug (up to 70 weeks)|Approximately 15 months\",\"Progression-Free Survival (PFS)|Duration of Response (DOR)|Time-to-progression (TTP)\",\"Terminated\",\"Phase 2\"\n",
      "490,\"Phase II Study of Velcade, Decadron, and Doxil Followed by Cyclophosphamide in Multiple Myeloma\",\"Efficacy of Drug Combination as Therapy for Myeloma (Overall Response Rate)\",\"Best response at any point during each respective study phase was collected - once after consolidation/prior to mobilization (approximately 6 cycles after start of treatment), and once after mobilization\",\"Yield of CD34+ Stem Cells|Progression Free Survival\",\"Completed\",\"Phase 2\"\n",
      "491,\"Health Through Activity: A Pilot Study of a Rehabilitation Intervention for People Living With Multiple Myeloma\",\"Rate of Participant Enrollment|Assessment Completion Rate|Screening Rate|Eligibility Rate\",\"At screening|Up to 4 months|Up to 4 months|Up to 4 months\",\"Intervention Completion Rate|Participant Satisfaction\",\"Not yet recruiting\",\"Not Applicable\"\n",
      "492,\"A Study of CC-95266 in Participants With Relapsed and/or Refractory Multiple Myeloma\",\"Number of participants with Adverse Events (AEs)|Number of participants with significant laboratory abnormalities|Number of participants with Dose Limiting Toxicities (DLTs)|Maximum Tolerated Dose (MTD)|Recommended Phase 2 Dose (RP2D)\",\"Up to 2 years after CC-95266 infusion|Up to 2 years after CC-95266 infusion|Up to 2 years after CC-95266 infusion|Up to 2 years after CC-95266 infusion|Up to 2 years after CC-95266 infusion\",\"Pharmacokinetics - Maximum plasma concentration of drug (Cmax)|Pharmacokinetics - Time to peak (maximum) serum concentration (tmax)|Pharmacokinetics - Area under the curve for days 1-29 after CC-95266 infusion (AUC1-29)|Overall response rate (ORR)|Complete response rate (CRR)|Very good partial response (VGPR) or better|Duration of response (DOR)|Duration of complete response (DOCR)|Time to response (TTR)|Time to complete response (TTCR)|Progression-free survival (PFS)|Overall survival (OS)\",\"Recruiting\",\"Phase 1\"\n",
      "493,\"Multiple Myeloma Turkish Prospective Patient Registry\",\"Overall Survival|Progression Free Survival\",\"[Time Frame: 5 Years]|[Time Frame: 5 Years]\",,\"Recruiting\",\n",
      "494,\"Belantamab Mafodotin, Cyclophosphamide, and Dexamethasone in Relapsed/Refractory Multiple Myeloma\",\"Overall incidence and severity of AEs in Dose Escalation|Response rate in Expansion Cohort\",\"Up to 6 weeks|Up to 12 weeks\",\"Time to progression|Progression free survival|Overall survival|Cytokine Profile Data\",\"Recruiting\",\"Phase 1|Phase 2\"\n",
      "495,\"Belantamab Mafodotin Plus Pomalidomide and Dexamethasone (Pd) Versus Bortezomib Plus Pd in Relapsed/Refractory Multiple Myeloma\",\"Progression-free survival (PFS)\",\"Up to 84 months\",\"Duration of response (DoR)|Minimal residual disease (MRD) negativity rate|Overall survival (OS)|Overall response rate (ORR)|Complete response rate (CRR)|Very good partial response (VGPR) or better rate|Time to best response (TTBR)|Time to response (TTR)|Time to progression (TTP)|Progression-free survival on subsequent line of therapy (PFS2)|Number of participants with adverse events (AEs) and serious adverse events (SAEs)|Number of participants with clinically significant changes in hematology, clinical chemistry and urinalysis lab parameters|Number of participants with abnormal ocular findings on ophthalmic examination|Plasma concentrations of belantamab mafodotin at indicated time points|Plasma concentrations of monomethyl auristatin-F with a cysteine linker (cys-mcMMAF) at indicated time points|Maximum observed concentration (Cmax) for pomalidomide|Time of Cmax (Tmax) for pomalidomide|Area under the plasma concentration-time curve from time zero to time of last quantifiable concentration (AUC[0-t]) for pomalidomide|Number of participants with positive anti-drug antibodies (ADAs) against belantamab mafodotin|Titers of ADAs against belantamab mafodotin|Number of participants with maximum post-baseline changes in patient-reported outcome version of the common terminology criteria for adverse events (PRO-CTCAE) scores for each item attribute|Change from Baseline in health related quality of life (HRQoL) as measured by European Organization for Research and Treatment of Cancer Quality of life Questionnaire 30-item core module (EORTC QLQ-C30)|Change from Baseline in HRQoL as measured by EORTC item library 52 (IL52)|Change from Baseline in HRQoL as measured by EORTC QLQ-20-item Multiple Myeloma Module (MY20)\",\"Recruiting\",\"Phase 3\"\n",
      "496,\"Sorafenib and Everolimus in Treating Patients With Relapsed or Refractory Lymphoma or Multiple Myeloma\",\"Number of Participants Reporting a Dose Limiting Toxicity (DLT)|Proportion of Confirmed Tumor Responses\",\"First cycle (28 days) of study treatment|Up to 12 cycles of treatment\",\"Survival Time|Progression Free Survival\",\"Completed\",\"Phase 1|Phase 2\"\n",
      "497,\"Suramin in Treating Patients With Refractory or Relapsed Multiple Myeloma or Castleman's Disease\",,,,\"Completed\",\"Phase 2\"\n",
      "498,\"Study to Evaluate the Safety and Efficacy of Anti-CD38 CAR-T in Relapsed or Refractory Multiple Myeloma Patients\",\"Determine the MTD\",\"28 days\",\"Determine the CAR2 Anti-CD38 A2 CAR-T cell blood concentrations (Pharmacokinetic [PK] Profile) to evaluate the Cmax|Determine the CAR2 Anti-CD38 A2 CAR-T cell blood concentrations (Pharmacokinetic [PK] Profile) to evaluate the AUC|Evaluate the safety of Anti-CD38 A2 CAR-T cells in Patients with RRMM by incidence of treatment-emergent adverse events|Assess preliminary efficacy by response rate in accordance with the modified International Myeloma Working Group (IMWG) criteria|Assess preliminary efficacy by depth of response in accordance with the modified International Myeloma Working Group (IMWG) criteria.|Assess preliminary efficacy by duration of response in accordance with the modified International Myeloma Working Group (IMWG) criteria.|Assess preliminary efficacy by progression-free survival.|Assess preliminary efficacy by overall survival.|The determination of the recommended phase 2 dose (RP2D) will be based on an evaluation of treatment-emergent events.|The determination of the recommended phase 2 dose will be based on an evaluation of overall response rate.|The determination of the recommended phase 2 dose (RP2D) will be based on an evaluation of depth of response.|The determination of the recommended phase 2 dose (RP2D) will be based on an evaluation of duration of response.|The determination of the recommended phase 2 dose (RP2D) will be based on an evaluation of progression-free survival.|The determination of the recommended phase 2 dose (RP2D) will be based on an evaluation of overall survival.\",\"Completed\",\"Phase 1\"\n",
      "499,\"Lenalidomide With or Without Dexamethasone in Treating Patients With Newly Diagnosed Multiple Myeloma\",\"Progression-free Survival (PFS) Rate at 12 Months\",\"12 months from registration\",\"Confirmed Response Rate|Overall Survival (OS)|Progression-free Survival (PFS)|Number of Participants Who Experienced at Least One Grade 3 or Higher Adverse Event at Least Possibly Related to Treatment (Toxicity)\",\"Completed\",\"Phase 2\"\n",
      "500,\"Study to Evaluate the Safety and Efficacy of Pomalidomide Monotherapy in Subjects With Refractory or Relapsed Refractory Multiple Myeloma\",\"Percentage of Participants With an Objective Response According to International Myeloma Working Group (IMWG) Uniform Response Criteria Based on Investigator Assessment\",\"From randomization through the study follow-up phase; up to the data cut-off of 31 July 2014; Maximum time on follow-up was 141.1 weeks.\",\"Percentage of Participants With Objective Response According to European Group for Blood and Marrow Transplantation (EBMT) Criteria Based on Investigator Assessment|Number of Participants With Adverse Events and Type of Adverse Events|Kaplan Meier Estimates for Progression Free Survival (PFS) by Investigator Based on IMWG|Kaplan-Meier Estimate for Time to Progression (TTP) Based on Investigator Assessment Using IMWG Criteria|Kaplan-Meier Estimate Duration of Response Based on Investigator Assessment Using IMWG Criteria|Kaplan-Meier Estimate for Overall Survival|Time to Response Based on IMWG and Assessed by the Investigator\",\"Completed\",\"Phase 3\"\n",
      "501,\"Adjuvant Bortezomib Maintenance Therapy After Autologous Peripheral Stem Cell Transplantation in Treating Patients With Intermediate or Advanced Multiple Myeloma\",\"Progression-free Survival\",\"signed consent to progression or end of trial. Up to 5 years.\",\"Overall Survival\",\"Completed\",\"Phase 1|Phase 2\"\n",
      "502,\"Study of CART-ddBMCA in Relapsed or Refractory Multiple Myeloma (iMMagine-1)\",\"Overall Response Rate (ORR)\",\"24 Months\",\"Stringent complete response (sCR) or complete response (CR) rate|Overall Response Rate (ORR) of subjects limited to three lines of prior treatment|Duration of Response (DoR)|Very Good Partial Response (VGPR) Rate and Partial Response (PR) Rate|Time to Initial Response|Progression Free Survival (PFS)|Overall Survival (OS)|Safety Profile of CART-ddBCMA|Define the Pharmacokinetics of CART-ddBCMA|Anti-CART-ddBCMA Antibodies|Health Related Quality of Life (HRQoL)\",\"Recruiting\",\"Phase 2\"\n",
      "503,\"Phase 2 Study of Carfilzomib in Relapsed Multiple Myeloma\",\"Best Overall Response Rate (ORR) in the Response Evaluable Subset Population\",\"Disease response was assessed on Day 15 of Cycle 1, Day 1 of Cycles 2 through 12, and at End of Study, 30 days after last dose. Median duration of treatment was 100 days for Part 1 and 170 days for Part 2 participants.\",\"Best Overall Response Rate (ORR) in the Response Evaluable Population|Clinical Benefit Rate (CBR)|Duration of Response (DOR)|Time to Progression (TTP)|Progression-free Survival (PFS)|Overall Survival (OS)\",\"Completed\",\"Phase 2\"\n",
      "504,\"FCH vs FDG PET/CT in Detection of Lesions in Patients With Multiple Myeloma (MIM)\",\"number of hypermetabolic foci of myeloma detected by FCH PET versus by FDG PET during the initial extension assessment\",\"before maintenance treatment\",,\"Recruiting\",\"Not Applicable\"\n",
      "505,\"A Multi-center Open-label Phase 2 Study of Ixazomib, Iberdomide and Dexamethasone in Elderly Patients With Multiple Myeloma at First Relapse.\"\"\",\"Percentage of patients have very good partial response (VGPR) or better\",\"approximate 18 months\",\"Number of adverse events|Number of responses|Number of responses|Number of the death|Number of progression|Percentage of time to progression|Percentage of duration of response|Percentage of duration of therapy|Percentage of time to response|Percentage of Overall Response Rate|Percentage of value of biological prognostic factors|Percentage of frailty scores|Percentage of score of quality of life\",\"Recruiting\",\"Phase 2\"\n",
      "506,\"Interferon Alfa and Interleukin-6 in Treating Patients With Recurrent Multiple Myeloma\",\"Response Rate as Assessed by Number of Participants With Partial or Complete Response by Bladé Criteria.|Toxicity as Measured by Number of Participants Who Discontinued Treatment Due to Adverse Events|Optimal Dose of Interleukin-6|Impact of Treatment on Growth of Myeloma Cells\",\"Up to 5 months|Up to 5 months|Up to 5 months|Day 0, Day 14, Months 1, 2, 4, and 6 of combined therapy, and end of study\",,\"Terminated\",\"Early Phase 1\"\n",
      "507,\"Comparison of Ibandronate - Zoledronate Regarding Nephrotoxicity in Multiple Myeloma\",\"Percentage of Participants With Deterioration in Renal Function According to Reduction in Creatinine Clearance (CrCl) From Baseline to Week 44|Percentage of Participants With Deterioration in Renal Function According to Reduction in CrCl From Baseline to Week 92\",\"Baseline, Week 44|Baseline, Week 92\",\"Percentage of Participants With Skeletal-Related Events (SREs)|Time to First SRE|Number of SREs for Each Participant|Percentage of Participants With Osteonecrosis of Jaw|Number of Events of Osteonecrosis of Jaw for Each Participant|Percentage of Participants With Zoledronate Dose Reduction|Number of Zoledronate Dose Reductions for Each Participant|Percent Change From Baseline in N-Acetyl-Beta-D-Glucosaminidase (B-NAG)|Percent Change From Baseline in Alpha (A) 1-Microglobulin|Percent Change From Baseline in Gamma-Glutamyltransferase (GGT)|Percentage of Participants With Elevation of Serum Creatinine (SCr) From Baseline|Percent Change From Baseline in CrCl\",\"Terminated\",\"Phase 3\"\n",
      "508,\"Tandem Transplantation in Multiple Myeloma (MM) Patients With <12 Months of Prior Treatment\",\"To Determine Whether, in Comparison to TT II, the Median EFS Can be Increased From 4.8 Years to 6.2 Years, Which Represents an Increase in Median EFS of Approximately 30%|In Assessing Patient Safety, we Will Examine Treatment Toxicity Related Mortality and SAEs. Historical Study Results Indicate That a Mortality Rate of Greater Than 10% is Not Acceptable in This Population, Nor is an SAE Rate of Greater Than 15%.\",\"After enrollment of 204 subjects is completed|Interim analyses for safety will be performed after 20, 100, 200, and 300 patients have been enrolled.\",\"Overall Survival Will be Compared to a Historical Control (UARK 98-026, TT2)as a Secondary Outcome.\",\"Completed\",\"Phase 2\"\n",
      "509,\"A Evaluation of the Safety of Oncocort IV Pegylated Liposomal Dexamethasone Phosphate in Patients With Progressive Multiple Myeloma\",\"Number of participants with treatment-related adverse events as assessed by CTCAE v4.0\",\"Week 8\",\"Response according to IMWG Criteria|Percentage change of myeloma-related measures|Quality of life questionnaire|Peak Plasma Concentration (Cmax)|Area under the plasma concentration versus time curve (AUC)\",\"Terminated\",\"Phase 1|Phase 2\"\n",
      "510,\"Study Testing Radium-223 Dichloride in Relapsed Multiple Myeloma\",\"Phase 1: MTD/RP2D Determined by the Incidence of DLTs|Phase 1: The Number of Subjects With Treatment-emergent Adverse Events (TEAEs), Drug-related TEAEs, and Treatment-emergent Serious AE\",\"From the start of study medication through 3 weeks after administration of the second dose of radium-223 dichloride, assessed up to 9 weeks|From the start of study drug (radium-223 dichloride) to 30 days after last dose of study treatment (radium-223 dichloride, BOR, or DEX, whichever is last), assessed up to approximately 2 years\",\"Phase 1: The Number of Subjects With Complete Response (CR) and Very Good Partial Response (VGPR)\",\"Terminated\",\"Phase 1|Phase 2\"\n",
      "511,\"DARA RVD For High Risk SMM\",\"Proportion of high risk smoldering multiple myeloma (SMM) patients who are MRD negative (MRD-)\",\"2 years\",\"Objective Response Rate|Duration of Response|Progression-free survival|Number of Participants with Treatment Related Adverse Events as Assessed by CTCAE v4.0\",\"Recruiting\",\"Phase 2\"\n",
      "512,\"Expanded Access to Elotuzumab (Empliciti) for Multiple Myeloma\",,,,\"No longer available\",\n",
      "513,\"Xcellerated T CellsTM in Patients With Multiple Myeloma\",,,,\"Completed\",\"Phase 2\"\n",
      "514,\"Safety and Dose Determining Study of BT062 in Patients With Relapsed or Refractory Multiple Myeloma\",\"Dose limiting toxicity|Maximum tolerated dose\",\"On a weekly basis for the duration of the study|About every 2 months for the duration of the study\",\"Qualitative and quantitative toxicities|Pharmacokinetics|Anti-tumor activity\",\"Completed\",\"Phase 1\"\n",
      "515,\"Impact of a Health Technology Intervention on Patient Activation in Multiple Myeloma\",\"Patient Activation\",\"24 months\",\"Evaluate associations between Patient Activation and symptom burden|Evaluate the feasibility and acceptability of participation in All4Cure's digital platform for survivors with multiple myeloma\",\"Not yet recruiting\",\n",
      "516,\"A Pharmacokinetic Study of Bortezomib in Taiwanese Participants With Multiple Myeloma\",\"Initial Observed Plasma Drug Concentration (Co)|Maximum Observed Plasma Concentration (Cmax)|Area Under Plasma Concentration-Time Curve From Time 0 to Last Quantifiable Time Point|Area Under Plasma Concentration-Time Curve From Time 0 to Infinity (AUC-Infinity)|Terminal Half-life (t1/2)|Terminal rate constant (lamda[z])|Systemic clearance (CL)|Apparent Volume of Distribution (Vd)\",\"72 hours pre-dose on Day 1 (Baseline); post-dose on Day 11, 12, 13 and 14|72 hours pre-dose on Day 1 (Baseline); post-dose on Day 11, 12, 13 and 14|72 hours pre-dose on Day 1 (Baseline); post-dose on Day 11, 12, 13 and 14|72 hours pre-dose on Day 1 (Baseline); post-dose on Day 11, 12, 13 and 14|72 hours pre-dose on Day 1 (Baseline); post-dose on Day 11, 12, 13 and 14|72 hours pre-dose on Day 1 (Baseline); post-dose on Day 11, 12, 13 and 14|72 hours pre-dose on Day 1 (Baseline); post-dose on Day 11, 12, 13 and 14|72 hours pre-dose on Day 1 (Baseline); post-dose on Day 11, 12, 13 and 14\",,\"Completed\",\"Phase 4\"\n",
      "517,\"A Study of CAR-T Cells Targeting GPRC5D in the Treatment of r/r Multiple Myeloma\",\"Dose limited toxicity (DLT)|AE and SAE\",\"From date of initial treatment to Day 28 post GPRC5D CAR-T infusion.|From admission to the end of the follow-up, up to 2 years\",\"Concentration of CAR-T cells|Objective Response Rate, ORR|Disease control rate, DCR|Duration of remission, DOR|Progression-free survival, PFS|Overall survival, OS\",\"Active, not recruiting\",\"Early Phase 1\"\n",
      "518,\"Lenalidomide and Melphalan in Treating Patients With Previously Untreated Multiple Myeloma\",\"Incidence of dose-limiting toxicity within first 3 courses of treatment\",,\"Toxicity|Disease response after 2 courses, 6 courses, 12 courses, and 6 months of maintenance therapy|Time to progression|Overall survival|Duration of disease-free interval|Time to dose modification|Time to dose discontinuation\",\"Completed\",\"Phase 2\"\n",
      "519,\"Allogeneic Stem Cell Transplantation vs. Conventional Therapy as Salvage Therapy for Relapsed / Progressive Patients With Multiple Myeloma After First-line Therapy\",\"Overall survival at five years after randomization\",\"at 5 years after randomization\",\"Event-free survival at 1 year after randomization|Event-free survival at 3 years after randomization|Event-free survival at 5 years after randomization|Change from baseline in total EORTC score at 1 year after randomization|Change from baseline in total EORTC score at 3 years after randomization|Change from baseline in total EORTC score at 5 years after randomization|Time to first occurrence of remission after randomization|Non-relapse mortality (NRM) at 1 year after randomization|Non-relapse mortality (NRM) at 3 years after randomization|Non-relapse mortality (NRM) at 5 years after randomization|Cumulative incidence of acute GvHD after allogeneic stem cell transplantation at 1 year after randomization|Cumulative incidence of acute GvHD after allogeneic stem cell transplantation at 3 years after randomization|Cumulative incidence of acute GvHD after allogeneic stem cell transplantation at 5 years after randomization|Cumulative incidence of chronic GvHD after allogeneic stem cell transplantation at 1 year after randomization|Cumulative incidence of chronic GvHD after allogeneic stem cell transplantation at 3 years after randomization|Cumulative incidence of chronic GvHD after allogeneic stem cell transplantation at 5 years after randomization|Time to first occurrence of infection reported as cumulative incidence of infection with CTCAE grade 3 - 5 at 1 year after randomization|Time to first occurrence of infection reported as cumulative incidence of infection with CTCAE grade 3 - 5 at 3 years after randomization|Time to first occurrence of infection reported as cumulative incidence of infection with CTCAE grade 3 - 5 at 5 years after randomization\",\"Recruiting\",\"Phase 3\"\n",
      "520,\"Lenalidomide, Cyclophosphamide, and Dexamethasone in Treating Patients With Newly Diagnosed Multiple Myeloma\",\"Number of Participants Who Achieved a Confirmed Response (CR), Very Good Partial Response (VGPR) or Partial Response (PR) During Treatment\",\"Duration of Treatment (up to 5 years)\",\"Overall Survival (OS)|Progression-free Survival (PFS)|Duration of Response (DOR)\",\"Completed\",\"Phase 2\"\n",
      "521,\"A Safety and Efficacy Study Evaluating CTX120 in Subjects With Relapsed or Refractory Multiple Myeloma\",\"Part A (dose escalation): Incidence of adverse events|Part B (cohort expansion): Objective response rate\",\"From CTX120 infusion up to 28 days post-infusion|From CTX120 infusion up to 60 months post-infusion\",\"Progression Free Survival|Overall Survival\",\"Active, not recruiting\",\"Phase 1\"\n",
      "522,\"Safety/Efficacy Study of LDE225 (Sonidegib) Plus Bortezomib in Patients With Relapsed or Relapsed/Refractory Multiple Myeloma\",\"Maximum Tolerated Dose (MTD) of LDE225 Plus Bortezomib|Time to Disease Progression\",\"every 3 weeks up to 48 weeks|every 3 weeks up to 48 weeks, then every 3 months thereafter up to 3 years from initiation of study treatment.\",\"Overall Response\",\"Terminated\",\"Phase 2\"\n",
      "523,\"Pamidronate Prophylaxis in Multiple Myeloma 30 mg/Month Versus 90 mg/Month\",\"Physical function at 12 months estimated by EORTC QLQ-C30 questionnaire\",,\"Skeletal related event (time to first SRE)|Cost-utility analysis|Subgroup analysis (conventional chemotherapy vs. high dose chemotherapy with stem cell support)|Response, recons duration, survival|Quality of Life estimated by fatigue and pain according to EORTC QLQ-C30\",\"Completed\",\"Phase 3\"\n",
      "524,\"An Open-Label, Phase 1b Study of Acalabrutinib With and Without Dexamethasone in Subjects With Multiple Myeloma\",\"Safety Profile of Acalabrutinib With and Without Dexamethasone\",\"From first dose of study drug up to Cycle 12 (48 weeks). Subjects who showed benefit from study drugs were allowed to continue until disease progression.\",\"Pharmacokinetic (PK) Parameters Calculated for Acalabrutinib: AUC0-4, AUClast, AUCINF, Cmax, Tmax, λz, t1/2, CL/F, and Vz/F. PK Parameters Calculated for Dexamethasone: Tmax, Cmax, AUC0-4 and AUClast.|Bruton Tyrosine Kinase (BTK) Occupancy|Response Assessed According to Guidelines Proposed by the International Myeloma Workshop Consensus Panel and European Group for Blood and Marrow Transplant\",\"Completed\",\"Phase 1\"\n",
      "525,\"Weekly 70 mg/m2 Carfilzomib for Multiple Myeloma Patients Refractory to 27 mg/m2 Carfilzomib\",\"Overall response rate (ORR)|Clinical Benefit Rate (CBR)|Number of patients undergoing adverse events\",\"up to 30 months|up to 30 months|up to 36 months\",\"Time to Progression (TTP)|Progression-Free Survival (PFS)|Time to Response (TTR)|Duration of Response (DOR)|Overall Survival (OS)\",\"Unknown status\",\"Phase 2\"\n",
      "526,\"Comparison of 25mg Versus 5 mg Lenalidomide as Maintenance Therapy in Patients With Multiple Myeloma\",\"event-free survival\",\"6 years\",\"safety, tolerability and feasibility|Improvement of remission rate|evaluate quality of life\",\"Completed\",\"Phase 3\"\n",
      "527,\"Open-label Study, to Evaluate the Safety and Tolerability of Zoledronic Acid in Patients With Bone Lesions Secondary to Multiple Myeloma.\",,,,\"Withdrawn\",\"Phase 4\"\n",
      "528,\"Dexamethasone With or Without Thalidomide in Treating Patients With Newly Diagnosed Multiple Myeloma\",,,,\"Completed\",\"Phase 3\"\n",
      "529,\"VELCADE/Melphalan/Prednisone Versus Melphalan/Prednisone in Patients With Previously Untreated Multiple Myeloma\",\"Time to progression\",,\"Progression-free survival, overall response rate, overall survival, time to first response, duration of response, CR rate, and patient reported outcomes as assessed using the EORTC QLQ-C30, FACIT-F and EQ-5D instruments.\",\"Completed\",\"Phase 3\"\n",
      "530,\"Diagnostic Performance of Spot Urine Sample for the Monoclonal Components Detection in Patients With Multiple Myeloma\",\"Evaluate the detection sensitivity of the urine monoclonal component on spot urine sample\",\"at the first Day of Cycle n°2 (each cycle is 28 days or 21 days)\",\"Evaluate the specificity of urine monoclonal component detection on spot urine sample|Evaluate the sensitivity and specificity of urine monoclonal component detection on spot urine sample|Compare the responses rate|Compare the monoclonal component / creatininuria ratios|Define the equivalent of 200 mg / 24H (current consensus threshold of measurable urinary disease)|Assess the association between the rate of serum light chains and concentration of monoclonal components|Evaluate the urine monoclonal component by the difference between proteinuria and albuminuria\",\"Recruiting\",\n",
      "531,\"A Study of BCMA-targeted CAR-T Cells Therapy for Refractory/Relapsed Multiple Myeloma\",\"Dose-limiting toxicity (DLT)|Incidence of treatment-emergent adverse events (TEAEs)\",\"Baseline up to 28 days after BCMA targeted CAR T-cells infusion|Up to 2 years after BCMA targeted CAR T-cells infusion\",\"Overall response rate (ORR)|Overall survival (OS)|Quality of life(EORTC QLQ-C30) Core 30 (EORTC QLQ-C30)|Instrumental Activities of Daily Living (IADL) score|Activities of Daily Living (ADL) score|Hospital Anxiety and Depression Scale (HADS) score\",\"Recruiting\",\"Early Phase 1\"\n",
      "532,\"Rituximab in Treating Patients With Multiple Myeloma\",,,,\"Completed\",\"Phase 2\"\n",
      "533,\"Ph 1b Study to Evaluate GSK2110183 in Combination With Bortezomib and Dexamethasone in Subjects With Multiple Myeloma\",\"The recommended Phase II dose (RP2D) and schedule of GSK2110183, bortezomib and dexamethasone dosed in combination.\",\"Estimation is that each subject may be assessed for up to 48 months.\",\"Pharmacokinetics of GSK2110183, bortezomib and dexamethasone. Composite (or Profile) of Pharmacokinetics Time Frame: predose, 0, 5 min, 15 min, 1, 2, 3, 4, 6, 8, 10-12, 14-22, and 24 hrs post-dose.|Clinical activity|Relationships between GSK2110183, Pharmacokinetic (PK), Pharmacodynamic (PD) and clinical activity. Composite (or Profile) of Serial Pharmacokinetics Time Frame: predose, 5 min, 15 min, 1,2,3,4,6,8, 10-12, 14-22, and 24 hours post-dose.|Exploratory Translational Research\",\"Completed\",\"Phase 1\"\n",
      "534,\"A Study of Venetoclax and ABBV-838 Combination Therapy With Dexamethasone in Participants With Multiple Myeloma Whose Cancer Has Come Back or Had No Response to Recent Cancer Treatment\",\"Maximum tolerated dose (MTD), and recommended phase two dose (RPTD) of venetoclax and ABBV-838 combination therapy when administered with dexamethasone|Number of participants with adverse events\",\"Minimum first cycle of dosing (21 or 28 days, depending on arm)|Up to approximately 2 years following the first dose of the last subject enrolled\",\"Maximum observed plasma concentration (Cmax) of venetoclax|Time to Cmax (Tmax) of venetoclax|Area under the plasma concentration-time curve over the 24-hour dose interval (AUC0-24) of venetoclax|Objective Response Rate (ORR)|Cmax of ABBV-838|Tmax of ABBV-838|AUC over the dose interval (AUC0-τ) of ABBV-838|Total monoclonal anti-CS1 antibody (total mAb)|Monomethyl auristatin E (MMAE) toxin levels|Minimal Residual Disease (MRD)|Terminal phase elimination rate constant (β) for ABBV-838|Terminal elimination half-life (t1/2) for ABBV-838\",\"Withdrawn\",\"Phase 1\"\n",
      "535,\"A Study of Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) Followed by Ciltacabtagene Autoleucel Versus Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) Followed by Autologous Stem Cell Transplant (ASCT) in Participants With Newly Diagnosed Multiple Myeloma\",\"Progression free survival (PFS)|Sustained MRD-negative CR\",\"up to 10 years ( or 300 PFS events)|up to 24 months\",\"Overall Response (OR)|Complete Response (CR) or better status|Overall Minimal Residual Disease (MRD) -negative CR|Time to subsequent antimyeloma therapy|Progression Free Survival on Next-line Therapy (PFS2)|Overall Survival (OS)|Change from Baseline in Health-Related Quality of Life (HRQoL) as Assessed by European Organization for Research and Treatment of Cancer Quality-of-life Questionnaire Core 30 (EORTC-QLQ-C30) Scale Score|Change from Baseline in Health-Related Quality of Life as Assessed by MySIm-Q Scale Score|Change from Baseline in Health-Related Quality of Life as Assessed by European Quality of Life - 5 Dimensions-5 Levels (EQ-5D-5L) Scale Scor|Change from Baseline in Health-Related Quality of Life as Assessed by Patient Global Impression of Symptom Severity (PGIS) Scale Score|Patient-reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE)\",\"Not yet recruiting\",\"Phase 3\"\n",
      "536,\"A Study of Doxil, Vincristine and Decadron (DVd) +/ CC-5013 in Relapsed Refractory Multiple Myeloma (MM)\",,,,\"Completed\",\"Phase 1\"\n",
      "537,\"Bortezomib, Selinexor, and Dexamethasone in Patients With Multiple Myeloma\",\"Progression-free Survival (PFS) as Assessed by IRC\",\"From date of randomization until IRC-confirmed documented PD or death, censored date, whichever occurred first (up to 32 months)\",\"Overall Response Rate (ORR) as Assessed by IRC|Percentage of Participants With Response Rates|Overall Survival (OS)|Duration of Response (DOR) as Assessed by IRC|Time-to-next-treatment (TTNT)|Time-to-response (TTR) as Assessed by IRC|Number of Participants With Grade >= 2 Peripheral Neuropathy Events|Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Serious TEAEs|Patient-reported Peripheral Neuropathy Measured by European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire (QLQ)-CIPN20 Instrument\",\"Active, not recruiting\",\"Phase 3\"\n",
      "538,\"A Study of Humanized BCMA-targeted CAR-T Cells Therapy for Refractory/Relapsed Multiple Myeloma\",\"Dose-limiting toxicity (DLT)|Incidence of treatment-emergent adverse events (TEAEs)\",\"Baseline up to 28 days after BCMA targeted CAR T-cells infusion|Up to 2 years after BCMA targeted CAR T-cells infusion\",\"Overall response rate (ORR)|Overall survival (OS)|Quality of life(EORTC QLQ-C30) Core 30 (EORTC QLQ-C30)|Instrumental Activities of Daily Living (IADL) score|Activities of Daily Living (ADL) score|Hospital Anxiety and Depression Scale (HADS) score\",\"Not yet recruiting\",\"Early Phase 1\"\n",
      "539,\"Study of Novel Regimens in Relapsed or Refractory Multiple Myeloma\",\"Number of participants with any adverse events (AEs) and serious adverse events (SAEs)|Number of participants with dose limiting toxicity (DLT)|Recommended Phase 2 dose (RP2D) of EOS884448 alone or in combinations with iberdomide with or without dexamethasone in participants with relapse/refractory multiple myeloma|Number of participants with overall response (partial or better) as determined by IMWG criteria\",\"From first study treatment administration up to 120 days after the last dose|From first study treatment administration up to 120 days after the last dose|up to 2 years|up to 2 years\",\"Progression-free-survival (PFS)|Duration of Response (DOR)|Time to Response (TTR)|Maximum concentration (Cmax) of EOS884448 at each dose level|Percentage of participants with anti-drug antibodies to EOS884448\",\"Recruiting\",\"Phase 1|Phase 2\"\n",
      "540,\"Study to Evaluate Two Lenalidomide Dose Regimens With Low Dose Dexamethasone for the Treatment Relapsed Multiple Myeloma\",\"Serious Adverse Events|Duration Until Best Response (at Least MR or Minimal Response)\",\"Data was collected for each subject for the duration of the participation in the study, ranging between 75 to 475 days.|Data was collected for each subject for the duration of the participation in the study, ranging between 75 to 475 days.\",,\"Completed\",\"Phase 2\"\n",
      "541,\"Study of ZIO-101 in Multiple Myeloma\",\"Phase I: toxicity defined in the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events v3.0 (CTCAE) 12/12/03|Phase II efficacy using EMBT criteria.|Safety\",\"6 months|6 months|6 months\",\"Pharmacokinetics of ZIO-101\",\"Completed\",\"Phase 1|Phase 2\"\n",
      "542,\"Study of Combination Therapy With VELCADE, Doxil, and Dexamethasone (VDd) in Multiple Myeloma\",\"Estimate an overall response rate to combination therapy with VELCADE, Doxil, and Dexamethasone, defined as at least partial response (PR), i.e. > 50% reduction in serum monoclonal protein and/or >90% reduction in Bence-Jones protein by EBMT criteria.\",\"6 months\",\"Estimate a rate of complete response (CR), very good partial response (VGPR, >90% reduction in serum monoclonal protein), minimal response (MR, >25% and <50% reduction in monoclonal)|Estimate the duration of response, progression-free survival, overall survival\",\"Completed\",\"Not Applicable\"\n",
      "543,\"Study of Pomalidomide, Oral Dexamethasone and Very Low-dose Cyclophosphamide in Patients With Refractory Multiple Myeloma Who Have Received Lenalidomide and Bortezomib\",\"Best response\",\"Every 28 days (each cycle is 28 days) from randomization until progression or withdrawal of the subject, whichever came first, assessed up to 60 months.\",\"Time to Response|Duration of Response|Time to Progression|Global Survival|Progression Free Survival|Tolerability of the study medication|Angiogenesis markers of metronomic chemotherapy activity|Angiogenesis markers of metronomic chemotherapy activity 2|Immune system evaluation of metronomic chemotherapy activity\",\"Terminated\",\"Phase 2\"\n",
      "544,\"ASCT With Nivolumab in Patients With Multiple Myeloma\",\"Overall response\",\"3 months\",\"Progression free survival (PFS)|Overall Survival (OS)|Frequency of grade 3 or higher treatment-related adverse events by CTCAE 4.03\",\"Recruiting\",\"Phase 1|Phase 2\"\n",
      "545,\"Pegylated Liposomal Doxorubicin, Low Freq Dexamethasone & Revlimid (Dd-R) in Newly Diagnosed Multiple Myeloma (MM)\",\"Overall Response Rate (ORR) - Percentage of Participants With Partial Response or Better With Induction Regimen|Percentage of Participants With Very Good Partial Remission (VGPR) or Better\",\"24 Months|24 Months\",\"Median Progression Free Survival (PFS) in Months|2 Year Overall Survival (OS) Rate|Occurrence of Induction Toxicities\",\"Completed\",\"Phase 2\"\n",
      "546,\"Arsenic Trioxide in Treating Patients With Multiple Myeloma\",,,,\"Terminated\",\"Phase 2\"\n",
      "547,\"Daratumumab Retreatment in Participants With Multiple Myeloma Who Have Been Previously Treated With Daratumumab\",\"Percentage of Participants Achieving Very Good Partial Response (VGPR) or Better Response\",\"Up to 6 years and 9 months\",\"Overall Response Rate (ORR)|Percentage of Participants Achieving Complete Response (CR) or Stringent Complete Response (sCR)|Progression Free Survival (PFS)|Overall Survival (OS)|Percentage of Participants With Negative Minimal Residual Disease (MRD)|Time to Next Treatment|Serum Concentrations of Daratumumab|Number of Participants with Anti-Daratumumab Antibodies|Number of Participants with Anti-recombinant Human Hyaluronidase (rHuPH20) Antibodies\",\"Terminated\",\"Phase 2\"\n",
      "548,\"Study Comparing Daratumumab, Lenalidomide, and Dexamethasone With Lenalidomide and Dexamethasone in Participants With Previously Untreated Multiple Myeloma\",\"Primary: Progression-free Survival (PFS)\",\"From randomization to disease progression, death, subsequent anti-myeloma therapy, withdrawal of consent to study participation or clinical cut-off (CCO) whichever occurs first (up to 3.5 years)\",\"Percentage of Participants With Complete Response (CR) or Better|Percentage of Participants With Very Good Partial Response (VGPR) or Better|Percentage of Participants With Negative Minimal Residual Disease (MRD)|Overall Response Rate (ORR)|Overall Survival (OS)|Time to Disease Progression (TTP)|Time to Response|Duration of Response (DoR)|Time to Subsequent Anti-myeloma Treatment|Progression-free Survival on Next Line of Therapy (PFS2)|Change From Baseline in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ)-C30 Global Health Status Score to Day 1 of Cycle 3, 6, 9 and 12|Change From Baseline in EuroQol-5 Dimensions-5 Levels (EQ-5D-5L) Visual Analogue Scale (VAS) to Day 1 of Cycle 3, 6, 9 and 12|Change From Baseline in EuroQol-5 Dimensions-5 Levels (EQ-5D-5L) Utility Score to Day 1 of Cycle 3, 6, 9 and 12\",\"Active, not recruiting\",\"Phase 3\"\n",
      "549,\"Trial of Plitidepsin (Aplidin®) in Combination With Bortezomib and Dexamethasone in Multiple Myeloma Patients Double Refractory to Bortezomib and Lenalidomide\",\"Overall Response|Overall Response Rate\",\"From the date of first drug administration to the date of at least one disease assessment, up to 100 weeks|From the date of first drug administration to the date of at least one disease assessment, up to 100 weeks\",\"Clinical Benefit Rate|Disease Control Rate|Duration of Response|Time to Progression|Percentage of Participants With Progression Disease at 3 Months|Percentage of Participants With Progression Disease at 6 Months|Percentage of Participants With Progression Disease at 12 Months|Progression-free Survival|Percentage of Participants With Progression-free Survival at 3 Months|Percentage of Participants With Progression-free Survival at 6 Months|Percentage of Participants With Progression-free Survival at 12 Months|Event-free Survival|Percentage of Participants With Event-free Survival at 3 Months|Percentage of Participants With Event-free Survival at 6 Months|Percentage of Participants With Event-free Survival at 12 Months|Overall Survival|Percentage of Participants With Overall Survival at 6 Months|Percentage of Participants With Overall Survival at 12 Months\",\"Terminated\",\"Phase 2\"\n",
      "550,\"Phase II Evaluation of FTase Inhibitor (FTI)in Treatment of Advanced Multiple Myeloma\",\"Objective Response Rate (ORR)\",\"26 months\",,\"Completed\",\"Phase 2\"\n",
      "551,\"Early Access Treatment With Daratumumab for (Relapsed or Refractory) Multiple Myeloma\",,,,\"Approved for marketing\",\n",
      "552,\"S0833, Bortezomib, Thalidomide, Lenalidomide, Combination Chemotherapy, and Autologous Stem Cell Transplant in Treating Patients With Newly Diagnosed Multiple Myeloma\",\"Progression-free survival at 3 years\",\"3 years\",\"Overall survival|Frequency and severity of toxicities|Gene expression profiling analysis of CD138+ purified plasma cells\",\"Withdrawn\",\"Phase 2\"\n",
      "553,\"A Study of Durvalumab in Combination With Lenalidomide With and Without Dexamethasone in Adults With Newly Diagnosed Multiple Myeloma\",\"Participants With Dose-Limiting Toxicities (DLTs) During the Dose-Determining Timeframe (Day 1 - Day 28)\",\"First treatment cycle: Day 1 to Day 28\",\"Participants With Treatment Emergent Adverse Events (TEAE)|Overall Response Rate (ORR) for Cohorts A and B: Percentage of Participants Who Achieved a Partial Response or Better According to the International Myeloma Working Group (IMWG) Uniform Response Criteria|Response Improvement Rate (RIR) for Cohort C: Percentage of Participants Achieving a Response Improved From Cycle 1 Day 1 as Assessed by the Investigators Using the International Myeloma Working Group (IMWG) Uniform Response Criteria|Time to Response (for Cohorts A and B)|Kaplan-Meier Estimates for Duration of Response (for Cohort A and B)|Durvalumab (DURVA) Serum Pharmacokinetic (PK) Parameters in Cycle 1: Area Under the Concentration-time Curve From Time Zero to the Last Measured Time Point (AUC0-last)|Durvalumab (DURVA) Serum PK Parameters in Cycle 1: Area Under the Concentration-time Curve From Time Zero to Infinity (AUC0-inf)|Durvalumab (DURVA) Serum PK Parameters in Cycle 1: Maximum Observed Concentration (Cmax)|Durvalumab (DURVA) Serum PK Parameters in Cycle 1: Time to Maximum Observed Concentration (Tmax)|Durvalumab (DURVA) Serum PK Parameters in Cycle 1: Terminal Elimination Half-life (t1/2)|Durvalumab (DURVA) Serum PK Parameters in Cycle 1: Clearance (CL)|Durvalumab (DURVA) Serum PK Parameters in Cycle 1: Volume of Distribution (Vz)|Lenalidoide (LEN) Plasma Pharmacokinetic (PK) Parameters in Cycle 1 Day 1: Area Under the Concentration-time Curve From Time Zero to the Last Measured Time Point (AUC0-last)|Lenalidoide (LEN) Plasma Pharmacokinetic (PK) Parameters in Cycle 1 Day 1: Area Under the Concentration-time Curve From Time Zero to Infinity (AUC0-inf)|Lenalidoide (LEN) Plasma Pharmacokinetic (PK) Parameters in Cycle 1 Day 1: Maximum Observed Concentration (Cmax)|Lenalidoide (LEN) Plasma Pharmacokinetic (PK) Parameters in Cycle 1 Day 1: Time to Maximum Observed Concentration (Tmax)|Lenalidoide (LEN) Plasma Pharmacokinetic (PK) Parameters in Cycle 1 Day 1: Terminal Elimination Half-life (t1/2)|Lenalidoide (LEN) Plasma Pharmacokinetic (PK) Parameters in Cycle 1 Day 1: Apparent Clearance (CL/F)|Lenalidoide (LEN) Plasma Pharmacokinetic (PK) Parameters in Cycle 1 Day 1: Apparent Volume of Distribution (Vz/F)|Lenalidomide Plasma PK Parameters in Cycle 1 Day 15: Area Under the Concentration-time Curve From Time Zero to the Last Measured Time Point (AUC0-last)|Lenalidoide (LEN) Plasma Pharmacokinetic (PK) Parameters in Cycle 1 Day 15: Maximum Observed Concentration (Cmax)|Lenalidoide (LEN) Plasma Pharmacokinetic (PK) Parameters in Cycle 1 Day 15: Time to Maximum Observed Concentration (Tmax)|Participants Who Developed Anti-drug Antibody Against Durvalumab|Participants Who Had Either Disease Progression or Death|Participants Who Died Up To Data Cut-off Date (15 December 2017)\",\"Completed\",\"Phase 1|Phase 2\"\n",
      "554,\"A Study of JNS002 (Doxorubicin Hydrochloride Liposome Injection) in Relapsed or Refractory Multiple Myeloma\",\"Number of patients with adverse events as a measure of safety and tolerability\",\"Up to 21 days\",\"Number of subjects who achieved a complete response or partial response\",\"Completed\",\"Phase 1\"\n",
      "555,\"A Study of Bortezomib, Lenalidomide and Dexamethasone (VRd) Followed by Cilta-cel, a CAR-T Therapy Directed Against BCMA Versus VRd Followed by Lenalidomide and Dexamethasone (Rd) Therapy in Participants With Newly Diagnosed Multiple Myeloma for Whom ASCT is Not Planned as Initial Therapy\",\"Progression Free Survival (PFS)\",\"Up to 4 years and 5 months\",\"Sustained Minimal Residual Disease (MRD) Negative CR|MRD Negative CR at 9 Months|Overall MRD Negative CR|Overall Survival (OS)|Complete Response or Better|Time to Subsequent Anti-myeloma Therapy|Progression Free Survival on Next-line Therapy (PFS2)|Number of Participants with Adverse Events (AEs), Abnormalities in Laboratory Parameters, 12-Lead Electrocardiogram (ECG), Physical Examination, and Vital Signs|Arm B: Systemic Cytokine Concentrations|Arm B: Levels of Chimeric Antigen Receptor T cell (CAR-T) Cell Activation Markers|Arm B: Levels of Soluble B-cell Maturation Antigen (BCMA)|Arm B: Levels of Cilta-cel Expansion (proliferation), and Persistence|Arm B: Number of Participants with Anti-cilta-cel Antibodies|Arm B: Number of Participants with Presence of Replication Competent Lentivirus|Change from Baseline in Health-Related Quality of Life (HRQoL) as Assessed by European Organization for Research and Treatment of Cancer Quality-of-life Questionnaire Core 30 (EORTC-QLQ-C30) Scale Score|Change from Baseline in Health-Related Quality of Life as Assessed by MySIm-Q Scale Score|Change from Baseline in Health-Related Quality of Life as Assessed by European Quality of Life - 5 Dimensions-5 Levels (EQ-5D-5L) Scale Score|Change from Baseline in Health-Related Quality of Life as Assessed by Patient Global Impression of Symptom Severity (PGIS) Scale Score|Patient-reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) Items|Time to Worsening of Symptoms, Functioning and Overall Well-being\",\"Recruiting\",\"Phase 3\"\n",
      "556,\"An Investigational Drug, Palbociclib (PD-0332991), Is Being Studied In Combination With Velcade And Dexamethasone In Patients With Multiple Myeloma. Patients Must Have Received Prior Treatment For Multiple Myeloma.\",\"Maximum Tolerated Dose (MTD) of PD-0332991: Phase 1|Recommended Phase II Dose (RP2D) of PD-0332991: Phase 1|Percentage of Participants With Objective Response (OR): Phase 2\",\"Day 1 up to Day 28 during Cycle 1 in schedule A, Day 1 up to Day 21 during Cycle 1 in schedule B|Day 1 up to Day 28 during Cycle 1 in schedule A, Day 1 up to Day 21 during Cycle 1 in schedule B|Cycle 1 Day 1 (baseline) up to end of study (up to cycle 22 for schedule B)\",\"Percent Change From Screening in Phosphorylated Retinoblastoma (Rb), Tumor Biomarkers and Soluble Biomarkers Levels: Phase 1|Best Overall Response: Phase 1|Time to Tumor Progression (TTP): Phase 2|Progression-free Survival (PFS): Phase 2|Duration of Objective Response (DR): Phase 2|Overall Survival (OS): Phase 2|Number of Participants With Adverse Events (AEs) by Severity: Phase 2|Number of Participants With Treatment-Emergent Adverse Events (TEAEs) by Relationship to Study Medication: Phase 2|Number of Participants With Laboratory Abnormalities: Phase 2|European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire (EORTC QLQ-C30): Phase 2|Quality of Life Questionnaire Multiple Myeloma Module (QLQ-MY20): Phase 2|Modified Version of Brief Pain Inventory - Short Form (m-BPI-sf) Questionnaire: Phase 2\",\"Completed\",\"Phase 2\"\n",
      "557,\"First In Human (FIH) Study of REGN5459 in Adult Patients With Relapsed or Refractory Multiple Myeloma (MM)\",\"Incidence of dose-limiting toxicities (DLTs) from the first dose through the end of the DLT observation period|Incidence and severity of treatment-emergent adverse events (TEAEs) during REGN5459 treatment period|Incidence and severity of adverse events of special interest (AESI) with REGN5459 treatment period|Objective response rate (ORR) as measured using the International Myeloma Working Group (IMWG) criteria\",\"Up to 35 Days|Up to 12 Weeks After the Last Dose|Up to 12 Weeks After the Last Dose|Up to Approximately 104 Weeks\",\"Concentrations of REGN5459 in the serum over time|Incidence over time of anti-drug antibodies (ADAs) to REGN5459|Duration of response (DOR) using the IMWG criteria|Progression-free survival (PFS) as measured using the IMWG criteria|Rate of minimal residual disease (MRD) negative status using the IMWG criteria|Overall survival (OS)|Patient-reported Quality of Life (QOL) per European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30)|Patient-reported QOL per EORTC Quality of Life Questionnaire-Multiple Myeloma module 20 (EORTC QLQ-MY20)|Patient-reported QOL per EuroQoL-5 Dimension-3 Level Scale (EQ-5D-3L)|Change in patient-reported global health status/QOL per EORTC QLQ-C30|Time to definitive deterioration in patient-reported global health status/QOL per EORTC QLQ-C30|Change in patient-reported general health status per EQ-5D-3L|ORR as measured using the IMWG criteria|Incidence and severity of TEAEs during REGN5459 treatment period|Incidence and severity of AESI during REGN5459 treatment period\",\"Active, not recruiting\",\"Phase 1|Phase 2\"\n",
      "558,\"T Cells Expressing a Bispecific CAR Targeting CS1 and BCMA in Relapsed/Refractory Multiple Myeloma\",\"Incidence of Treatment-related Adverse Events\",\"within 2 years after infusion\",\"Overall response rate(ORR) and complete response rate(CRR) of administering T cells Expressing a bispecific CAR Targeting CS1 and BCMA in Relapsed/Refractory Multiple Myeloma|Overall survival(OS), duration of Response(DOR), progress-free survival(PFS) of administering T cells Expressing a bispecific CAR Targeting CS1 and BCMA in Relapsed/Refractory Multiple Myeloma\",\"Recruiting\",\"Phase 1\"\n",
      "559,\"MagnetisMM-5: Study of Elranatamab (PF-06863135) Monotherapy and Elranatamab + Daratumumab Versus Daratumumab + Pomalidomide + Dexamethasone in Participants With Relapsed/Refractory Multiple Myeloma\",\"Part 1 Safety Lead-In: Incidence of dose limiting toxicities|Part 2 Randomized: Progression free survival per International Myeloma Working Group criteria\",\"First 42 days after first elranatamab dose|From date of randomization to date of progressive disease, discontinuation from the study, death, or censoring, whichever occurs first, assessed up to 32 months\",\"Part 1 Safety Lead-In: Progression free survival per International Myeloma Working Group criteria|Overall survival|Objective response rate per International Myeloma Working Group criteria|Duration of response per International Myeloma Working Group criteria|Time to response per International Myeloma Working Group criteria|Complete response rate per International Myeloma Working Group criteria|Duration of complete response per International Myeloma Working Group criteria|Minimal residual disease negativity rate per International Myeloma Working Group criteria|Sustained minimal residual disease negativity rate per International Myeloma Working Group criteria|Progression free survival on next-line treatment per International Myeloma Working Group criteria|Frequency of treatment-emergent adverse events|Frequency of abnormal laboratory results|Rate of Grade ≥2 cytokine release syndrome|Elranatamab pharmacokinetics by pre- and post-dose concentrations|Elranatamab immunogenicity by anti-drug antibodies against elranatamab|Daratumumab pharmacokinetics by pre-dose concentrations|Health-related quality of life by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire - Core 30|Health-related quality of life by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire - Myeloma 20\",\"Recruiting\",\"Phase 3\"\n",
      "560,\"MMRF CureCloud Research Initiative\",\"Collection and Analyses of Clinical Information and Peripheral Blood Samples\",\"5 years\",,\"Active, not recruiting\",\n",
      "561,\"Clinical Research of Pomalidomide Maintenance Therapy for Primary Multiple Myeloma\",\"2-year progression-free survival(2y-PFS)\",\"up to 24 months.\",\"2-year overall survival(2y-OS)|Complete remission(CR)|very good partial remission(VGPR)|negative rate of minimal residual disease|adverse events\",\"Recruiting\",\"Not Applicable\"\n",
      "562,\"Study of 4 Bone Turnover Markers in Patients With Multiple Myeloma Treated With Intravenous Bisphosphonate in Routine Care\",\"Changes in bone turnover markers\",\"Baseline, then every 2 months in 12 months\",\"time to maximum variation of bone turnover markers|Doses of intravenous bisphosphonate|Rate of intravenous bisphosphonate|evolution of bone lesions by imaging|Number of new bone events|Number of adverse events likely to be related to bisphosphonate|Changes in Monoclonal protein\",\"Recruiting\",\n",
      "563,\"CID-103 (Anti-CD38 Antibody) in Previously Treated Relapsed or Refractory Multiple Myeloma\",\"Adverse events\",\"approximately 18 months after study start\",\"Recommended Phase 2 dose|Optimal pre- and post-medication regimens|Target engagement assays and ex vivo testing|PK - AUC of CID-103|PK - Cmax of CID-103|PK - t1/2 of CID-103|PK - Vd of CID-103|PK - accumulation of CID-103|Objective response rate|Duration of response|Progression-free survival|Overall survival\",\"Active, not recruiting\",\"Phase 1\"\n",
      "564,\"Carfilzomib, Pomalidomide, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma\",\"Maximum tolerated dose (MTD) of carfilzomib when administered in combination with pomalidomide and dexamethasone|Partial response rate after 4 courses according to International Myeloma Working Group (IMWG) criteria|Response rates of carfilzomib, pomalidomide, dexamethasone, and daratumumab dosing according to International Myeloma Working Group (IMWG) criteria\",\"28 days|4 months|4 months\",\"Overall response rate|Time to progression|Duration of response|Progression-free survival|Overall survival\",\"Recruiting\",\"Phase 1|Phase 2\"\n",
      "565,\"IXAZOMIB Plus Lenalidomide and Dexamethasone Versus Placebo Plus Lenalidomide and Dexamethasone in Adult Patients With Newly Diagnosed Multiple Myeloma\",\"Progression Free Survival (PFS)\",\"Up to data cut off: 2 December 2019 (Up to approximately 79 months)\",\"Overall Survival (OS)|Complete Response (CR) Rate|Pain Response Rate as Assessed by the Brief Pain Inventory- Short Form (BPI-SF) and Analgesic Use|Overall Response Rate (ORR)|Time to Response|Duration of Response|Time to Progression (TTP)|Progression Free Survival (PFS)-2|Percentage of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Score|Percentage of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)|Percentage of Participants With Abnormal Laboratory Values|Change From Baseline in Health-Related Quality of Life (HRQOL) Measured by European Organisation for Research and Treatment of Cancer-Quality of Life Questionnaire (EORTC-QLQ)-C30 Scale Total Score|Change From Baseline in HRQOL Measured by EORTC-QLQ)-MY20 Scale|OS in High-risk Population Carrying Del(17p), Amp(1q21), t(4;14), or t(14;16) Mutations|PFS in High-risk Population Carrying Del(17p), Amp(1q21), t(4;14), or t(14;16) Mutations|Percentage of Participants With MRD-Negative Status as Assessed by Flow Cytometry|Time to Pain Progression|Cmax: Maximum Plasma Concentration for IXAZOMIB and Its Metabolite MLN2238|Percentage of Participants With New or Worsening of Existing Skeletal-related Events (SREs)\",\"Completed\",\"Phase 3\"\n",
      "566,\"Intravenous rhMBL in Patients With Multiple Myeloma Receiving Chemotherapy Followed by Stem Cell Transplant\",\"Safety and tolerability of rhMBL\",\"2 months\",\"Pharmacokinetic (PK) of rhMBL|Pharmacodynamics (PD) of rhMBL|Immunogenicity of rhMBL, incidence of infectious complications\",\"Completed\",\"Phase 1\"\n",
      "567,\"A Study of CS1-targeted CAR-T Cells Therapy for Relapsed Multiple Myeloma After BCMA CAR-T Cells Therapy\",\"Dose-limiting toxicity (DLT)|Incidence of treatment-emergent adverse events (TEAEs)\",\"Baseline up to 28 days after CS1 targeted CAR T-cells infusion|Up to 2 years after CS1 targeted CAR T-cells infusion\",\"Overall response rate (ORR)|Overall survival (OS)|Quality of life|Instrumental Activities of Daily Living (IADL) score|Activities of Daily Living (ADL) score|Hospital Anxiety and Depression Scale (HADS) score\",\"Not yet recruiting\",\"Early Phase 1\"\n",
      "568,\"Bortezomib, Doxorubicin Hydrochloride Liposome, and Thalidomide as First-line Therapy in Treating Patients With Previously Untreated Stage I, II, or III Multiple Myeloma\",\"Overall Response Rate (Complete and Partial)\",\"Every 3 months\",\"Complete Response Rate|Time to Disease Progression\",\"Completed\",\"Phase 2\"\n",
      "569,\"Pomalidomide (POM) in Combination With Low Dose Dexamethasone (LD-Dex) in Patients With Relapsed or Refractory Multiple Myeloma\",,,,\"Approved for marketing\",\n",
      "570,\"Bone Marker Assessment of Multiple Myeloma Patients Treated With Aminobisphosphonates\",\"Number of Participants With Urinary NTX Levels Less Than or Equal to 50nmol/mmol Cr\",\"6 months\",,\"Completed\",\"Phase 2\"\n",
      "571,\"Pomalidomide for Lenalidomide for Relapsed or Refractory Multiple Myeloma Patients\",\"Maximum Tolerated Dose (MTD)|Number of subjects with adverse events|Overall Response Rate|Clinical Benefit Rate (CBR)\",\"Cycles 1-3 for selected regimens (up to 3 months)|up to 36 months|up to 36 months|up to 36 months\",\"Time to Progression|Progression-free survival (PFS)|Time to first response (TTP)|Duration of response (DOR)|Overall survival (OS)\",\"Unknown status\",\"Phase 2\"\n",
      "572,\"XL184 For Relapsed/Refractory Multiple Myeloma (MM) With Bone Disease\",\"Safety of Cabozantinib\",\"2 years\",\"Changes in Biochemical Markers|Effect of Cabozantinib on Bone Disease|Objective Response per IMWG|Pain Assessment\",\"Completed\",\"Phase 1\"\n",
      "573,\"Study of bb21217 in Multiple Myeloma\",\"Incidence of adverse events (AEs), DLTs, and changes in laboratory results\",\"Day 1 through Month 60\",\"Disease-specific response criteria\",\"Active, not recruiting\",\"Phase 1\"\n",
      "574,\"Allogeneic Bone Marrow Transplantation From Unrelated Donors in Multiple Myeloma\",\"Overall survival|Event-free survival\",\"1 year|1 year\",,\"Completed\",\n",
      "575,\"APG-2575 Monotherapy or in Combination With Lenalidomide/DXMS in Subjects With Relapsed or Refractory Multiple Myeloma\",\"Dose Limiting Toxicity\",\"28 days\",,\"Recruiting\",\"Phase 1|Phase 2\"\n",
      "576,\"Anti-neoplastic Treatment, Based on PRO Data Reported Through a MHealth App Solution in Multiple Myeloma\",\"Time registrations of side effects using an app|patient registration of side effects using an app\",\"18 months|18 months\",\"Qualitative perspectives interview\",\"Completed\",\n",
      "577,\"Therapy With Zoledronic Acid in Patients With Multiple Myeloma Stage I\",\"Days of Progression Free Survival\",\"48 months\",\"Number of Patients With Progression by Individual Criteria|The Number of Participants With the Development of Skeletal Complications\",\"Terminated\",\"Phase 3\"\n",
      "578,\"A Study Evaluating ABT-199 in Multiple Myeloma Subjects Who Are Receiving Bortezomib and Dexamethasone as Standard Therapy\",\"Determination of peak concentration (Cmax) of ABT-199|Determine maximum tolerated dose (MTD), and recommended phase two dose (RPTD) of ABT-199|Number of participants with adverse events|Determination of trough concentration (Ctrough) of ABT-199|Determination of area under the concentration versus time curve (AUC) of ABT-199|Determine recommended phase two dose (RPTD) of ABT-199\",\"Approximately 5 days in Cycle 1 then on Day 1 of Cycles 2,4,6,8|Minimum first cycle of dosing (21 days)|From subject's first dose of ABT-199 until 30 days after subject's last dose of ABT-199; up to 2 years following last subject first dose.|Approximately 5 days in Cycle 1 then on Day 1 of Cycles 2,4,6,8|Approximately 5 days in Cycle 1 then on Day 1 of Cycles 2,4,6,8|Minimum first cycle of dosing (21 days\",\"Duration of Response|Objective Response Rate|Time to Disease Progression\",\"Completed\",\"Phase 1\"\n",
      "579,\"High-Dose Chemotherapy and Stem Cell Transplant in Treating Patients With Newly Diagnosed Stage I, Stage II, or Stage III Multiple Myeloma\",\"Number of patients with engraftment after induction chemotherapy\",,\"Number and proportion of patients from whom ≥ 2 x 10e6 CD34-positive cells/kg are harvested|Number and proportion of patients from whom ≥ 4 x 10e6 CD34-positive cells/kg are harvested|CD34-positive cells/kg yield in each leukapheresis|Number of leukaphereses to collect ≥ 2 x 10e6 CD34-positive cells/kg|Number of leukaphereses to collect ≥ 4 x 10e6 CD34-positive cells/kg|Proportion of patients with platelet recovery ≥ 20 x 10e9/L in the absence of transfusion for at least 7 days|Proportion of patients with ANC recovery of ≥ 0.5 x 10e9/L|Time to neutrophil recovery, defined as the time to neutrophil engraftment (i.e., ANC ≥ 0.5 x 10e9/L for 3 consecutive days)|Time to ANC ≥ 1.0 x 10e9/L|Time to platelet recovery, defined as the time to platelets ≥ 20 x 10e9/L in the absence of platelet transfusion support for at least 7 days|Incidence and duration of hospitalization during mobilization phase and during post-transplantation phase|Incidence and severity of adverse events during and after the use of pegfilgrastim 12 mg or pegfilgrastim 18 mg and filgrastim\",\"Unknown status\",\"Phase 2\"\n",
      "580,\"A Phase II Study of Daratumumab, Clarithromycin, Pomalidomide And Dexamethasone (D-ClaPd) In Multiple Myeloma Patients Previously Exposed to Daratumumab\",\"Best response rate within 8 cycles of induction therapy\",\"Approximately 3 years\",\"Median estimate of months that participants have progression free survival|Median number of months of participant's overall survival|Time to Complete Hematologic Response|Time to Hematologic progression|Duration of hematologic response|Time until next treatment therapy|Time to complete response (CR)|Duration of Very Good Partial Response (VGPR)|Rate of minimal residual disease (MRD) negativity after 8 months|Rate of minimal residual disease (MRD) negativity after 32 months|Rate of improvement in response during maintenance therapy\",\"Recruiting\",\"Phase 2\"\n",
      "581,\"Filgrastim Compared With Sargramostim Plus Chemotherapy, Peripheral Stem Cell Transplantation, and Interferon Alfa in Treating Patients With Multiple Myeloma\",,,,\"Terminated\",\"Phase 2\"\n",
      "582,\"Melphalan and Panobinostat (LBH589) for the Treatment of Patients With Recurrent Multiple Myeloma\",\"Maximum Tolerated Dose (MTD)|MTD|Overall Response Rate (ORR) and Clinical Benefit Rate (CBR) [ORR= Complete Response (CR) + Very Good Partial Response (VGPR) + Partial Response (PR)]; CBR=ORR + Minimal Response (MR)] Following Treatment With Panobinostat and Melphalan\",\"12 months|12 months|24 months\",\"Duration of Response|Time to Progression\",\"Completed\",\"Phase 1|Phase 2\"\n",
      "583,\"A Phase II Trial If Nivolumab, Lenalidomide and Dexamethasone in High Risk Smoldering Myeloma\",\"2 Year Progression Free Rate\",\"2 Year\",\"Objective Response Rate|Time to Progression Rate|Duration of Response Rate|Progression Free Survival (PFS) Rate|Overall Survival Rate|Progression Free Survival Rate-Without cyclophosphamide|Number of Participants with Adverse Events\",\"Suspended\",\"Phase 2\"\n",
      "584,\"Autologous Memory-like NK Cell Therapy With BHV-1100 (Formerly KP1237), Low Dose IL-2 in Multiple Myeloma Patients\",\"Dose limiting toxicities following Combination Product dministration|Incidence and severity of side effects related to the Combination Product\",\"100 days post Combination Product administration|100 days post Combination Product administration\",\"Rate of MRD conversion from positive to negative|Rate of MRD conversion from positive to negative|Rate of MRD conversion from positive to negative during the maintenance phase|Rate of PFS|Rate of OS|Best overall response rate per the International Myeloma Working Group (IMWG) Uniform Response Criteria for Multiple Myeloma|Incidence and severity of cytokine release syndrome per ASBMT consensus grading|Incidence and severity of other Immune-related toxicities by CTCAE version 5.0|PK of the KP1237 by determining plasma Cmax|PK of the KP1237 by determining plasma Cmin|PK of the KP1237 by determining plasma AUC|PK of the KP1237 by determining plasma t1/2\",\"Recruiting\",\"Phase 1\"\n",
      "585,\"Daratumumab Based Response Adapted Therapy for Older Adults With Newly Diagnosed Multiple Myeloma\",\"Overall Response Rate\",\"Up to 8 months\",\"Progression Free Survival|Overall Survival\",\"Active, not recruiting\",\"Phase 2\"\n",
      "586,\"An Expanded Treatment Protocol of Panobinostat in Combination Therapy for Relapsed, and Relapsed and Refractory Multiple Myeloma\",,,,\"No longer available\",\n",
      "587,\"Study of ISB 1342, a CD38/CD3 Bispecific Antibody, in Subjects With Previously Treated Multiple Myeloma\",\"Maximal tolerated dose (MTD) and/or recommended part 2 dose (RP2D) of ISB 1342 (Part 1)|Proportion of subjects with an investigator-assessed objective response (at least a partial response or better), complete response, disease control (stable disease or better) to ISB 1342, per International Myeloma Working Group (IMWG) criteria (Part 2)\",\"28 days|28 days\",\"Number of subjects with adverse events based on frequency and severity as assessed by common terminology criteria for adverse events (CTCAE) v5.0 (Part 1 and Part 2)|Maximum serum concentration (Cmax) of ISB 1342 (Part 1 and Part 2)|Time to reach maximum observed plasma concentration (Tmax) of ISB 1342 (Part 1 and Part 2)|Area under the serum concentration time curve from zero to time t (AUC0-t) of ISB 1342 (Part 1 and Part 2)|Area under the curve from time zero to end of dosing interval (AUC0-tau) of ISB 1342 (Part 1 and Part 2)|Immunogenicity of ISB 1342 by anti-drug antibody (ADA) formation (Part 1 and Part 2)|Percent incidence of neutralizing antibody formation from positive anti-drug antibody (ADA) samples assessed from baseline until end of treatment (EOT) (Part 1 and Part 2)|Efficacy of ISB 1342 (duration of response [DOR]) (Part 1 and Part 2)|Efficacy of ISB 1342 (disease control rate [DCR]) (Part 1 and Part 2)|Efficacy of ISB 1342 (duration of disease control) (Part 1 and Part 2)|Efficacy of ISB 1342 (time to minimal residual disease [MRD] negative status) (Part 1 and Part 2)|Efficacy of ISB 1342 (progression free survival [PFS]) (Part 2)|Efficacy of ISB 1342 (time to treatment failure [TTF]) (Part 2)|Efficacy of ISB 1342 (time to disease progression [TTP]) (Part 2)|Efficacy of ISB 1342 (overall survival [OS]) (Part 2)|Proportion of subjects with investigator-assessed objective response (at least a partial response or better), complete response, disease control (stable disease or better) to ISB 1342, per International Myeloma Working Group (IMWG) criteria (Part 1)\",\"Recruiting\",\"Phase 1\"\n",
      "588,\"Pharmacokinetic Study of Propylene Glycol-Free Melphalan HCl for Myeloablative Conditioning in Multiple Myeloma Patients Undergoing Autologous Transplantation\",\"Cmax (Pharmacokinetics)|AUC0-t (Pharmacokinetics)\",\"Day -2|Day -2\",\"Transplant-Related Mortality (TRM) Following Autologous Stem-Cell Transplantation (ASCT)\",\"Completed\",\"Phase 2\"\n",
      "589,\"Phase 1/2 Study of REGN5458 in Patients With Relapsed or Refractory Multiple Myeloma\",\"Incidence of dose-limiting toxicities (DLTs) from the first dose through the end of the DLT observation period|Incidence and severity of treatment-emergent adverse events (TEAEs)|Incidence and severity of adverse events of special interest (AESI)|Objective response rate (ORR) as measured using the International Myeloma Working Group (IMWG) criteria|Concentrations of REGN5458 in serum over time\",\"Up to 28 days|Up to 5 years|Up to 5 years|Up to 5 years|Up to 5 years\",\"Concentrations of REGN5458 in the serum over time|Incidence over time of anti-drug antibodies (ADAs) to REGN5458|Duration of response (DOR) using the IMWG criteria|Progression-free survival (PFS) as measured using the IMWG criteria|Rate of minimal residual disease (MRD) negative status using the IMWG criteria|Overall survival (OS)|ORR as measured using the IMWG criteria|Effects of REGN5458 on HRQOL and patient-reported symptoms and functioning per European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30)|Effects of REGN5458 on HRQOL and patient-reported symptoms and functioning per Quality of Life Questionnaire-Multiple Myeloma module 20 [QLQ-MY20])|Effects of REGN5458 on HRQOL and patient-reported symptoms and functioning per EuroQoL-5 Dimension-3 Level Scale [EQ-5D-3L])|Change in patient-reported global health status/QoL per EORTC QLQ-C30|Time to definitive deterioration in patient-reported global health status/QoL per EORTC QLQ-C30|Effects of REGN5458 on general health status per EQ-5D-3L|Effects of REGN5458 on patient-reported functions and symptoms per EORTC QLQ-C30|Effects of REGN5458 on patient-reported functions and symptoms per QLQ-MY20|Incidence and severity of TEAEs with REGN5458|Incidence and severity of AESIs with REGN5458\",\"Active, not recruiting\",\"Phase 1|Phase 2\"\n",
      "590,\"Study of Plinabulin and Pegfilgrastim in People With Multiple Myeloma Undergoing an Autologous Hematopoietic Stem Cell Transplant (AHCT)\",\"Average duration of absolute neutropenia\",\"1 year\",\"Incidence of toxicities\",\"Recruiting\",\"Phase 2\"\n",
      "591,\"Bortezomib/Adriamycine/Melfalan/Prednisone (VAMP)/Thalidomide/Cyclophosphamide/Dexamethasone (TaCyDex) or Bortezomib/Melfalan/Prednisone (V-MP)/TaCyDex) in Refractary or Relapsed Multiple Myeloma\",\"Efficacy of a sequential scheme treatment with Bortezomib, Melfalan,Prednisone (V-MP) or Bortezomib, Adriamycine, Melfalan,Prednisone (VAMP) followed by Thalidomide, Cyclophosphamide and Dexamethasone (TaCyDex) in relapsed or refractory MM patients\",\"1 year\",\"Evaluate the response type in function to different initial situation (primary resistance, relapse, progression)|To analyze the response duration\",\"Completed\",\"Phase 4\"\n",
      "592,\"Study of ATLCAR.CD138 Cells for Relapsed/Refractory Multiple Myeloma\",\"Proportion of participants with dose limiting toxicities as a measure of maximum tolerated dose of CAR138 T cells\",\"4 weeks from infusion of the CAR138 T cells\",\"Survival of CAR138 T cells in vivo as assessed by PCR and flow cytometry|Overall survival after infusion of CAR138 T cells|Progression free survival after infusion of CAR138 T cells|Overall response rate (ORR) as defined as the percentage of subjects achieving a confirmed partial response or better based on the International Myeloma Working Group (IMWG) response criteria.\",\"Recruiting\",\"Phase 1\"\n",
      "593,\"Vactosertib in Combination w/ Pomalidomide in Relapsed or Relapsed and Refractory Multiple Myeloma\",\"To determine the maximum tolerated dose (MTD) or maximum tested dose level of Vactosertib given in combination with POM for the treatment of relapsed or RRMM\",\"Up to 30 days after treatment ends (24 weeks + 30 days)\",\"Overall response rate|Progression-free survival (PFS)|Progression-free survival at 6 months (PFS-6)|Duration of Response|clinical benefit rate|Overall Survival\",\"Active, not recruiting\",\"Phase 1\"\n",
      "594,\"64Cu-LLP2A for Imaging Multiple Myeloma\",\"Feasibility of imaging MM patients with 64Cu-LLP2A-PET/MR as measured by average organ activity concentration of 64Cu-LLP2A|Feasibility of imaging MM patients with 64Cu-LLP2A-PET/MR as measured by the number of participants who experience an adverse event related to 64Cu-LLP2A|Feasibility of imaging MM patients with 64Cu-LLP2A-PET/MR as measured by the optimal image time after injection of 64Cu-LLP2A|Feasibility of imaging MM patients with 64Cu-LLP2A-PET/MR as measured by image quality of 64Cu-LLP2A-PET/MR images|Feasibility of imaging MM patients with 64Cu-LLP2A-PET/MR as measured by lesion detection of 64Cu-LLP2A-PET/MR images\",\"Up to 30 hours after imaging|Through 48 hours after last administration of 64Cu-LLP2A (estimated to be at most 4 days)|Up to 30 hours after imaging|Up to 30 hours after imaging|Up to 30 hours after imaging\",\"Comparison of tumor burden (SUVmax) of 64Cu-LLP2A to clinical stage|Comparison of tumor burden (SUVmax) of 64Cu-LLP2A to clinical tumor measurement of tumor burden as measured by M-protein of myeloma|Comparision of tumor burden (SUVmax) of 64Cu-LLP2A to clinical measurement of tumor burden as measured by the plasma cell fraction within the bone marrow\",\"Recruiting\",\"Early Phase 1\"\n",
      "595,\"Continuous Versus Intermittent Dosing Regimens for Pomalidomide in Relapsed/Refractory Multiple Myeloma\",\"Percentage of Participants With Response, Analyzed Per International Myeloma Working Group Response Criteria|Percentage of Participants With Response, Analyzed Per International Myeloma Working Group Response Criteria\",\"Efficacy assessments will be made after the first two cycles of therapy (approximately 56 days--each cycle is 28 days)|After the initial efficacy assessment at the completion of cycle 2 (at approximately 56 days), efficacy assessments will be made after every other cycle (approximately every 56 days).\",\"To Compare the Effect of Continuous Versus Intermittent Regimens on F Actin Polymerization in Peripheral Blood Mononuclear Cells and Activation of Tumor Antigen-specific T Cells, as Well as Innate Lymphocytes (Natural Killer or Natural Killer T Cells).|To Correlate Drug Induced Changes in F Actin Polymerization With Adverse Effects and Clinical Responses.|To Correlate Drug Induced Changes in F Actin With Cytokine Profile.\",\"Completed\",\"Phase 2\"\n",
      "596,\"Myeloma Registry Platform (MYRIAM)\",\"Course of treatment (treatment reality)\",\"5 years per patient\",\"Best Response|Progression-free survival|Overall survival|Health-related quality of life (Patient-reported outcome)|Myeloma-specific health-related quality of life (Patient-reported outcome)|Quality of life (Patient-reported outcome)\",\"Recruiting\",\n",
      "597,\"MGTA-145 + Plerixafor in the Mobilization of Hematopoietic Stem Cells for Autologous Transplantation in Multiple Myeloma\",\"Number of Participants For Whom 2.0 x 10e6 CD34+ HSC Cells/kg Could be Collected in 1 or 2 Apheresis Harvests\",\"2 days\",\"Other Measures of Hematopoietic Stem Cell (HSC) Yield in the Apheresis Product|Time To Neutrophil Engraftment|Maintenance of Neutrophil Engraftment [Absolute Neutrophil Count (ANC) ≥ 0.5 x 10e9/L]|Time To Platelet Engraftment ≥ 20 x 10e9/L|Time To Platelet Engraftment ≥ 50 x 10e9/L|Infusion-related Toxicities|Progression-free Survival (PFS)|Transplant-related Mortality|Non-relapse-related Mortality|Overall Survival (OS)\",\"Completed\",\"Phase 2\"\n",
      "598,\"Efficacy and Safety of Statin on the Course of Progressive Smoldering Multiple Myeloma\",\"Paraprotein level\",\"18 months\",,\"Withdrawn\",\"Phase 2\"\n",
      "599,\"A Phase II Trial of ZIO-101 in Advanced Multiple Myeloma: Protocol SGL2001b\",\"Response Rate\",\"6 months\",\"Survival (overall and progression free)|toxicities\",\"Unknown status\",\"Phase 2\"\n",
      "600,\"Study of Carfilzomib in Multiple Myeloma Relapsed After High-dose Melphalan With Autologous Stem Cell Support\",\"Comparison of time to progression after high-dose melphalan with stem cell support (HDT) performed at diagnosis and time to progression after a salvage HDT combined with carfilzomib-cyclophosphamide-dexamethasone|Comparison of time to progression between carfilzomib-dexamethasone maintenance and observation in patients treated with salvage HDT.\",\"3 years|3 years\",\"Adverse events assessed by CTCAE v4.0 in carfilzomib-cyclophosphamide-dexamethasone induction regime and carfilzomib as part of the high-dose melphalan conditioning|Response rates of carfilzomib-cyclophosphamide-dexamethasone induction therapy and HDT|Time to marrow regeneration (neutrophil- and platelet recovery) after the HDT|Adverse events assessed by CTCAE v4.0 in maintenance treatment with carfilzomib-dexamethasone|Comparison of overall survival between carfilzomib-dexamethasone maintenance and observation in patients treated with a salvage HDT|Quality of life assessed by EORTC QLQ-MY20 and EORTC QLQ-C30\",\"Unknown status\",\"Phase 2\"\n",
      "601,\"A Trial of Skeletal Targeted Radiotherapy Using Holmium-166-DOTMP in Patients With Multiple Myeloma\",,,,\"Terminated\",\"Phase 1|Phase 2\"\n",
      "602,\"CC-4047 and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma or Amyloidosis\",\"The Number of Confirmed Hematologic Responses (Complete, Partial, or Very Good Partial Response)\",\"Duration of study (up to 3 years)\",\"Progression Free Survival (PFS)|Duration of Response\",\"Completed\",\"Phase 2\"\n",
      "603,\"A Study to Determine Dose, Safety, Tolerability, Drug Levels, and Efficacy of CC-220 Monotherapy, and in Combination With Other Treatments in Participants With Multiple Myeloma\",\"Establish maximum tolerated doses (MTDs) of CC-220 as monotherapy and in combination with other treatment|Establish Recommended Phase 2 doses (RP2Ds) of CC-220 as monotherapy and in combination with other treatment|Overall response rate (ORR) of CC-220 in combination with Dexamethasone (DEX) in Cohort D\",\"Approximately 1 year|Approximately 1 year|Approximately 3 years\",\"Adverse Events (AEs)|Overall response rate (ORR)|Time to Response (TTR)|Duration of Response (DOR)|Progression-free Survival (PFS)|Overall Survival (OS) in Part 2 relapsed and refractory multiple myeloma (RRMM) cohorts|Pharmacokinetics - Area under the plasma concentration-time curve from time zero to tau, where tau is the dosing interval (AUC[TAU])|Pharmacokinetics - Maximum plasma concentration of drug (Cmax)|Pharmacokinetics - Time to maximum plasma concentration of drug (Tmax)|Very good partial response or better rate (VGPR)\",\"Recruiting\",\"Phase 1|Phase 2\"\n",
      "604,\"Study of the Efficacy and Safety of RsqVD Combination Therapy for Patients With Newly Diagnosed Multiple Myeloma\",\"To evaluate the overall response rate (ORR) after 4 induction cycles\",\"After 4 cycles (84 days)\",\"a) To evaluate the rate and severity of Peripheral Neuropathy (PN) of SQ bortezomib in combination with lenalidomide, and dexamethasone after the 4th and after the final cycle of induction therapy.|Progression of disease|Progression free survival|Duration of response\",\"Completed\",\"Phase 2\"\n",
      "605,\"A Post-Approval Pharmacokinetic Study of Bortezomib in Participants With Multiple Myeloma\",\"Number of Participants With Response to Treatment at Day 1 of Cycle 5|Number of Participants With Response to Treatment at Day 1 of Cycle 7|Number of Participants With Response to Treatment at Day 11 of Cycle 8|Number of Participants With Karnofsky Performance Status (KPS) Score at Baseline|Number of Participants With KPS Score at Day 1 of Cycle 1|Number of Participants With KPS Score at Day 1 of Cycle 3|Number of Participants With KPS Score at Day 1 of Cycle 5|Number of Participants With KPS Score at Day 1 of Cycle 7|Number of Participants With KPS Score at Day 11 of Cycle 8|Maximum Observed Plasma Concentration (Cmax) of Bortezomib on Day 1 of Cycle 1|Maximum Observed Plasma Concentration (Cmax) of Bortezomib on Day 11 of Cycle 1|Time to Reach Maximum Observed Plasma Concentration (Tmax) of Bortezomib on Day 1 of Cycle 1|Time to Reach Maximum Observed Plasma Concentration (Tmax) of Bortezomib on Day 11 of Cycle 1|Elimination Half-Life Period (T1/2) of Bortezomib on Day 1 of Cycle 1|Elimination Half-Life Period (T1/2) of Bortezomib on Day 11 of Cycle 1|Terminal Rate Constant (Lambda[z]) of Bortezomib on Day 1 of Cycle 1|Terminal Rate Constant (Lambda[z]) of Bortezomib on Day 11 of Cycle 1|Area Under the Plasma Concentration-Time Curve From Time Zero to Time at Last Observed Quantifiable Concentration (AUC[0-t]) of Bortezomib on Day 1 of Cycle 1|Area Under the Plasma Concentration-Time Curve From Time Zero to Time at Last Observed Quantifiable Concentration (AUC[0-t]) of Bortezomib on Day 11 of Cycle 1|Area Under the Plasma Concentration-Time Curve From Time Zero to Infinite Time (AUC[0-infinity]) of Bortezomib on Day 1 of Cycle 1|Area Under the Plasma Concentration-Time Curve From Time Zero to Infinite Time (AUC[0-infinity]) of Bortezomib on Day 11 of Cycle 1|Area Under First Moment Plasma Concentration-Time Curve (AUMC) of Bortezomib on Day 1 of Cycle 1|Area Under First Moment Plasma Concentration-Time Curve (AUMC) of Bortezomib on Day 11 of Cycle 1|Mean Residence Time (MRT) of Bortezomib in the Body on Day 1 of Cycle 1|Mean Residence Time (MRT) of Bortezomib in the Body on Day 11 of Cycle 1|Systemic Clearance (CL) of Bortezomib on Day 1 of Cycle 1|Systemic Clearance (CL) of Bortezomib on Day 11 of Cycle 1|Volume of Distribution at Steady-State (Vss) of Bortezomib on Day 1 of Cycle 1|Volume of Distribution at Steady-State (Vss) of Bortezomib on Day 11 of Cycle 1\",\"Day 1 of Cycle 5|Day 1 of Cycle 7|Day 11 of Cycle 8|Baseline|Day 1 of Cycle 1|Day 1 of Cycle 3|Day 1 of Cycle 5|Day 1 of Cycle 7|Day 11 of Cycle 8|0 hour (Pre-dose) and 0.08, 0.25, 0.5, 1, 2, 4, 6, 8, 12, 24, 48, 72 hours (post-dose) on Day 1 of Cycle 1|0 hour (Pre-dose) and 0.08, 0.25, 0.5, 1, 2, 4, 6, 8, 12, 24, 48, 72 hours (post-dose) on Day 11 of Cycle 1|0 hour (Pre-dose) and 0.08, 0.25, 0.5, 1, 2, 4, 6, 8, 12, 24, 48, 72 hours (post-dose) on Day 1 of Cycle 1|0 hour (Pre-dose) and 0.08, 0.25, 0.5, 1, 2, 4, 6, 8, 12, 24, 48, 72 hours (post-dose) on Day 11 of Cycle 1|0 hour (Pre-dose) and 0.08, 0.25, 0.5, 1, 2, 4, 6, 8, 12, 24, 48, 72 hours (post-dose) on Day 1 of Cycle 1|0 hour (Pre-dose) and 0.08, 0.25, 0.5, 1, 2, 4, 6, 8, 12, 24, 48, 72 hours (post-dose) on Day 11 of Cycle 1|0 hour (Pre-dose) and 0.08, 0.25, 0.5, 1, 2, 4, 6, 8, 12, 24, 48, 72 hours (post-dose) on Day 1 of Cycle 1|0 hour (Pre-dose) and 0.08, 0.25, 0.5, 1, 2, 4, 6, 8, 12, 24, 48, 72 hours (post-dose) on Day 11 of Cycle 1|0 hour (Pre-dose) and 0.08, 0.25, 0.5, 1, 2, 4, 6, 8, 12, 24, 48, 72 hours (post-dose) on Day 1 of Cycle 1|0 hour (Pre-dose) and 0.08, 0.25, 0.5, 1, 2, 4, 6, 8, 12, 24, 48, 72 hours (post-dose) on Day 11 of Cycle 1|Day 1 of Cycle 1|0 hour (Pre-dose) and 0.08, 0.25, 0.5, 1, 2, 4, 6, 8, 12, 24, 48, 72 hours (post-dose) on Day 11 of Cycle 1|0 hour (Pre-dose) and 0.08, 0.25, 0.5, 1, 2, 4, 6, 8, 12, 24, 48, 72 hours (post-dose) on Day 1 of Cycle 1|0 hour (Pre-dose) and 0.08, 0.25, 0.5, 1, 2, 4, 6, 8, 12, 24, 48, 72 hours (post-dose) on Day 11 of Cycle 1|0 hour (Pre-dose) and 0.08, 0.25, 0.5, 1, 2, 4, 6, 8, 12, 24, 48, 72 hours (post-dose) on Day 1 of Cycle 1|0 hour (Pre-dose) and 0.08, 0.25, 0.5, 1, 2, 4, 6, 8, 12, 24, 48, 72 hours (post-dose) on Day 11 of Cycle 1|0 hour (Pre-dose) and 0.08, 0.25, 0.5, 1, 2, 4, 6, 8, 12, 24, 48, 72 hours (post-dose) on Day 1 of Cycle 1|0 hour (Pre-dose) and 0.08, 0.25, 0.5, 1, 2, 4, 6, 8, 12, 24, 48, 72 hours (post-dose) on Day 11 of Cycle 1|0 hour (Pre-dose) and 0.08, 0.25, 0.5, 1, 2, 4, 6, 8, 12, 24, 48, 72 hours (post-dose) on Day 1 of Cycle 1|0 hour (Pre-dose) and 0.08, 0.25, 0.5, 1, 2, 4, 6, 8, 12, 24, 48, 72 hours (post-dose) on Day 11 of Cycle 1\",,\"Completed\",\"Phase 3\"\n",
      "606,\"UARK 2010-35, A Study of Expanded Natural Killer Cell Therapy for Multiple Myeloma\",\"Therapeutic Efficacy\",\"180 days\",,\"Completed\",\"Phase 2\"\n",
      "607,\"Efficacy of Response-adapted Treatment in Patients With Multiple Myeloma Candidates for Bone Marrow Transplantation\",\"Progression Free Survival|Overall Survival|Proportion of patients with serious adverse effects|Average grade 3 or higher adverse events per patient|Annual incidence of grade 3 or higher adverse effects\",\"Time elapsed from start of treatment until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 102 months.|Time elapsed from start of treatment to end of follow-up or patient death, whichever came first, assessed up to 102 months.|Time elapsed from start of treatment to end of follow-up or patient death, whichever came first, assessed up to 102 months.|Time elapsed from start of treatment to end of follow-up or patient death, whichever came first, assessed up to 102 months.|Time elapsed from start of treatment to end of follow-up or patient death, whichever came first, assessed up to 102 months.\",,\"Completed\",\"Not Applicable\"\n",
      "608,\"Arsenic Trioxide Plus Vitamin C in Treating Patients With Recurrent or Refractory Multiple Myeloma\",\"Disease response as measured by M protein quantitation and the percentage of plasma cell infiltration in bone marrow biopsies after every course\",,\"Toxicity as measured by CTCAE criteria\",\"Completed\",\"Phase 1|Phase 2\"\n",
      "609,\"ABC294640 (Opaganib) in Refractory / Relapsed Multiple Myeloma\",\"Maximum Tolerated Dose\",\"6 months\",\"To Assess the Antitumor Activity of Single Agent Opaganib in Patients With Refractory or Relapsed Multiple Myeloma After 3 Cycles of Treatment.|Number of Patients With Dose Limiting Toxicity|Maximum Concentration (Cmax) of ABC294640\",\"Terminated\",\"Phase 1|Phase 2\"\n",
      "610,\"Cyclosporine in Combination With Carfilzomib and Dexamethasone in Relapsed Multiple Myeloma Refractory to Carfilzomib and High Expression of PPIA Gene in Myeloma Cells\",\"Number of Participants With Abnormal Laboratory Values and/or Adverse Events That Are Related to Treatment parameters.\",\"follow-up 2 years post study\",\"Overall response rate ORR|Progression free survival PFS|Duration of Response DOR|Time to Response TTR|Depth of Best Response (DpR)|Time to progression (TTP)|Overall Survival (OS)|Extramedullary progression|Extramedullary progression|Percentage of cyclosporine trough levels tests in acceptable range|Mean % of levels in acceptable range will be calculated for the efficacy population.\",\"Recruiting\",\"Phase 1\"\n",
      "611,\"A Study of DFRF4539A in Patients With Relapsed or Refractory Multiple Myeloma\",\"Safety: Incidence of adverse events|Safety: Maximum tolerated dose/dose-limiting toxicities|Recommended Phase II dose for every-3-week or weekly administration of DFRF4539A\",\"approximately 3.5 years|approximately 1.5 years|approximately 3.5 years\",\"Immunogenicity: Serum antitherapeutic antibody levels|Pharmacokinetics: Area under the concentration - time curve (AUC)|Objective response, tumor assessments according to International Myeloma Working Group (IMWG) Uniform Response Criteria and/or European Bone Marrow Transplant (EBMT) Criteria|Duration of objective response, defined as time from first documented objective response to progression or death of any cause|Progression-free survival, defined as time from first study treatment (Cycle 1, Day 1) to disease progression or death during study or within 30 days after last dose of study drug, whichever occurs first\",\"Completed\",\"Phase 1\"\n",
      "612,\"Stem Cell Transplant With Lenalidomide Maintenance in Patients With Multiple Myeloma (BMT CTN 0702)\",\"Percentage of Participants With Progression-free Survival (PFS)\",\"38 months post-randomization\",\"Percentage of Participants With Disease Progression|Percentage of Participants With Overall Survival (OS)|Percentage of Participants With Treatment-related Mortality (TRM)|Number of Participants With Treatment Response|FACT-G Total Score|FACT-BMT Score|FACT-BMT Trial Outcome Index|MOS SF-36 Physical Component Summary|MOS SF-36 Mental Component Summary\",\"Completed\",\"Phase 3\"\n",
      "613,\"Melphalan and Filgrastim to Stimulate Peripheral Stem Cells in Patients With Multiple Myeloma\",,,,\"Completed\",\"Phase 2\"\n",
      "614,\"Plasma-free Replacement in Patients With Multiple Myeloma\",\"Change from M protein content in plasma at Week 18|Change from Blood routine in plasma at Week 18|Change from Blood routine in plasma at Week 18|Change from Blood routine in plasma at Week 18|Change from Blood routine in plasma at Week 18|Change from Blood routine in plasma at Week 18|Change from Blood routine in plasma at Week 18|Change from liver and kidney function at Week 18|Change from liver and kidney function at Week 18|Change from liver and kidney function at Week 18|Change from liver and kidney function at Week 18|Change from liver and kidney function at Week 18|Change from liver and kidney function at Week 18|Adverse event: Low blood pressure|Adverse event:|Adverse event: Difficulty breathing|Adverse event: Numbness\",\"Day 0，Day 1，Week 1，Week4，Week 12，Week 18|Day 0，Day 1，Week 1，Week4，Week 12，Week 18|Day 0，Day 1，Week 1，Week4，Week 12，Week 18|Day 0，Day 1，Week 1，Week4，Week 12，Week 18|Day 0，Day 1，Week 1，Week4，Week 12，Week 18|Day 0，Day 1，Week 1，Week4，Week 12，Week 18|Day 0，Day 1，Week 1，Week4，Week 12，Week 18|Day 0，Day 1，Week 1，Week4，Week 12，Week 18|Day 0，Day 1，Week 1，Week4，Week 12，Week 18|Day 0，Day 1，Week 1，Week4，Week 12，Week 18|Day 0，Day 1，Week 1，Week4，Week 12，Week 18|Day 0，Day 1，Week 1，Week4，Week 12，Week 18|Day 0，Day 1，Week 1，Week4，Week 12，Week 18|Day 1|Day 1|Day 1|Day 1\",\"Safety and Tolerability Assess patient symptoms\",\"Completed\",\"Phase 1\"\n",
      "615,\"Clinical Study of CAR-BCMA T Cells in Patients With Refractory or Relapsed Multiple Myeloma\",\"Number of participants with CAR-BCMA T cell therapy-related adverse events as assessed by CTCAE v4.03\",\"24 weeks\",\"Engraftment|Anti-tumor response of CAR-BCMA T cell infusion|Statistical parameter of efficacy assessment#PFS|Statistical parameter of efficacy assessment#DCR|Statistical parameter of efficacy assessment#ORR|Statistical parameter of efficacy assessment#OS\",\"Active, not recruiting\",\"Not Applicable\"\n",
      "616,\"Validation of a Personalised Medicine Tool for Multiple Myeloma That Predicts Treatment Effectiveness in Patients\",\"MMpredictor as a personalised medicine tool\",\"1 year\",\"- Genetic subtyping with the MMprofiler of 800 bio-banked MM patient samples|- Clinical validation of genetic subtypes correlating with specific treatment effect|- Establish a treatment decision matrix that will guide physicians in treatment decision-making|- Perform a Medical Technology Assessment (MTA) to evaluate health economic benefits|- File addendum to current CE-IVD registration, while also renaming the test to \"\"MMpredictor\"\"|- Develop and execute commercialisation and marketing plan for the MMpredictor\",\"Active, not recruiting\",\n",
      "617,\"Fluphenazine in Treating Patients With Refractory Advanced Multiple Myeloma\",\"Safety|Efficacy\",,,\"Completed\",\"Phase 1|Phase 2\"\n",
      "618,\"Impact of Budesonide on Incidence of ≥ Gr2 Diarrhea in Multiple Myeloma (MM) Patients Undergoing Autologous Stem Cell Transplant\",\"Proportion of patients with delayed engraftment (engraftment after day 18) and severe infection related complications (≥ Grade 4 NCI CTCAE v5).|incidence of Grade 2 or higher diarrhea from the time of ASCT until day 14 post ASCT as measured by NCI Common-Terminology Criteria (CTCAE).\",\"18 days|14 days\",\"proportion of patients reporting \"\"frequent\"\" or \"\"almost constant\"\" diarrhea on Day -1 of transplant on the PRO-CTCAE score|proportion of patients reporting \"\"frequent\"\" or \"\"almost constant\"\" diarrhea on Day 7 of transplant on the PRO-CTCAE score|proportion of patients reporting \"\"frequent\"\" or \"\"almost constant\"\" diarrhea on Day 14 of transplant on the PRO-CTCAE score|proportion of patients reporting \"\"frequent\"\" or \"\"almost constant\"\" diarrhea on Day 30 of transplant on the PRO-CTCAE score|proportion of patients reporting \"\"frequent\"\" or \"\"almost constant\"\" diarrhea 3 months post ACST on the PRO-CTCAE score|proportion of patients in each arm reporting \"\"frequent\"\" or \"\"almost constant\"\" abdominal pain on Day -1 of transplant on the PRO-CTCAE score|proportion of patients in each arm reporting \"\"frequent\"\" or \"\"almost constant\"\" abdominal pain on Day 7 aof transplant on the PRO-CTCAE score|proportion of patients in each arm reporting \"\"frequent\"\" or \"\"almost constant\"\" abdominal pain on Day 14 of transplant on the PRO-CTCAE score|proportion of patients in each arm reporting \"\"frequent\"\" or \"\"almost constant\"\" abdominal pain on Day 30 of transplant on the PRO-CTCAE score|proportion of patients in each arm reporting \"\"frequent\"\" or \"\"almost constant\"\" abdominal pain 3 months post ACST on the PRO-CTCAE score|proportion of patients in each arm reporting \"\"frequent\"\" or \"\"almost constant\"\" nausea on Day 1 of transplant on the PRO-CTCAE score|proportion of patients in each arm reporting \"\"frequent\"\" or \"\"almost constant\"\" nausea on Day 7 of transplant on the PRO-CTCAE score|proportion of patients in each arm reporting \"\"frequent\"\" or \"\"almost constant\"\" nausea on Day 14 of transplant on the PRO-CTCAE score|The proportion of patients in each arm reporting \"\"frequent\"\" or \"\"almost constant\"\" nausea on Day 30 of transplant on the PRO-CTCAE score.|The proportion of patients in each arm reporting \"\"frequent\"\" or \"\"almost constant\"\" nausea 3 months post ACST on the PRO-CTCAE score.|The proportion of patients in each arm reporting \"\"frequent\"\" or \"\"almost constant\"\" vomiting on Day 1 of transplant on the PRO-CTCAE score.|The proportion of patients in each arm reporting \"\"frequent\"\" or \"\"almost constant\"\" vomiting on Day 7 of transplant on the PRO-CTCAE score.|The proportion of patients in each arm reporting \"\"frequent\"\" or \"\"almost constant\"\" vomiting on Day 14 of transplant on the PRO-CTCAE score.|The proportion of patients in each arm reporting \"\"frequent\"\" or \"\"almost constant\"\" vomiting on Day 30 of transplant on the PRO-CTCAE score.|The proportion of patients in each arm reporting \"\"frequent\"\" or \"\"almost constant\"\" vomiting 3 months post ACST on the PRO-CTCAE score.|Length of stay in hospital|Time to engraftment|Proportion of patients using supportive anti-diarrheal and pain medications|Change in Bristol Stool Scale|Incidence of post ASCT infection prior to engraftment|Median score of EORTC QLQ-C30 for participants in each arm|proportion of patients with engraftment syndrome|Proportion of patients reporting none, mild, moderate, severe or very severe mouth sores as measured by PRO-CTCAE on Day -1|Proportion of patients reporting none, mild, moderate, severe or very severe mouth sores as measured by PRO-CTCAE on Day 7|Proportion of patients reporting none, mild, moderate, severe or very severe mouth sores as measured by PRO-CTCAE on Day 14|Proportion of patients reporting none, mild, moderate, severe or very severe mouth sores as measured by PRO-CTCAE on Day 30|Proportion of patients reporting none, mild, moderate, severe or very severe mouth sores as measured by PRO-CTCAE 3 months post ACST|Proportion of patients reporting none, a little bit, somewhat, quite a bit or very mouth interference with daily activity as a result of their mouth sores as measured by PRO-CTCAE on Day -1|Proportion of patients reporting none, a little bit, somewhat, quite a bit or very mouth interference with daily activity as a result of their mouth sores as measured by PRO-CTCAE on Day 7|Proportion of patients reporting none, a little bit, somewhat, quite a bit or very mouth interference with daily activity as a result of their mouth sores as measured by PRO-CTCAE on Day 14|Proportion of patients reporting none, a little bit, somewhat, quite a bit or very mouth interference with daily activity as a result of their mouth sores as measured by PRO-CTCAE on Day 30|Proportion of patients reporting none, a little bit, somewhat, quite a bit or very mouth interference with daily activity as a result of their mouth sores as measured by PRO-CTCAE 3 months post ACST|Proportion of patients reporting none, mild, moderate, severe or very severe problems with concentration as measured by PRO-CTCAE on Day -1|Proportion of patients reporting none, mild, moderate, severe or very severe problems with concentration as measured by PRO-CTCAE on Day 7|Proportion of patients reporting none, mild, moderate, severe or very severe problems with concentration as measured by PRO-CTCAE on Day 14|Proportion of patients reporting none, mild, moderate, severe or very severe problems with concentration as measured by PRO-CTCAE on Day 30|Proportion of patients reporting none, mild, moderate, severe or very severe problems with concentration as measured by PRO-CTCAE 3 months post ACST|Proportion of patients reporting none, a little bit, somewhat, quite a bit or very much interference with daily activity as a result of concentration problems as measured by PRO-CTCAE on Day -1|Proportion of patients reporting none, a little bit, somewhat, quite a bit or very much interference with daily activity as a result of concentration problems as measured by PRO-CTCAE on Day 7|Proportion of patients reporting none, a little bit, somewhat, quite a bit or very much interference with daily activity as a result of concentration problems as measured by PRO-CTCAE on Day 14|Proportion of patients reporting none, a little bit, somewhat, quite a bit or very much interference with daily activity as a result of concentration problems as measured by PRO-CTCAE on Day 30|Proportion of patients reporting none, a little bit, somewhat, quite a bit or very much interference with daily activity as a result of concentration problems as measured by PRO-CTCAE 3 months post ACST|Proportion of patients reporting none, mild, moderate, severe or very severe problems with memory as measured by PRO-CTCAE on Day -1|Proportion of patients reporting none, mild, moderate, severe or very severe problems with memory as measured by PRO-CTCAE on Day 7|Proportion of patients reporting none, mild, moderate, severe or very severe problems with memory as measured by PRO-CTCAE on Day 14|Proportion of patients reporting none, mild, moderate, severe or very severe problems with memory as measured by PRO-CTCAE on Day 30|Proportion of patients reporting none, mild, moderate, severe or very severe problems with memory as measured by PRO-CTCAE 3 months post ACST|Proportion of patients reporting none, a little bit, somewhat, quite a bit or very much interference with daily activity as a result of problems with memory as measured by PRO-CTCAE on Day -1|Proportion of patients reporting none, a little bit, somewhat, quite a bit or very much interference with daily activity as a result of problems with memory as measured by PRO-CTCAE on Day 7|Proportion of patients reporting none, a little bit, somewhat, quite a bit or very much interference with daily activity as a result of problems with memory as measured by PRO-CTCAE on Day 14|Proportion of patients reporting none, a little bit, somewhat, quite a bit or very much interference with daily activity as a result of problems with memory as measured by PRO-CTCAE on Day 30|Proportion of patients reporting none, a little bit, somewhat, quite a bit or very much interference with daily activity as a result of problems with memory as measured by PRO-CTCAE 3 months post ACST|Proportion of patients reporting none, mild, moderate, severe or very severe fatigue as measured by PRO-CTCAE on Day -1|Proportion of patients reporting none, mild, moderate, severe or very severe fatigue as measured by PRO-CTCAE on Day 7|Proportion of patients reporting none, mild, moderate, severe or very severe fatigue as measured by PRO-CTCAE on Day 14|Proportion of patients reporting none, mild, moderate, severe or very severe fatigue as measured by PRO-CTCAE on Day 30|Proportion of patients reporting none, mild, moderate, severe or very severe fatigue as measured by PRO-CTCAE 3 months post ACST|Proportion of patients reporting none, a little bit, somewhat, quite a bit or very much interference with daily activity as a result of fatigue as measured by PRO-CTCAE on Day -1|Proportion of patients reporting none, a little bit, somewhat, quite a bit or very much interference with daily activity as a result of fatigue as measured by PRO-CTCAE on Day 7|Proportion of patients reporting none, a little bit, somewhat, quite a bit or very much interference with daily activity as a result of fatigue as measured by PRO-CTCAE on Day 14|Proportion of patients reporting none, a little bit, somewhat, quite a bit or very much interference with daily activity as a result of fatigue as measured by PRO-CTCAE on Day 30|Proportion of patients reporting none, a little bit, somewhat, quite a bit or very much interference with daily activity as a result of fatigue as measured by PRO-CTCAE 3 months post ACST\",\"Recruiting\",\"Phase 2\"\n",
      "619,\"Compare Lenalidomide and Subcutaneous Daratumumab vs Lenalidomide and Dexamethasone in Frail Subjects With Previously Untreated Multiple Myeloma Who Are Ineligible for High Dose Therapy\",\"Comparison of the efficacy of Daratumumab SC injection when combined with Lenalidomide (R-Dara SC) vs Lenalidomide and Dexamethasone (Rd): PFS\",\"From date of randomization until the date of first documented progression or date of toxicity or date of death from any cause, whichever came first, assessed up to 84months\",\"Time-to-treatment failure|Time-to-next treatment|PFS2 time|Overall survival (OS) time|Complete remission (CR)|Very good partial response (VGPR) or better.|Overall response (CR + VGPR + partial response [PR]).|Occurrence of grade 3 or more side effects.|Safety and tolerability of Daratumumab SC when administered in combination with Revlimid: NCI-CTCAE V5.0.|Evaluation of quality of life based on MY20 questionnaires|Evaluation of quality of life based on EORTC C30 questionnaires|Evaluation of quality of life based on EQ-5D questionnaires|Minimal residual disease (MRD) negative rate at 12 months.|Event Free Survival\",\"Active, not recruiting\",\"Phase 3\"\n",
      "620,\"A Safety Confirmation Study on Lenalidomide With Dexamethasone In Japanese Patients With Previously Treated Multiple Myeloma\",\"Number of Participants Experiencing Treatment-Emergent Adverse Events (TEAE)\",\"Day 1 of study drug through 28 days after the last dose of study drug; maximum treatment duration was 60.3 weeks\",\"Myeloma Response Rate|Kaplan-Meier Estimates of Duration of Response (DoR)\",\"Completed\",\"Phase 3\"\n",
      "621,\"A Phase 1 Dose-Escalation Study in Advanced Solid Tumors, Lymphomas or Multiple Myeloma\",\"Dose Limiting Toxicity and Recommended Phase 2 dose\",\"Following 4 weeks of treatment\",\"Pharmacokinetic (PK) profile of AV-299, and erlotinib (for subjects enrolled in the Phase 1b only).|Evaluate the effects of AV-299 and combination of AV-299 and erlotinib on exploratory biomarkers in blood, body fluid, tumor tissue, and/or bone marrow.|Study the preliminary antineoplastic activity of AV-299 in subjects with advanced solid tumors, lymphoma, or multiple myeloma, and the preliminary antineoplastic activity of AV 299 in combination with erlotinib in subjects with advanced solid tumor.|Investigate the effect of AV-299 and of the combination of AV-299 and erlotinib on gene expression patterns in peripheral blood mononuclear cells and/or bone marrow.|Assess dosing schedules of AV-299 (e.g. every 2-week and every 3-week schedules).|Assess safety and tolerability of the RP2D of AV-299 in expansion cohort(s).\",\"Completed\",\"Phase 1\"\n",
      "622,\"Curcumin (Diferuloylmethane Derivative) With or Without Bioperine in Patients With Multiple Myeloma\",\"Percent Change of NF-kB Protein Expression in Peripheral Blood Mononuclear Cells From Baseline Through 4 Weeks of Treatment\",\"Baseline through 4 weeks of treatment\",,\"Completed\",\"Not Applicable\"\n",
      "623,\"Daratumumab, VELCADE (Bortezomib), Lenalidomide and Dexamethasone Compared to VELCADE, Lenalidomide and Dexamethasone in Subjects With Previously Untreated Multiple Myeloma\",\"Progression Free Survival (PFS)\",\"from randomization to the date of disease progression or death (approximately up to 9 years)\",\"Post-consolidation MRD negativity rate,|Overall Response Rate (ORR)|Progression-free survival on the next line of therapy (PFS2)|Overall Survival (OS)|Time to response|Duration of response|Pharmacokinetic concentrations of daratumumab|Determine the incidence of anti-daratumumab antibodies (immunogenicity) for all subjects who receive at least 1 dose of daratumumab and determine the incidence of anti-rHuPH20 antibodies|Change in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire 30-item Core module (EORTC QLQ-C30) score and the difference between-treatment arms|Change in EORTC QLQ- 20-item Multiple Myeloma module (MY-20) score and the difference between-treatment arms|EQ-5D-5L health utility values and the difference between-treatment arms|Stem cell yield after mobilization|Time to engraftment post-ASCT\",\"Active, not recruiting\",\"Phase 3\"\n",
      "624,\"Multiple Myeloma (MM) Quality of Life (QOL) Study\",\"Quality of life (QOL) Patient Description|Quality of life (QOL) Caregiver Description\",\"Up to 1 year|Up to 1 year\",\"QOL-Functional Assessment|Patient Burden Assessment-ESAS|Patient Fatigue Symptoms|Patient anxiety symptoms|Patient Depression symptoms|Patient Post-traumatic stress symptoms|Patient coping|Caregiver Quality of Life (QOL)|Caregiver Burden|Caregiver anxiety|Caregiver Depression|Caregiver Coping\",\"Unknown status\",\n",
      "625,\"Efficacy of NF-kB Inhibition for Reducing Symptoms During Maintenance Therapy in Multiple Myeloma Patients\",\"AUC from 3 months Post-Transplantation to 9 months Post-Transplantation\",\"Assessments within +/-3 days of 4 week cycle start date for 6 cycles.\",,\"Withdrawn\",\"Phase 2\"\n",
      "626,\"Phase I Study of Perifosine + Lenalidomide and Dexamethasone for Patients With Multiple Myeloma\",\"Adverse Events\",\"Every cycle\",\"Clinically significant changes in the patient's physical examination, vital signs, and clinical laboratory results\",\"Completed\",\"Phase 1\"\n",
      "627,\"Study of the Immune Response After Vaccination in Multiple Myeloma Patients\",\"Evaluate composition of T cells, B cells, NK cell and monocyte populations from pre-vaccination though 24 weeks post-vaccination|Measure of interferon -gamma in activated T cells from pre-vaccination though 24 weeks post-vaccination|Measure of antigen specific B cells from pre-vaccination though 24 weeks post-vaccination|Total PnC-IgG, IgG2, PnC-IgG1 and IgG3 levels from pre-vaccination though 24 weeks post-vaccination|Evaluate both FcyRIIa and FcyRIII polymorphisms\",\"24 weeks|24 weeks|24 weeks|24 weeks|up to 24 weeks\",\"Assess outcomes of MM patients after vaccination\",\"Completed\",\n",
      "628,\"Safety and Efficacy Study for the Prevention of Nausea and Vomiting in Multiple Myeloma Patients Receiving Stem Cell Transplantation.\",,,,\"Completed\",\"Phase 2\"\n",
      "629,\"Safety and Dose Study of GRN163L Administered to Treat Patients With Refractory or Relapsed Multiple Myeloma\",\"Safety and MTD\",\"First 3 weeks\",\"PK, PD, and efficacy\",\"Completed\",\"Phase 1\"\n",
      "630,\"Study of ACE-041 in Patients With Advanced Solid Tumors or Relapsed/Refractory Multiple Myeloma\",\"To evaluate the safety and tolerability of ACE-041 in patients with advanced solid tumors or relapsed/refractory multiple myeloma by monitoring adverse events, clinical laboratory tests, vital signs, physical examinations, and anti-drug antibody tests.\",\"4 months\",\"To evaluate the pharmacokinetic effect of ACE-041 through the collection of blood samples and to evaluate the preliminary anti-tumor activity of ACE-041 through tumor response evaluation, collection of blood biomarkers, and imaging techniques.\",\"Completed\",\"Phase 1\"\n",
      "631,\"Study of Disulfiram and Copper Gluconate in Patients With Treatment-Refractory Multiple Myeloma\",\"Rate of dose limiting toxicities (DLTs) during the DLT evaluation period.\",\"time from cycle one day one until cycle two day one (28 days)\",,\"Terminated\",\"Phase 1\"\n",
      "632,\"PHE885 CAR-T Therapy in Adult Participants With Relapsed and Refractory Multiple Myeloma\",\"Overall response rate (ORR) per Independent Review Committee (IRC) in Efficacy Analysis Set\",\"24 Months\",\"Key Secondary End point: MRD Negativity rate in Bone Marrow|Complete response rate (CRR)|Time to response|Duration of Response (DOR)|Progression free survival (PFS)|Time to next anti-myeloma treatment (TTNT)|Overall Survival (OS)|Durability of Minimal Residual Disease (MRD)negativity|Patient Reported Outcomes (PRO): EQ-5D-5L Health Questionnaire|Patient Reported Outcomes (PRO): EORTC-QLQ-C30|Patient Reported Outcomes (PRO): EORTC-QLQ-MY20|PHE885 manufacturing success rate|Manufacturing turnaround time|Transgene of PHE885 concentrations over time in peripheral blood and bone marrow|Cellular kinetics parameter: Cmax|Cellular kinetics parameter: Tmax|Cellular kinetics parameter: AUC|Immunogenicity to PHE885\",\"Recruiting\",\"Phase 2\"\n",
      "633,\"A Study to Assess Adverse Events of Intravenously (IV) Infused ABBV-383 in Adult Participants With Relapsed or Refractory Multiple Myeloma\",\"Number of Grade >= 2 Cytokine Release Syndrome (CRS) Events\",\"Up to Day 28\",\"Number of Cytokine Release Syndrome (CRS) Events\",\"Recruiting\",\"Phase 1\"\n",
      "634,\"Studying Blood Samples From Patients With Multiple Myeloma Who Were Treated With Thalidomide or Lenalidomide\",\"Proportion of patients with failed disease based on expectations for changes in cathepsin G (CG) levels\",\"1 month\",\"Mechanism of development of thalidomide/lenalidomide-induced venous thromboembolism (VTE)|Intensity, dynamics, and specificity of CG upregulation in response to thalidomide and lenalidomide treatment|Specificity and threshold levels of CG for induction of platelet aggregation in response to thalidomide and lenalidomide and the resulting risk for VTE development\",\"Completed\",\n",
      "635,\"Trisenox, Ascorbic Acid and Bortezomib in Patients With Relapsed/Refractory Multiple Myeloma\",\"Toxicity\",\"30 days post last dose of study drug\",\"Response\",\"Terminated\",\"Phase 1\"\n",
      "636,\"An Efficacy and Safety Study of Bortezomib Re-treatment in Multiple Myeloma\",\"Best Confirmed Response to Bortezomib Re-Treatment\",\"Day 1 of every alternate cycle starting from Cycle 1 up to End of Treatment (30 to 42 days after last dose administration of bortezomib)\",\"Participants With Percent Change in Baseline Serum Monoclonal Protein (M-protein) Best Confirmed Response Category|Participants with Percent Change in Baseline Urine Monoclonal Protein (M-protein) Best Confirmed Response Category|Duration of Best Confirmed Response (DOR)|Time to Progression (TTP) for Best Confirmed Response\",\"Completed\",\"Phase 2\"\n",
      "637,\"CAR-T Re-treatment for Refractory/Relapsed Multiple Myeloma\",\"Occurrence of treatment related adverse events\",\"Day 1-30 days after injection\",\"Anti-myeloma responses|Anti-myeloma responses\",\"Unknown status\",\"Phase 1\"\n",
      "638,\"Study of Initial Treatment With Elotuzumab, Carfilzomib, Lenalidomide and Dexamethasone in Multiple Myeloma\",\"Rate of sCR|Rate of negative MRD\",\"At the end of eight months|At the end of eight months\",\"Number of participants with adverse events of elotuzumab in combination with KRd|Rate of MRD|Duration of response|Progression free survival|Time to progression|Overall survival\",\"Active, not recruiting\",\"Phase 2\"\n",
      "639,\"Bortezomib, Ascorbic Acid, and Melphalan in Treating Patients With Newly Diagnosed Multiple Myeloma\",\"Overall response rate (complete response [CR], near CR, partial response, and minimal response)|Safety and tolerability as assessed by NCI CTCAE v3.0|Proportion of patients responding|Time to disease progressionin patients receiving maintenance treatment\",,\"Time to response|Progression-free survival|Overall survival as assessed by the Kaplan-Meier method|Time to disease progression\",\"Completed\",\"Phase 2\"\n",
      "640,\"Melphalan, Prednisone, and Lenalidomide in Treating Patients With Newly Diagnosed Multiple Myeloma\",\"Patients With Overall Confirmed Response\",\"Every cycle during treatment\",\"Progression-free Survival|Overall Survival (OS) at 3 Years|Duration of Response (DOR)|Percentage of Participants With Toxicity, Assessed Using National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) Version 3.0 (v3)\",\"Completed\",\"Phase 1|Phase 2\"\n",
      "641,\"TriPRIL CAR T Cells in Multiple Myeloma\",\"Incidence of adverse events (AEs)|Incidence of Dose Limiting Toxicity (DLT)\",\"Week 24 post dosing, and every three months until two years.|Week 24 post dosing, and every three months until two years.\",\"Overall Response Rate (ORR)|Overall Survival (OS)|Progression Free Survival (PFS)\",\"Recruiting\",\"Phase 1\"\n",
      "642,\"INCB053914 and Pomalidomide With Dexamethasone for Relapsed and/or Refractory Multiple Myeloma\",\"The number of subjects with dose-limiting toxicities.\",\"28 days\",\"The recommended phase II dose of INCB053914.|Progression-free survival.|Overall survival.|Duration of response.|Efficacy of bone protective effect of INCB053914 in combination with pomalidomide and dexamethasone in patients with relapsed and/or refractory multiple myeloma.|The bone protective effect of INCB053914 in combination with pomalidomide and dexamethasone in patients with relapsed and/or refractory multiple myeloma.|The number of subjects with reduction of osteolytic lesions.|The number of subjects with reduction of sclerosis formation.\",\"Withdrawn\",\"Phase 1\"\n",
      "643,\"Bendamustine Plus Bortezomib Plus Dexamethasone in Relapsed or Refractory Multiple Myeloma\",\"efficacy\",\"8 cycles à 28 days plus follow-up phase\",\"efficacy and safety\",\"Completed\",\"Phase 2\"\n",
      "644,\"Daratumumab in Combination With Lenalidomide and Dexamethasone in Relapsed and Relapsed-refractory Multiple Myeloma\",\"Phase 1: Percentage of Participants With Overall Response Rate (ORR)|Phase 2: Percentage of Participants With Overall Response Rate (ORR)\",\"Up to 3 years|Up to 3 years\",\"Phase 2: Time to Progression (TTP)|Phase 2: Duration of Response|Phase 2: Progression-Free Survival (PFS)|Phase 1: Time to Response|Phase 2: Time to Response|Phase 2: Overall Survival (OS)\",\"Active, not recruiting\",\"Phase 1|Phase 2\"\n",
      "645,\"Ixazomib, Cyclophosphamide and Dexamethasone for Multiple Myeloma\",\"Evaluation of the Response Rate of Ixazomib With Metronomic Cyclophosphamide and Dexamethasone for First-line Treatment of Multiple Myeloma.\",\"Through study treatment completion, an average of 2 years\",\"Evaluation of the Toxicities Associated With Ixazomib With Metronomic Cyclophosphamide and Dexamethasone.\",\"Active, not recruiting\",\"Phase 2\"\n",
      "646,\"The Effect of Epoetin Alfa on the Anemia of Patients With Multiple Myeloma\",\"Proportion of patients requiring transfusion and number of units transfused relative to whether or not patients received transfusion(s) before the study.\",,\"Increase in hemoglobin, hematocrit, developing red blood cells in the blood; Changes in quality-of-life; Safety evaluations (incidence of adverse events, laboratory tests, and vital signs) including changes in underlying multiple myeloma.\",\"Completed\",\"Phase 3\"\n",
      "647,\"Combination Chemotherapy and Thalidomide in Treating Patients With Stage I, Stage II, or Stage III Multiple Myeloma\",,,,\"Completed\",\"Phase 2\"\n",
      "648,\"High-Dose Melphalan, Total-Body Irradiation, and Peripheral Stem Cell Transplantation in Treating Patients With Multiple Myeloma in First Relapse\",,,,\"Completed\",\"Phase 2\"\n",
      "649,\"Study of Ibrutinib in Combination With Revlimid/Dexamethasone in Relapsed/Refractory Multiple Myeloma\",\"Maximum Tolerated Dose for Combination|Objective Response Rate\",\"19 Months|34 Months\",\"Progression Free Survival|Overall Survival|Duration of Response|Maximum Toxicity Grade\",\"Recruiting\",\"Phase 1\"\n",
      "650,\"Study to Determine Recommended Phase 2 Dose of Intravenous (IV) Eftozanermin Alfa in Combination With IV or Subcutaneous (SC) Bortezomib and Oral Dexamethasone Tablet and to Assess Change in Disease Symptoms in Adult Participants With Relapsed or Refractory Multiple Myeloma\",\"Recommended Phase 2 Dose (RP2D) of Eftozanermin Alfa in Combination With Bortezomib and Dexamethasone (Safety Lead-In Arm)|Objective Response Rate (ORR) (Dose Expansion Arm)\",\"Up to approximately 3 weeks after the first dose of study drug|Up to approximately 44 weeks after the first dose of study drug\",\"Rate of Very Good Partial Response (VGPR) or Better per IMWG Criteria|Duration of Response (DOR) for ORR|Duration of Response (DOR) for VGPR or Better|Number of Participants With Dose-Limiting Toxicities (DLTs)|Number of Participants With Adverse Events (AEs)|Change in Vital Sign Measurements|Electrocardiogram (ECG)|Number of Participants With Abnormal Clinical Laboratory Test Results|Trough Concentration (Ctrough) of Eftozanermin Alfa|Maximum Serum Concentration (Cmax) of Eftozanermin Alfa|Antidrug Antibody (ADA)/Neutralizing Antibody (Nab) Assay\",\"Active, not recruiting\",\"Phase 1\"\n",
      "651,\"Bortezomib, Arsenic Trioxide, and Melphalan in Treating Patients Undergoing an Autologous Stem Cell Transplant For Multiple Myeloma\",\"Evaluate toxicity of the conditioning treatment regimen.\",\"3 ¼ years\",\"Evaluate response and overall survival (OS).|Determine what correlative laboratory and clinical parameters, if any, are associated with efficacy\",\"Withdrawn\",\"Phase 1\"\n",
      "652,\"Doxorubicin Hydrochloride Liposome, Bortezomib, and Dexamethasone in Treating Patients With Newly Diagnosed Multiple Myeloma\",\"Response rate (complete response, very good partial response, partial response, and minimal response) as assessed by modified Bladé criteria at baseline, on day 1 of each course, and at end-of-study\",,\"Safety and tolerability as assessed by NCI CTCAE v3.0|Time to progression|Time to response|Duration of response|Progression-free survival|Overall survival|Changes in serum M-protein|Changes in 24-hour urine M-protein\",\"Unknown status\",\"Phase 2\"\n",
      "653,\"PS-341 (VELCADE™) Versus High-Dose Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma\",,,,\"Completed\",\"Phase 3\"\n",
      "654,\"Thalidomide Plus Dexamethasone as Maintenance Therapy for Multiple Myeloma\",\"Progression Free survival\",\"36 months\",\"Overall survival|safety of thalidomide\",\"Completed\",\"Phase 3\"\n",
      "655,\"Combined Bone Marrow and Kidney Transplant for Multiple Myeloma With Kidney Failure\",\"Remission status of multiple myeloma|Renal allograft acceptance and ability to discontinue immunosuppressive therapy\",\"Throughout study|Throughout study\",\"Graft vs. host disease (GVHD)|Opportunistic infections|T-cell recovery and immune reconstitution\",\"Completed\",\"Phase 1\"\n",
      "656,\"Bevacizumab in Treating Patients With Relapsed or Refractory Multiple Myeloma\",\"Confirmed hematologic response|Progression-free survival at 1 year\",,\"Toxicity as measured by NCI CTCAE v3.0|Time to progression|Duration of response|Survival\",\"Completed\",\"Phase 2\"\n",
      "657,\"Combination Chemotherapy Followed by Bone Marrow or Peripheral Stem Cell Transplantation in Treating Patients With Multiple Myeloma\",,,,\"Completed\",\"Phase 2\"\n",
      "658,\"Melphalan on Disease Burden Measured by Next Generation Sequencing Before AHCT (Autologous Hematopoietic Cell Transplant) for Multiple Myeloma\",\"Residual myeloma cell number measured by NGS|Residual myeloma cell number measured by NGS\",\"At baseline|After treatment, day 15\",\"Toxicity in pre-transplant period assessed according to CTCAE v. 5.0|Percent of participants with pre-transplant period safety|Percent of participants with diarrhea and oral mucositis and other non-hematologic toxicities|Percent of participants with post-transplant period safety|Percent of participants with engraftment failure|Percent of participants with safety stopping endpoints\",\"Recruiting\",\"Early Phase 1\"\n",
      "659,\"Thalidomide and Prednisone Following Peripheral Stem Cell Transplantation in Treating Patients With Multiple Myeloma\",\"incidence of drop-out or dose reduction\",\"2 years\",\"Response rate|Time to progression|Overall survival\",\"Completed\",\"Phase 2\"\n",
      "660,\"Treatment With a Scheme With Low Doses of Bortezomib / Melphalan / Prednisone (MPV) in Patients With Multiple Myeloma\",\"Progression-free survival\",\"18 months\",,\"Terminated\",\"Phase 4\"\n",
      "661,\"A Phase 1 Study Evaluating CPI-0610 in Patients With Previously Treated Multiple Myeloma\",\"Frequency of dose-limiting toxicities (DLTs) associated with CPI-0610 administration during the first cycle (first 21 days) of treatment\",\"DLTs asessed during Cycle 1 (first 21 days on study)\",\"Safety and tolerability of CPI-0610 as assessed by: frequency of adverse events and serious adverse events; changes in hematology and clinical chemistry values; changes in physical examination, vital signs, electrocardiogram, ECHO and ECOG score|Pharmacokinetic parameters of CPI-0610: AUC(0-t), AUC(0-inf), AUCtau,ss, Tmax, Cmax, Ctrough, T1/2, Vd/F, CL/F|Pharmacodynamic effects of CPI-0610: Changes in the expression of MYC and other genes in malignant tumor cells; changes in cellular proliferation and in the extent of apoptosis|Changes in the expression of a set of genes in peripheral blood mononuclear cells (PBMCs) that are sensitive to BET inhibition|Anti-myeloma activity associated with CPI-0610 treatment\",\"Completed\",\"Phase 1\"\n",
      "662,\"ATRA, Celecoxib, and Itraconazole as Maintenance\",\"Number of Participants with Adverse Events as a Measure of Safety\",\"6 months\",\"Blood and Bone Marrow Aspirate Samples as a measure of changes to the MMSC (multiple myeloma stem cell) fraction.\",\"Completed\",\"Phase 1\"\n",
      "663,\"Daratumumab-containing Induction Effects on Stem Cells Mobilization, colLection and Engraftment in Newly Diagnosed Multiple MyelomA Patients.\",\"To assess the difference in the mean number of collected CD34+ cells/kg during total harvest between Daratumumab and control group.\",\"12 months\",\"Proportion (%) of patients achieving at least two minimum transplant doses (4x10^6 CD34+ cells/kg) at first day of apheresis in Daratumumab versus control group.|Proportion (%) of patients who received plerixafor rescue for poor mobilization in Daratumumab versus control group.|Graft composition in Daratumumab group in term of concentration of CD34+ cells x10^6/kg, TNC (total nucleated cells) x 10^8/kg, and MNC (mononuclear cells) x 10^8/kg.|Rate (%) of CD38 expression and clonogenic potential of collected CD34+ cells in both groups.|To compare transplant outcome in term of time (days) to platelets and neutrophils engraftment in Daratumumab versus control group.\",\"Recruiting\",\n",
      "664,\"agenT-797 in Participants With Relapsed/Refractory Multiple Myeloma\",\"Number Of Participants With Treatment-related Adverse Events|Number Of Dose-limiting Toxicities\",\"Baseline through Day 28 post cell infusion|Baseline through Day 14 post cell infusion\",\"Persistence Of agenT-797 In Peripheral Blood|Overall Response Rate (ORR)|Duration Of Response (DOR)|Duration Of Clinical Benefit|Time To Response (TTR)|Measurement Of Serum Alloantibodies To Major Histocompatibility Complex Class I And II\",\"Active, not recruiting\",\"Phase 1\"\n",
      "665,\"Total-Body Irradiation, Busulfan, and Interferon Alfa Followed by Peripheral Stem Cell or Bone Marrow Transplantation in Treating Patients With Multiple Myeloma\",,,,\"Completed\",\"Phase 2\"\n",
      "666,\"A Phase 1/2 Study of a Fully Human BCMA-targeting CAR (CT103A) in Patients With Relapsed/Refractory Multiple Myeloma (FUMANBA-1)\",\"Phase 1: Incidence and Severity of Adverse Events|Phase 1: Laboratoty tests|Phase 1: Vital signs|Phase 1: Physical examination|Phase 2: Overall response rate (ORR) evaluated by an Independent Review Committee (IRC)\",\"Minimum of 2 years post CT103A infusion|Minimum of 2 years post CT103A infusion|Minimum of 2 years post CT103A infusion|Minimum of 2 years post CT103A infusion|3 months post CT103A infusion\",\"Overall response rate (ORR) evaluated by the investigators|Overall Survival (OS)|Duration of Response (DOR)|Progression-free Survival (PFS)|Time to Response (TTR)|Laboratoty tests|Vital signs|Physical examination|Minimal Residual Disease (MRD)|Pharmacokinetics - Cmax|Pharmacokinetics - Tmax|Pharmacokinetics - AUC0-28days|Pharmacokinetics - AUC0-90days|soluble BCMA levels\",\"Recruiting\",\"Phase 1|Phase 2\"\n",
      "667,\"The Ambient Light Multiple Myeloma Study\",\"Changes in Urinary Melatonin\",\"Baseline visit and 3 days after the Autologous Stem Cell Transplant\",\"Sleep Efficiency using Actigraphy at 7 days post-transplant|Sleep Efficiency using Actigraphy at 3 days after engraftment|Sleep Efficiency using Actigraphy at 4 weeks after engraftment|Inflammatory cytokine CRP levels at Baseline|Inflammatory cytokine CRP levels at 7 days following transplant|Inflammatory cytokine CRP levels at 3 days following engraftment|Inflammatory cytokine CRP levels at 4 weeks following engraftment|Number of Neutropenic Fevers at 7 days post-transplant|Number of Neutropenic Fevers at 3 days after engraftment|Number of Neutropenic Fevers at 4 weeks after engraftment|Circadian Light levels measured with Daysimeter (light monitor) at 7 days post-transplant|Circadian Light levels measured with Daysimeter (light monitor) at 3 days after engraftment|Circadian Light levels measured with Daysimeter (light monitor) at 4 weeks after engraftment|MD Anderson Symptom Inventory Score-Multiple Myeloma (MDASI-MM) at Baseline|MD Anderson Symptom Inventory Score-Multiple Myeloma (MDASI-MM) at 7 days following transplant|MD Anderson Symptom Inventory Score-Multiple Myeloma (MDASI-MM) at 3 days following engraftment|MD Anderson Symptom Inventory Score-Multiple Myeloma (MDASI-MM) at 4 weeks following engraftment|Perceived Stress Scale Score at Baseline|Perceived Stress Scale Score at 7 days post-transplant|Perceived Stress Scale Score at 3 days following engraftment|Perceived Stress Scale Score at 4 weeks following engraftment|Patient-Reported Outcomes Measurement Information System -Sleep Disturbance Short Form (PROMIS-SD) Score at Baseline|Patient-Reported Outcomes Measurement Information System -Sleep Disturbance Short Form (PROMIS-SD) Score at 7 days post-engraftment|Patient-Reported Outcomes Measurement Information System -Sleep Disturbance Short Form (PROMIS-SD) Score at 3 days following engraftment|Patient-Reported Outcomes Measurement Information System -Sleep Disturbance Short Form (PROMIS-SD) Score at 4 weeks following engraftment|Patient-Reported Outcomes Measurement Information System (PROMIS)- Fatigue Score at Baseline|Patient-Reported Outcomes Measurement Information System (PROMIS)- Fatigue Score at 7 days following transplant|Patient-Reported Outcomes Measurement Information System (PROMIS)- Fatigue Score at 3 days following engraftment|Patient-Reported Outcomes Measurement Information System (PROMIS)- Fatigue Score at 4 weeks following engraftment\",\"Recruiting\",\"Not Applicable\"\n",
      "668,\"Bortezomib, Cyclophosphamide, Dexamethasone, and Thalidomide in Treating Patients With Newly Diagnosed, Previously Untreated Multiple Myeloma\",\"Response rate\",,\"Safety and tolerability\",\"Unknown status\",\"Phase 2\"\n",
      "669,\"Treatment of Newly Diagnosed Elderly Patients With Multiple Myeloma\",\"Overall survival\",,\"Best response rate|Progression-free survival|Survival after progression|Toxicity\",\"Completed\",\"Phase 3\"\n",
      "670,\"Study Evaluating AMG 424 in Subjects With Multiple Myeloma\",\"Subject incidence of treatment emergent and treatment related adverse events as assessed by CTCAE version 4.0|Subject incidence of dose limiting toxicities (DLTs)\",\"12 Months|28 Days\",\"Anti-tumor activity|Duration of Response|Maximum concentration (Cmax) of AMG 424|Minimum concentration (Cmin) of AMG 424|Time of maximum concentration (Tmax) of AMG 424|Area under the concentration-time curve (AUC) of AMG 424|Time to progression|Progression-Free Survival|Overall Survival\",\"Terminated\",\"Phase 1\"\n",
      "671,\"Safety and Efficacy Study of OPC-415 in Patients With Relapsed and/or Refractory Multiple Myeloma\",\"Phase1: Dose Limiting Toxicity|Phase2: Response rate\",\"Day1~Day28|Day1~Day366\",,\"Recruiting\",\"Phase 1|Phase 2\"\n",
      "672,\"Safety, Efficacy, and Pharmacodynamics of a 60-Minute Infusion of Carfilzomib for Progressive Multiple Myeloma\",\"Establish maximum tolerated dose (MTD)\",\"monthly, up to 24 months\",\"Establish efficacy as assessed by the overall response rate\",\"Unknown status\",\"Phase 1|Phase 2\"\n",
      "673,\"A Study of Efficacy of Treatment With Bortezomib (in Combination With Doxorubicin and Dexamethasone) in Previously Untreated Patients With Multiple Myeloma\",\"Overall Response Rate (ORR): Number of Participants Who Are Responders (Had Stringent Complete Response [sCR], CR, Very Good Partial Response [VGPR] or Partial Response [PR]) After 4 Cycles of Bortezomib, Doxorubicin and Dexamethasone (PAD) Induction\",\"84 days\",\"Disease Response After 4 Cycles of Bortezomib, Doxorubicin and Dexamethasone (PAD) Induction|Overall Response Rate (ORR) to Bortezomib, Doxorubicin and Dexamethasone (PAD) Induction 3-months Following Autologous Stem Cell Transplant (ASCT).|Disease Response 3-months After Autologous Stem Cell Transplant (ASCT)|Event Free Survival (EFS)|Overall Survival|Assessment of Quality of Life (AQoL) Scores|Overall Response Rate (ORR) Stratified by Protein Expression (p53)|Overall Response Rate (ORR) Stratified by Protein Expression (Cyclin D1).|Overall Response Rate (ORR) Stratified by Protein Expression (Bcl-2)|Overall Response Rate (ORR) Stratified by Protein Expression (FGFR3)|Overall Survival (OS) Stratified by Protein Expression (p53).|Overall Survival (OS) Stratified by Protein Expression (Cyclin D1)|Overall Survival (OS) Stratified by Protein Expression (Bcl-2)|Overall Survival (OS) Stratified by Protein Expression (FGFR3)\",\"Completed\",\"Phase 2\"\n",
      "674,\"Monoclonal Antibody-Based Sequential Therapy for Deep Remission in Multiple Myeloma\",\"Percentage of patients with MRD(-) remissions at the completion of consolidation therapy\",\"Baseline until MRD(-) is reached estimated to be up to 15 months.\",\"Serious adverse events (SAEs) from the KRdD treatment|Percentage of patients with MRD(-) status at the completion of induction therapy|Percentage of patients with auto-HCT that convert from positive to negative MRD|Percentage of patients achieving complete remission following complete therapy|Percentage of patients that convert from MRD(-) to MRD(+) following treatment discontinuation|Progression-free survival|Overall survival\",\"Active, not recruiting\",\"Phase 2\"\n",
      "675,\"Clinical Trial of Expanded and Activated Autologous NK Cells to Treat Multiple Myeloma\",\"Number of Participants With Adverse Events During NKAE Treatment\",\"16 months\",\"Number of Participants With Peripheral Blood Monoclonal Protein Reduction or Stabilization\",\"Completed\",\"Phase 1\"\n",
      "676,\"Expanded Access Request Program for Belantamab Mafodotin (GSK2857916) in Multiple Myeloma\",,,,\"Available\",\n",
      "677,\"A Study of Pembrolizumab (MK-3475) in Combination With Standard of Care Treatments in Participants With Multiple Myeloma (MK-3475-023/KEYNOTE-023)\",\"Number of Participants Experiencing Dose-Limiting Toxicities (DLTs) According to National Cancer Institute Common Terminology Criteria for Adverse Events Version 4.0 (NCI-CTCAE v.4.0)|Number of Participants Who Experienced One or More Adverse Events (AEs)|Number of Participants Who Discontinued Study Treatment Due to an Adverse Event (AE)\",\"Up to 28 days in Cycle 1|Up to approximately 72.7 months|Up to approximately 72.7 months\",\"Objective Response Rate (ORR) Evaluated According to the International Myeloma Working Group (IMWG) 2006 Response Criteria by Confirmed Investigator Assessment|Disease Control Rate (DCR) Evaluated According to the International Myeloma Working Group (IMWG) 2006 Response Criteria by Confirmed Investigator Assessment\",\"Terminated\",\"Phase 1\"\n",
      "678,\"A Study of a Human Anti-Intercellular Adhesion Molecule-1 Monoclonal Antibody, in Patients With Multiple Myeloma\",\"Safety assessed as Adverse Events, ECG, vital signs and clinical laboratory tests\",\"four weeks\",,\"Completed\",\"Phase 1\"\n",
      "679,\"Alternative Schedule of Velcade/Dexamethasone Plus Doxil for Patients With Multiple Myeloma\",\"Incidence of Treatment-emergent Peripheral Neuropathy\",\"Every 4 weeks from start of treatment until end of treatment\",\"Time to Progression (TTP)|Number of Participants With Treatment Response|Relative Dose Intensity of Bortezomib\",\"Terminated\",\"Phase 2\"\n",
      "680,\"Multiple Myeloma Molecular Monitoring Study\",\"Sensitivity of Minimal Residual Disease (MRD) Assays|Sensitivity of Minimal Residual Disease (MRD) Assays\",\"100 days post-treatment|12 months post-maintenance therapy\",\"Comparison of Sensitivity of MRD Assays with PET scans|Predicting Progression-Free Survival Using MRD Assessment|Predicting Overall Survival Using MRD Assessment|Quality-Adjusted Life Years (QALYs) Gained|Incremental Cost-Effectiveness of MRD Testing|Productivity Costs Associated with MRD Testing|Multiple Myeloma Patients' Quality of Life (QOL)|Correlative Study: Sensitivity and Specificity of Drug Resistance Assays|Correlative Study: Circulating Tumor DNA|Correlative Study: Describing Myeloma Progenitor Populations\",\"Recruiting\",\n",
      "681,\"Safety and Efficacy of Single-agent CC-5013 in Subjects With Relapsed and Refractory Multiple Myeloma\",\"Myeloma response\",\"randomization to progression\",\"Time to tumor progression|Duration of response|Survival (1-year and overall survival)|Time to first skeletal-related event (SRE) (clinical need for radiation or surgery to bone)|Safety (type, frequency, severity, and relationship of adverse events to study drug)\",\"Completed\",\"Phase 2\"\n",
      "682,\"A Study to Compare MPR With MP in Newly Diagnosed Multiple Myeloma Subjects 65 Years Old or Older.\",\"Kaplan Meier Estimates of Progression-free Survival (PFS) Based on the Response Assessment by the Central Adjudication Committee (CAC)\",\"up to 165 weeks\",\"Kaplan Meier Estimates of Progression-free Survival (PFS) From Start of Maintenance Therapy Period Based on the Response Assessment by the Central Adjudication Committee (CAC)|Kaplan Meier Estimates of Overall Survival (OS)|Kaplan Meier Estimates of Time to Progression (TTP) Based on the Response Assessment by the Central Adjudication Committee (CAC)|Number of Participants in Disease Response Categories Representing Their Best Response During the Double-blind Treatment Period|Time to First Response|Kaplan Meier Estimates for Duration of Response as Determined by the Central Adjudication Committee (CAC)|Kaplan Meier Estimates for Time to Next Antimyeloma Therapy|Summary of Participants With Treatment-Emergent Adverse Events (TEAE) During the Double-Blind Treatment Period|Change From Baseline to Cycles 4, 7, 10, 13 and 16 in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire for Patients With Cancer (EORTC QLQ-C30) Global Quality of Life Scale|Change From Baseline to Cycles 4, 7, 10, 13 and 16 in European Organization for Research and Treatment of Cancer Questionnaire for Patients With Cancer (EORTC QLQ-C30) Physical Functioning Scale|Change From Baseline to Cycles 4, 7, 10, 13 and 16 in European Organization for Research and Treatment of Cancer Questionnaire for Patients With Cancer (EORTC QLQ-C30) Role Functioning Scale|Change From Baseline to Cycles 4, 7, 10, 13 and 16 in European Organization for Research and Treatment of Cancer Questionnaire for Patients With Cancer (EORTC QLQ-C30) Emotional Functioning Scale|Change From Baseline to Cycles 4, 7, 10, 13 and 16 in European Organization for Research and Treatment of Cancer Questionnaire for Patients With Cancer (EORTC QLQ-C30) Congitive Functioning Scale|Change From Baseline to Cycles 4, 7, 10, 13 and 16 in European Organization for Research and Treatment of Cancer Questionnaire for Patients With Cancer (EORTC QLQ-C30) Social Functioning Scale|Change From Baseline to Cycles 4, 7, 10, 13 and 16 in European Organization for Research and Treatment of Cancer Questionnaire for Patients With Cancer (EORTC QLQ-C30) Fatigue Scale|Change From Baseline to Cycles 4, 7, 10, 13 and 16 in European Organization for Research and Treatment of Cancer Questionnaire for Patients With Cancer (EORTC QLQ-C30) Nausea and Vomiting Scale|Change From Baseline to Cycles 4, 7, 10, 13 and 16 in European Organization for Research and Treatment of Cancer Questionnaire for Patients With Cancer (EORTC QLQ-C30) Pain Scale|Change From Baseline to Cycles 4, 7, 10, 13 and 16 in European Organization for Research and Treatment of Cancer Questionnaire for Patients With Cancer (EORTC QLQ-C30) Dyspnoea Scale|Change From Baseline to Cycles 4, 7, 10, 13 and 16 in European Organization for Research and Treatment of Cancer Questionnaire for Patients With Cancer (EORTC QLQ-C30) Insomnia Scale|Change From Baseline to Cycles 4, 7, 10, 13 and 16 in European Organization for Research and Treatment of Cancer Questionnaire for Patients With Cancer (EORTC QLQ-C30) Appetite Loss Scale|Change From Baseline to Cycles 4, 7, 10, 13 and 16 in European Organization for Research and Treatment of Cancer Questionnaire for Patients With Cancer (EORTC QLQ-C30) Constipation Scale|Change From Baseline to Cycles 4, 7, 10, 13 and 16 in European Organization for Research and Treatment of Cancer Questionnaire for Patients With Cancer (EORTC QLQ-C30) Diarrhoea Scale|Change From Baseline to Cycles 4, 7, 10, 13 and 16 in European Organization for Research and Treatment of Cancer Questionnaire for Patients With Cancer (EORTC QLQ-C30) Financial Difficulties Scale|Change From Baseline to Cycles 4, 7, 10, 13, 16 in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire for Patients With Multiple Myeloma (EORTC QLQ-MY20) Disease Symptoms Scale|Change From Baseline to Cycles 4, 7, 10, 13, 16 in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire for Patients With Multiple Myeloma (EORTC QLQ-MY20) In Side Effects of Treatment Scale|Change From Baseline to Cycles 4, 7, 10, 13, 16 in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire for Patients With Multiple Myeloma (EORTC QLQ-MY20) In Future Perspective Scale|Change From Baseline to Cycles 4, 7, 10, 13, 16 in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire for Patients With Multiple Myeloma (EORTC QLQ-MY20) In Body Image Scale\",\"Completed\",\"Phase 3\"\n",
      "683,\"Dose Escalation Trial of WT1-specific Donor-derived T Cells Following T-Cell Depleted Allogeneic Hematopoietic Stem Cell Transplantation for Patients With Relapsed/Refractory Multiple Myeloma\",\"assess the toxicities|maximum tolerated dose (MTD)\",\"21 days|1 year\",\"serologic response|survival\",\"Active, not recruiting\",\"Phase 1\"\n",
      "684,\"Zoledronic Acid Treatment (Every 4 or 12 Weeks) to Prevent Skeletal Complications in Advanced Multiple Myeloma Participants\",\"Percentage of Participants With ≥1 SRE at the End of 1 Year on Study\",\"1 year\",\"Time to First SRE on Study|Percentage of Participants Who Experienced Pathologic Bone Fracture|Percentage of Participants Who Experienced Spinal Cord Compression|Percentage of Participants Who Experienced Radiation to Bone|Percentage of Participants Who Experienced Surgery to Bone|Percentage of Participants Who Experienced HCM|Skeletal Related Event (SRE) Rate|Change From Baseline in Urinary N-telopeptide of Type 1 Collagen (uNTx)|Time to Death\",\"Completed\",\"Phase 4\"\n",
      "685,\"Phase 1/2 Study of Anti GM-2 Monoclonal Antibody To Treat Multiple Myeloma\",\"Serum M protein levels\",\"one month\",\"Time to progression or death\",\"Terminated\",\"Phase 1\"\n",
      "686,\"Melphalan With or Without Holmium Ho 166 DOTMP Followed by Peripheral Stem Cell Transplantation in Treating Patients With Multiple Myeloma\",,,,\"Completed\",\"Phase 3\"\n",
      "687,\"Extension Study of the Efficacy and Safety of Oral SCIO-469 in Relapsed, Refractory Patients With Multiple Myeloma\",\"Rate of response during therapy as measured by the European Group for Blood and Marrow Transplantation (EBMT) criteria.\",\"Baseline to Day 168\",\"Time to first response and time to best response|Size and number of lytic bone lesions were summarized.|Pain was assessed by Pain Intensity Categorical Scale and Pain Intensity Visual Aid Scale.|Performance status was evaluated by Karnofsky scale.|Bone disease was monitored by assessing various biomarkers.|Number of patients with disease progression\",\"Completed\",\"Phase 2\"\n",
      "688,\"Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone Versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell Transplantation\",\"Progression Free Survival (PFS)\",\"from randomization to the date of disease progression or death (approximately up to 8 years)\",\"Comparison of efficacy|Overall Survival (OS)|Change in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire 30-item Core module (EORTC QLQ-C30) score and the difference between-treatment arms|EQ-5D-5L health utility values and the difference between-treatment arms|MySIm-Q Symptom and Impacts in Patients With Multiple Myeloma and the difference between treatment arms|PRO-CTCAE to evaluate symptomatic toxicities by self-report and the difference between treatment arms|PGIS to evaluate the patient global impression of severity of the Multiple Myeloma and the difference between treatment arms\",\"Recruiting\",\"Phase 3\"\n",
      "689,\"Study of Canfosfamide in Refractory or Relapsed Mantle Cell, Diffuse Large B Cell Lymphoma and Multiple Myeloma\",\"Objective Response Rate|Objective Response Rate|Objective Response Rate|Objective Response Rate\",\"At 6 weeks of treatment|At 12 weeks of treatment|At 18 weeks of treatment|At 24 weeks of treatment\",\"Duration of Response|Safety Assessments\",\"Completed\",\"Phase 2\"\n",
      "690,\"Chemotherapy Plus Steroid Therapy in Treating Patients With Multiple Myeloma\",,,,\"Unknown status\",\"Phase 3\"\n",
      "691,\"The TG01 Study With TG01/QS-21 Vaccine in Patients With High-risk Smouldering Multiple Myeloma and Multiple Myeloma\",\"Percentage of participants with adverse events (AEs)|Percentage of participants discontinuing treatment secondary to treatment-related adverse events\",\"Baseline until 30 days after last dose of study drug, up to approximately 3 years|Up to approximately 3 years\",\"Progression Free Survival (PFS)|Prevalence of TG01-specific T-cell specific cytokine production|Overall response rate|Overall Survival (OS)|Time to next treatment (TTNT)\",\"Not yet recruiting\",\"Phase 1|Phase 2\"\n",
      "692,\"NOX-A12 in Combination With Bortezomib and Dexamethasone in Relapsed Multiple Myeloma\",\"Overall response rate (ORR = best response at least partial response (PR))|Safety and tolerability of NOX A12 alone and in combination with VD\",\"6 months|18 months\",\"Effect of NOX A12 alone and combined with VD on the mobilization of peripheral blood CD34+ cells, plasma cells and myeloma cells|Additional response criteria such as Minor Response (MR), immunophenotypic Complete Response and molecular Complete Response|Time to event endpoints such as Progression Free Survival (PFS), Time To Progression (TTP) and Duration Of Response (DOR) following treatment with NOX A12 in combination with VD|Plasma concentration of SDF-1 after treatment with NOX-A12 alone (pilot group only) and in combination with VD|Pharmacokinetics of NOX A12 alone (pilot group only) and combined with VD\",\"Completed\",\"Phase 2\"\n",
      "693,\"Arsenic Trioxide and Dexamethasone in Treating Patients With Recurrent or Refractory Stage II or Stage III Multiple Myeloma\",,,,\"Terminated\",\"Phase 2\"\n",
      "694,\"A Study to Learn About the Medicine (Called Elranatamab) in People With Relapsed Refractory Multiple Myeloma\",\"Objective response rate\",\"assessed over at least the first 9 months from index therapy start\",\"Time to response|Duration of response\",\"Completed\",\n",
      "695,\"C11-Acetate PET/CT in Multiple Myeloma: Added Value to F18-Fluorodeoxyglucose PET/CT\",\"Pretreatment lesion detection\",\"Within 2 weeks before initiation of therapy\",\"Post-induction response assessment|Post-ASCT response assessment\",\"Completed\",\"Not Applicable\"\n",
      "696,\"Masitinib in Relapse or Refractory Multiple Myeloma With t(4/14) Translocation Expressing or Not FGFR3\",\"Tumor Response Rate, based on the criteria published by Blade and on the criteria SWOG\",\"16 weeks\",\"Tumor response rate with AB1010 plus dexamethasone|Time to tumor progression and duration of response in responder patients\",\"Completed\",\"Phase 2\"\n",
      "697,\"Pembrolizumab in Treating Patients With Intermediate or High-Risk Smoldering Multiple Myeloma\",\"Overall Response Rate (ORR)\",\"From cycle 1 to cycle 8, up to 168 days\",\"Number of Participants That Had Progression to Multiple Myeloma|Clinical Benefit Rate|Overall Survival\",\"Active, not recruiting\",\"Early Phase 1\"\n",
      "698,\"Study of High Dose Carfilzomib in Multiple Myeloma Patients Who Have Progressed On Standard Dose Carfilzomib\",\"Safety and Efficacy of High Dose Carfilzomib\",\"up to 4 years\",\"Progression Free Survival (PFS)|Overall Response Rate (ORR)|Duration of Response to High Dose Carfilzomib|Markers of ER Stress\",\"Completed\",\"Phase 2\"\n",
      "699,\"Selinexor (KPT-330) and Liposomal Doxorubicin For Relapsed and Refractory Multiple Myeloma\",\"Maximum Tolerated Dose (MTD)|Overall Response Rate (ORR) - All Participants|Overall Response Rate (ORR) -All Participants Treated at Recommended Phase 2 Dose\",\"Up to 12 months|Up to 24 months|Up to 24 months\",,\"Completed\",\"Phase 1|Phase 2\"\n",
      "700,\"Bevacizumab With or Without Thalidomide in Treating Patients With Relapsed or Refractory Multiple Myeloma\",,,,\"Completed\",\"Phase 2\"\n",
      "701,\"Filanesib (ARRY-520) in Combination With Pomalidomide and Dexamethasone for Relapsed/Refractory (R/R) Multiple Myeloma (MM) Patients\",\"Maxim Tolerability Dose measured by common toxicity criteria v4.0\",\"6 months\",\"Eficcacy measured by the rate of responses\",\"Completed\",\"Phase 1|Phase 2\"\n",
      "702,\"High-Dose Melphalan With or Without Radiolabeled Monoclonal Antibody in Treating Patients With Multiple Myeloma Undergoing an Autologous Stem Cell Transplant\",\"Remission status pre- and post-transplantation, specifically the number of patients who achieve complete remission, as measured by the European Blood and Marrow Transplantation Organization Response Criteria\",\"end of study\",\"Disease response, as measured by changes in serum free light chains (in those patients with serum free light chains that are informative)|Disease response, including the proportion of patients with partial remission, stable disease, and progressive disease and remission duration (time to disease progression)|Engraftment quality, as measured by time to recovery of peripheral blood neutrophils to > 500/mm³ and platelets > 50, 000/mm³ and duration of recovery for > 180 days post-transplantation|Treatment-related mortality|Overall survival|Toxicity profile of yttrium Y 90 anti-CD66 monoclonal antibody BW250/183 in the context of autologous stem cell transplantation|Pharmacokinetics of indium In 111 anti-CD66 monoclonal antibody BW250/183 as measured by serial blood samples and serial planar and single-photon emission computed tomography (SPECT) gamma camera imaging of selected organs|Development of a dosimetry model based on SPECT and whole body gamma camera imaging|Proportion of patients who form human anti-murine antibodies (HAMA) after treatment with targeted radiotherapy in the context of an autologous hematopoietic stem cell transplantation\",\"Terminated\",\"Phase 2\"\n",
      "703,\"Clinical Trial to Evaluate Zevor-cel (CT053) in Patients With Relapsed and/or Refractory Multiple Myeloma (LUMMICAR STUDY 2)\",\"Incidence of Treatment Related adverse events (AEs)|Identification of Maximum Tolerated Dose (MTD)|Objective response rate\",\"Day 1 - Month 60|Day 1 - Month 60|Day 1 - Month 60\",\"Evaluate additional clinical efficacy outcomes with zevor-cel treatment in patients with rrMM|Determine the efficacy of zevor-cel treatment in patients with rrMM, by investigator assessment|Evaluate zevor-cel PK profile|Evaluate ADA profile|Evaluate HRQoL in patients with rrMM from baseline up to study completion|Evaluate utilization of hospital resources\",\"Recruiting\",\"Phase 1|Phase 2\"\n",
      "704,\"Study of MAGE-A3 and NY-ESO-1 Immunotherapy in Combo With DTPACE Chemo and Auto Transplantation in Multiple Myeloma\",\"The Number of Participants Experiencing a Response to the Peptide Vaccines.\",\"2 week intervals\",,\"Completed\",\"Phase 2|Phase 3\"\n",
      "705,\"A Nationwide Phase 2 Trial of Patients With Smoldering and Active Multiple Myeloma (MM)\",\"Rate of MRD negativity\",\"36 months after study enrollment\",\"Progression free survival|Overall survival\",\"Enrolling by invitation\",\"Phase 2\"\n",
      "706,\"Daratumumab (HuMax®-CD38) Safety Study in Multiple Myeloma\",\"Number of Participants With Adverse Events\",\"Up to Week 28 (for Part 1) and up to approximately 2.5 years (for Part 2)\",\"Overall Response Rate|Part 1: Time to Response|Part 2: Time to Progression (TTP)|Part 2: Duration of Response as Assessed Using the Method of Kaplan-Meier|Part 2: Progression-Free Survival|Part 2: Time to Response|Part 2: Overall Survival\",\"Completed\",\"Phase 2\"\n",
      "707,\"Studying T Cells in Blood and Bone Marrow Samples From Patients With Multiple Myeloma\",\"Percentage of Myeloma-specific T Cells ex Vivo Expanded Using Flow Cytometry\",\"Collection of PBMCs over a period of 9-12 months, and the laboratory component will be performed over another year.\",\"Cell Counts of Myeloma-specific T Cells ex Vivo Expanded Before and After CD3/CD28 Stimulation\",\"Terminated\",\n",
      "708,\"Ohio State University Multiple Myeloma and Amyloidosis Data Registry and Sample Resource\",\"Develop a data and sample resource that can be used to facilitate research with the ultimate goal of reducing the morbidity and/or mortality of patients diagnosed or living with Multiple Myeloma in the state of Ohio\",\"up to 3 years\",\"Surveillance|Contact|Research\",\"Recruiting\",\n",
      "709,\"A Study to Determine the Efficacy, Safety and Pharmacokinetics of GMI-1271 as Adjunct to Standard of Care for the Treatment of Multiple Myeloma\",\"Safety assessed by frequency, severity and relatedness of AEs|Overall Response Rate\",\"up to 6 months|up to 18 months\",\"Clinical benefit rate = Stringent Complete Response + Complete Response + Very Good Partial Response + Partial Response + Minimal Response + Stable Disease|Time to response|Time to progression|Duration of response|Progression free survival|Overall survival|Time versus plasma concentration profile of GMI-1271\",\"Completed\",\"Phase 1\"\n",
      "710,\"Clinical Study of CAR-BCMA T in Patients With Refractory or Relapsed Multiple Myeloma\",\"Safety and effectivity - Incidence of study related adverse events|Engraftment\",\"24 weeks|2 years\",\"Statistical parameter of efficacy assessment：PFS|Statistical parameter of efficacy assessment：DCR|Statistical parameter of efficacy assessment：ORR|Statistical parameter of efficacy assessment：OS\",\"Active, not recruiting\",\"Phase 1\"\n",
      "711,\"Dexamethasone With or Without Oblimersen in Treating Patients With Relapsed or Refractory Multiple Myeloma\",,,,\"Completed\",\"Phase 3\"\n",
      "712,\"A Study of Fully Human BCMA Chimeric Antigen Receptor Autologous T Cell Injection (CT103A) in the Treatment of Patients With Relapsed/Refractory Multiple Myeloma\",\"Incidence and severity of adverse events|Incidence and severity of cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS)|Number of participants with laboratory abnormalities\",\"Up to 2 years after CT103A infusion.|Up to 2 years after CT103A infusion.|Up to 2 years after CT103A infusion.\",\"Overall response rate (ORR)|Progression-free survival (PFS)|Overall survival (OS)|Duration of response (DOR)|Time to response (TTR)|Time to complete response (TTCR)|MRD response assessment|The duration of MRD-negativity|CAR transgene level in peripheral blood.|Soluble BCMA (sBCMA) in peripheral blood.\",\"Not yet recruiting\",\"Phase 1\"\n",
      "713,\"Study to Determine Efficacy and Safety of Lenalidomide Plus Low-dose Dexamethasone Versus Melphalan, Prednisone, Thalidomide in Patients With Previously Untreated Multiple Myeloma\",\"Kaplan-Meier Estimates of Progression-free Survival (PFS) Based on the Response Assessment by the Independent Review Adjudication Committee (IRAC)|Kaplan-Meier Estimates of PFS Based on the Response Assessment by the Investigator At the Time of Final Analysis\",\"From date of randomization until the data cut-off date of 24 May 2013. Median follow-up time for all participants was 17.1 months.|From date of randomization to date of data cut-off date of 21 January 2016; median follow-up for all participants was 17.7 months\",\"Kaplan Meier Estimates of Overall Survival at the Time of Final Analysis (OS)|Percentage of Participants With an Objective Response Based on IRAC Review|Percentage of Participants With an Objective Response Based on Investigator Assessment at Time of Final Analysis|Kaplan Meier Estimates of Duration of Myeloma Response as Determined by the IRAC|Kaplan Meier Estimates of Duration of Myeloma Response as Determined by an Investigator Assessment at Time of Final Analysis|Time to First Response Based on the Review by the IRAC|Time to First Response Based on the Investigator Assessment at the Time of Final Analysis|Kaplan Meier Estimates of Time to Treatment Failure (TTF)|Kaplan Meier Estimates of Time to Treatment Failure (TTF) at the Time of Final Analysis|Kaplan Meier Estimates for Time to Second-line Anti-myeloma Treatment (AMT)|Kaplan Meier Estimates of Time to Second Line Therapy AMT at the Time of Final Analysis|Percentage of Participants With an Objective Response After Second-line Anti-myeloma Treatment at the Time of Final Analysis|Percentage of Participants With a Myeloma Response by Adverse Risk Cytogenetic Risk Category Based on IRAC Review.|Percentage of Participants With a Myeloma Response by Favorable Hyperdiploidy Risk Cytogenetic Risk Category Based on IRAC Review|Percentage of Participants With a Myeloma Response by Normal Risk Cytogenetic Risk Category Based on IRAC Review|Percentage of Participants With a Myeloma Response by Uncertain Risk Cytogenetic Risk Category Based on IRAC Review|Change From Baseline in the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire for Patients With Cancer (EORTC QLQ-C30) Global Health Status Domain|Change From Baseline in the EORTC QLQ-C30 Physical Functioning Domain|Change From Baseline in the EORTC QLQ-C30 Role Functioning Domain|Change From Baseline in the EORTC QLQ-C30 Emotional Functioning Domain|Change From Baseline in the EORTC QLQ-C30 Cognitive Functioning Domain|Change From Baseline in the EORTC QLQ-C30 Social Functioning Domain|Change From Baseline in the EORTC QLQ-C30 Fatigue Domain|Change From Baseline in the EORTC QLQ-C30 Pain Domain|Change From Baseline in the EORTC QLQ-C30 Nausea/Vomiting Domain|Change From Baseline in the EORTC QLQ-C30 Dyspnea Domain|Change From Baseline in the EORTC QLQ-C30 Insomnia Domain|Change From Baseline in the EORTC QLQ-C30 Appetite Loss Domain|Change From Baseline in the EORTC QLQ-C30 Constipation Domain|Change From Baseline in the EORTC QLQ-C30 Diarrhea Domain|Change From Baseline in the EORTC QLQ-C30 Financial Difficulties Domain|Change From Baseline in the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire for Patients With Multiple Myeloma (EORTC QLQ-MY20) Disease Symptoms Scale|Change From Baseline in the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire for Patients With Multiple Myeloma (EORTC QLQ-MY20) Side Effects Treatment Scale|Change From Baseline in the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire for Patients With Multiple Myeloma (EORTC QLQ-MY20) Future Perspective Scale|Change From Baseline in the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire for Patients With Multiple Myeloma (EORTC QLQ-MY20) Body Image Scale|Change From Baseline in the European Quality of Life-5 Dimensions (EQ-5D) Health Utility Index Score|Healthcare Resource Utilization (HRU): Rate of Inpatient Hospitalizations Per Year|Number of Participants With Adverse Events (AEs) During the Active Treatment Phase|Shift From Baseline to Most Extreme Postbaseline Value in Creatinine Clearance (CrCl) During the Active Treatment Phase|Shift From Baseline to Most Extreme Postbaseline Value in Absolute Neutrophil Count During the Active Treatment Phase|Shift From Baseline to Most Extreme Postbaseline Value in Hemoglobin During the Active Treatment Phase|Shift From Baseline to Most Extreme Postbaseline Value in Platelet Count During the Active Treatment Phase.|Improvement of Infection Rate by Observing the Historical Data Compared to the Clinical Data Base\",\"Completed\",\"Phase 3\"\n",
      "714,\"Study of ACY-1215 in Combination With Lenalidomide, and Dexamethasone in Multiple Myeloma\",\"To determine DLT of ACY-1215 administered in combination with lenalidomide and dexamethasone in patient with relapsed/refractory MM|To determine MTD of ACY-1215 administered in combination with lenalidomide and dexamethasone in patient with relapsed/refractory MM|Objective Response Rate of ACY-1215\",\"up to 7 years|up to 7 years|up to 7 years\",\"Duration of Response|Adverse Events (AEs)|Disease Control Rate|Progression-free Survival|Evaluate the pharmacodynamics of ACY-1215 in combination with lenalidomide and dexamethasone in patients with relapsed or relapsed/refractory MM|Pharmacokinetic- Cmax|Pharmacokinetic- Cmin|Pharmacokinetic- Tmax|Pharmacokinetic- AUC|Pharmacokinetic- t1/2\",\"Completed\",\"Phase 1\"\n",
      "715,\"Study of Subcutaneous Versus Intravenous Administration of Bortezomib in Patients With Multiple Myeloma in China\",\"pharmacokinetic\",\"6 months\",\"curative effect\",\"Unknown status\",\"Phase 1|Phase 2\"\n",
      "716,\"Total Marrow Irradiation and High-dose Melphalan for Double Autologous Hematopoietic Stem Cell Transplantation in Multiple Myeloma\",\"Progression-free survival\",\"three years\",\"Rate of complete and very good partial responses\",\"Unknown status\",\"Phase 2\"\n",
      "717,\"A Study of Bevacizumab in Combination With Bortezomib in Patients With Relapsed or Refractory Multiple Myeloma (AMBER)\",\"Progression-free Survival (PFS)\",\"From randomization to disease progression or death on study (up to 116 weeks).\",\"Number of Participants With an Overall Response|Percentage of Participants With an Overall Response|Duration of Response|Overall Survival (OS)|Number of Participants With Selected Adverse Events (AEs)\",\"Completed\",\"Phase 2\"\n",
      "718,\"Study of Carfilzomib, Daratumumab and Dexamethasone for Patients With Relapsed and/or Refractory Multiple Myeloma.\",\"Progression-free Survival (PFS) as Assessed by the Independent Review Committee (Data Cut-off Date 14 July 2019)\",\"From randomization until the data cut-off date of 14 July 2019; as of the data cut-off date, a median of 40.29 weeks of treatment (any study drug) in the Kd group and 70.14 weeks of treatment (any study drug) in the KdD group.\",\"Overall Response (OR) as Assessed by the Independent Review Committee (Data Cut-off Date 14 July 2019)|Minimal Residual Disease Negative Complete Response Rate (MRD[-]CR) at 12 Months as Assessed by the Independent Review Committee (Data Cut-off Date 14 July 2019)|Overall Survival|Number of Participants With Treatment-Emergent Adverse Events (TEAEs) (Data Cut-off Date 14 July 2019)|Kaplan-Meier Estimate for Duration of Response (DOR) (Data Cut-off Date 14 July 2019)|Kaplan-Meier Estimate for Time to Next Treatment (TTNT) (Data Cut-off Date 14 July 2019)|Kaplan-Meier Estimates for Time to Progression (TTP) as Assessed by the Independent Review Committee (Data Cut-off Date 14 July 2019)|Time to Progression (TTP): Percentage of Participants Who Had Not Had Disease Progression as Assessed by the Independent Review Committee at Months 3, 6, 12, and 18 (Data Cut-off Date 14 July 2019)|Time to Overall Response as Assessed by the Independent Review Committee (Data Cut-off Date 14 July 2019)|Percentage of Participants Who Achieved and Maintained a Minimal Residual Disease Negative Complete Response (MRD[-]CR) for 12 Months or More (Data Cut-off Date 14 July 2019)|Time to Complete Response (CR) as Assessed by the Independent Review Committee (Data Cut-off Date 14 July 2019)|Percentage of Participants Who Achieved Minimal Residual Disease Negative (MRD[-]) Status as Assessed by Next Generation Sequencing at 12 Months|Quality of Life Core Module (QLQ-C30) Global Health Status/Quality of Life Scores For Baseline Up to the First Follow-Up Visit After the Last Dose (Data Cut-off Date 14 July 2019)\",\"Completed\",\"Phase 3\"\n",
      "719,\"Safety Study of Dasatinib With Bortezomib (Velcade®) and Dexamethasone for Multiple Myeloma\",\"Maximum Tolerated Dose (MTD) and Recommended MTD of Dasatinib in Combination With Bortezomib and Dexamethasone|MTD and Recommended MTD of Bortezomib in Combination With Dasatinib and Dexamethasone\",\"Days 1 to 21|Days 1 to 21\",\"Best Overall Tumor Response Rate (RR) As Assessed Using International Uniform Response Criteria for Multiple Myeloma and Criteria of the European Bone Marrow Transplant Registry|Duration of Response|Progression-free Survival|Number of Participants With Death As Outcome, Serious Adverse Events (SAEs), Drug-related SAEs, Drug-related Adverse Events (AEs) Leading to Discontinuation, AEs Leading to Discontinuation, AEs, and Drug-related AEs by Grade\",\"Terminated\",\"Phase 1\"\n",
      "720,\"A Study of Daratumumab in Japanese Participants With Relapsed or Refractory Multiple Myeloma\",\"Number of Participants With Dose Limiting Toxicities (DLT)|Number of Participants affected by Adverse Events\",\"Day 1 up to Day 36|Baseline up to 4 Weeks after the last dose of study drug administration\",\"Percentage of Participants With Overall Response|Time to Response\",\"Completed\",\"Phase 1\"\n",
      "721,\"Panobinostat/Velcade in Multiple Myeloma\",\"Toxicity of bortezomib combined with one of 3 doses of panobinostat IV as measured by the occurrence of dose-limiting toxicity (DLT)\",\"up to 42 days (two 21-day cycles)\",,\"Terminated\",\"Phase 1\"\n",
      "722,\"Human BCMA Targeted T Cells Injection Therapy for BCMA-positive Relapsed/Refractory Multiple Myeloma\",\"Number of participants with treatment-related adverse events as assessed by NCI-CTCAE 5.0\",\"28 days post infusion\",\"Concentration of Anti-BCMA CAR T Cells in blood|Concentration of Anti-BCMA CAR T Cells in bone marrow|Pharmacodynamics (Levels of Cytokines in Serum)|Pharmacodynamics (Content of clonal plasma cells in bone marrow)|Overall response rate (ORR) after administration|Negative proportion of minimal residual disease (MRD)|Duration of remission (DOR) after administration|Progress Free Survival (PFS) after administration|Overall Survival (OS)after administration|Positive incidence of anti-drug antibody\",\"Recruiting\",\"Phase 1\"\n",
      "723,\"Treatment of Selinexor in Combination With Clarithromycin, Pomalidomide and Dexamethasone for Relapsed Refractory Multiple Myeloma Patients\",\"Percentage of Participants With Overall Response Rate of Partial Response or Better\",\"Approximately 40 months\",\"Number of Participants with Adverse Events\",\"Terminated\",\"Phase 2\"\n",
      "724,\"Study of Oral SCIO-469 in Relapsed, Refractory Patients With Multiple Myeloma\",\"Patient responses (CR, PR, MR, and overall response) are assessed using EBMT criteria, which primarily involve assessments of monoclonal paraprotein in the serum and urine and assessment of changes in soft tissue plasmacytomas and bone lesions.\",\"Day 73\",\"Time to first response, time to best response, and percentage of patients with disease progression were assessed.|Size and number of lytic bone lesions were summarized.|Quality of life and pain was assessed.|Performance status was evaluated.|Bone disease was monitored by assessing various markers.\",\"Completed\",\"Phase 2\"\n",
      "725,\"Teclistamab-Daratumumab and Talquestamab-Daratumumab in Newly Diagnosed High-risk Multiple Myeloma\",\"Evaluate efficacy in terms of Measurable Residual Disease (MRD) negative Complete Remission rate by Next Generation Flow Cytometry after Teclistamab plus Daratumumab intensification.|Evaluate efficacy in terms of Measurable Residual Disease (MRD) negative Complete Remission rate by Fluorodeoxyglucose Positron Emission Tomography-Computerized Tomography (FDG PET-CT) scan using the Deauville score, after Tec-Dara intensification.\",\"22 months approximately|22 months approximately\",\"To evaluate MRD negative CR rate after Daratumumab plus bortezomib, lenalidomide and dexamethasone (D-VRD) induction.|To evaluate MRD negativity after Teclistamab plus Daratumumab (Tec-Dara) intensification using alternative methods|To evaluate MRD conversion after early rescue intervention with Talqutamab plus Daratumumab (Tal-Dara)|To evaluate MRD conversion after Tec-Dara intensification|To evaluate sustained MRD negativity during maintenance treatment in both Tec-Dara and Tal-Dara treatment arms|To assess reappearance of MRD positivity or relapse from CR in patients during the Tec-Dara treatment.|To assess Time to PFS|To assess Time to EFS|To assess Time to TNT|To assess Time to DoR|To assess Time to OS|To assess the safety of the treatment described in the protocol|Immune profiling and genetic characterization\",\"Not yet recruiting\",\"Phase 2\"\n",
      "726,\"Addition of Daratumumab to Combination of Bortezomib and Dexamethasone in Participants With Relapsed or Refractory Multiple Myeloma\",\"Progression-free Survival (PFS)\",\"From the date of randomization to either progressive disease or death, whichever occurs first (approximately 3 years)\",\"Time to Disease Progression (TTP)|Percentage of Participants With a Very Good Partial Response (VGPR) or Better|Overall Response Rate (ORR)|Percentage of Participants With Negative Minimal Residual Disease (MRD)|Overall Survival (OS)\",\"Active, not recruiting\",\"Phase 3\"\n",
      "727,\"Evaluation of Safety of Pomalidomide in Combination With Dexamethasone (Low Dose) in Patients With Refractory or Relapsed and Refractory Multiple Myeloma\",\"Number of Participants With Treatment Emergent Adverse Events (TEAE)\",\"From the first dose of study treatment up to 28 days following the last dose of study treatment. The median duration of treatment with pomalidomide and LD-dex was 21.4 weeks.\",\"Overall Response|Time to Response|Kaplan Meier Estimate of Duration of Response|Kaplan Meier Estimate of Progression Free Survival (PFS) According to the European Medicines Agency Guidelines|Kaplan Meier Estimate of Time to Progression|Kaplan Meier Estimate of Overall Survival (OS)|Pomalidomide Exposure - Apparent (Oral) Clearance (CL/F)|Pomalidomide Exposure - Apparent Volume of Distribution (V/F)|Cytogenetic Analysis\",\"Completed\",\"Phase 3\"\n",
      "728,\"Short Course Daratumumab in Patients With Multiple Myeloma\",\"Rate of MRD negativity by the completion of 6 months of daratumumab therapy\",\"6 months\",,\"Completed\",\"Phase 2\"\n",
      "729,\"Elotuzumab in Autologous Stem Cell Transplantation (ASCT) and Lenalidomide Maintenance for Multiple Myeloma\",\"Incidence of completion of treatment\",\"up to 24 months\",\"IFE level|sFLC level|Bone marrow MRD analysis|Progression-Free Survival|CyTOF mass cytometry|SPEP level\",\"Completed\",\"Phase 1\"\n",
      "730,\"CyBorD vs. PAD in the Treatment of Newly Diagnosed Multiple Myeloma\",\"At least very good partial response rate (according to the criteria IMWG) after four cycles of induction therapy\",\"date from randomization to 1 month after completion of 4 cycles of induction therapy (up to 6 months)\",\"complete response rate(according to the criteria IMWG) after four cycles of induction therapy|At least partial response rate (according to the criteria IMWG) after four cycles of induction therapy\",\"Unknown status\",\"Phase 3\"\n",
      "731,\"Open-label Study of TH-302 and Dexamethasone With or Without Bortezomib or Pomalidomide in Subjects With Relapsed/Refractory Multiple Myeloma\",\"Number of participants with adverse events (AEs)|Type of adverse events(AEs)|Severity of adverse events(AEs)|dose-limiting toxicities (DLTs) and the maximum tolerated dose (MTD) of TH-302 and dexamethasone with or without bortezomib or pomalidomide|recommended Phase 2 dose for TH-302 and dexamethasone with or without bortezomib or pomalidomide\",\"Up to 30 days after last dose|Up to 30 days after last dose|Up to 30 days after last dose|2 years|2 years\",\"Overall Survival (OS)|Progression-free survival(PFS)|Duration of Response (DOR)|relationship between hypoxia within the bone marrow of subjects with relapsed/refractory multiple myeloma and response to TH-302 and dexamethasone with or without bortezomib or pomalidomide using markers of hypoxia|Maximum plasma concentration of TH-302 and bortezomib\",\"Unknown status\",\"Phase 1|Phase 2\"\n",
      "732,\"Real-world Use of Carfilzomib Among Multiple Myeloma Patients in Europe\",\"Carfilzomib starting dose|Carfilzomib dose|Carfilzomib dose modification|Time to carfilzomib dose modification|Reason for dose modification|Number of cycles started|Carfilzomib regimen|Carfilzomib dosing frequency|Carfilzomib dosing schedule|Carfilzomib duration of treatment|Starting dose of concomitant anti-myeloma agents|Dose modification for concomitant anti-myeloma agents|Reason for frequency modification|Reason for change in frequency of concomitant multiple myeloma therapies\",\"18 months|18 months|18 months|18 months|18 months|18 months|18 months|18 months|18 months|18 months|18 months|18 months|18 months|18 months\",\"International Staging System (ISS) score and revised ISS stage at diagnosis and carfilzomib regimen initation|Eastern Cooperative Oncology Group (ECOG) performance status|Cytogenetic risk profile at diagnosis|Presence of CRAB features (i.e. hypercalcemia, renal insufficiency, anemia and/or bone pain)|Presence of comorbidities|Previously received anti-myeloma treatment|Response to prior treatment|Number of prior relapses|Adverse event|Time to adverse event|Electrocardiogram (ECG) changes|Decrease in left ventricular ejection fraction (LVEF)|Initiation or dose increase of antihypertensive treatment|Initiation or dose increase of existing heart failure treatment|Response to carfilzomib treatment|Type of relapse|Number of unplanned hospitalisations|Concomitant therapy not part of the carfilzomib regimen|Planned subsequent treatment regimen|Patient age|Patient sex|Patient height|Patient weight|MRI (magnetic resonance imaging) performed at MM diagnosis and carfilzomib regimen initiation.|PET-CT (positron emission tomography-computed tomography) performed at MM diagnosis and carfilzomib regimen initiation.|Measurement of Serum M component at MM diagnosis and carfilzomib regimen initiation.|Measurement of Urine M component at MM diagnosis and carfilzomib regimen initiation.|Measurement of serum albumin at MM diagnosis and carfilzomib regimen initiation.|Measurement of serum beta-2-microglobulin at MM diagnosis and carfilzomib regimen initiation.|Measurement of percent of plasma cells in bone marrow at MM diagnosis and carfilzomib regimen initiation.|Baseline measurement of lactate dehydrogenase at MM diagnosis and carfilzomib regimen initiation.|ECG (electrocardiogram)|Echocardiogram|LVEF (left ventricular ejection fraction) assessment|Computed Tomography (CT) performed at MM diagnosis and carfilzomib regiment initiation.|Myeloma/Osteolytic lesions detected by MRI, PET-CT, and X-ray at MM diagnosis and carfilzomib regimen initiation\",\"Completed\",\n",
      "733,\"Nivolumab, Ixazomib, Cyclophosphamide, and Dexamethasone in Relapsed/Refractory Myeloma\",\"Objective response rate\",\"2 Years\",\"Progression Free Survival\",\"Active, not recruiting\",\"Phase 2\"\n",
      "734,\"Daratumumab as Maintenance After Peripheral Blood Stem Cell Transplantation From HLA-identical or Haploidentical Family Donor in the Treatment of Refractory or Relapsed Multiple Myeloma: a Phase 2 Trial\",\"safety and efficacy of Daratumumab assessed by free survival\",\"1-year progression free survival in such patients\",\"Disease response rate|Overall survival|GVHD-free|Relapse-free survival|Cumulative incidence of relapse, death from disease, and non-relapse mortality|Cumulative incidence of chronic GVHD as assessed by NIH Consensus Criteria|Serious adverse events of Daratumumab and number of infusion per patient|Serious adverse events of prophylactic donor lymphocytes infusion (pDLI) and number of infusion per patient|Quality of Life|immune response analysis\",\"Withdrawn\",\"Phase 2\"\n",
      "735,\"A Study of Venetoclax Plus Lenalidomide and Dexamethasone for the Treatment of Newly Diagnosed t(11;14)-Positive Multiple Myeloma in Subjects Who Are Ineligible for High-Dose Therapy\",\"Percentage of Participates Who Achieve CR\",\"From baseline up to approximately 24 months\",\"Percent of Participants Who Achieve MRD Negativity|Percent of Participants Who Achieve VGPR or Better|Overall Response Rate (ORR)|Time to Response (TTR)|Duration of response (DOR)|Progression-free Survival (PFS)|Minimal Residual Disease (MRD) Negativity Rate at 12 Months|Time to Disease Progression (TTP)|Time to Next Treatment (TTNT)|Overall Survival (OS) Rate\",\"Withdrawn\",\"Phase 2\"\n",
      "736,\"Phase 1b/2 Study Testing Radium-223 Dichloride/Bortezomib/Dexamethasone Combination in Relapsed Multiple Myeloma\",\"Joint positive adjudication of safety summary in Phase 1b by steering committee, investigator and sponsor (Yes/No)|Progression-free survival (PFS) in Phase 2, defined as the time (in days) from date of randomization to disease progression\",\"At 13 months|Up to 25 months\",\"Objective response rate (ORR) in Phase 1b, in the proportion of subjects in the analysis population who have complete response (CR), stringent complete response (sCR), very good partial response (VGPR), partial response (PR), or stable disease (SD)|Duration of response in Phase 1b, defined as the time (in days) from the date of first response to treatment (CR, sCR, VGPR, PR) to the date of disease progression or death|Number of participants with adverse events in phase 2|Overall survival (OS) in Phase 2, defined as the time (in days) from date of randomization until death from any cause|Time to Symptomatic Skeletal Event (SSE) in Phase 2, defined as the time (days) from the date of randomization to the date of the first on-study SSE|Symptomatic skeletal event free survival in Phase 2, defined as the time from randomization to the occurrence of 1 of the following: First on-study SSE or Death from any cause if death occurs before a documented SSE|Time to pain progression in Phase 2|Duration of response in Phase 2|Objective Response Rate (ORR) in Phase 2\",\"Withdrawn\",\"Phase 1|Phase 2\"\n",
      "737,\"Trial of Romidepsin and Bortezomib for Multiple Myeloma\",\"Count of Participant Best Overall Response As Assessed by the Investigator\",\"up to 8 months\",\"Participants With Treatment-emergent Adverse Events (TEAEs)|Area Under the Concentration-time Curve From Time 0 Extrapolated to Infinity (AUC0-∞)|Maximum Observed Concentration (Cmax)|Time to Maximum Observed Concentration (Tmax)|Terminal Half-life (t1/2)|Total Clearance (CL)|Total Volume of Distribution (Vz)|Kaplan Meier Estimate for Time to Progression Assessed by the Investigator|Kaplan Meier Estimate for Time to Response Assessed by the Investigator|Kaplan Meier Estimate for Duration of Response Assessed by the Investigator|Kaplan Meier Estimates for Progression-free Survival Assessed by the Investigator|Kaplan Meier Estimates for Overall Survival\",\"Terminated\",\"Phase 2\"\n",
      "738,\"A Study for Patients That Have Been Previously Been Treated in Waldenstrom's Macroglobulinemia or Multiple Myeloma\",\"Percentage of Participants With Complete Response (CR), Partial Response (PR) and Minimal Response (MR) or Minor Response (MinR): (Response Rate)\",\"Baseline to measured progressive disease up to 40.51 months\",\"Duration of Response (DOR)|Time to Progressive Disease|Number of Participants With Adverse Events (Safety and Adverse Events)\",\"Completed\",\"Phase 2\"\n",
      "739,\"Isa-KRd vs KRd in Newly Diagnosed Multiple Myeloma Patients Eligible for Autologous Stem Cell Transplantation (IsKia TRIAL)\",\"Rate of MRD negativity after ASCT consolidation treatment by NGS\",\"The end of consolidation, average of 12 months\",\"Post induction MRD negativity rate by NGS|Progression-free survival (PFS) in the 2 arms|Post light-consolidation MRD negativity rate by NGS|Overall Response Rate (ORR) post-induction|Overall Response Rate (ORR) post-transplant|Overall Response Rate (ORR) post-consolidation|Overall Response Rate (ORR) post light-consolidation|Post ASCT MRD negativity rate by NGS|MRD negativity rate by NGF post induction|MRD negativity rate by NGF post induction|MRD negativity rate by NGF post consolidation|MRD negativity rate by NGF post light consolidation|Duration of response|Duration of MRD negativity (by NGS and NGF)|Determine the rate of sustained for 1-year MRD negativity (by NGF and NGS) from post ASCT consolidation to post light consolidation|Determine the time to progression (TTP)|Overall Survival (OS)|Time to next therapy (TNT)|Progression-free survival on the next line of therapy (PFS2)\",\"Active, not recruiting\",\"Phase 3\"\n",
      "740,\"A Study of Subcutaneous Daratumumab Versus Active Monitoring in Participants With High-Risk Smoldering Multiple Myeloma\",\"Progression-free Survival (PFS)\",\"From the date of randomization to active multiple myeloma (MM) or the date of death, whichever occurs first (up to approximately 8 years)\",\"Time to Biochemical or Diagnostic (SLiM-CRAB) Progression|Overall Response Rate (ORR)|Complete Response (CR) Rate|Time to First-Line Treatment for Multiple Myeloma (MM)|Progression-Free Survival on First-Line Treatment for MM (PFS2)|Overall Survival (OS)|Percentage of Participants who Progress to MM With Adverse Prognostic Features|Serum Daratumumab Pharmacokinetic (PK) Concentration|Maximum Observed Concentration (Cmax) of Daratumumab|Minimum Observed Concentration (Cmin) of Daratumumab|Number of Participants With Anti-daratumumab Antibodies|Number of Participants With Anti-Recombinant Human Hyaluronidase (rHuPH20) Antibodies|Change From Baseline in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30) Score|Change From Baseline in the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire for Patients With Multiple Myeloma (EORTC QLQ-MY20) Future Perspective Scale|Change From Baseline in European Quality (EuroQoL) 5-Dimension 5-Level Health Status (EQ-5D-5L) Questionnaire|Duration of Response|Time to Response\",\"Active, not recruiting\",\"Phase 3\"\n",
      "741,\"Efficacy Study of PAD and TAD in Newly Diagnosed Multiple Myeloma\",\"The overall response rate of PAD and TAD in patients with MM assessed by International Myeloma Working Group(IMWG) criteria\",\"every treatment cycle\",\"The concentrations of bone metabolites|chromosome examination by cytogenetic and interphase Fluorescence in situ hybridization(FISH) method|Overall survival(OS) and progression-free survival(FPS)|European Organisation for Research and Treatment of Cancer Quality Of life-Questionnaires-C30 (EORTC QLQ-C30)\",\"Unknown status\",\"Phase 4\"\n",
      "742,\"A Study Comparing Daratumumab, Lenalidomide, and Dexamethasone With Lenalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma\",\"Progression-free Survival (PFS)\",\"From randomization to either disease progression or death whichever occurs first until 21 months\",\"Time to Disease Progression (TTP)|Percentage of Participants Who Achieved Very Good Partial Response (VGPR) or Better|Percentage of Participants With Negative Minimal Residual Disease (MRD)|Overall Response Rate|Overall Survival (OS)|Time to Response|Duration of Response (DOR)\",\"Active, not recruiting\",\"Phase 3\"\n",
      "743,\"Detection of Poor Mobilizer (PM) in Multiple Myeloma (MM) Patients\",\"Assessment of success rate expressed as % of patients mobilizing ≥2x106 CD34+ cells/kg in maximum 3 apheresis and patient who achieves the optimal target of 4x106 CD34+ cells/kg up to 5 apheresis.\",\"3 years\",\"% of patients having received plerixafor in the study population|Evaluate in patients failing mobilisation how many of them received plerixafor and how many did not|Evaluation of speed of mobilization using plerixafor, in terms of increase in number of circulating CD34+ cells from time 0 to 6-11 hours after the first dose of plerixafor.|Total number of CD34+ cells collected per apheresis day|Confirmation of factors predicting a poor mobilization: patients who experienced grade 3-4 haematological toxicity during induction, used lenalidomide as induction treatment, aged > 60 years old and experienced cytopenia at diagnosis.\",\"Active, not recruiting\",\n",
      "744,\"Ph 2 Bortezomib, Dexamethasone, + Doxorubicin With ALCAR for Previously Treated Multiple Myeloma\",\"Confirmed Anti-tumor Response Rate (Complete Response and Partial Response) to the Combination of Bortezomib, Dexamethasone, Doxorubicin, and ALCAR\",\"Every 21 days, up to 24 weeks\",\"Overall Survival|Progression-free Survival\",\"Completed\",\"Phase 2\"\n",
      "745,\"Stem Cell Transplantation in Individuals With Multiple Myeloma (BMT CTN 0102)\",\"Progression-Free Survival (PFS)\",\"Year 3\",\"Overall Survival (OS) for Standard Risk|Overall Survival (OS) for High Risk|Cumulative Incidence of Progression/Relapse|Cumulative Incidence of Treatment Related Mortality (TRM)|Interval From First to Second Transplantation|Incidences of Graft Versus Host Disease (GVHD)|Incidences of Chronic GVHD\",\"Completed\",\"Phase 3\"\n",
      "746,\"A Study of Combination Therapy With Venetoclax, Daratumumab and Dexamethasone (With and Without Bortezomib) in Participants With Relapsed or Refractory Multiple Myeloma\",\"Overall Response Rate (ORR)|Very Good Partial Response or Better Response Rate (VGPR)|Complete Response (CR) or Better Rate|Time to Response (TTR)|Duration of Response (DOR)|Time to Progression (TTP)|Progression-Free Survival (PFS)|Overall Survival (OS)\",\"Up to approximately 3.5 years after the last participant is enrolled|Up to approximately 3.5 years after the last participant is enrolled|Up to approximately 3.5 years after the last participant is enrolled|Up to approximately 3.5 years after the last participant is enrolled|Up to approximately 3.5 years after the last participant is enrolled|Up to approximately 3.5 years after the last participant is enrolled|Up to approximately 3.5 years after the last participant is enrolled|Up to approximately 3.5 years after the last participant is enrolled\",\"Minimal Residual Disease (MRD)|Cmax of Venetoclax|Tmax of Venetoclax|AUC0-24 of Venetoclax\",\"Active, not recruiting\",\"Phase 2\"\n",
      "747,\"Blmf, Lenalidomide and Dexamethasone in Transplant-ineligible Patients With Newly Diagnosed Multiple Myeloma\",\"Number of participants with dose-limiting toxicities (DLTs) in each of the cohorts 1-3|Overall Response rate as per IMWG by Investigator Assessment, defined as the percentage of participants with a confirmed PR, VGPR, CR or sCR|Number of participants with adverse events (AEs) and serious adverse events (SAEs) in each of the cohorts 1-3|Number of participants with adverse events (AEs) and serious adverse events (SAEs) in patients receiving the Recommended Phase 2 Dose\",\"Five (5) years after last participant randomization|Five (5) years after last participant randomization|Five (5) years after last participant randomization|Five (5) years after last participant randomization\",,\"Recruiting\",\"Phase 1|Phase 2\"\n",
      "748,\"Ixazomib as a Replacement for Carfilzomib and Bortezomib for Multiple Myeloma Patients\",\"Maximum tolerated dose (MTD) for selected regimens|Number of subjects with adverse events|Overall response rate (ORR)|Clinical benefit rate (CBR)\",\"Cycles 1-2 for selected regimens (up to 2 months)|up to 48 months|up to 48 months|up to 48 months\",\"Time to Progression|Progression-free survival (PFS)|Time to response (TTR)|Duration of response (DOR)|Overall survival (OS)|Peripheral Neuropathy (PN)\",\"Unknown status\",\"Phase 1|Phase 2\"\n",
      "749,\"STUDY TO DETERMINE THE EFFICACY AND SAFETY OF STANDARD SCHEDULE VERSUS A NEW ALGORITHM OF DOSE REDUCTIONS IN ELDERLY AND UNFIT NEWLY DIAGNOSED MULTIPLE MYELOMA PATIENTS RECEIVING LENALIDOMIDE PLUS STEROIDS\",\"Event-free survival\",\"3 years\",\"Progression-free survival (PFS)|Overall survival (OS)|Time to progression (TTP)|Overall response rate (ORR)|Time to response (TTR)|Duration of response (DOR)|Time to the next therapy (TNT)|Incidence of dose reduction and drug discontinuation|Health care cost|Correlation between tumor response and outcome with baseline prognostic factors|Quality of life assessment (HRQOL)\",\"Active, not recruiting\",\"Phase 3\"\n",
      "750,\"Melphalan, Peripheral Stem Cell Transplantation, and Interleukin-2 Followed by Interferon Alfa in Treating Patients With Advanced Multiple Myeloma\",\"Overall Survival|Initial Response to Therapy|Time to Disease Progression|Proportion of Patients Alive and in Remission\",\"12.9 Median Years|Evaluated at Day +84-90 Post-Transplant|12.9 years (median)|12.9 Median Years\",\"Number of Patients <56 Years Old Experiencing Grade 3-4 Regimen Related Toxicity|Number of Patients ≥56 Years Old Experiencing Grade 3-4 Regimen Related Toxicity\",\"Completed\",\"Phase 2\"\n",
      "751,\"Vorinostat, Bortezomib, and Doxorubicin Hydrochloride Liposome in Treating Patients With Relapsed or Refractory Multiple Myeloma\",\"Maximum tolerated dose of vorinostat\",\"4 years\",\"Overall response rate|Duration of response\",\"Terminated\",\"Phase 1\"\n",
      "752,\"A Study of Subcutaneous (SC) AMG 701 in Participants With Relapsed or Refractory Multiple Myeloma (RRMM)\",\"Number of participants who experience dose-limiting toxicities (DLTs)|Number of participants who experience one or more treatment-emergent adverse events (TEAEs)|Number of participants who experience one or more treatment-related TEAEs|Number of participants with abnormal changes in vital signs|Number of participants with abnormal changes in electrocardiograms (ECGs) findings|Number of participants with abnormal changes in clinical laboratory tests\",\"28 days|up to approximately 9 months|up to approximately 9 months|up to approximately 9 months|up to approximately 9 months|up to approximately 9 months\",\"Maximum serum concentration (Cmax) of AMG 701|Time to maximum concentration (Tmax) of AMG 701|Area under the concentration-time curve (AUC) of AMG 701|Minimum concentration over the dosing interval (Ctrough) of AMG 701|Incidence of anti-AMG 701 antibody formation|Overall response (OR)|Best overall response (BOR)|Time to response|Duration of response (DOR)|Progression-free survival (PFS)|Overall survival (OS)\",\"Withdrawn\",\"Phase 1\"\n",
      "753,\"The Use of Dendritic Cell/Tumor Fusions as a Novel Tumor Vaccine in Patients With Multiple Myeloma\",\"To assess the toxicity associated with vaccination of patients multiple myeloma with dendritic cell(DC)/tumor cell fusions co-administered with GM-CSF.\",\"5 years\",\"To determine whether evidence of tumor specific cellular and humoral immunity can be induced by serial vaccination with DC/tumor cell fusion cells co-administered with GMCSF|to determine if vaccination with DC/tumor cell fusions co-administered with GM-CSF results in clinical disease response.\",\"Completed\",\"Phase 1\"\n",
      "754,\"A Study of Bortezomib and Pegylated Liposomal Doxorubicin in Patients With Relapsed Multiple Myeloma Previously Treated With Bortezomib\",\"The primary endpoint is the overall response rate defined as the partial or complete response to treatment according to EBMT criteria. Overall response will be assessed at each treatment cycle up to 8 cycles.\",\"Assessed at each 21-day treatment cycle up to 8 cycles and over 6 months following discontinuation of all study drugs.\",\"Secondary endpoints include time to disease progression (treatment start to disease progression or death due to progression); best response assessed by the investigator; duration of response; and overall survival (treatment start to death by any cause).\",\"Withdrawn\",\"Phase 2\"\n",
      "755,\"A Study to Determine the Safety and Efficacy for the Combination of Durvalumab and Daratumumab in Relapsed and Refractory Multiple Myeloma\",\"Overall Response Rate (ORR)|Number of Participants With Adverse Events (AEs)|Number of Participants With Serious Adverse Events (SAEs)\",\"From first dose to up to approximately 66 months|From first dose to 90 days after last dose (up to approximately 58 months)|From first dose to 90 days after last dose (up to approximately 58 months)\",\"Time-To-Response (TTR)|Kaplan-Meier Estimate of Duration of Response (DOR) - Simon Stage 1: D2 Arm|Kaplan-Meier Estimate of Duration of Response (DOR) - PD3 Arm|Kaplan-Meier Estimate of Progression-Free Survival (PFS) - Simon Stage 1: D2 Arm|Kaplan-Meier Estimate of Progression-Free Survival (PFS) - PD3 Arm|Maximum Observed Plasma Concentration (Cmax) - Simon Stage 1: D2 Arm|Time of Maximum Observed Concentration (Tmax) - Simon Stage 1: D2 Arm|Area Under the Plasma Concentration-Time Curve to the Last Measurable Plasma Concentration [AUC(0-Last)] - Simon Stage 1: D2 Arm|Area Under the Plasma Concentration-Time Curve in 1 Dosing Interval [AUC(TAU)] - Simon Stage 1: D2 Arm\",\"Terminated\",\"Phase 2\"\n",
      "756,\"Combination Chemotherapy in Treating Patients With Multiple Myeloma\",,,,\"Completed\",\"Phase 2\"\n",
      "757,\"Phase II Study of the CD38 Antibody Daratumumab in Patients With High-Risk MGUS and Low-Risk Smoldering Multiple Myeloma\",\"The Proportion Of Patients In Deep Response\",\"2 years\",\"Objective Response Rate|Duration of Response|Complete Response Rate|Overall Response Rate|Progression Free Survival|Incidence of Treatment Emergent Adverse Events (Safety and Tolerability)\",\"Active, not recruiting\",\"Phase 2\"\n",
      "758,\"A Study to Learn How Linvoseltamab (REGN5458) Will Work Compared to the Elotuzumab, Pomalidimide and Dexamethasone (EPd) Combination, in Participants With Relapsed/Refractory Multiple Myeloma\",\"Progression Free Survival (PFS) per International Myeloma Working Group (IMWG) response criteria determined by Independent Review Committee (IRC)\",\"Up to approximatively 5 years\",\"Objective Response (OR) greater or equal to Partial Response (PR) per IMWG response criteria as determined by the IRC|Objective Response Rate (ORR) greater or equal to Very Good Partial Response (VGPR) per IMWG response criteria as determined by IRC|Objective Response Rate (ORR) greater or equal to Complete Response (CR) per IMWG response criteria as determined by IRC|Incidence of minimal residual disease (MRD) negative status|Overall Survival (OS)|Mean change from baseline in the worst pain score measured by Brief Pain Inventory-Short Form (BPI-SF) Item 3|Progression-free Survival (PFS) per IMWG response criteria as determined by the investigator|Incidence of treatment emergent adverse events (TEAEs)|Severity of treatment emergent adverse events (TEAEs)|Incidence of adverse events of special interest (AESI)|Severity of adverse events of special interest (AESI)|Incidence of Serious Adverse Events (SAE)|Severity of Serious Adverse Events (SAE)|ORR greater or equal to PR per IMWG response criteria as determined by the investigator|ORR greater or equal to VGPR per IMWG response criteria as determined by the investigator|ORR greater or equal to CR per IMWG response criteria as determined by the investigator|Duration of Response (DoR) as per IMWG response criteria as determined by the investigator|DoR as per IMWG response criteria as determined by the IRC|Duration of MRD negative status in the bone marrow|Time from randomization to objective response (≥PR) as per IMWG response criteria as determined by the IRC|Time from randomization to objective response (≥PR) as per IMWG response criteria as determined by the investigator|Concentration of linvoseltamab in the serum over time|Incidence of antidrug antibodies (ADAs)|Titer of antidrug antibodies (ADAs)|Incidence of neutralizing antibodies (Nabs) to linvoseltamab over time|Proportion of Pain Responders|Change from baseline in patient-reported global health status/quality of life (QoL), per European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30)|Change from baseline in patient reported disease symptoms per EORTC Quality of Life Questionnaire-Multiple Myeloma (MM) module 20 [QLQ-MY20])|Patient-Reported Outcomes in Patient Global Impression of Symptom Severity (PGIS)|Patient-Reported Outcomes in Patient Global Impression of Change (PGIC)|Change from baseline in patient-reported general health status per EuroQoL-5 Dimension-5 Level Scale [EQ-5D-5L])\",\"Not yet recruiting\",\"Phase 3\"\n",
      "759,\"Carfilzomib In Combination With Bendamustine And Dexamethasone In Refractory Or Relapsed Multiple Myeloma\",\"Identification of dose-limiting toxicity (DLT)\",\"1 year\",\"Determine the rate of very good partial response (VGPR) or more with the CBd association:\",\"Active, not recruiting\",\"Phase 1|Phase 2\"\n",
      "760,\"Relevance Evaluation of [68Ga]Ga-PentixaFor for Initial Staging and Detection of Minimal Residual Disease in Multiple Myeloma Patients.\",\"Sensitivity\",\"6 months\",\"Specificity, positive predictive value (PPV) and negative predictive value (NPV) of [68Ga]Ga-PentixaFor-PET.|Prognostic impact of FDG-PET and of [68Ga]Ga-PentixaFor-PET depending on the uptake detected by each imaging technique.|Discrepancies rate between FDG-PET and [68Ga]Ga-PentixaFor-PET and factors associated with.|Correlation between FDG-PET and [68Ga]Ga-PentixaFor-PET uptakes evaluated by SUV.|Correlation between FDG-PET and [68Ga]Ga-PentixaFor-PET uptakes evaluated by the RNAseq data evaluated on the myelogram.|Prognostic impact of FDG-PET and [68Ga]Ga-PentixaFor-PET depending on the positivity, number and intensity of uptake detected by each imaging technique.|Link between FDG-PET, [68Ga]Ga-PentixaFor-PET results and minimal residual disease evaluated by NGS.|Tolerance of [68Ga]Ga-PentixaFor-PET.\",\"Not yet recruiting\",\"Phase 2\"\n",
      "761,\"Study of Magrolimab Combinations in Patients With Relapsed/Refractory Multiple Myeloma\",\"Percentage of Participants Experiencing Dose-limiting Toxicities (DLTs) According to the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 (Safety Run-in Cohorts)|Percentage of Participants Experiencing Treatment-emergent Adverse Events (TEAE's) According to the NCI CTCAE Version 5.0 (Safety Run-in Cohorts)|Percentage of Participants Experiencing Treatment-emergent Laboratory Abnormalities According to the NCI CTCAE Version 5.0 (Safety Run-in Cohorts)|Objective Response Rate (ORR) (Dose Expansion Cohorts)\",\"First dose date up to the end of the first dosing cycle (Cycle 1=35 days)|From date of first dose of any study drug up to the date of last dose of any study drug plus 30 days (Up to 2.5 years)|From baseline to the date of last dose of any study drug plus 30 days (Up to 2.5 years)|Up to 2.5 years\",\"Percentage of Participants Experiencing TEAE's According to the NCI CTCAE Version 5.0 (Dose Expansion Cohorts)|Percentage of Participants Experiencing Treatment-emergent Laboratory Abnormalities According to the NCI CTCAE Version 5.0 (Dose Expansion Cohorts)|Duration of Response (Dose Expansion Cohorts)|Progression-free Survival (Dose Expansion Cohorts)|Overall Survival (Dose Expansion Cohorts)|Serum Concentrations of Magrolimab (Dose Expansion Cohorts)|Antidrug Antibody (ADA) Against Magrolimab (Dose Expansion Cohorts)\",\"Recruiting\",\"Phase 2\"\n",
      "762,\"A Study to Learn About the Study Medicine (Elranatamab) Either Alone or in Combination With Dexamethasone in Participants With Multiple Myeloma That Has Come Back After Responding to Treatment or Has Not Responded to Treatment\",\"Proportion of participants with Grade 2 or higher Cytokine Release Syndrome (CRS) (Part 1 and 2)|Number of participants with overall response rate (ORR) per International Myeloma Working Group (IMWG) criteria (Part 3).\",\"Cycle 1 (28 days)|From the date of first dose until the first documentation of progressive disease (PD), death or start of new anticancer therapy, whichever occurs first (timeframe: approximately 2 years).\",\"Incidence of Dose Limiting Toxicities (Part 2A and 2C)|Frequency of Adverse Events|Frequency of laboratory abnormalities|Objective response rate|Complete Response Rate|Time to response|Duration of response|Duration of complete response rate|Progression Free Survival|Overall Survival|Minimal Residual Disease negativity rate|Pre- and postdose concentrations of elranatamab|Incidence and titers of Anti-Drug Antibody and Neutralizing Antibody against elranatamab|Proportion of participants with Grade 2 or higher Cytokine Release Syndrome (CRS) (Part 3)\",\"Recruiting\",\"Phase 2\"\n",
      "763,\"High-Dose Melphalan and a Second Stem Cell Transplant or Low-Dose Cyclophosphamide in Treating Patients With Relapsed Multiple Myeloma After Chemotherapy\",\"Time to disease progression\",,\"Response rate to bortezomib, doxorubicin hydrochloride, and dexamethasone (PAD)|Overall response rate following randomized treatments|Overall survival|Progression-free survival|Toxicity and safety of autologous stem cell transplantation|Toxicity and safety of weekly cyclophosphamide|Toxicity and safety of PAD therapy|Feasibility of stem cell collection|Pain|Quality of life\",\"Unknown status\",\"Phase 3\"\n",
      "764,\"Study of CC-93269, a BCMA x CD3 T Cell Engaging Antibody, in Participants With Relapsed and Refractory Multiple Myeloma\",\"Adverse Events (AEs)|Dose Limiting Toxicity (DLT)|Non-Tolerated Dose (NTD)|Maximum Tolerated Dose (MTD)\",\"Up to 60 months|Up to 60 months|Up to 60 months|Up to 60 months\",\"Overall Response Rate (ORR)|Time to Response|Duration of Response|Progression Free Survival|Overall Survival|Pharmacokinetics - Cmax|Pharmacokinetics - Cmin|Pharmacokinetics - AUC|Pharmacokinetics - tmax|Pharmacokinetics - t1/2|Pharmacokinetics - CL|Pharmacokinetics - Vss|Pharmacokinetics - accumulation index of alnuctamab|Presence and frequency of anti-drug antibodies (ADA)|Evaluate measures of tumor sensitivity/ resistance to CC-93269\",\"Recruiting\",\"Phase 1\"\n",
      "765,\"UARK 2014-08 A Phase II Open-Label, Multiple-Dose, Single Agent Study to Evaluate the Overall Response Rate of Orally Administered Trametinib\",\"The response rate of Trametinib when administered orally to patients with relapsed multiple myeloma\",\"28 day\",,\"Withdrawn\",\"Phase 2\"\n",
      "766,\"The Diagnostic Pattern and Prognosis of Multiple Myeloma Patients With Myocardial Amyloidosis Were Evaluated by NMR Based Metabolomics\",\"The long axial strain of echocardiography\",\"From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 36 mouths\",,\"Enrolling by invitation\",\n",
      "767,\"Phase I, Multi-Center, Open-Label, Dose Escalation Study of HuLuc63 in Subjects With Advanced Multiple Myeloma\",\"Not applicable for this trial.\",\"Not applicable for this trial.\",,\"Completed\",\"Phase 1\"\n",
      "768,\"A Study of Thalidomide Plus Dexamethasone (Thal-Dex) Versus DOXIL plusThalidomide Plus Dexamethasone (DOXIL -Thal-Dex) in Patients With Newly Diagnosed Multiple Myeloma\",\"Complete Response Rate: Number of Participants Who Achieved a Complete Response\",\"From Cycle 2 until 28 days following completion of treatment\",\"Overall Response: Number of Participants Who Achieved a Complete Response (CR) or Partial Response (PR)|Time to 1st Response|Time to Progression|Overall Survival: Number of Participants Died Due to Any Cause|Transplantation: Number of Participants Who Underwent Transplantation (Peripheral Stem Cell / Bone Marrow)|Engraftment: Number of Participants Who Underwent Engraftment\",\"Completed\",\"Phase 3\"\n",
      "769,\"A Phase II Study of Bevacizumab and Bortezomib in Patients With Relapsed/Refractory Multiple Myeloma\",\"Median Number of Cycles to Tumor Progression (TTP)|Overall Survival (OS) - Number of Participants Alive at Study Completion\",\"18 months|18 months\",,\"Terminated\",\"Phase 2\"\n",
      "770,\"Evaluation of Efficacy and Safety of Belantamab Mafodotin, Bortezomib and Dexamethasone Versus Daratumumab, Bortezomib and Dexamethasone in Participants With Relapsed/Refractory Multiple Myeloma\",\"Progression-free survival\",\"Up to an average of 34 months\",\"Complete response rate (CRR)|Overall response rate (ORR)|Duration of response (DoR) after administration of study treatment|Time to response (TTR) after administration of study treatment|Time to Progression (TTP) after administration of study treatment|Overall survival (OS)|Progression-free survival on subsequent line of therapy (PFS2)|Minimal Residual Disease (MRD) negativity rate after administration of study treatment|Number of participants with adverse events (AEs)|Number of participants with serious adverse events (SAEs)|Number of participants with abnormal ocular findings on ophthalmic examination|Plasma concentrations of belantamab mafodotin at indicated time points|Plasma concentrations of total monoclonal antibody (mAb) at indicated time points|Plasma concentrations of monomethyl auristatin-F with a cysteine linker (cys-mcMMAF) at indicated time points|Number of participants with positive anti-drug antibodies (ADAs) against belantamab mafodotin|Titers of ADAs against belantamab mafodotin|Change from Baseline in symptoms as measured by Patient-Reported Outcome Version of the Common Term Criteria for Adverse Events (PRO-CTCAE)|Change from Baseline in impacts as measured by PRO-CTCAE|Change from Baseline in health related quality of life (HRQoL) as measured by European Organization for Research and Treatment of Cancer Quality of life Questionnaire 30-item core module (EORTC QLQ-C30)|Change from Baseline in HRQoL as measured by EORTC, 20-Item Multiple Myeloma Module (QLQ-MY20)\",\"Active, not recruiting\",\"Phase 3\"\n",
      "771,\"A Study to Learn About the Effects of the Combination of Elranatamab (PF-06863135), Daratumumab, and Lenalidomide Compared With Daratumumab, Lenalidomide, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Who Are Not Candidates for Transplant\",\"Part 1 Dose Limiting Toxicity|Part 2: Progression free survival by blinded independent central review|Part 2: Sustained minimal residual disease negativity rate\",\"From the first dose of elranatamab until 28 days (+/- visit window) from the first administration of the EDR combination|From randomization up to 73 months.|For at least 12 months after randomization\",\"Overall minimal residual disease negativity rate|Duration of minimal residual disease negativity (Part 2)|PFS by investigator|PFS2 by investigator (Part 2)|Objective Response Rate|Complete Response Rate|Time to Response|Duration of Response|Duration of Complete Response|Frequency of treatment-emergent adverse events|Frequency of abnormal laboratory results|Elranatamab pharmacokinetics by pre-dose concentrations when used with lenalidomide and daratumumab|Elranatamab pharmacokinetics by post-dose concentrations when used with lenalidomide and daratumumab|Incidence of Anti-Drug Antibody and Neutralizing Antibody against elranatamab|Titers of Anti-Drug Antibody and Neutralizing Antibody against elranatamab|Part 2: Health-related quality of life by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire -Myeloma 20|Part 2: Health-related quality of life by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30|Part 1: Daratumumab and lenalidomide pharmacokinetics by pre-dose concentrations in combination with elranatamab\",\"Recruiting\",\"Phase 3\"\n",
      "772,\"Tocladesine in Treating Patients With Recurrent or Refractory Multiple Myeloma\",,,,\"Completed\",\"Phase 2\"\n",
      "773,\"Study of Single Agent CJM112, and PDR001 in Combination With LCL161 or CJM112 in Patients With Multiple Myeloma\",\"Number of patients reporting dose limiting toxicities|The number of patients who experience a treatment-related adverse event after being treated with a single dose of single agent CJM112, or two doses of PDR001 in combination with CJM112 or LCL161|The number of patients requiring interruptions after a single dose of single agent CJM112, or two doses of PDR001 in combination with CJM112 or LCL161|The number of patients treated with single agent CJM112, or PDR001 in combination with either CJM112 or LCL161, who discontinued treatment|The number of patients requiring a dose reduction after a single dose of single agent CJM112, or two doses of PDR001 in combination with CJM112 or LCL161\",\"2 months|24 months|24 months|24 months|24 months\",\"Immunogenicity of PDR001 and CJM112|Overall Response Rate (ORR)|Best Overall Response (BOR)|Progression Free Survival (PFS)|Disease Control Rate (DCR)|AUC of PDR001, CJM112 and LCL161|Cmax of PDR001, CJM112 and LCL161|Tmax of PDR001, CJM112 and LCL161|Half-life of PDR001, CJM112 and LCL161|Concentration vs time profile of PDR001, CJM112 and LCL161\",\"Completed\",\"Phase 1\"\n",
      "774,\"Evaluation of Lenalidomide, Doxorubicin and Dexamethasone (RAD) in Patients With Relapsed or Refractory Multiple Myeloma\",\"Part A (phase I)|To determine the safety and maximum tolerated dose (MTD) of|Revlimid in combination with Doxorubicin and Dexamethasone|(RAD) administered as a VAD-like regimen in subjects with relapsed or refractory multiple myeloma.|Part B (Phase II):|To determine the efficacy of RAD as treatment for subjects with relapsed or refractory multiple myeloma by estimating the objective response rate (PR, RR and CR).\",,\"Secondary objectives of the study are:|Part A plus Part B|To determine the efficacy of RAD as treatment for subjects with relapsed or refractory multiple myeloma by estimating the objective response rate (PR, RR and CR).|To estimate duration of response (PR, RR and CR) and disease control rate (SD, PR and CR).\",\"Completed\",\"Phase 1|Phase 2\"\n",
      "775,\"Vaccination With Peptides From Anti-apoptotic Proteins in Relapsed Multiple Myeloma\",\"Number of participants with adverse events\",\"15 months\",,\"Completed\",\"Phase 1|Phase 2\"\n",
      "776,\"Study of Ibrutinib in Combination With Pomalidomide and Dexamethasone in Subjects With Relapsed/Refractory Multiple Myeloma\",\"Overall Response Rate (ORR) According to the IMWG Response Criteria Per Investigator Assessment\",\"14 Months\",\"Clinical Benefit Response (CBR)|Duration of Response (DOR)\",\"Terminated\",\"Phase 1|Phase 2\"\n",
      "777,\"Vorinostat and Lenalidomide After Autologous Stem Cell Transplant in Treating Patients With Multiple Myeloma\",\"Safety of patients receiving SAHA and lenalidomide following autologous PBSCT\",\"up to 3 years\",\"Duration of response|Time to progression (TTP)|Progression-free survival (PFS)|Time to response|Duration of overall response|Overall survival|Response rate\",\"Completed\",\"Phase 1\"\n",
      "778,\"CC-5013 Plus Dexamethasone Versus Dexamethasone Alone in Previously Treated Subjects With Multiple Myeloma\",\"Time to Tumor Progression (TTP)\",\"60 weeks (median Time To Progression of CC-5013/Dex treatment group)\",\"Overall Survival|Myeloma Response|Time to First Worsening of Eastern Cooperative Oncology Group (ECOG) Performance Status Scale (Best Score=0, Fully Active, Able to Carry on All Pre-disease Performance Without Restriction; Worst Score=5, Dead.)\",\"Completed\",\"Phase 3\"\n",
      "779,\"FT576 in Subjects With Multiple Myeloma\",\"Incidence and nature of DLTs within each dose-escalation cohort to determine the MTD or MAD|Determine the RP2D which will be based on the overall safety and anti-tumor activity among the dose escalation and dose expansion cohorts|Incidence, nature, and severity of adverse events\",\"Cycle 1 Day -5 to Day 29 for Regimen A and A1; Cycle 1 Day -11 to Day 29 (each cycle is 40 days) for Regimen B and B1|From FPI to LPI's end of Cycle 1 study treatment (End of cycle is Day 29 from Day 1 FT576 infusion)|Cycle 1 Day -5 to Day 29 for Regimen A and A1; Cycle 1 Day -11 to Day 29 (each cycle is 40 days) for Regimen B and B1\",\"Objective response rate (ORR)|Duration of response (DOR)|Progression-free survival (PFS)|Relapse-free survival (RFS) from complete response (CR)|Overall survival (OS)|Pharmacokinetics (PK) of FT576\",\"Recruiting\",\"Phase 1\"\n",
      "780,\"Study of Selinexor (KPT- 330), Lenalidomide, & Dexamethasone in Relapsed/Refractory Multiple Myeloma Patients\",\"Determine maximum tolerated dose (MTD)|Overall response rate (ORR)\",\"12 months|12 months\",,\"Withdrawn\",\"Phase 1|Phase 2\"\n",
      "781,\"Clinical Trial of Consolidation Treatment With Iodine I 131 Tositumomab for Multiple Myeloma\",\"Percentage of Patients With an Objective Response\",\"3 months\",\"Number of Participants With Complete Response (CR)|Duration of Response|Progression Free Survival Time|Time to Treatment Failure\",\"Active, not recruiting\",\"Phase 2\"\n",
      "782,\"Descartes-11 in Multiple Myeloma\",\"Incidence (number) of Treatment-Emergent Adverse Events\",\"14 Days\",\"Treatment Response\",\"Active, not recruiting\",\"Phase 1|Phase 2\"\n",
      "783,\"A Study of ATN-224 and Bortezomib in Patients With Multiple Myeloma\",\"Phase I: Determine a safe dose of ATN-224 and bortezomib to be used in the phase II portion of the study|Phase II: Efficacy\",\"Ongoing|End of Study\",\"Phase I: Preliminary evidence of efficacy|Phase II: progression-free survival and duration of response\",\"Terminated\",\"Phase 1|Phase 2\"\n",
      "784,\"A Study of JNJ-54767414 (Daratumumab) in Combination With Bortezomib and Dexamethasone (D-Vd) in Japanese Participants With Relapsed or Refractory Multiple Myeloma\",\"Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)\",\"Approximately 2 years\",\"Minimum Observed Serum Concentration (Cmin) of JNJ-54767414 (Daratumumab)|Maximum Observed Serum Concentration (Cmax) of JNJ-54767414 (Daratumumab)|Serum Concentration of JNJ-54767414 (Daratumumab) Antibodies|Percentage of Participants With Overall Response Rate (ORR)|Percentage of Participants with Complete Response (CR) or better|Percentage of Participants with a Very Good Partial Response (VGPR) or better|Time to Response\",\"Completed\",\"Phase 1\"\n",
      "785,\"Novel Support Options in Autologous Stem Cell Transplant for Multiple Myeloma\",\"Quality of life\",\"30 days\",\"Time to engraftment|Rate of febrile neutropenia\",\"Completed\",\"Not Applicable\"\n",
      "786,\"MagnetisMM-3: Study Of Elranatamab (PF-06863135) Monotherapy in Participants With Multiple Myeloma Who Are Refractory to at Least One PI, One IMiD and One Anti-CD38 mAb\",\"objective response rate\",\"assessed approximately every 4 weeks [up to approximately 2 years]\",\"objective response rate by baseline extramedullary disease status|duration of response|complete response rate|duration of complete response|progression free survival|time to response|minimal residual disease negativity rate|frequency of treatment-emergent adverse events|frequency of laboratory abnormalities|concentrations of elranatamab (PF-06863135)|immunogenicity of elranatamab (PF-06863135)|overall survival\",\"Active, not recruiting\",\"Phase 2\"\n",
      "787,\"Study of Lenalidomide and Dexamethasone With or Without Pembrolizumab (MK-3475) in Participants With Newly Diagnosed Treatment Naive Multiple Myeloma (MK-3475-185/KEYNOTE-185)\",\"Progression Free Survival (PFS) Evaluated According to the International Myeloma Working Group (IMWG) Response Criteria 2011 by Clinical Adjudication Committee (CAC) Blinded Central Review\",\"Up to approximately 30 months\",\"Overall Survival (OS)|Overall Response Rate (ORR) Evaluated According to the IMWG Response Criteria by CAC Blinded Central Review|Duration of Response (DOR) Evaluated According to IMWG Response Criteria by CAC Blinded Central Review|Disease Control Rate (DCR) Evaluated According to the IMWG Response Criteria by CAC Blinded Central Review|Second Progression Free Survival (PFS2)|Number of Participants Who Experienced One or More Adverse Events (AEs)|Number of Participants Discontinuing Study Treatment Due to an AE\",\"Terminated\",\"Phase 3\"\n",
      "788,\"Study of Carfilzomib, Lenalidomide, Dexamethasone and Belantamab Mafodotin in Multiple Myeloma\",\"Establish Maximum Tolerated Dose (MTD)|Evaluate Complete Response (CR)\",\"time to complete Cycle 1 (28 days)|up to 5 years\",\"Complete Response (CR)|Best Response|Very Good Partial Response (VGPR)|Overall Response|MRD Negative|Time to First Response (TTFR)|Time to Best Response (TTBR)|Time to Progression (TTP)|Duration of Response (DoR)|Overall Survival (OS)|Progression Free Survival (PFS)\",\"Recruiting\",\"Phase 1|Phase 2\"\n",
      "789,\"Thalidomide-Dexamethasone for Multiple Myeloma\",\"Response Rate\",\"Baseline, with each course and monthly tests\",,\"Completed\",\"Phase 2|Phase 3\"\n",
      "790,\"Combination Chemotherapy Following GM-CSF in Treating Patients With Multiple Myeloma\",,,,\"Completed\",\"Phase 2\"\n",
      "791,\"Anti-thymocyte Globulin and Melphalan in Treating Patients With Relapsed Multiple Myeloma\",\"Hematological Response Rate Defined as the Number of Participants Who Achieve a Confirmed Response\",\"4 months\",\"Overall Survival (OS)|Progression-free Survival (PFS)|Duration of Response (DOR)|Number of Participants With Severe Non-hematological Adverse Events\",\"Terminated\",\"Phase 2\"\n",
      "792,\"Anti-CXCR4 (BMS-936564) Alone and in Combination With Lenalidomide/Dexamethasone or Bortezomib/Dexamethasone in Relapsed/Refractory Multiple Myeloma\",\"Determination of maximum tolerated dose|Determination of maximum tolerated dose\",\"42 days in Arm A|35 days in Arm B\",\"Safety and tolerability will be analyzed for all patients. Safety endpoints will be based on adverse event reports, and include frequent adverse event (AE)s, serious adverse event (SAE)s and lab abnormalities|Pharmacokinetic (PK) measures will be collected for all patients who received study medication. The pharmacokinetic parameters will be maximum observed concentration (Cmax)|Pharmacokinetic (PK) measures will be collected for all patients who received study medication. The pharmacokinetic parameters will be trough observed concentration (Cmin)|Pharmacokinetic (PK) measures will be collected for all patients who received study medication. The pharmacokinetic parameters will be time of maximum observed concentration (Tmax)|Pharmacokinetic (PK) measures will be collected for all patients who received study medication. The pharmacokinetic parameters will be area under the concentration-time curve in one dosing interval (AUC (TAU))|Pharmacokinetic (PK) measures will be collected for all patients who received study medication. The pharmacokinetic parameters will be half-life (T-Half)|Pharmacokinetic (PK) measures will be collected for all patients who received study medication. The pharmacokinetic parameters will be area under the concentration-time curve from time zero extrapolated to infinite time (AUC(INF))|Pharmacokinetic (PK) measures will be collected for all patients who received study medication. The pharmacokinetic parameters will be total body clearance (CLT)|Pharmacokinetic (PK) measures will be collected for all patients who received study medication. The pharmacokinetic parameters will be volume of distribution at steady-state (Vss)|Individual tumor responses as defined by the International Myeloma Working Group Uniform Response Criteria (IMWG) for Multiple Myeloma (MM) will be used to monitor efficacy. For this assessment blood urine, and/or bone marrow assessment will be used|Anti-tumor response will be assessed by IMWG criteria (blood and urine; Bone marrow will not be collected unless to confirm complete response (CR))|Anti-tumor response will be assessed by IMWG criteria (blood and urine; Bone marrow assessment will be collected during screening period, at end of cycle 1, end of cycle 4 and to confirm CR )|Samples will be collected to characterize immunogenicity|Samples will be collected to characterize immunogenicity|Baseline level of cytokines/chemokines/growth factors will be determined, but not limited to SDF1 in peripheral blood and bone marrow\",\"Completed\",\"Phase 1\"\n",
      "793,\"Study Evaluating Safety, Tolerability and Clinical Activity of GSK2857916 in Combination With Pembrolizumab in Subjects With Relapsed/Refractory Multiple Myeloma (RRMM)\",\"Part 1 - Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)|Part 1 - Number of Participants With Dose Limiting Toxicities (DLTs)|Part 1 - Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters|Part 1 - Number of Participants With Worst-case Change Post-baseline in Hematology Parameters|Part 1 - Number of Participants With Worst-case Grade Change From Baseline in Lab Chemistry Parameters|Part 1 - Number of Participants With Worst-case Change Post-baseline in Lab Chemistry Parameters|Part 1 - Number of Participants With Worst-case Change Post-baseline Urinalysis Results|Part 1 - Changes From Baseline in Urine Potential of Hydrogen (pH)|Part 1 - Changes From Baseline in Urine Specific Gravity|Part 1 - Number of Participants With Worst-case Grade Change From Baseline in Vital Signs: Diastolic Blood Pressure (DBP) and Systolic Blood Pressure (SBP)|Part 1 - Number of Participants With Worst-case Change From Baseline in Vital Signs: Pulse Rate and Body Temperature|Part 2 - Percentage of Participants With Overall Response Rate (ORR)\",\"Up to approximately 31 months|Up to 21 days|Baseline (Day 1) and up to approximately 31 months|Baseline (Day 1) and up to approximately 31 months|Baseline (Day 1) and up to approximately 31 months|Baseline (Day 1) and up to 31 months|Baseline (Day 1) and up to approximately 31 months|Baseline (Day 1) and Week 46|Baseline (Day 1) and Week 46|Baseline (Day 1) and up to approximately 31 months|Baseline (Day 1) and up to approximately 31 months|Up to approximately 31 months\",\"Part 1 - Percentage of Participants With ORR|Part 2 - Number of Participants With AEs and SAEs|Part 2 - Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters|Part 2 - Number of Participants With Worst-case Change Post-baseline in Hematology Parameters|Part 2 - Number of Participants With Worst-case Grade Change From Baseline in Lab Chemistry Parameters|Part 2 - Number of Participants With Worst-case Change Post-baseline in Lab Chemistry Parameters|Part 2 - Number of Participants With Worst-case Change Post-baseline Urinalysis Results|Part 2 - Changes From Baseline in Urine Specific Gravity|Part 2 - Changes From Baseline in Urine pH|Part 2 - Number of Participants With Worst-case Grade Change From Baseline in Vital Signs: DBP and SBP|Part 2 - Number of Participants With Worst-case Change From Baseline in Vital Signs: Pulse Rate and Body Temperature|Part 2 - Number of Participants With Maximum Worst-case Change From Baseline in Best Corrected Visual Acuity Test (BCVA) Scores|Part 2 - Time Taken for the Onset of First Occurrence of Worsening in BCVA Score|Part 2 - Outcome of First Occurrence of Worsening Eye in BCVA Score|Part 2 - Duration of First Occurrence of Worsening in BCVA Score|Part 2 - Number of Participants According to the Number of Definite Events of Worsening of Vision|Part 2 - Number of Participants With Resolution of Post Treatment Exposure Worsening in BCVA Score|Part 2 - Duration of Resolution Post-treatment Exposure of Worsening in BCVA Score|Part 2 - Number of Participants With Post-baseline Decline in BCVA to Light Perception or no Light Perception|Part 2 - Number of Participants With Worst-case Shift From Baseline in Ophthalmological Epithelium Exam|Part 2 - Number of Participants With Worst-case Shift From Baseline in Corneal Examinations|Part 2 - Number of Participants With Worse Case Post-baseline Punctate Keratopathy Findings|Part 2 - Number of Participants With Worst-case Shift From Baseline in Lens Examinations|Part 2 - Percentage of Participants With Clinical Benefit Rate|Part 2 - Duration of Response|Part 2 - Time to Response|Part 2 - Time to Best Response|Part 2 - Progression-free Survival|Part 2 - Time to Disease Progression|Part 2 - Overall Survival|Part 1 - Maximum Concentration (Cmax) for Belantamab Mafodotin After First Dose|Part 2 - Cmax for Belantamab Mafodotin After First Dose|Part 1 - End of Infusion Concentration (C-EOI) for Belantamab Mafodotin|Part 2 - C-EOI for Belantamab Mafodotin|Part 1 - Time of Cmax (Tmax) for Belantamab Mafodotin After First Dose|Part 2 - Tmax for Belantamab Mafodotin After First Dose|Part 1 - Trough Concentration Prior to the Next Dose for Each Cycle (Ctrough) for Belantamab Mafodotin|Part 2 - Ctrough for Belantamab Mafodotin|Part 1 - Last Time Point Where the Concentration is Above the Limit of Quantification (Tlast) for Belantamab Mafodotin After First Dose|Part 2 - Tlast for Belantamab Mafodotin After First Dose|Part 1 - Area Under Plasma Concentration-time Curve (AUC) From Time 0 to End of the Dosing Interval [AUC (0-tau)] for Belantamab Mafodotin After First Dose|Part 2 - AUC (0-tau) for Belantamab Mafodotin After First Dose|Part 1 - Cmax for Total Monoclonal Antibody (mAb) After First Dose|Part 2 - Cmax for Total mAb After First Dose|Part 1 - C-EOI for Total mAb|Part 2 - C-EOI for Total mAb|Part 1 - Tmax for Total mAb After First Dose|Part 2 - Tmax for Total mAb After First Dose|Part 1 - Ctrough for Total mAb|Part 2 - Ctrough for Total mAb|Part 1 - Last Time Point Where the Concentration is Above the Limit of Quantification (Tlast) for Total mAb After First Dose|Part 2 - Tlast for Total mAb After First Dose|Part 1 - AUC (0-tau) for Total mAb After First Dose|Part 2 - AUC (0-tau) for Total mAb After First Dose|Part 1 - Cmax for Cysteine Maleimidocaproyl Monomethyl Auristatin F (Cys-mcMMAF) After First Dose|Part 2 - Cmax for Cys-mcMMAF After First Dose|Part 1 - C-EOI for Cys-mcMMAF After First Dose|Part 2 - C-EOI for Cys-mcMMAF After First Dose|Part 1 - Tmax for Cys-mcMMAF After First Dose|Part 2 - Tmax for Cys-mcMMAF After First Dose|Part 1 - Tlast for Cys-mcMMAF After First Dose|Part 2 - Tlast for Cys-mcMMAF After First Dose|Part 1 - Ctrough for Cys-mcMMAF|Part 2 - Ctrough for Cys-mcMMAF|Part 1 - AUC From Time 0 to 168 h After Dosing [AUC (0-168h)] for Cys-mcMMAF After First Dose|Part 2 - AUC (0-168 h) for Cys-mcMMAF After First Dose|Part 1 - Cmax for Pembrolizumab After First Dose|Part 2 - Cmax for Pembrolizumab After First Dose|Part 1 - Tmax for Pembrolizumab After First Dose|Part 2 - Tmax for Pembrolizumab After First Dose|Part 1 - AUC (0-tau) for Pembrolizumab After First Dose|Part 2 - AUC (0-tau) for Pembrolizumab After First Dose|Part 1 - Number of Participants With Post-baseline Positive Anti-drug Antibodies (ADAs) Against Belantamab Mafodotin|Part 2 - Number of Participants With Post-baseline Positive ADAs Against Belantamab Mafodotin|Part 1 - Titers of ADAs Against Belantamab Mafodotin|Part 2 - Titers of ADAs Against Belantamab Mafodotin\",\"Active, not recruiting\",\"Phase 1|Phase 2\"\n",
      "794,\"Liposomal Doxorubicin, Vincristine, & Dexamethasone Plus Arsenic Trioxide in Untreated Symptomatic Multiple Myeloma\",\"Assess the ability of DVd plus arsenic trioxide to achieve an overall response (complete and partial) rate in patients with untreated Multiple myeloma(MM)\",\"2004-2008\",,\"Completed\",\"Phase 2\"\n",
      "795,\"Panobinostat or Placebo With Bortezomib and Dexamethasone in Patients With Relapsed Multiple Myeloma\",\"Progression-free Survival Events in Patients Treated With Panobinostat in Combination With Bortezomib and Dexamethasone vs. Patients Treated by Placebo in Combination With Bortezomib and Dexamethasone.|Progression Free Survival in Patients Treated With Panobinostat in Combination With Bortezomib and Dexamethasone vs. Patients Treated by Placebo in Combination With Bortezomib and Dexamethasone.\",\"45 months|45 months\",\"Overall Survival in Patients Treated With Panobinostat in Combination With Bortezomib and Dexamethasone vs. Patients Treated by Placebo in Combination With Bortezomib and Dexamethasone|Overall Survival in Patients Treated With Panobinostat in Combination With Bortezomib and Dexamethasone vs. Patients Treated by Placebo in Combination With Bortezomib and Dexamethasone|Overall Response Rate in Patients Treated With Panobinostat in Combination With Bortezomib and Dexamethasone vs. Patients Treated by Placebo in Combination With Bortezomib and Dexamethasone.|Time to Response Per Investigator Assessment (mEBMT Criteria) of Response Patients Treated With Panobinostat in Combination With Bortezomib and Dexamethasone vs. Patients Treated by Placebo in Combination With Bortezomib and Dexamethasone.|Duration of Response Per Investigator Assessment (mEBMT Criteria) Patients Treated With Panobinostat in Combination With Bortezomib and Dexamethasone vs. Patients Treated by Placebo in Combination With Bortezomib and Dexamethasone.|Time to Progression/Relapse Per Investigator Assessment (mEBMT Criteria) Patients Treated With Panobinostat in Combination With Bortezomib and Dexamethasone vs. Patients Treated by Placebo in Combination With Bortezomib and Dexamethasone.|European Organization for Research and Treatment of Cancer Multiple Myeloma Module (EORTC) QLQ-MY20-Change From Baseline by Treatment Group|European Organization for Research and Treatment of Cancer Multiple Myeloma Module (EORTC ) QLQ-C30 - Summary Statistics by Treatment Group|Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System : FACT/GOG-NTX-Change From Baseline by Treatment Group\",\"Completed\",\"Phase 3\"\n",
      "796,\"A Study to Compare Iberdomide Maintenance Versus Lenalidomide Maintenance Therapy Following Autologous Stem Cell Transplant in Participants With Newly Diagnosed Multiple Myeloma\",\"Progression-free survival (PFS)\",\"Up to 6 years\",\"Achieving minimal residual disease (MRD) negativity in participants with complete response (CR) or better at 12 (± 3) months of maintenance treatment|Overall Survival|Recommended iberdomide dose for Stage 2|Area under the iberdomide plasma concentration-time curve from time zero to tau|Area under the iberdomide plasma concentration-time curve within a dosing interval AUC (TAU)|Maximum iberdomide concentration (Cmax)|Time to maximum iberdomide plasma concentration (Tmax)|Number of participants with adverse events (AEs)|Progression-free survival on next line of treatment (PFS2)|Achieving MRD negativity in participants with CR or better at any time after the date of randomization|Conversion from MRD positive to MRD negative in participants with CR or better|Achievement of CR or better and maintaining MRD-negative status in 2 bone marrow aspirate assessments that are a minimum of 6 months or 1 year apart, without any examination showing MRD positive status in between assessments|Time to progression (TTP)|Time to next treatment (TTNT)|Best response achieved prior to progressive disease (PD)|Patient-reported health-related quality of life (HRQoL) outcomes and multiple myeloma-related symptoms as measured by the European Organization for Research and Treatment of Cancer [EORTC] Quality of Life C30 questionnaire (QLQ-C30)|Patient-reported HRQoL outcomes and multiple myeloma-related symptoms as measured by the EORTC Quality of Life Multiple Myeloma Module (QLQ-MY20)\",\"Not yet recruiting\",\"Phase 3\"\n",
      "797,\"Novel Combination of Belantamab Mafodotin and Elotuzumab to Enhance Therapeutic Efficacy in Multiple Myeloma\",\"Maximum tolerated dose of elotuzumab in combination with belantamab mafodotin in subjects|Number of Participants who Experienced Dose-Limiting Toxicities (DLTs)\",\"28 days|28 days\",\"Preliminary evaluation of clinical efficacy/response rate|To evaluate progression free survival (PFS)|To evaluate overall survival (OS)|To evaluate minimal residual disease (MRD) by multi-parameter flow cytometry and by next-generation sequencing (NGS)\",\"Recruiting\",\"Phase 1|Phase 2\"\n",
      "798,\"PTK/ZK as Post Transplant Maintenance Therapy in Patients With Multiple Myeloma\",\"Detectable Paraprotein Level (IgG or IgA)at ≤5 g/dL Who Show a 50% Reduction (Complete Response + Partial Response) in Their Paraprotein After Starting Treatment With the Study Drug\",\"Day 90\",\"Time to Progression|Safety and Tolerability of PTK787/ZK 222584|Disease Free Survival\",\"Terminated\",\"Phase 2\"\n",
      "799,\"Lenalidomide and Low Dose Dexamethasone Versus Bortezomib, Lenalidomide and Low Dose Dexamethasone for Induction, in Patients With Previously Untreated Multiple Myeloma\",\"comparison progression-free survival (PFS) in patients with newly diagnosed myeloma treated with lenalidomide plus low dose dexamethasone versus bortezomib plus lenalidomide and low dose dexamethasone\",\"Four years\",,\"Completed\",\"Phase 3\"\n",
      "800,\"Pethema Multiple Myeloma 2000\",,,,\"Completed\",\"Phase 3\"\n",
      "801,\"Alternate Day Dosing of Pomalidomide in Patients With Refractory Multiple Myeloma\",\"Overall Response Rate (ORR)\",\"From date of registration until 28 days after last dose of trial medication with longest treatment time of approximately 36 months\",\"Overall Survival (OS)|Overall Survival (OS) at 12 months|Progression-free survival (PFS)\",\"Terminated\",\"Phase 2\"\n",
      "802,\"Phase 1b Study Evaluating ACY-1215 (Ricolinostat) in Combination With Pomalidomide and Dexamethasone in Relapsed or Relapsed-and-Refractory Multiple Myeloma\",\"Determine Maximum Tolerated Dose (MTD) if any, and recommended dose schedule\",\"Every 56 days on treatment, estimated average of 4 months.\",\"Safety|Anti-Tumor Activity|Pharmacokinetics|Pharmacodynamics\",\"Completed\",\"Phase 1\"\n",
      "803,\"Novel BCMA-targeted CAR-T Cell Therapy for Multiple Myeloma\",\"Rate of grade 3 or 4 treatment related adverse effect|Overall response rate (ORR) after treated by CAR-T treatment\",\"24 weeks after last dose of CAR-T treatment|up to 2 years after CAR-T treatment\",\"Pharmacokinetics of CAR-T cells (implantation endpoint)|Overall survival|Progression free survival\",\"Recruiting\",\"Phase 1\"\n",
      "804,\"Evaluation of Vertebral Compression Fracture Fixation With RF Kyphoplasty in Patients With Multiple Myeloma\",\"Improvement in functional status, as measured by the Oswestry Disability Index (ODI)\",\"1 month\",\"Change in Quality of Life (SF-35 Health Survey)|Change in Back Pain (VAS)|Change in Physical Disability associated with back pain (Roland-Morris Disability Questionnaire)\",\"Withdrawn\",\"Phase 4\"\n",
      "805,\"A Phase 1 Study of CNTO 328 (Siltuximab) in Relapsed or Refractory Multiple Myeloma\",\"Number of patients with adverse events as a measure of safety and tolerability\",\"Up to 14 months\",\"Serum siltuximab concentration|Number of patients with a positive immune response to siltuximab|Number of patients with an overall response (complete response and partial response)\",\"Terminated\",\"Phase 1\"\n",
      "806,\"Study of Lenalidomide and Low-Dose Dexamethasone in Chinese Subjects With Relapsed/Refractory Multiple Myeloma\",\"Overall Response Rate\",\"Up to 24 months\",\"Adverse Events|Progression Free Survival (PFS)|Overall Survival|Response duration|Maximum observed concentration in plasma|Area under the plasma concentration-time curve|Time to maximum concentration|Terminal half-life|Apparent total body clearance|Apparent volume of distribution\",\"Completed\",\"Phase 2\"\n",
      "807,\"Antithymocyte Globulin in Treating Patients Undergoing Stem Cell Transplant for Multiple Myeloma\",\"Response rate, as measured by International Bone Marrow Transplant Registry (IBMTR)/European Group for Blood and Marrow Transplantation (EBMT) Response Criteria, at 4 weeks\",,\"Toxicity as assessed by NCI CTC v2.0|Formation of antirabbit antibodies\",\"Completed\",\"Phase 2\"\n",
      "808,\"Combination Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Multiple Myeloma\",,,,\"Unknown status\",\"Phase 2\"\n",
      "809,\"Phase I Study of MIK665, a Mcl-1 Inhibitor, in Patients With Refractory or Relapsed Lymphoma or Multiple Myeloma\",\"Incidence and severity of AEs and SAEs, incl. changes in laboratory parameters, vital signs and ECGs.|Incidence of DLTs during the first cycle of treatment with single agent MIK665 during the dose escalation phase only|Tolerability: Dose interruptions|Tolerability: Dose reductions|Tolerability: Dose intensity\",\"2 years|2 years|2 years|2 years|2 years\",\"Best Overall response (BOR) per International Myeloma Working Group (IMWG) criteria for Myeloma; and per revised criteria for staging of the International Working Group (IWG) guidelines for Lymphoma|Area Under Curve (AUC)|Maximum Plasma Concentration (Cmax)|Terminal elimination half-life (T1/2)|Apparent volume of distribution (Vz)|Clearance (CL)|Duration of Response (DOR)per International Myeloma Working Group (IMWG) criteria for Myeloma; and per revised criteria for staging of the International Working Group (IWG) guidelines for Lymphoma|Progression Free Survival (PFS) per International Myeloma Working Group (IMWG) criteria for Myeloma; and per revised criteria for staging of the International Working Group (IWG) guidelines for Lymphoma\",\"Completed\",\"Phase 1\"\n",
      "810,\"VitD3 Supplementation in Patients With Multiple Myeloma\",\"To describe the lymphocyte subset analysis for the two treatment arms at 120 days post autologous stem cell transplant [120 days]\",\"120 days\",\"To report the 3-year progression-free survival for both treatment arms - intensified vs. therapeutic Vitamin D supplementation|To report the overall response rate for both treatment arms 120 days after ASCT for adult patients with multiple myeloma.|To report the overall response rate for both treatment arms 2 years after transplantation|To report the 3-year overall survival for the two treatment arms after transplantation.|To report the minimal residual disease status for the two treatment arms at randomization, and within 120 days after transplantation and 2 years after transplantation.|To report the vitamin D levels between the two treatments arms before autologous stem cell transplant, within 120 days, and 3-years post-transplantation|To describe the adverse events for the two treatment arms|To report time to neutrophil and platelet engraftment as well as transfusion independence after transplantation in both treatment arms\",\"Not yet recruiting\",\"Early Phase 1\"\n",
      "811,\"Consolidation Therapy With Bortezomib in Elderly Patients With Multiple Myeloma\",\"The difference in event-free survival time will be compared between both arms\",\"Every 35 days during treatment phase, after 4, 8, 12, 18, 24 months during follow-up\",\"Best response to chemotherapy, response rate to chemotherapy , duration of response, toxicities and quality of life; timepoints for assessments will be at end of study, at 1,5 + 4 + 8 +12 + 18 + 24 + 30 months and thereafter 6 monthly\",\"Completed\",\"Phase 3\"\n",
      "812,\"Real World Insights During Treatment for Relapsed/Refractory Multiple Myeloma With Isatuximab\",\"Change in Patient's Qualitative Assessment of Treatment Real World version (PQAT-RW)|Qualitative Interview\",\"Change in baseline perception of treatment experience at 3 months|Within the last month of study participation\",\"Change in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC-QLQ-C30)|Change in Quality of Life Questionnaire Multiple Myeloma (QLQ-MY20)|Change in European QoL-5 Dimensions (EQ5D)|Change in Cancer Behavior Inventory-Brief Form (CBI-B)|Change in Patient Global Impression of Severity (PGIS) Scale|Change in Patient Global Impression of Change (PGIC) Scale|Change in Center for Adherence Support Evaluation (CASE) Medication Adherence Index|Change in Comprehensive Score for Financial Toxicity (COST) Instrument\",\"Recruiting\",\"Not Applicable\"\n",
      "813,\"Samarium 153 and Bortezomib in Treating Patients With Relapsed or Refractory Multiple Myeloma\",\"Maximum tolerated dose and dose-limiting toxicity\",,\"Response rate (complete, partial, and minimal response)|Time to disease progression and time to response|Progression-free and overall survival|Antitumor effects\",\"Completed\",\"Phase 1\"\n",
      "814,\"A Phase I-Ib/II Study to Determine the Maximum Tolerated Dose (MTD) of AUY922 Alone and in Combination With Bortezomib, With or Without Dexamethasone, in Patients With Relapsed or Refractory Multiple Myeloma.\",\"The safe dose of AUY922 when administered once a week.\",\"54 weeks (Maximum Tolerated Dose (MTD))\",\"The safe dose of AUY922 when administered once a week in combination with bortezomib and dexamethasone.|Efficacy of AUY922 administered once a week alone and in combination\",\"Completed\",\"Phase 1|Phase 2\"\n",
      "815,\"Phase 1b Study of Weekly Carfilzomib in Combination With Lenalidomide and Dexamethasone in Subjects With Multiple Myeloma\",\"Number of Participants With Adverse Events (AEs)|Change From Baseline in Hemoglobin Levels|Change From Baseline in Platelet Count|Change From Baseline in Neutrophil Count|Change From Baseline in Bilirubin|Change From Baseline in Creatinine\",\"From the first dose of any study drug up to 30 days after the last dose of any study drug; median (range) duration of treatment with carfilzomib was 32 (1.1, 76.7) weeks in RRMM participants and 26 (1.0, 94.4) weeks in NDMM participants.|Baseline and Cycle 1, days 8 and 15 and Cycle 2 days 1, 8, and 15|Baseline and Cycle 1, days 8 and 15 and Cycle 2 days 1, 8, and 15|Baseline and Cycle 1, days 8 and 15 and Cycle 2 days 1, 8, and 15|Baseline and Cycle 2 day 1|Baseline and Cycle 1, days 8 and 15 and Cycle 2 days 1, 8, and 15\",\"Maximum Plasma Concentration of Carfilzomib on Day 8 of Cycle 1 by Dose Group|Time to Maximum Plasma Concentration of Carfilzomib on Day 8 of Cycle 1 by Dose Group|Area Under the Curve From Time Zero to Time of Last Quantifiable Concentration of Carfilzomib on Day 8 of Cycle 1 by Dose Group|Overall Response Rate (ORR)|Complete Response Rate (CRR)|Progression-free Survival (PFS)|Duration of Response (DOR)\",\"Completed\",\"Phase 1\"\n",
      "816,\"A Phase II Study of BI-505 in Smoldering Multiple Myeloma\",\"To assess the change in disease activity measured as M-protein levels in serum/urine following BI-505 treatment compared to base line according to the International Myeloma Working Group (IMWG) uniform response criteria\",\"M-protein will be measured at screening, prior to each dose and at end of study visit, for up to 19 weeks.\",\"The clinical safety of BI-505 will be assessed by reporting the numbers of AEs, the severity and the relationship to IMP.|The pharmacokinetic profile of BI-505 will be determined by calculating the following pharmacokinetic parameters: AUC, % AUCex, Cmax, Tmax, CL, Vss and T1/2.|The pharmacodynamics of BI-505 will be assessed by measuring soluble biomarkers and ICAM-1 saturation on bone marrow plasma cells.|The immunogenicity profile of BI-505 will be assessed by measuring antibodies towards BI-505.\",\"Terminated\",\"Phase 2\"\n",
      "817,\"A Study to Determine the Efficacy of the Combination of Daratumumab (DARA) Plus Durvalumab (DURVA) (D2) in Subjects With Relapsed and Refractory Multiple Myeloma (RRMM)\",\"Percentage of Participants With an Objective Response According to International Myeloma Working Group (IMWG) Uniform Response Criteria\",\"From randomization until the data cut-off date of 17 April 2018. The median duration of treatment for durvalumab and daratumumab was 7.9 weeks and 8.0 weeks respectively.\",\"Time-to-Response (TTR)|Duration of Response (DOR)|Progression Free Survival|Overall Survival|Area Under the Plasma Concentration-time Curve From Time 0 to the Time of the Last Quantifiable Concentration Of Durvalumab|Area Under the Plasma Concentration-time Curve From Time 0 to Extrapolated to Infinity (AUC-inf) of Durvalumab|Maximum Observed Concentration (Cmax) Of Durvalumab|Time to Reach Maximum Concentration (Tmax) of Durvalumab|Terminal Half-Life (T1/2) of of Durvalumab|Apparent Total Clearance (CL/F) of of Durvalumab|Apparent Volume of Distribution (Vz/F) of Durvalumab|Participants With Treatment-Emergent Adverse Events (TEAEs)\",\"Completed\",\"Phase 2\"\n",
      "818,\"UARK 2014-14: Phase II Prospective Evaluation of Bone Remodeling During Ixazomib Treatment\",\"Change in Serum Osteocalcin From Baseline to End of Study in Patients With Relapsed/Refractory Multiple Myeloma.\",\"Baseline, Treatment (28-day cycles for 6 cycles)\",,\"Completed\",\"Phase 2\"\n",
      "819,\"Safety and Efficacy Evaluation of BCMA-CART for Treating Multiple Myeloma\",\"Objective response rate (ORR)\",\"Up to 90 days after T cell infusion\",\"Incidence and Severity of Adverse Events as a Measure of Safety|Duration of persistence of BCMA-CART\",\"Withdrawn\",\"Not Applicable\"\n",
      "820,\"Study of Azacitidine to Treat Relapsed or Refractory Multiple Myeloma\",\"Overall response rate\",,\"time to progression|duration of response|number of cycles of azacitidine required to first achieve a response|progression free survival|safety|tolerability\",\"Terminated\",\"Phase 2\"\n",
      "821,\"Autologous Dendritic Cell Therapy in Patients With Relapsed or Refractory Multiple Myeloma\",\"Number of participants with adverse events\",\"1 years\",\"Clinical response after completion of Vax-DC/MM injection|Progression free survival\",\"Unknown status\",\"Phase 1|Phase 2\"\n",
      "822,\"Avelumab in Combination With Hypofractionated Radiotherapy in Patients With Relapsed Refractory Multiple Myeloma\",\"Overall Response Rate (ORR)\",\"up to end of study, an average of 11 months\",\"Fraction of Participants Who Experience a Complete Response (CR) or Stringent Complete Response (sCR) Using the Study Treatment|Fraction of Participants Who Experience a Minimal Residual Disease Negative (MRDneg)Complete Response (CR) Using the Study Treatment|Percent Change in Aberrant Circulating Plasma Cells in the Peripheral Blood (PB) and Bone Marrow (BM) From Baseline|Percent Reduction in Size of On-irradiated Extramedullary Lesions|Fluorodeoxyglucose (FDG) Avidity Positron-Emission Tomography/Computed Tomography (PET/CT) of Non-irradiated Extramedullary Lesions (Abscopal Effect) Compared to Baseline|Progression-free Survival (PFS)|Percentage of Participants With Overall Survival (OS)|Number of Participants With Grade ≥1 Non-serious Adverse Events|Number of Participants Overall Best Response\",\"Terminated\",\"Phase 2\"\n",
      "823,\"Chemotherapy, Holmium Ho 166 DOTMP, and Peripheral Stem Cell Transplantation in Treating Patients With Multiple Myeloma\",,,,\"Completed\",\"Phase 1|Phase 2\"\n",
      "824,\"Interferon-gamma or Aldesleukin and Vaccine Therapy in Treating Patients With Multiple Myeloma\",\"Confirmed response (i.e., clinical or immunological)\",,,\"Completed\",\"Phase 2\"\n",
      "825,\"A Study of Weekly Carfilzomib in Combination With Dexamethasone for Progressive Multiple Myeloma\",\"Phase 1: Number of Participants With Dose-limiting Toxicities (DLTs)|Overall Response Rate (ORR)\",\"28 days|Disease response was assessed once every treatment cycle (28 days) and 30 days after last dose; the median overall treatment duration was 33.6 weeks.\",\"Clinical Benefit Response Rate|Progression-free Survival|Time To Progression|Duration of Response|Number of Participants With Adverse Events|Time to Maximum Plasma Concentration of Carfilzomib|Maximum Plasma Concentration of Carfilzomib|Area Under the Plasma Concentration-time Curve From Time 0 to the Time of Last Quantifiable Concentration (AUClast) for Carfilzomib|Area Under the Plasma Concentration-time Curve From Time 0 to Infinity (AUCinf) fo Carfilzomib|Area Under the Plasma Concentration-time Curve During the Dosing Interval (0-168 Hours) for Carfilzomib|Volume of Distribution Observed at Steady State (Vss) for Carfilzomib|Terminal Half-life (T1/2,z) for Carfilzomib|Clearance of Carfilzomib After IV Infusion|Mean Residence Time Observed From Time Zero to Infinity (MRT0-∞) for Carfilzomib\",\"Completed\",\"Phase 1|Phase 2\"\n",
      "826,\"Impacts on Health Outcomes and Resources Utilization of Hospital-at-home for Elderly Patients With Multiple Myeloma\",\"Change in Quality of life using questionnaires EORTC QLQ-30|Change in Quality of life using questionnaires EORTC QLQ-MY20\",\"At baseline, at the 6th month and the 12th month|At baseline, at the 6th month and the 12th month\",\"Survival|Multidimensional evaluation of home care|Toxicity of treatment|family quality of life|Total Cost|Fate-to-face interview with patients, caregivers and healthcare staff\",\"Recruiting\",\n",
      "827,\"Tivantinib in Treating Patients With Relapsed, or Relapsed and Refractory Multiple Myeloma\",\"Overall Response Rate (ORR)|Toxicities of Single Agent Tivantinib: Grade 3 Nonhematologic or Grade 4 Hematologic Toxicities According to the Common Terminology Criteria for Adverse Events (CTCAE), Version 4\",\"Up to 30 days|Up to 30 days\",\"Time to Next Treatment (TTNT)\",\"Completed\",\"Phase 2\"\n",
      "828,\"A Phase 1/2a Study of Human Anti-CD 38 Antibody MOR03087 (MOR202) in Relapsed/Refractory Multiple Myeloma\",\"Determination of Maximum Tolerated Dose and / or Recommended Dose and Dosing Regimen of MOR03087|Number of Participants Who Develop Anti-MOR03087 Antibodies\",\"First cycle of treatment|during treatment period, maximum 3 years after 1st dose\",\"Overall Response Rate|Time to Progression|Progression-free Survival|Duration of Response|Pharmacokinetics: Cmax - Maximum Observed Serum Concentration for MOR202|Pharmacokinetics: AUC Cycle 1+2 - Area Under the Time/Concentration Curve for MOR202\",\"Completed\",\"Phase 1|Phase 2\"\n",
      "829,\"P-BCMA-101 Tscm CAR-T Cells in the Treatment of Patients With Multiple Myeloma (MM)\",\"Phase 1: Assess the Safety of P-BCMA-101|Phase 1: Maximum tolerated dose of P-BCMA-101|Phase 2: Assess the safety of P-BCMA-101|Phase 2: Assess the efficacy of P-BCMA-101 (ORR)|Phase 2: Assess the efficacy of P-BCMA-101 (DOR)\",\"Baseline through Day 28|Baseline through Day 28|Baseline through 24 months|Baseline through 24 months|Baseline through 24 months\",\"Phase 1:Assess the safety of P-BCMA-101|Phase 1:Assess the feasibility P-BCMA-101|Phase 1: Anti-myeloma effect of P-BCMA-101 (ORR)|Phase 1: Anti-myeloma effect of P-BCMA-101 (TTR)|Phase 1: Anti-myeloma effect of P-BCMA-101 (DOR)|Phase 1: Anti-myeloma effect of P-BCMA-101 (PFS)|Phase 1: Anti-myeloma effect of P-BCMA-101 (OS)|Phase 1: The effect of cell dose to guide selection of doses for further assessment in Phase 2/3 studies|Phase 2: Incidence and severity of cytokine release syndrome (CRS)|Phase 2: Evaluate Efficacy Endpoints (IL-6)|Phase 2: Evaluate Efficacy Endpoints (C)|Phase 2: Evaluate Efficacy Endpoints (R)|Phase 2: Evaluate Efficacy Endpoints (OS)|Phase 2: Evaluate Efficacy Endpoints (PFS)|Phase 2: Evaluate Efficacy Endpoints (TTR)|Phase 2: Evaluate Efficacy Endpoints (MRD)\",\"Terminated\",\"Phase 1|Phase 2\"\n",
      "830,\"Haploidentical Bone Marrow Stem Cell Transplantation in Patients With Multiple Myeloma\",\"Progression free survival (scale)\",\"1 year\",\"Response rate (scale)|Incidence of graft failure, engraftment and time to neutrophil and platelet recovery (hematology)|Incidence and Severity of Acute and Chronic GVHD (scale)|Non-Relapse Mortality (number)|Evaluation of infections after haploBMT and T cell reconstitution (scale)|NK cell repertoire reconstitution and maturation rates including alloreactivity (facs)|NK cell repertoire in the Bone Marrow before and after transplantation (facs)|Cost calculation (euro)|Quality of Life (questionnaire)\",\"Unknown status\",\"Phase 1|Phase 2\"\n",
      "831,\"High-Dose Weekly Carfilzomib Plus Cyclophosphamide and Dexamethasone in the Treatment of Relapsed Multiple Myeloma\",\"Overall Response Rate After 4 Cycles\",\"4 months\",\"Progression-free Survival|Overall Survival\",\"Completed\",\"Phase 2\"\n",
      "832,\"Study to Evaluate the Safety and Tolerability of CC-92328 in Participants With Relapsed and/or Refractory Multiple Myeloma\",\"Dose-Limiting Toxicities (DLTs)|Maximum Tolerated Dose (MTD)|Incidence of Adverse Events (AEs)\",\"Up to 28 days after the first dose|Up to 12 weeks after the last dose|Up to 12 weeks after the last dose\",\"Preliminary Efficacy - Overall Response Rate (ORR)|Preliminary Efficacy - Time to response|Preliminary Efficacy - Duration of response|Preliminary Efficacy - Progression-free Survival (PFS)|Preliminary Efficacy - Overall Survival (OS)|Pharmacokinetics - Cmax|Pharmacokinetics - Cmin|Pharmacokinetics - AUC|Pharmacokinetics - tmax|Pharmacokinetics - t1/2|Pharmacokinetics - CL|Pharmacokinetics - Vd|Pharmacokinetics - Accumulation index of CC-92328|Presence of Anti-CC92328 antibodies (ADA)|Frequency of Anti-CC92328 antibodies (ADA)\",\"Recruiting\",\"Phase 1\"\n",
      "833,\"Selinexor, Carfilzomib, and Dexamethasone Versus Placebo, Carfilzomib, and Dexamethasone in Multiple Myeloma\",\"Progression Free Survival (PFS)\",\"From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 24 months\",\"Overall Response Rate (ORR)\",\"Withdrawn\",\"Phase 2\"\n",
      "834,\"A Study of Selinexor Plus Low-dose Dexamethasone in Participants With Penta-refractory Multiple Myeloma or Selinexor and Bortezomib Plus Low-dose Dexamethasone in Participants With Triple-class Refractory Multiple Myeloma\",\"Overall Response Rate (ORR)\",\"From the date of randomization up to death (approximately 14 months)\",\"Duration of Response (DOR)|Clinical Benefit Rate (CBR)|Disease control rate (DCR)|Progression-Free Survival (PFS)|Overall Survival (OS)|Time to Next Treatment (TTNT)|Number of Participants with Adverse Events (AE)\",\"Recruiting\",\"Phase 2\"\n",
      "835,\"Peripheral Stem Cell Transplantation Plus Combination Chemotherapy in Treating Patients With Multiple Myeloma\",,,,\"Completed\",\"Phase 2\"\n",
      "836,\"Follow-up of Patients With Multiple Myeloma in the West-Occitanie Region \"\"Living With a Myeloma in West-Occitanie\"\"\",\"Treatment lines and procedures followed by the patients|Transplants|Treatments discontinuation|Therapeutic medical care description|Unconventional alternative medicine|Outpatient support structure\",\"5 to 10 years|5 to 10 years|5 to 10 years|5 to 10 years|5 to 10 years|5 to 10 years\",\"Best response (BR)|Progression-free Survival (PFS)|PFS after the second therapeutic line|Overall Survival (OS);|Quality of life (QOL) during the treatment course|Second primary cancers (SPC) and grade 3 and higher neuropathies\",\"Recruiting\",\n",
      "837,\"Isa-Rd for Frail and/or Much Older Patients With Newly Diagnosed Multiple Myeloma\",\"Overall Response Rate (ORR)\",\"From Day 1 of study treatment up to 60 months\",\"Treatment failure-free survival (TFFS) Time|Progression-Free Survival (PFS)|Maximum Depth of Response|Rate of achievement of bone marrow minimal residual disease (MRD) negativity|Clinical Benefit Rate (minimal response (MR) + ORR)|Time to Response|Duration of Response|Time to Next Treatment|Overall Survival|Toxicity Rate\",\"Recruiting\",\"Phase 2\"\n",
      "838,\"Third-line Therapy of Multiple Myeloma a Prospective Phase I /II Trial\",\"response rate\",\"2012\",\"Time to progression\",\"Unknown status\",\"Phase 1|Phase 2\"\n",
      "839,\"Velcade + Cyclophosphamide in Newly Diagnosed Multiple Myeloma\",\"Overall Response Rate (ORR) During Induction Therapy\",\"Up to 8 months\",\"Severe Adverse Event Rate|Maximum Depth of Response During Induction Therapy|Maximum Depth of Response During Maintenance Therapy|Median Time to Response|Median Duration of Response|Median Progression-free Survival|Median Overall Survival|QLQ-C30 Question 29|QLQ-C30 Question 30|Functionality as Assessed Using the Cancer and Leukemia Group B (CALGB) Geriatric Assessment Tool|Risk Score as Assessed Using the Cancer and Leukemia Group B (CALGB) Geriatric Assessment Tool\",\"Terminated\",\"Phase 2\"\n",
      "840,\"Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Multiple Myeloma\",,,,\"Completed\",\"Phase 2\"\n",
      "841,\"Vorinostat in Combination With Bortezomib, Doxorubicin and Dexamethasone (VBDD) in Patients With Refractory or Relapsed Multiple Myeloma (MM)\",\"Maximal Tolerated Dose (MTD)\",\"28 days (within first treatment cycle)\",\"Response|Rates of Adverse Events (AE),Serious Adverse Events and AEs leading to permanent treatment discontinuation|Quality of Life|Duration of Response|Progression-free survival (PFS)|Overall survival (OS)\",\"Completed\",\"Phase 1|Phase 2\"\n",
      "842,\"Bortezomib in Treating Patients With Multiple Myeloma Who Have Undergone an Autologous Peripheral Blood Stem Cell Transplant\",\"Maximum tolerated dose|Safety and tolerability\",\"At course 8|At course 8\",\"Overall response rate by Southwest Oncology Group (SWOG) criteria|Complete response rate by SWOG criteria|Response duration by SWOG criteria\",\"Completed\",\"Phase 1\"\n",
      "843,\"A Study of PS-341 Given to Patients With Multiple Myeloma Who Experienced Progressive Disease After Receiving Dexamethasone in M34101-039\",,,,\"Completed\",\"Phase 3\"\n",
      "844,\"Samarium Sm 153 Lexidronam Pentasodium and Bortezomib in Treating Patients With Relapsed or Refractory Multiple Myeloma\",\"Toxicity (Phase I)|Confirmed clinical response (complete response, very good partial response, partial response, or minimal response) (Phase II)\",,\"Immunoglobulin free light chain response|Changes in complete blood cell count and micronucleated reticulocyte count\",\"Completed\",\"Phase 1|Phase 2\"\n",
      "845,\"Study of SyB L-0501 to Treat Relapsed/Refractory Multiple Myeloma\",\"Response Rate [Stringent CR (sCR)+Complete Response (CR)+Very Good PR (VGPR)+Partial Response (PR)]Based on International Myeloma Working Group (IMWG) Criteria\",\"up to around 44 weeks\",\"Response Rate (sCR+CR) Based on IMWG Criteria|Complete Response (CR) Based on the Blade Criteria|Response Rate (CR+PR) Based on the Blade Criteria|Progression-Free Survival (PFS)|Time to Treatment Failure (TTF)|Duration of Response (DOR)|Overall Survival (OS)|Adverse Events|Number of Subjects With Abnormality (Grade ≥3) in Laboratory Test Values|Number of Abnormalities (Grade ≥3) in Laboratory Test Values\",\"Completed\",\"Phase 2\"\n",
      "846,\"Pomalidomide and Dexamethasone Effects in Multiple Myeloma Patients With Del 17p or t (4;14)\",\"Time to disease progression (from the date of the first dose to the date of the first observation of disease progression)\",\"The final analysis of disease progression will be run when at least 29 events will occur (expected average of 32months ).\",\"Safety of pomalidomide and dexamethasone|Overall Response rate (Partial Response and better), Very Good Partial Response (VGPR) + Complete Response (CR) rate and stringent Complete Response (sCR) rate to pomalidomide and dexamethasone in MM patients|Time to response and Response duration of pomalidomide and dexamethasone.|Overall Survival of pomalidomide and dexamethasone and event free survival|Response and Time to disease progression with regards to cytogenetic abnormalities in the bone marrow tumor plasma cells\",\"Completed\",\"Phase 2\"\n",
      "847,\"A Study of Talquetamab in Participants With Relapsed or Refractory Multiple Myeloma\",\"Overall Response Rate (ORR)\",\"Up to 2 years and 10 months\",\"Duration of Response (DOR)|Very Good Partial Response (VGPR) or Better Rate|Complete Response (CR) or Better Rate|Stringent Complete Response (sCR) Rate|Time to Response (TTR)|Progression-Free Survival (PFS)|Overall Survival (OS)|Minimal Residual Disease (MRD) Negative Rate|Number of Participants with Adverse Events (AEs) as a Measure of Safety and Tolerability|Number of Participants with Serious Adverse Events (SAEs) as a Measure of Safety and Tolerability|Number of Participants with AEs by Severity|Number of Participants with Abnormalities in Clinical Laboratory Values|Serum Concentration of Talquetamab|Number of Participants with Talquetamab Antibodies|Change from Baseline in Health-Related Quality of Life (HRQoL) as Assessed by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core-30 item (EORTC QLQ-C30)|Change from Baseline in HRQoL as Assessed by EuroQol Five Dimension Five Level Questionnaire (EQ-5D-5L)|Change from Baseline in HRQoL as Assessed by Patient Global Impression of Severity (PGIS)|Overall Response Rate (ORR) in Participants with High-risk Molecular Features\",\"Recruiting\",\"Phase 2\"\n",
      "848,\"Peripheral Stem Cell Transplantation Plus Combination Chemotherapy in Treating Patients With Multiple Myeloma\",,,,\"Completed\",\"Phase 2\"\n",
      "849,\"Melphalan+Prednisolon With or Without Thalidomide in Previously Untreated Elderly Patients With Multiple Myeloma\",\"response rate\",\"12 months\",\"time to relapse|overall survival\",\"Completed\",\"Phase 3\"\n",
      "850,\"A Single-centre Prospective Study to Explore the Role of Frailty in Patients With Multiple Myeloma.\",\"Frailty status defined according to Geriatric assessment|Frailty status defined according to biomarkers of frailty: Teleomere Length|Frailty status defined according to biomarkers of frailty: miRNAs|Frailty status defined according to biomarkers of frailty: CDKN2A|Frailty status defined according to Geriatric assessment|Frailty status defined according to Geriatric assessment\",\"18 months from Recruitment End|18 months from Recruitment End|18 months from Recruitment End|18 months from Recruitment End|18 months from Recruitment End|18 months from Recruitment End\",,\"Active, not recruiting\",\n",
      "851,\"Frontline Therapy in de Novo Multiple Myeloma Patients Under 65\",\"Evaluation of the best response after consolidation\",\"6 to 8 months after start of induction for each patient = after consolidation therapy for all patients\",\"Response Evaluation after 3 cycles|Safety and tolerability : number and nature of Adverse Events|Stem Cells Collection|Response After HDT-ASCT and 2 cycles|Progression Free Survival\",\"Completed\",\"Phase 2\"\n",
      "852,\"Quality of Life of Non-transplant Candidate Multiple Myeloma Patients Treated With Early Bortezomib\",\"The change in the quality of life as measured by EORTC QLQ-C30 and EQ-5D before and after the administration of bortezomib\",\"On day 1 at the first cycle, 12 weeks, 24 weeks\",\"Relationship between the primary outcome and the complete remission (CR) rate|Relationship between the primary outcome and overall response|Relationship between the primary outcome and the time to response|Relationship between the primary outcome and the survival|Adverse events\",\"Completed\",\n",
      "853,\"Panobinostat in Combination With Carfilzomib and Dexamethasone in Relapsed or Relapsed and Refractory Multiple Myeloma\",\"Overall response rate (ORR) using investigator's response assessment\",\"All patients treated for 6 cycles (cycle=28 days)\",\"Very Good Partial Response (VGPR) or better as best response using investigator response assessment based on International Myeloma Working Group (IMWG) criteria|Progression-free survival (PFS) using investigator's response assessment based on IMWG criteria|Overall survival (OS)|Time to response (TTR) using investigator's response assessment based on IMWG criteria|Duration of Response (DOR) using investigator's response assessment based on IMWG criteria|Time to progression (TTP) using investigator's response assessment based on IMWG criteria|Time to reach Cmax for panobinostat (PAN) and carfilzomib (CFZ)|Minimum observed plasma concentration (Cmin) for carfilzomib|Concentration of panobinostat in blood plasma in 48 hrs after the dose.|Total carfilzomib exposure over time in blood plasma .|Health related quality of life (HRQoL) change over time measured by EORTC questionnaire QLQ-C30 and QLQ-MY20 for disease symptoms\",\"Withdrawn\",\"Phase 2\"\n",
      "854,\"A Phase IIa Study of Sotatercept on Bone Mass and Turnover in Patients With Multiple Myeloma\",\"Presence of biochemical bone turnover\",\"Average of 3 months\",\"Number of Adverse Events related to sotatercept|Bone marrow density|Change in biochemical myeloma markers|Size of target bone lesions\",\"Withdrawn\",\"Phase 2\"\n",
      "855,\"A Study of TTI-622 in Combination With Daratumumab Hyaluronidase-fihj in People With Multiple Myeloma\",\"Incidence of dose-limiting toxicities\",\"28-day observation period following C1D1 of therapy\",\"Overall response of TTI-621|Overall response of TTI-622\",\"Recruiting\",\"Phase 1\"\n",
      "856,\"Anti-BCMA CAR-NK Cell Therapy for the Relapsed or Refractory Multiple Myeloma\",\"Overall Remission Rate (ORR)|Incidence of dose limiting toxicity (DLTs)\",\"2 monthes after infusion|within 2 monthes after infusion\",\"Progression-free survival (PFS)|Duration of Response (DOR)\",\"Recruiting\",\"Early Phase 1\"\n",
      "857,\"Carfilzomib With Bendamustine and Dexamethasone in Multiple Myeloma\",\"Maximum Tolerated Dose (MTD) of Carfilzomib in combination with bendamustine and dexamethasone\",\"6 months\",\"Overall response rate (ORR)|Duration of response (DOR)|Progression free survival (PFS)|Time to best response|Overall survival (OS) rate|Number of adverse events (AEs)|Number of adverse events in relation to carfilzomib maintenance\",\"Completed\",\"Phase 1|Phase 2\"\n",
      "858,\"Doxorubicin Hydrochloride Liposome, Melphalan, and Bortezomib in Treating Patients With Relapsed or Refractory Stage I, Stage II, or Stage III Multiple Myeloma\",\"Proportion of patients experiencing treatment-related ≥ grade 3 hematologic or nonhematologic toxicity or treatment-related death (phase I)\",,\"Time to response (phase II)|Progression-free survival (phase II)|Overall survival (phase II)|Toxicities by NCI criteria (phase II)\",\"Unknown status\",\"Phase 1|Phase 2\"\n",
      "859,\"Radiation Therapy Using Holmium Ho 166 DOTMP Plus Melphalan and Peripheral Stem Cell Transplantation in Treating Patients With Multiple Myeloma\",,,,\"Completed\",\"Phase 1|Phase 2\"\n",
      "860,\"A Phase 3 Study to Evaluate Efficacy and Safety of Masitinib in Patients With Relapse or Refractory Multiple Myeloma\",\"Progression Free Survival\",\"Analysis to be conducted after a minimum of 201 events\",\"Overall Time to Progression|Overall Survival\",\"Terminated\",\"Phase 3\"\n",
      "861,\"P-BCMA-ALLO1 Allogeneic CAR-T Cells in the Treatment of Subjects With Multiple Myeloma\",\"Part 1: Assess the maximum tolerated dose (MTD) of P-BCMA-ALLO1 based on dose limiting toxicities (DLT)|Part 2: Assess the safety and tolerability of P-BCMA-ALLO1 when administered as a fixed dose of cells.\",\"Baseline through Day 28|Baseline through 36 months\",\"The safety of P-BCMA-ALLO1|The anti-myeloma effect of P-BCMA-ALLO1 (ORR)|The anti-myeloma effect of P-BCMA-ALLO1 (TTR)|The anti-Myeloma effect of P-BCMA-ALLO1 (DOR)|The anti-Myeloma effect of P-BCMA-ALLO1 (PFS)|The anti-Myeloma effect of P-BCMA-ALLO1 (OS)|The effect of cell dose and study arm to guide selection of doses and LD regimen for further assessment in Phase 2/3 studies\",\"Recruiting\",\"Phase 1\"\n",
      "862,\"Platform Study of Belantamab Mafodotin as Monotherapy and in Combination With Anti-cancer Treatments in Participants With Relapsed/Refractory Multiple Myeloma (RRMM) (DREAMM 5)\",\"DE Phase: Number of participants achieving dose limiting toxicities (DLT)|DE Phase: Number of participants with adverse events (AEs) and serious adverse events (SAEs)|DE Phase: Number of participants with clinically significant changes in hematology, clinical chemistry and urinalysis lab parameters|CE Phase: Number of participants achieving Overall Response Rate (ORR)\",\"Up to 12 months|Up to 12 months|Up to 12 months|Up to 36 months\",\"DE Phase: Number of participants achieving ORR|CE Phase: Number of participants achieving Clinical Benefit Rate (CBR)|DE Phase: Number of participants achieving Partial Response (PR)|CE Phase: Number of participants achieving PR|DE Phase: Number of participants achieving Very Good Partial Response (VGPR)|CE Phase: Number of participants achieving VGPR|DE Phase: Number of participants achieving Complete Response (CR)|CE Phase: Number of participants achieving CR|DE Phase: Number of participants achieving stringent Complete Response (sCR)|CE Phase: Number of participants achieving sCR|DE Phase: Belantamab mafodotin concentrations when administered in combination with anti-cancer treatments|CE Phase: Belantamab mafodotin concentrations when administered in combination with anti-cancer treatments|DE Phase: GSK3174998 concentration when administered in combination with belantamab mafodotin|CE Phase: GSK3174998 concentration when administered in combination with belantamab mafodotin|DE Phase: Feladilimab concentration when administered in combination with belantamab mafodotin|CE Phase: Feladilimab concentration when administered in combination with belantamab mafodotin|DE Phase: Nirogacestat concentration when administered in combination with belantamab mafodotin|CE Phase: Nirogacestat concentration when administered in combination with belantamab mafodotin|DE Phase: Dostarlimab concentration when administered in combination with belantamab mafodotin|CE Phase: Dostarlimab concentration when administered in combination with belantamab mafodotin|DE Phase: Isatuximab concentration when administered in combination with belantamab mafodotin|CE Phase: Isatuximab concentration when administered in combination with belantamab mafodotin|DE Phase: Concentration of anti-drug antibodies (ADAs) against belantamab mafodotin when administered in combination with anti-cancer treatments|CE Phase: Concentration of ADAs against belantamab mafodotin when administered in combination with anti-cancer treatments|DE Phase: Concentration of ADAs against GSK3174998 when administered in combination with belantamab mafodotin|CE Phase: Concentration of ADAs against GSK3174998 when administered in combination with belantamab mafodotin|DE Phase: Concentration of ADAs against feladilimab when administered in combination with belantamab mafodotin|CE Phase: Concentration of ADAs against feladilimab when administered in combination with belantamab mafodotin|DE Phase: Concentration of ADAs against dostarlimab when administered in combination with belantamab mafodotin|CE Phase: Concentration of ADAs against dostarlimab when administered in combination with belantamab mafodotin|DE Phase: Concentration of ADAs against isatuximab when administered in combination with belantamab mafodotin|CE Phase: Concentration of ADAs against isatuximab when administered in combination with belantamab mafodotin|DE Phase: Number of participants with adverse events of special interest (AESI) for belantamab mafodotin|CE Phase: Number of participants with AESI for belantamab mafodotin|DE Phase: Number of participants with AESI for GSK3174998|CE Phase: Number of participants with AESI for GSK3174998|DE Phase: Number of participants with AESI for Feladilimab|CE Phase: Number of participants with AESI for Feladilimab|DE Phase: Number of participants with AESI for Nirogacestat|CE Phase: Number of participants with AESI for Nirogacestat|DE Phase: Number of participants with AESI for Dostarlimab|CE Phase: Number of participants with AESI for Dostarlimab|DE Phase: Number of participants with AESI for Isatuximab|CE Phase: Number of participants with AESI for Isatuximab|DE Phase: Number of participants with abnormal ocular findings on ophthalmic examination|CE Phase: Number of participants with abnormal ocular findings on ophthalmic examination|CE Phase: Number of participants achieving Progression-free survival (PFS)|CE Phase: Duration of response (DoR)|CE Phase: Time to response (TTR)|CE Phase: Number of participants achieving Overall survival (OS)|CE Phase: Number of participants with AEs and SAEs|CE Phase: Number of participants with AEs leading to discontinuation|CE Phase: Number of participants with dose reduction or delay|CE Phase: Number of participants with clinically significant changes in hematology, clinical chemistry and urinalysis lab parameters\",\"Recruiting\",\"Phase 1|Phase 2\"\n",
      "863,\"UARK 2003-41: A Study of High-Dose Density Therapy in Patients With Multiple Myeloma\",\"To evaluate whether high-dose density treatment during the initial seven months, including tandem transplants within six months after starting therapy, results in superior event-free and overall survival rates as compared to historical controls.\",\"seven months\",\"To evaluate the ability of pegfilgrastim to mobilize stem cells when administered following DTPACE in MM patients with active disease, compared to historical controls mobilized with DTPACE and either GM-CSF or G-CSF.\",\"Completed\",\"Phase 2\"\n",
      "864,\"A Study of the Safety and Pharmacology of SGN-40 Administered in Combination With Bortezomib in Patients With Relapsed or Refractory Multiple Myeloma\",\"Determine the maximum tolerated dose of SGN-40 when combined with bortezomib\",\"Length of study\",\"Determine safety, pharmacokinetics, and clinical response rate for combination therapy with SGN-40 and bortezomib\",\"Completed\",\"Phase 1\"\n",
      "865,\"Panobinostat (LBH589): Multiple Myeloma - Autologous Hematopoietic Cell Transplantation (HCT)\",\"Relative Dose Intensity (RDI) Per Cohort\",\"Up to 2 years\",\"Complete Response Rate|Progression Free Survival (PFS)|Overall Survival (OS)\",\"Completed\",\"Phase 2\"\n",
      "866,\"Chloroquine in Combination With VELCADE and Cyclophosphamide for Relapsed and Refractory Multiple Myeloma\",\"Response Rate (CR + PR After 2 Cycles)\",\"Up to 2 years\",\"Number of Participants With Adverse Events of Grade 3 or Higher|Percentage of Subjects Who Have Complete Response or Partial Response and Have 2+ or Higher Autophagy|Median Duration of Response of This Regimen\",\"Terminated\",\"Phase 2\"\n",
      "867,\"UARK 89-001 Phase II Study of Intensive \"\"TOTAL THERAPY\"\" For Untreated or Minimally Treated Patients With Multiple Myeloma\",\"Percentage of Participants That Are Relapse-free 5 Years After Initial Therapy\",\"5 years\",,\"Completed\",\"Phase 2\"\n",
      "868,\"Autologous Transplantation for Multiple Myeloma\",\"Complete or near Complete Response Rate\",,\"Relapse-free Survival|Event-free Survival|Overall Survival\",\"Completed\",\"Phase 3\"\n",
      "869,\"Lenalidomide Intensification in Patients With Serologic/Asymptomatic Progression of Multiple Myeloma While on Lenalidomide Maintenance\",\"Overall Response Rate (ORR)\",\"6 months\",\"Number of Participants Evaluated for Toxicity\",\"Completed\",\"Phase 2\"\n",
      "870,\"A Study to Record in an Observational Manner the Treatment of Multiple Myeloma as it is Being Done in Every Day Practice Without Providing Any Investigational Drug or Prescribing Any Procedure\",\"Description of current treatment regimens for MMY.\",\"Every 3 months from baseline to 3 years after last patient recruited\",\"Utilisation of current treatment regimens for MMY|Quality of life and health economic parameters associated with MMY treatment regimens|Safety profile of current treatment regimens for MMY|The effectiveness of current treatment regimens for MMY\",\"Completed\",\n",
      "871,\"Study Evaluating the Safety and Efficacy of JCARH125 in Subjects With Relapsed and/or Refractory Multiple Myeloma\",\"Phase 1: Incidence of dose-limiting toxicities (DLTs)|Phase 1: Incidence and severity of adverse events|Phase 1: Incidence and severity of clinically significant laboratory abnormalities|Phase 1 Anakinra Cohort only: Incidence and severity of Grade 2 or higher cytokine release syndrome (CRS)|Phase 1 Anakinra Cohort only: Percentage of subjects with no CRS on Days 1, 2, or 3 following JCARH125 infusion|Phase 1 Anakinra Cohort only: Time to onset of Grade 2 or higher CRS|Phase 2: Overall response rate\",\"21 days|2 years|2 years|2 years|2 years|2 years|2 years\",\"Phase 1 and Phase 2: Maximum concentration (Cmax) of JCARH125 in the blood|Phase 1 and Phase 2: Time to maximum concentration (Tmax) of JCARH125 in the blood|Phase 1 and Phase 2: Area under the concentration vs time curve (AUC) of JCARH125 in the blood|Phase 1 and Phase 2: Duration of persistence of JCARH125 CAR T cells in the blood|Phase 1: Overall response rate|Phase 1 and Phase 2: Complete response (CR) rate|Phase 2: Duration of response|Phase 2: Duration of CR|Phase 2: incidence and severity of adverse events|Phase 2: Incidence and severity of clinically significant laboratory abnormalities|Phase 2: Overall survival|Phase 2: Progression-free survival|Phase 2: Time to response|Phase 2: Time to CR|Phase 2 (excluding Phase 2a): Changes in measures of health-related quality of life (HRQoL)|Phase 2 (excluding Phase 2a): Numbers of days in the intensive care unit (ICU)|Phase 2 (excluding Phase 2a): Number of non-ICU inpatient days\",\"Active, not recruiting\",\"Phase 1|Phase 2\"\n",
      "872,\"Samarium Sm 153 Lexidronam Pentasodium and High-Dose Melphalan in Treating Patients With Multiple Myeloma Undergoing Stem Cell Transplant\",\"Number of toxicity incidents (Phase I)|Proportion of successes (Phase II)\",,\"Number of responses (Phase I)|Overall survival (Phase II)|Progression-free survival (Phase II)|Time to progression (Phase II)|Progressive disease variables\",\"Completed\",\"Phase 1|Phase 2\"\n",
      "873,\"Safety and Efficacy of bb2121 (Ide-cel) Combinations in Multiple Myeloma\",\"Does Limiting Toxicity (DLT) rates _Phase 1|Complete Response Rate (CRR)_ Phase 2\",\"Up to 28 days from start of the combination therapy|Up to 24 months\",\"Incidence of Adverse Event (AEs)|Overall Response Rate (ORR)|Progression-free Survival (PFS)|Overall Survival (OS)|Time to response (TTR)|Duration of Response (DoR)|Time to next antimyeloma treatment (TTNT)|Progression-free survival after next antimyeloma therapy (PFS2)|Feasibility of maintenance therapy in combination with bb2121|Pharmacokinetics - Cmax_Phase 1 and 2|Pharmacokinetics - Tmax_Phase 1 and 2|Pharmacokinetics - AUC_Phase 1 and 2|Pharmacokinetics - AUC0-28days _Phase 1 and 2|Pharmacokinetics - Tlast _Phase 1 and 2\",\"Recruiting\",\"Phase 1|Phase 2\"\n",
      "874,\"Lenalidomide and Low-Dose Dexamethasone in Patients With Previously Treated Multiple Myeloma and Kidney Dysfunction\",\"Number of Participants in Phase I Component With Dose Limiting Toxicities During the First Cycle of Therapy|Percentage of Participants Who Experience a Response [sCR, CR, VGPR, PR]\",\"First cycle of therapy (28 days)|56 months\",\"Overall Survival Time|Duration of Response|Worst Degree Treatment-Related Adverse Events Across All Event Types Per Patient|Renal Function Over Time|Pharmacokinetics of Lenalidomide in Impaired Renal Function|Progression-free Survival\",\"Terminated\",\"Phase 1|Phase 2\"\n",
      "875,\"Acupuncture for Chemo-Induced Peripheral Neuropathy in Multiple Myeloma Patients\",\"Evaluate the change of neuropathy in actively treated multiple myeloma subjects diagnosed with CIPN who received acupuncture vs standard of care management.\",\"approx. 10 weeks\",\"Assess Specific features of CIPN - Nausea|Assess Specific features of CIPN - Sadness|Assess Specific features of CIPN - Nervousness|Assess Specific features of CIPN - Sleep quality|Assess Specific features of CIPN - Lack of energy|Assess Specific features of CIPN - Pain|Assess Specific features of CIPN - Constipation|Assess Specific features of CIPN - Dizziness|Assess Specific features of CIPN - Dry Mouth|Assess Quality of Life\",\"Recruiting\",\"Not Applicable\"\n",
      "876,\"Bortezomib and Dexamethasone in Treating Patients With Multiple Myeloma That Has Relapsed or Has Not Responded to Treatment\",\"Overall response rate\",,\"Toxicity|Tolerability|Duration of response after completion of treatment|Time to progression|Overall and progression-free survival\",\"Unknown status\",\"Phase 2\"\n",
      "877,\"Steroid Sparing Treatment With in Newly Diagnosed Transplant Ineligible Patients With Multiple Myeloma\",\"Daratumumab Related Infusion Reactions\",\"28 days\",\"Determination of Response Rates\",\"Recruiting\",\"Phase 2\"\n",
      "878,\"A Trial for Relapsed and Relapsed/Refractory Multiple Myeloma Patients\",\"Minimal residual disease (MRD)\",\"5 years\",\"Progression-free survival (PFS)|Overall response rate (ORR)|Progression-free survival 2 (PFS2)|Duration of response (DOR)|Overall survival (OS)|Safety as incidence of toxicities|Time to next therapy (TNT)|Percentage of patients with negative MRD and survival indices\",\"Active, not recruiting\",\"Phase 2\"\n",
      "879,\"A Study of Belantamab Mafodotin in Multiple Myeloma Participants With Normal and Impaired Hepatic Function\",\"Part 1 and Part 2: Maximum observed plasma concentration (Cmax) of GSK2857916|Part 1 and Part 2: Time to Cmax (Tmax) of GSK2857916|Part 1 and Part 2: Concentration at the end of infusion (C-EOI)|Part 1 and Part 2: Predose plasma concentration (Ctrough) of GSK2857916|Part 1 and Part 2: Area under the plasma concentration-time curve (from zero to the end of dosing interval)|Part 1 and Part 2 : AUC over the dosing interval (AUC[0-tau]) of GSK2857916|Part 1 and Part 2: Last time point where the concentration is above the limit of quantification (Tlast) of GSK2857916|Part 1 and Part 2: Cmax of total monoclonal antibody (mAb)|Part 1 and Part 2: Tmax of total mAb|Part 1 and Part 2: C-EOI of total mAB|Part 1 and Part 2: Ctrough of total mAb|Part 1 and Part 2: Area under the plasma concentration-time curve (from zero to the end of dosing interval)of total mAb|Part 1 and Part 2: AUC(0-tau) of total mAb|Part 1 and Part 2: Tlast of total mAb|Part 1 and Part 2: Cmax of Cys Monomethyl Auristatin F (cys-mcMMAF)|Part 1 and Part 2: Tmax of cys-mcMMAF|Part 1 and Part 2: C-EOI of cys-mcMMAF|Part 1 and Part 2: AUC(0-168 hours) of cys-mcMMAF|Part 1 and Part 2: tlast of cys-mcMMAF\",\"Up to 48 months|Up to 48 months|Up to 48 months|Up to 48 months|Up to 48 months|Up to 48 months|Up to 48 months|Up to 48 months|Up to 48 months|Up to 48 months|Up to 48 months|Up to 48 months|Up to 48 months|Up to 48 months|Up to 48 months|Up to 48 months|Up to 48 months|Up to 48 months|Up to 48 months\",\"Part 1 and Part 2: Change from Baseline in Vital Signs- Diastolic Blood Pressure (DBP) and Systolic Blood Pressure (SBP) (millimeters of mercury [mmHg])|Part 1 and Part 2: Change from Baseline in Vital Sign- Heart rate (beats per minute)|Part 1 and Part 2: Number of participants with adverse events (AEs) and serious adverse events (SAEs)|Part 1 and Part 2: Number of participants with toxicity grading for hematology parameters|Part 1 and Part 2: Number of participants with toxicity grading for clinical chemistry parameters|Part 1 and Part 2: Number of participants with toxicity grading for urine parameters|Part 1 and Part 2: Number of participants with abnormal physical examination parameters\",\"Recruiting\",\"Phase 1\"\n",
      "880,\"A Study of Carfilzomib Plus Dexamethasone in Adults With Relapsed or Refractory Multiple Myeloma at US Community Oncology Centers\",\"Number of Participants Who Completed 12 Cycles of Treatment|Percentage of Expected Dose of Carfilzomib Received in Cycles 1 to 12|Relative Dose Intensity of Carfilzomib in Cycles 1 to 12|Number of Participants With Carfilzomib Dose Modifications During Cycles 1 to 12|Number of Participants With Treatment-emergent Adverse Events\",\"12 cycles (each cycle is 28 days)|Up to 12 cycles (each cycle is 28 days)|Up to 12 Cycles (each cycle is 28 days)|Cycles 1 - 12 (each cycle is 28 days)|From the first dose of study drug until 30 days after the last dose (12 months)\",\"Percentage of Expected Dose of Carfilzomib Received in Cycles 1 to 6 and 7 to 12|Relative Dose Intensity of Carfilzomib in Cycles 1 to 6 and 7 to 12|Number of Participants With Carfilzomib Dose Modifications During Cycles 1 to 6|Number of Participants With Carfilzomib Dose Modifications During Cycles 7 to 12|Number of Participants Who Discontinued Carfilzomib in Cycles 1 to 6 and 7 to 12|Change From Baseline to Last Cycle of Treatment in European Organization for Research and Treatment of Cancer Quality-of-life Questionnaire (EORTC QLQ)-Core 30 (C30)|Change From Baseline in Average EORTC QLQ-C30 Scores During Cycles 2 to 6 in Participants Who Completed 12 Cycles of Treatment|Change From Cycle 7 Day 1 in Average EORTC QLQ-C30 Scores During Cycles 8 to 12 in Participants Who Completed 12 Cycles of Treatment|Change From Baseline to Last Cycle of Treatment in EORTC QLQ Multiple Myeloma Module (MY-20) Scores|Change From Baseline in Average EORTC QLQ-MY20 Scores During Cycles 2 to 6 in Participants Who Completed 12 Cycles of Treatment|Change From Cycle 7 Day 1 in Average EORTC QLQ-MY20 Scores Over Cycles 8 to 12 in Participants Who Completed 12 Cycles of Treatment|Overall Response Rate (ORR)|Overall Response Rate (ORR) After 6 Cycles|Overall Response Rate (ORR) by Prior Lines of Therapy|Percentage of Participants With Progression-free Survival (PFS) Events at 12 Months|Percentage of Participants With PFS Events by Prior Lines of Therapy\",\"Terminated\",\"Phase 2\"\n",
      "881,\"Combination Plerixafor (AMD3100)and Bortezomib in Relapsed or Relapsed/Refractory Multiple Myeloma\",\"Plerixafor Maximum Tolerated Dose (MTD) [Phase I]|Bortezomib Maximum Tolerated Dose (MTD) [Phase I]|Number of Participants With Dose Limiting Toxicity (DLT) [Phase I]|Response Rate of Plerixafor, Bortezomib, and Dexamethasone in Relapsed or Relapsed/ Refractory Multiple Myeloma (ORR) [Phase I and Phase II]\",\"Participants were assessed every 3 weeks while on study; The observation period for MTD evaluation was the first 21 days of treatment.|Participants were assessed every 3 weeks while on study; The observation period for MTD evaluation was the first 21 days of treatment.|Participants were assessed every 3 weeks while on study; The observation period for MTD evaluation was the first 21 days of treatment.|Disease was assessed for response every cycle on treatment. The maximum number of cycles received was 25.\",\"Time to Progression (TTP) [Phase II]|Duration of Response (DOR) [Phase II]\",\"Completed\",\"Phase 1|Phase 2\"\n",
      "882,\"A Study to Assess Adverse Events and Change in Disease Activity of Intravenously (IV) Infused ABBV-383 in Combination With Anti-Cancer Regimens for the Treatment of Adult Participants With Relapsed/Refractory Multiple Myeloma\",\"Number of Participants with Dose Limiting Toxicities (DLT) of ABBV-383|Number of Participants with Adverse Events (AEs)\",\"Up to approximately 28 Days|Up to Approximately 3 Years\",\"Overall Response Rate (ORR)|Progression-Free Survival (PFS)|Duration of Response (DOR)|Time-to-Progression (TTP)|Percentage of Participants with Minimal Residual Disease Negativity (MRD)\",\"Recruiting\",\"Phase 1\"\n",
      "883,\"Myeloma XIV: Frailty-adjusted Therapy in Transplant Non-Eligible Patients With Newly Diagnosed Multiple Myeloma\",\"Randomisation 1: Number of participants with early treatment cessation|Randomisation 2: Progression-free survival (PFS-R2)\",\"Within 60 days of Randomisation 1|The time from the date of Randomisation 2 to the date of first documented evidence of disease progression or death from any cause, up to 120 months\",\"Progression-free survival (PFS-R1)|Time to disease progression|Progression-free survival two (PFS2)|Overall survival (OS)|Survival after progression|Deaths within 12 months of Randomisation 1 (R1)|Overall response rate (ORR)|Attainment of ≥VGPR|Attainment of Minimal Residual Disease (MRD) negativity|Duration of response (DoR)|Time to improved response|Time to next treatment|Treatment compliance and total amount of therapy delivered|Incidence of treatment-emergent adverse events (Toxicity and safety, including incidence of second malignancies)|EORTC QLQ-C30_questionnaire|EORTC QLQ-MY20_questionnaire|EQ-5D-3L_questionnaire\",\"Recruiting\",\"Phase 3\"\n",
      "884,\"Melphalan and Busulfan Followed By Donor Peripheral Stem Cell Transplant, Tacrolimus, and Methotrexate in Treating Patients With Multiple Myeloma\",\"Transplant-related mortality at 180 days\",,\"Disease response (complete response)|Progression-free survival|Overall survival at 1 year\",\"Completed\",\"Phase 2\"\n",
      "885,\"CRISPR-Edited Allogeneic Anti-BCMA CAR-T Cell Therapy in Patients With Relapsed/Refractory Multiple Myeloma\",\"(Part A) Number of patients with dose limiting toxicities (DLT)|(Part B) Overall Response Rate (ORR)\",\"28 days|12 Months\",,\"Recruiting\",\"Phase 1\"\n",
      "886,\"Dovitinib Combined With Bortezomib and Dexamethasone for Relapsed/Refractory Multiple Myeloma\",\"Evaluate the safety and dose-limiting toxicity of treatment with dovitinib in combination with bortezomib/ dexamethasone.\",\"Treatment Cycle 1 (three weeks) for each participant.\",\"To assess the overall response rate for the combination dovitinib/bortezomib/ dexamethasone in patients receiving at least 4 cycles of therapy.\",\"Withdrawn\",\"Phase 1\"\n",
      "887,\"Leflunomide in Treating Patients With High-Risk Smoldering Multiple Myeloma\",\"Progression to multiple myeloma|Overall survival\",\"Up to 2 years|Up to 2 years\",\"Overall response rate (ORR)|Incidence of adverse events (AEs)|Freedom from progression|Change in quality of life\",\"Withdrawn\",\"Phase 2\"\n",
      "888,\"Study of BTK Inhibitor, Ibrutinib in Combination With Carfilzomib in Subjects With Relapsed and Refractory Multiple Myeloma\",\"Overall Response Rate (ORR)\",\"up to 4 years\",\"Duration of Response (DOR)|Overall Survival|Progression Free Survival (PFS)\",\"Completed\",\"Phase 1|Phase 2\"\n",
      "889,\"UARK 2003-25: A Study of Intravenous (IV) Busulfan (Busulfex®) in Multiple Myeloma Patients\",\"Maximal Dose of Busulfex® Given in a 2, 3, or 4 Day Period With Acceptable Toxicity to Myeloma Patients\",\"three years\",,\"Terminated\",\"Phase 1|Phase 2\"\n",
      "890,\"A Study of TNB-383B in Participants With Relapsed or Refractory Multiple Myeloma\",\"Number of Participants with Dose-limiting toxicities (DLT)|Number of Participants with Adverse Events (AEs) and/or Serious Adverse Events (SAEs)|Maximum Observed Plasma Concentration of TNB-383B (Cmax)|Time to Cmax of TNB-383B (Tmax)|Area Under the Concentration Versus Time Curve from Time Zero to the Last Measurable Concentration (AUClast)|Clearance (CL) of TNB-383B|Terminal Phase Elimination Rate Constant (Beta) of TNB-383B|Terminal Half-Life (t1/2) of TNB-383B|Number of Participants with of Anti-drug Antibody (ADA)\",\"Day 21|Up to 3 Years|Week 12|Week 12|Week 12|Week 12|Week 12|Week 12|Up to Month 48\",\"Objective Response Rate (ORR)|Percentage of Participants with Overall Survival (OS)|Percentage of Participants with Progression-Free Survival (PFS)|Time-to-Progression (TTP)|Time-to-Response (TTR)|Duration of Objective Response (DOR)\",\"Active, not recruiting\",\"Phase 1|Phase 2\"\n",
      "891,\"Isatuximab, Bendamustine, and Prednisone in Refractory Multiple Myeloma\",\"Maximum tolerated dose (MTD) or recommended phase 2 dose (RP2D) of regimen (Phase I only)|Overall response rate (ORR) (Phase II only)\",\"Completion of first cycle of treatment for all participants enrolled in Phase I portion (estimated to be 9 months)|6 months\",\"Number of adverse events experienced by participants (Phase I and Phase II)|Progression-free survival (PFS) (Phase II only)|Overall survival (OS) (Phase II only)\",\"Active, not recruiting\",\"Phase 1\"\n",
      "892,\"A Bioequivalence Study of SPARC_147709 in Patients With Multiple Myeloma\",\"90% confidence interval of the relative mean Cmax, AUC0-t, AUC0-∞, of the test and reference\",\"2 cycles\",\"Treatment Emergent Adverse Events\",\"Completed\",\"Phase 1\"\n",
      "893,\"A Study Evaluating Hypotension and Autonomic Nervous System Dysfunction in Multiple Myeloma (MM) Patients\",\"To determine whether the orthostatic hypotension reported among subjects during bortezomib-containing regimen is caused by a dysfunction of the autonomic nervous system (ANS).\",\"1 year\",\"To gather pilot data on the incidence of autonomic dysfunction in patients with Multiple Myeloma prior to treatment with Bortezomib.|To characterize the changes in the ANS including the fluctuations in blood pressure (hypotension /hypertension) associated with bortezomib.\",\"Unknown status\",\n",
      "894,\"Sorafenib and Bortezomib Treatment for Relapsed or Refractory Multiple Myeloma Patients\",\"Objective Response Rate (ORR), the Percentage of Patients Who Experience an Objective Benefit From Treatment\",\"24 months\",,\"Completed\",\"Phase 1|Phase 2\"\n",
      "895,\"Safety and Pharmacokinetics of Rising Doses of APO010 in Relapsed/Refractory Multiple Myeloma Patients Selected by DRP\",\"Maximum Tolerated Dosage|Recommended Dosage\",\"1 Year|1 Year\",\"Percentage (%) of patients with drug-related adverse events (adverse reactions)|The pharmacokinetic profile (AUC INF) for APO010 at doses above 60 µg/m2|The pharmacokinetic profile (AUC last) for APO010 at doses above 60 µg/m2|The pharmacokinetic profile (AUC 0-12hr) for APO010 at doses above 60 µg/m2|The Maximum Plasma Concentration (Cmax), for APO010 at doses above 60 µg/m2|The Observed maximum (Tmax), for APO010 at doses above 60 µg/m2|The Terminal half-life (T½), for APO010 at doses above 60 µg/m2|The HADA Antibody Response|The Tumor Response\",\"Terminated\",\"Phase 1|Phase 2\"\n",
      "896,\"Microtransplantation Versus Auto-SCT in ≥PR Multiple Myeloma Patients\",\"progression-free survival|overall survival\",\"2 years|2 years\",\"rate of complete remission|minimal residual disease|hematopoietic recovery|infection|GVHD|relapse\",\"Unknown status\",\"Not Applicable\"\n",
      "897,\"A Study Assessing Safety and Effectiveness of BORTEZOMIB Combination Therapy (Bortezomib + Doxorubicin Hydrochloride + Dexamethasone) in Previously Untreated Multiple Myeloma Patients\",\"The primary endpoint was complete response (CR) and near complete response rate (nCR) post induction therapy (i.e. 4 cycles of therapy). Each cycle consisted of 21 days.\",,\"The secondary endpoints included time to best response, assessment of peripheral blood stem cells harvesting ( 3 weeks post cycle 4 day 21) and engraftment (within 4 weeks of mobilization), CR post-engraftment, QoL and safety (every cycle).\",\"Completed\",\"Phase 2\"\n",
      "898,\"Randomized Trial of G-CSF Alone Versus Intermediate-dose Ara-C Plus G-CSF Mobilization in Multiple Myeloma Patients.\",\"The proportion of patients with stem cell yield at least 5 × 10^6 CD34+ cells/kg in each treatment arm.\",\"After up to three leukaphereses (7-20 days after starting mobilization regimen).\",\"Peak level of CD34+ cells in peripheral blood (/μl).|Total number of harvested CD34+cells/kg.|Number of leukaphereses needed to harvest target amount of stem cells.|The proportion of hematologic and non-hematologic complications.|Duration of neutropenia < 0.5 x10^9/L and thrombocytopenia <50 x10^9/L.|Number of blood transfusions needed and number of days of antibiotics therapy.|Duration of hospital stay.|Time of neutrophil and platelet engraftment after autologous stem cel transplantation.\",\"Completed\",\"Phase 3\"\n",
      "899,\"PD-L1 Peptide Vaccination in High Risk Smoldering Multiple Myeloma\",\"Overall response rate\",\"Planned analysis cut-off per patient: two weeks after last vaccination.\",\"Immunogenicity of the PD-L1 vaccine|Incidence of Treatment Emergent Adverse Events|Progression-free survival (PFS)|Time to progression (TTP)|Overall survival (OS)\",\"Terminated\",\"Phase 2\"\n",
      "900,\"LCI-HEM-MYE-CRD-004 (MMRC-073 CARJAK): Study of CRD for Carfilzomib-Refractory Multiple Myeloma\",\"4-Month Progression Free Survival|Dose Limiting Toxicity (DLT)\",\"4 months|28 days\",\"Objective Response Rate (ORR)|Clinical Benefit Rate|Disease Control Rate|Progression-free survival (PFS)|Time to Best Response|Overall Survival|Time to Progression|Duration of Response\",\"Active, not recruiting\",\"Phase 1|Phase 2\"\n",
      "901,\"Randomized Phase II Study in Elderly Patients With Newly Diagnosed Multiple Myeloma\",\"3-Year Progression-free survival (PFS)\",\"3-years after randomization\",\"Assessment of response\",\"Active, not recruiting\",\"Phase 2\"\n",
      "902,\"Velcade Combined With High-Dose Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma\",\"Complete remission after 4 cycles:|disappearance of serum and/or urine M-component (confirmed by immunofixation)|< 5% plasma cells in the bone marrow resolution of all extra-osseous plasmacytomas|no evidence of bone progression\",,,\"Terminated\",\"Phase 2\"\n",
      "903,\"A Study to Evaluate CC-92480, Bortezomib and Dexamethasone (480Vd) Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM)\",\"Progression-free Survival (PFS)\",\"From date of randomization to date of disease progression or death due to any cause (Up to approximately 5 years)\",\"Recommended CC- 92480 dose|Plasma concentrations of CC-92480|Overall Survival (OS)|Overall Response Rate (ORR)|Percentage of participants with Complete Response Rate (CRR) or better as assessed by the International Myeloma Working Group (IMWG) Uniform Response Criteria for Multiple Myeloma|Percentage of participants with Very Good Partial Response Rate (VGPRR) or better as assessed by the IMWG Uniform Response Criteria for Multiple Myeloma|Time to Response (TTR)|Duration of Response (DOR)|Time to Progression (TTP)|Time to Next Treatment (TTNT)|Progression-free Survival 2 (PFS-2)|Minimal Residual Disease (MRD) negativity rate|Number of participants with Adverse Events (AEs)|Change from baseline in European Organization for Research and Treatment of Cancer - Quality of Life C30 questionnaire (EORTC QLQ-C30) scores|Change from baseline in European Organization for Research and Treatment of Cancer - Quality of Life Multiple Myeloma Module (EORTC QLQ-MY20) score\",\"Recruiting\",\"Phase 3\"\n",
      "904,\"Pilot Study of an Oral Chemotherapy Teaching Tool to Improve Adherence in Patients With Multiple Myeloma\",\"Personal Patient Preference Towards Using the MOATT Intervention assessed by a 5 point Likert scale.\",\"18 months from study recruitment date.\",\"Objective adherence rate of medication assessed by number of cap openings.|Self Reported Adherence Rate assessed by Brief Adherence Rating Scale (BARS).|Toxicities of Oral Myeloma Treatment assessed by the Patient Reported Outcomes Common Terminology Criteria for Adverse Events (PRO-CTCAE tool).\",\"Unknown status\",\"Not Applicable\"\n",
      "905,\"An Efficacy and Safety Study of Daratumumab in Patients With Multiple Myeloma Who Have Received at Least 3 Prior Lines of Therapy (Including a Proteasome Inhibitor [PI] and Immunomodulatory Drug [IMiD]) or Are Double Refractory to a PI and an IMiD\",\"Percentage of Participants With Overall Response\",\"Up to 14.4 Months\",\"Duration of Response|Overall Survival|Percentage of Participants With Clinical Benefit|Time to Response|Progression Free Survival|Time to Disease Progression\",\"Completed\",\"Phase 2\"\n",
      "906,\"Arsenic Trioxide and Ascorbic Acid Combined With Bortezomib, Thalidomide, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma or Plasma Cell Leukemia\",\"To determine if arsenic trioxide and ascorbic acid at doses up to 0.25 mg/mg/dose can be given in combination with reduced-dose dexamethasone, bortezomib and thalidomide without dose limiting toxicity, especially sensory neuropathies.\",\"Days 1, 4, 8 & 11 of each 21 day cycle\",\"Estimate the Overall Response Rate (ORR), Complete Response Rate (CRR), and Response Duration (RD) in patients treated with the Maximally Tolerated Dose (MTD) of this regimen.|Determine if addition of Arsenic Trioxide[AT]/Ascorbic Acid (Vit C)[AA] starting in cycle 2 of treatment increases NF-kappa-B [NFKB] inhibition in cycles 2 and 3 compared to cycle 1.\",\"Completed\",\"Phase 1\"\n",
      "907,\"Allo Transplant Followed by Lenalidomide and Sirolimus Maintenance in High-Risk Multiple Myeloma (MM)\",\"Phase I: Number of Participants With Dose Limiting Toxicity|Phase II: Percent of Patients Alive and Free of Progression at 12 Months Following Transplant\",\"28 days|Transplant (Day 0) through 1 year post-transplant\",\"Phase II - Percent of Patients With Acute Graft Versus Host Disease (GvHD)|Phase II - Percent of Patients With Chronic Graft Versus Host Disease (GvHD)|Phase II - Percent of Patients With Treatment-related Deaths at 100 Days|Phase II - Percent of Patients With Treatment-related Deaths at 1 Year|Phase II - Time to Neutrophil Engraftment|Phase II - Time to Platelet Engraftment\",\"Terminated\",\"Phase 1|Phase 2\"\n",
      "908,\"Phase 2 Multi-center Study of Anti-PD-1 During Lymphopenic State After HDT/ASCT for Multiple Myeloma\",\"The Number of Patients That Achieve Complete Response\",\"180 days post-transplant\",\"The Estimated Percentage of Patients Alive Without Relapse or Progression at 2 Years|The Estimated Percentage of Patients Alive at 2 Years\",\"Completed\",\"Phase 2\"\n",
      "909,\"Safety Study of LBH589 When Given in Combination With Lenalidomide and Dexamethasone in Adult Patients With Multiple Myeloma.\",\"To determine the highest and safest dose of LBH589 when it is administered in combination with lenalidomide & dexamethasone\",\"24 weeks\",\"Safety and tolerability assessed by monitoring of adverse events, serious adverse events and laboratory parameters To characterize the pharmacokinetic profile of the study treatment To characterize the pharmacodynamic profile of the study treatment\",\"Completed\",\"Phase 1\"\n",
      "910,\"Study Comparing STR (Skeletal Targeted Radiotherapy) Plus Melphalan to Melphalan Alone, With Stem Cell Transplant in Multiple Myeloma\",,,,\"Terminated\",\"Phase 3\"\n",
      "911,\"A Study to Compare CNTO 328 (Anti-IL-6 Monoclonal Antibody) and VELCADE-Melphalan-Prednisone (VMP) With VMP Alone in Previously Untreated Multiple Myeloma Patients\",\"Percentage of Participants Who Achieved Complete Response (CR) - European Group for Blood and Marrow Transplantation (EBMT) Criteria\",\"Up to disease progression, approximately 3 years\",\"Percentage of Participants Who Achieved Overall Response ie, Complete Response (CR) or Partial Response (PR) - European Group for Blood and Marrow Transplantation (EBMT) Criteria|Percentage of Participants Who Achieved Stringent Complete Response (sCR) - International Myeloma Working Group (IMWG) Criteria|Progression-Free Survival (PFS)|1-year Progression-Free Survival (PFS) Rate|Duration of Response (DOR)|1-year Survival Rate|Overall Survival|Change From Baseline to Cycle 9 in Global Health Status/Quality of Life Subscale of the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ C30)\",\"Completed\",\"Phase 2\"\n",
      "912,\"Study of Bendamustine, Velcade and Dexamethasone in the Treatment of Elderly Patients With Multiple Myeloma\",\"To assess of the overall response rate (complete response (CR) + partial response (PR))\",\"After four 28-day consecutives cycles\",\"Time to best response|Progression-free survival|Time to progression|Overall survival|Rate of additional response|Toxicity/Adverse events\",\"Completed\",\"Phase 2\"\n",
      "913,\"Study of SGN-40, Lenalidomide, and Dexamethasone in Patients With Multiple Myeloma\",\"Adverse events and lab abnormalities.\",\"Within 3 weeks of final infusion of SGN-40\",\"Best clinical response, progression-free survival, and overall survival.|PK profile.|Anti-drug antibody immune responses.\",\"Completed\",\"Phase 1\"\n",
      "914,\"Quality of Life in Patients With Multiple Myeloma\",,,,\"Completed\",\n",
      "915,\"Multiparametric Imaging in Multiple Myeloma\",\"Quantitative measure of C11 Methionine uptake\",\"12 months\",,\"Completed\",\"Phase 1\"\n",
      "916,\"Linvolseltamab (Anti-BCMA x Anti-CD3 Bispecific Antibody) Plus Other Cancer Treatments for Participants With Relapsed/Refractory Multiple Myeloma (LINKER-MM2)\",\"Incidence of pre-defined safety criteria or dose-limiting toxicities (DLTs) from the first dose through the end of the DLT observation period|Incidence of treatment-emergent adverse events (TEAEs)|Severity of TEAEs|Incidence of serious adverse events (SAEs)|Severity of SAEs|Incidence of adverse events of special interest (AESIs)|Severity of AESIs|Incidence of laboratory abnormalities\",\"Up to 28 Days|Up to 5 Years|Up to 5 Years|Up to 5 Years|Up to 5 Years|Up to 5 Years|Up to 5 Years|Up to 5 Years\",\"Objective response rate (ORR) as measured by International Myeloma Working Group (IMWG) criteria|Duration of response (DOR) by IMWG criteria|Progression-free survival (PFS) as measured by IMWG criteria|Rate of minimal residual disease (MRD) negative status by IMWG criteria|Concentrations of total REGN5458 in serum over time|Incidence over time of anti-drug antibodies (ADAs) to REGN5458|Overall Survival (OS)\",\"Recruiting\",\"Phase 1\"\n",
      "917,\"Allogeneic Myeloma GM-CSF Vaccine With Lenalidomide in Multiple Myeloma Patients in Complete or Near Complete Remission\",\"2-year progression free survival\",\"2 years\",\"Response Conversion Rate|MRD Conversion Rate|Time to Response|Progression Free Survival (PFS)|Evaluate toxicity of allogenic myeloma vaccine|Measure tumor specific immunity and correlate with systemic immunity\",\"Active, not recruiting\",\"Phase 2\"\n",
      "918,\"A Safety Study of SEA-BCMA in Patients With Multiple Myeloma\",\"Incidence of adverse events (AEs)|Number of participants with laboratory abnormalities by grade|Incidence of dose-limiting toxicities (DLTs)\",\"Through 30-37 days following last dose, up to approximately 3 years|Through 30-37 days following last dose, up to approximately 3 years|Through up to 28 days following first dose\",\"Pharmacokinetic (PK) outcome: Cmax (maximum serum concentration)|PK outcome: AUC (area under the serum concentration-time curve)|Incidence of SEA-BCMA antitherapeutic antibodies (ATA)|Best response per the IMWG uniform response criteria|Objective response rate (ORR)|Duration of objective response (OR)|Duration of complete response (CR)|Progression-free survival (PFS)|Overall survival (OS)\",\"Active, not recruiting\",\"Phase 1\"\n",
      "919,\"Assessing the Impact of a Financial Navigation Program for Patients With Multiple Myeloma\",\"COmprehensive Score for Financial Toxicity (COST)\",\"4 months\",\"Functional Assessment of Cancer Therapy (FACT-G)|Patient Satisfaction Questionnaire Short-Form [PSQ-18]\",\"Active, not recruiting\",\"Not Applicable\"\n",
      "920,\"Comparison of Pomalidomide and Dexamethasone With or Without Daratumumab in Subjects With Relapsed or Refractory Multiple Myeloma Previously Treated With Lenalidomide and a Proteasome InhibitorDaratumumab/Pomalidomide/Dexamethasone vs Pomalidomide/Dexamethasone\",\"Comparison of Progression Free Survival Between Treatment Arms\",\"Assessed monthly from randomization until disease progression (PD) or death whichever occurs first (approximately up to 3 years)]\",\"Overall Response Rate|Depth of Response|Duration of Response|Time to Next Therapy|Overall Survival|Health-related Quality of Life-Time to Worsening in EORTC QLQ-C30 Scale Scores|Health-related Quality of Life-Time to Worsening in EQ-5D-5L Utility Score|Health-related Quality of Life-Time to Worsening in EQ-5D-5L Visual Analogue Scale\",\"Active, not recruiting\",\"Phase 3\"\n",
      "921,\"S0115, High-Dose Melphalan and Autologous Peripheral Stem Cell Transplantation in Treating Patients With Multiple Myeloma or Primary Systemic Amyloidosis\",\"Overall Survival\",\"5 years from initial registration, or until death, whichever occurred earlier, on average, about 4.5 years\",\"Hematologic Response\",\"Completed\",\"Phase 2\"\n",
      "922,\"Dose-Reduced Allogeneic Stem Cell Transplantation After Autologous High-Dose Chemotherapy in Patients With Multiple Myeloma\",\"Safety and efficacy of a conditioning regimen with Fludarabine, Melphalan and ATG prior allogeneic SCT after high dose chemotheraoie and autologous SCT. Evaluation of underlying disease and donor-recipient-chimerism.\",,\"Evaluation of engraftment of leucocytes and platelets|Evaluation of incidence of acute and chronic GvHD|Evaluation of infectious complications|Evaluation of the effects of DLI in case of no CR|Evaluation of disease-free and overall survival\",\"Completed\",\"Phase 2\"\n",
      "923,\"SL-401 in Combination With Pomalidomide and Dexamethasone in Relapsed or Relapsed and Refractory Multiple Myeloma\",\"The percentage of patients with treatment-related and treatment-emergent adverse events\",\"Up to 12 months\",\"SL-401 plasma concentration at multiple time points|SL-401 maximum plasma concentration|Overall response rate|Progression free survival\",\"Terminated\",\"Phase 1|Phase 2\"\n",
      "924,\"Phase I: Melphalan, Bendamustine and Carfilzomib for Autologous Transplant in Multiple Myeloma\",\"Dose Limiting Toxicity\",\"Assessed daily (while inpatient) through clinical and laboratory examinations up to 90 days.\",\"Engraftment\",\"Completed\",\"Phase 1\"\n",
      "925,\"Safety Study of a Chemokine Receptor (CXCR4) Antagonist in Multiple Myeloma Patients\",\"White blood cell (WBC) count\",\"24 hour\",\"CD34+ cells\",\"Completed\",\"Phase 1|Phase 2\"\n",
      "926,\"A Study to Evaluate Dara-CyBorD in Previously Untreated and Relapsed Subjects With Multiple Myeloma\",\"Percentage of Participants Who Achieved Complete Response (CR) or Very Good Partial Response (VGPR)\",\"After 4 cycles of Induction (Approximately 4 months)\",\"Overall Response Rate (ORR)|Time to Very Good Partial Response (VGPR) or Better|Time to Partial Response (PR) or Better|Duration of Response (DOR)|Progression Free Survival (PFS)|Time to Disease Progression (TTP)|Overall Survival (OS)|Percentage of Participants With Treatment Emergent-Adverse Event\",\"Completed\",\"Phase 2\"\n",
      "927,\"Phase I Study for Safety and Efficacy of P276-00 in Subjects With Myeloma\",\"maximum tolerated dose (MTD) in subjects with relapsed and relapsed/refractory Multiple Myeloma (MM)\",\"1year\",\"clinical response of P276-00 in subjects with relapsed and relapsed/refractory MM 2. Exploratory pharmacogenomic analysis of serum and molecular markers associated with P276-00 use in the study population\",\"Withdrawn\",\"Phase 1\"\n",
      "928,\"\"\"Monoclonal Antibodies for Treatment of Multiple Myeloma. Emphasis on the CD38 Antibody Daratumumab \"\"\",\"Response by IMWG criteria\",\"4 weeks\",\"T cell subset numbers\",\"Completed\",\"Phase 2|Phase 3\"\n",
      "929,\"A Study of Combination of Daratumumab and Velcade (Bortezomib) Melphalan-Prednisone (DVMP) Compared to Velcade Melphalan-Prednisone (VMP) in Participants With Previously Untreated Multiple Myeloma\",\"Progression Free Survival (PFS)\",\"From randomization to either disease progression or death whichever occurs first (up to 2.4 years)\",\"Overall Response Rate (ORR)|Percentage of Participants With Very Good Partial Response (VGPR) or Better|Percentage of Participants With Complete Response (CR) or Better|Percentage of Participants With Negative Minimal Residual Disease (MRD)|Overall Survival (OS)|Progression Free Survival on Next Line of Therapy (PFS2)|Percentage of Participants With Stringent Complete Response (sCR)|Time to Disease Progression (TTP)|Time to Response|Duration of Response (DOR)|Time to Next Treatment (TNT)|Percentage of Participants With Best M-protein Response|Change From Baseline in European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ)-C30: Emotional Functioning Score|Change From Baseline in EuroQol-5 Dimensions-5 Levels (EQ-5D-5L): Visual Analogue Scale (VAS)|Change From Baseline in EuroQol 5 Dimensions-5 Level (EQ-5D-5L) Utility Score\",\"Active, not recruiting\",\"Phase 3\"\n",
      "930,\"Investigate eNAMPT in Multiple Myeloma Biology and Establish Its Role in Disease Progression\",\"To strengthen preliminary data|Potential marker of PD|Analysis both MM cells and MM-BMSC compartment.|To investigate eNAMPT role|To determine the effects\",\"2 years|2 years|2 years|2 years|2 years\",,\"Recruiting\",\n",
      "931,\"A Study of an MMSET Inhibitor in Patients With Relapsed and Refractory Multiple Myeloma\",\"Incidence of dose-limiting toxicity (DLTs)\",\"Cycle 1 (28 days)\",\"Maximum plasma concentration (Cmax) of KTX-1001|Time to achieve Cmax (tmax) for KTX-1001|Area under the plasma concentration-time curve (AUC) for KTX-1001|Objective response rate (ORR) for KTX-1001|Duration of response (DOR) for KTX-1001|Progression-free survival (PFS) for KTX-1001|Overall survival (OS) for KTX-1001\",\"Recruiting\",\"Phase 1\"\n",
      "932,\"Safety Study of IPI-504 in Patients With Relapsed and Relapsed Refractory Multiple Myeloma\",\"To determine the safety and maximum tolerated dose of IPI-504|Recommend a dose for subsequent studies of IPI-504\",\"Following 1 cycle of treatment|Once MTD is reached\",\"To examine the pharmacokinetic parameters of IPI-504|To evaluate the potential anti-tumor activity with standard markers of disease progression|To examine pharmacodynamic markers of biologic activity of IPI-504\",\"Completed\",\"Phase 1\"\n",
      "933,\"Study of T Cells Targeting CD138/BCMA/CD19/More Antigens (CART-138/BCMA/19/More) for Chemotherapy Refractory and Relapsed Multiple Myeloma\",\"Determine if there is grade 3 to 5 cytokine release syndrome\",\"2 weeks-12 months after initial dose\",\"Investigators try to assess major reaction rate (MRR, PR+VGPR+CR) at the end of the research.\",\"Recruiting\",\"Phase 1|Phase 2\"\n",
      "934,\"A Multicentre, Single-arm, Open-label Safety Study of Lenalidomide Plus Dexamethasone in Previously Treated Subjects With Multiple Myeloma\",\"Overall Incidence of Treatment-emergent Adverse Events (TEAEs), by Severity, Seriousness, and Relationship to Treatment\",\"up to 123 weeks\",\"Participants With Adverse Events of Special Interest: Peripheral Neuropathy|Time to First Peripheral Neuropathy Treatment-Emergent Adverse Event (TEAE)|Participants With Adverse Events of Special Interest: Venous Thromboembolic Events|Time to First Venous Thromboembolic Treatment-Emergent Adverse Event (TEAE)|Change From Baseline to Week 24 in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire for Patients With Cancer (EORTC QLQ-C30) Physical Functioning Scale|Change From Baseline to Week 24 in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire for Patients With Cancer (EORTC QLQ-C30) Role Functioning Scale|Change From Baseline to Week 24 in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire for Patients With Cancer (EORTC QLQ-C30) Emotional Functioning Scale|Change From Baseline to Week 24 in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire for Patients With Cancer (EORTC QLQ-C30) Cognitive Functioning Scale|Change From Baseline to Week 24 in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire for Patients With Cancer (EORTC QLQ-C30) Social Functioning Scale|Change From Baseline to Week 24 in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire for Patients With Cancer (EORTC QLQ-C30) Fatigue Scale|Change From Baseline to Week 24 in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire for Patients With Cancer (EORTC QLQ-C30) Pain Scale|Change From Baseline to Week 24 in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire for Patients With Cancer (EORTC QLQ-C30) Nausea/Vomiting Scale|Change From Baseline to Week 24 in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire for Patients With Cancer (EORTC QLQ-C30) Constipation Scale|Change From Baseline to Week 24 in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire for Patients With Cancer (EORTC QLQ-C30) Diarrhea Scale|Change From Baseline to Week 24 in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire for Patients With Cancer (EORTC QLQ-C30) Insomnia Scale|Change From Baseline to Week 24 in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire for Patients With Cancer (EORTC QLQ-C30) Dyspnoea Scale|Change From Baseline to Week 24 in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire for Patients With Cancer (EORTC QLQ-C30) Appetite Loss Scale|Change From Baseline to Week 24 in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire for Patients With Cancer (EORTC QLQ-C30) Financial Problems Scale|Change From Baseline to Week 24 in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire for Patients With Cancer (EORTC QLQ-C30) Global Quality of Life Scale|Change From Baseline to Week 24 in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire for Patients With Multiple Myeloma (EORTC QLQ-MY20) Disease Symptoms Scale|Change From Baseline to Week 24 in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire for Patients With Multiple Myeloma (EORTC QLQ-MY20) Side Effects Scale|Change From Baseline to Week 24 in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire for Patients With Multiple Myeloma (EORTC QLQ-MY20) Future Perspective Scale|Change From Baseline to Week 24 in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire for Patients With Multiple Myeloma (EORTC QLQ-MY20) Body Image Scale\",\"Completed\",\"Phase 3\"\n",
      "935,\"Paclitaxel,Cyclophosphamide and Dexamethasone for Relapsed or Refractory Multiple Myeloma\",\"Overall Response Rate (ORR)\",\"30 months\",\"Progression Free Survival (PFS)|Overall survival (OS)|Safety of combination therapy assessed using the National Cancer institute-Common Toxicology Criteria (NCI-CTC) grade scale for AEs and Lab assessments\",\"Withdrawn\",\"Phase 2\"\n",
      "936,\"Combination Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Multiple Myeloma\",\"Incidence of mucositis\",\"5 years\",,\"Completed\",\"Phase 1\"\n",
      "937,\"A Study of DKN-01 and Lenalidomide/Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma\",\"Fluorine F18 sodium fluoride positron emission tomography (NaF-PET/CT) standard uptake value (SUV)|Fluorine F18 sodium fluoride positron emission tomography (NaF-PET/CT) influx constant (Ki)|F18 fluorodeoxyglucose positron emission tomography (FDG-PET/CT) standard uptake value (SUV)|Number of patients with treatment emergent adverse events\",\"Pre-study to after 6 months of therapy|Pre-study to after 6 months of therapy|Pre-study to after 6 months of therapy|Baseline to study completion (approximately 7 months)\",\"Overall response rate (ORR)|Progression free survival (PFS)|Duration of response|Overall survival|Pharmacokinetics: area under the concentration - time curve (AUC) of a single dose of DKN-01|Pharmacokinetics: maximum plasma concentration (Cmax) of a single dose of DKN-01|Pharmacokinetics: trough DKN-01 concentrations on Cycle 2 and Cycle 3\",\"Completed\",\"Phase 1\"\n",
      "938,\"Role of the Host Microbiota and Il-17 in Favoring Multiple Myeloma Progression\",\"the role of microbiota and IL17 in MM\",\"5YRS\",,\"Recruiting\",\n",
      "939,\"Bendamustine, Wkly Bortezomib, Lenalidomide and Dexamethasone for Multiple Myeloma\",\"Number of Patients Experiencing a Toxicity\",\"21 days\",,\"Terminated\",\"Phase 1|Phase 2\"\n",
      "940,\"Total Marrow Irradiation & Autologous Stem Cell Transplantation for Relapsed or Refractory Myeloma\",\"To determine the maximum tolerated dose of TMI when followed by aHSCT in patients with relapsed or refractory multiple myeloma\",\"30 days from the time of aSCT\",\"The frequency and timing of engraftment following TMI and aHSCT|The early morbidity and mortality associated with TMI and aHSCT|The intermediate morbidity and mortality associated with TMI and aHSCT|The late morbidity of TMI\",\"Recruiting\",\"Phase 1|Phase 2\"\n",
      "941,\"MLN9708 and Dexamethasone for High-Risk Smoldering Multiple Myeloma\",\"Response rate\",\"3 years\",\"Progression-free survival|Duration of response\",\"Withdrawn\",\"Phase 2\"\n",
      "942,\"Study Evaluating Safety and Efficacy of UCART Targeting CS1 in Patients With Relapsed/Refractory Multiple Myeloma (MELANI-01)\",\"Safety of UCARTCS1A\",\"24 months.\",\"Response Assessment|Duration of Response|Progression Free Survival|Overall Survival\",\"Recruiting\",\"Phase 1\"\n",
      "943,\"Anti-BCMA Chimeric Antigen Receptor T Cells for Relapsed or Refractory Multiple Myeloma\",\"Proportion of participants with treatment-emergent adverse events (AE) (Dose Escalation)|Proportion of participants who experience a dose-limiting toxicity (DLT) (Dose Escalation)|Overall Response Rate (ORR)\",\"From initiation of study treatment (day 1) to 29 days following CAR-T infusion|From initiation of study treatment (day 1) to 29 days following CAR-T infusion|Up to 12 months following CAR- T infusion\",\"Duration of response|Progression-free Survival (PFS)|Overall Survival|Proportion of participants for whom BCMA CAR T-cell therapy is manufactured successfully|Proportion of participants who complete study treatment|Proportion of participants with treatment-emergent adverse events (AE) (Dose Expansion)\",\"Recruiting\",\"Phase 1\"\n",
      "944,\"Bendamustine in Combination With Bortezomib and Pegylated Liposomal Doxorubicin for Multiple Myeloma\",\"Assessing Patient Response to Bendamustine - Phase I by assessing patient adverse events|Overall Response Rate of Treatment Regimen - Phase II by assessing patient response rates\",\"6 months|8 months\",\"Toxicity of Treatment Regimen - Phase I and II by assessing patient adverse events|Evaluation of Survival - Phase II by assessing patient survival times|Bendamustine Pharmacokinetics - Phase II by evaluating patient samples\",\"Terminated\",\"Phase 1|Phase 2\"\n",
      "945,\"Elranatamab Expanded Access Protocol in Adults With Relapsed/Refractory Multiple Myeloma\",,,,\"Available\",\n",
      "946,\"Combination Chemotherapy With or Without Cyclophosphamide and Prednisone in Treating Older Patients With Multiple Myeloma\",,,,\"Unknown status\",\"Phase 3\"\n",
      "947,\"An Open-label, Dose Escalation Study in Japanese Participants With Relapsed/Refractory Multiple Myeloma Who Have Failed Prior Anti Myeloma Treatments\",\"Part 1: Number of participants with dose limiting toxicities (DLTs)|Part 2: Arm A: Number of participants with DLTs|Part 2: Arm B: Number of participants with DLTs|Part 1 and Part 2: Number of participants with adverse events (AEs) and serious adverse events (SAEs)|Part 1 and Part 2: Number of participants with abnormal hematology, clinical chemistry, urinalysis parameters|Part 1 and Part 2: Number of participants with abnormal vital signs|Part 1 and Part 2: Number of participants with abnormal electrocardiogram (ECG) findings|Part 1 and Part 2: Number of participants with abnormal physical examination findings|Part 1 and Part 2: Number of participants with abnormal ocular examination findings|Part 1 and Part 2: Mean Eastern Cooperative Oncology Group (ECOG) scores\",\"Day 1 to 21 of Cycle 1 (each cycle of 21 days)|Day 1 to 21 of Cycle 1 (each cycle of 21 days)|Day 1 to 28 of Cycle 1 (each cycle of 28 days)|Up to approximately 2.2 years|Up to approximately 2.2 years|Up to approximately 2.2 years|Up to approximately 2.2 years|Up to approximately 2.2 years|Up to approximately 2.2 years|Up to approximately 2.2 years\",\"Part 1: Area under the plasma concentration time curve from time 0 to the time of the last quantifiable concentration (AUC [0 to t]) for GSK2857916 following single dose administration|Part 2: Arm A: AUC (0 to t) for GSK2857916 following single dose administration|Part 2: Arm B: AUC (0 to t) for GSK2857916 following single dose administration|Part 1: Area under the plasma concentration-time curve from time 0 to the end of dosing (AUC [0 to tau]) for GSK2857916 following single dose administration|Part 2: Arm A: AUC (0 to tau) for GSK2857916 following single dose administration|Part 2: Arm B: AUC (0 to tau) for GSK2857916 following single dose administration|Part 1: Area under the plasma concentration-time curve from time 0 to infinite time (AUC [0 to inf]) for GSK2857916 following single dose administration|Part 2: Arm A: AUC (0 to inf) for GSK2857916 following single dose administration|Part 2: Arm B: AUC (0 to inf) for GSK2857916 following single dose administration|Part 1: Maximum observed plasma concentration (Cmax) for GSK2857916 following single dose administration|Part 2: Arm A: Cmax for GSK2857916 following single dose administration|Part 2: Arm B: Cmax for GSK2857916 following single dose administration|Part 1: Time to Cmax (Tmax) for GSK2857916 following single dose administration|Part 2: Arm A: Tmax for GSK2857916 following single dose administration|Part 2: Arm B: Tmax for GSK2857916 following single dose administration|Part 1: Systemic clearance (CL) for GSK2857916 following single dose administration|Part 2: Arm A: CL for GSK2857916 following single dose administration|Part 2: Arm B: CL for GSK2857916 following single dose administration|Part 1: Volume of distribution at steady state (Vss) for GSK2857916 following single dose administration|Part 2: Arm A: Vss for GSK2857916 following single dose administration|Part 2: Arm B: Vss for GSK2857916 following single dose administration|Part 1: Terminal phase half-life (T1/2) for GSK2857916 following single dose administration|Part 2: Arm A: T1/2 for GSK2857916 following single dose administration|Part 2: Arm B: T1/2 for GSK2857916 following single dose administration|Part 1: Concentration at the end of infusion of GSK2857916 following repeat dose administration|Part 2: Arm A: Concentration at the end of infusion of GSK2857916 following repeat dose administration|Part 2: Arm B: Concentration at the end of infusion of GSK2857916 following repeat dose administration|Part 1: Trough plasma concentration (Ctrough) for GSK2857916 following repeat dose administration|Part 2: Arm A: Ctrough for GSK2857916 following repeat dose administration|Part 2: Arm B: Ctrough for GSK2857916 following repeat dose administration|Part 1: Observed accumulation ratio for GSK2857916 following repeat dose administration|Part 2: Arm A: Observed accumulation ratio for GSK2857916 following repeat dose administration|Part 2: Arm B: Observed accumulation ratio for GSK2857916 following repeat dose administration|Part 1: AUC (0 to t) for Cysteine maleimidocaproyl monomethyl auristatin F (cys-mcMMAF) following single dose administration|Part 2: Arm A: AUC (0 to t) for cys-mcMMAF following single dose administration|Part 2: Arm B: AUC (0 to t) for cys-mcMMAF following single dose administration|Part 1: AUC (0 to tau) for cys-mcMMAF following single dose administration|Part 2: Arm A: AUC (0 to tau) for cys-mcMMAF following single dose administration|Part 2: Arm B: AUC (0 to tau) for cys-mcMMAF following single dose administration|Part 1: AUC (0 to inf) for cys-mcMMAF following single dose administration|Part 2: Arm A: AUC (0 to inf) for cys-mcMMAF following single dose administration|Part 2: Arm B: AUC (0 to inf) for cys-mcMMAF following single dose administration|Part 1: Cmax for cys-mcMMAF following single dose administration|Part 2: Arm A: Cmax for cys-mcMMAF following single dose administration|Part 2: Arm B: Cmax for cys-mcMMAF following single dose administration|Part 1: Tmax for cys-mcMMAF following single dose administration|Part 2: Arm A: Tmax for cys-mcMMAF following single dose administration|Part 2: Arm B: Tmax for cys-mcMMAF following single dose administration|Part 1: T1/2 for cys-mcMMAF following single dose administration|Part 2: Arm A: T1/2 for cys-mcMMAF following single dose administration|Part 2: Arm B: T1/2 for cys-mcMMAF following single dose administration|Part 1: Concentration at end of infusion for cys-mcMMAF following repeat dose administration|Part 2: Arm A: Concentration at end of infusion for cys-mcMMAF following repeat dose administration|Part 2: Arm B: Concentration at end of infusion for cys-mcMMAF following repeat dose administration|Part 1: Ctrough for cys-mcMMAF following repeat dose administration|Part 2: Arm A: Ctrough for cys-mcMMAF following repeat dose administration|Part 2: Arm B: Ctrough for cys-mcMMAF following repeat dose administration|Part 1: Observed accumulation ratio for cys-mcMMAF following repeat dose administration|Part 2: Arm A: Observed accumulation ratio for cys-mcMMAF following repeat dose administration|Part 2: Arm B: Observed accumulation ratio for cys-mcMMAF following repeat dose administration|Part 1 and Part 2: Number of participants who develop anti-drug antibodies (ADAs) against GSK2857916|Part 1 and Part 2: Titers of anti-GSK2857916 antibodies|Part 1 and Part 2: Overall response rate|Part 1 and Part 2: Clinical benefit rate\",\"Active, not recruiting\",\"Phase 1\"\n",
      "948,\"Study to Evaluate the Safety and Efficacy of KITE-585 in Participants With Relapsed/Refractory Multiple Myeloma\",\"Percentage of Participants Experiencing Dose Limiting Toxicities (DLTs)\",\"From KITE-585 infusion until 28 days after KITE-585 infusion\",\"Objective Response Rate (ORR) as Determined by Study Investigators According to the International Myeloma Working Group (IMWG) Consensus Panel 1 Criteria|Progression Free Survival (PFS) as Determined by Study Investigators According to the IMWG Consensus Panel 1|Overall Survival (OS)|Percentage of Participants Experiencing Treatment-Emergent Adverse Events|Percentage of Participants Experiencing Clinically Significant Laboratory Abnormalities|Duration of Response (DOR) as Determined by Study Investigators According to the IMWG Consensus Panel 1|Time to Next Treatment (TTNT)\",\"Terminated\",\"Phase 1\"\n",
      "949,\"The Myeloma Pack: A Multi-Modality Educational Intervention Strategy to Engage Patients With Multiple Myeloma\",\"Assess baseline anxiety levels in MM patients undergoing therapy using the PROMIS assessment tool for anxiety|Assess anxiety levels 12 weeks after educational program (MPI) in MM patients undergoing therapy using the PROMIS assessment tool for anxiety|Assess anxiety levels 24 weeks after educational program (MPI) in MM patients undergoing therapy using the PROMIS assessment tool for anxiety\",\"Baseline|12 weeks post intervention|24 weeks post intervention\",\"Assess baseline depression levels in MM patients using the PROMIS assessment tool for depression|Assess depression levels 12 weeks after education intervention (MPI) in MM patients using the PROMIS assessment tool for depression|Assess depression levels 24 weeks after education intervention (MPI) in MM patients using the PROMIS assessment tool for depression|Assess baseline patient self-efficacy for symptom management in MM patients using the PROMIS assessment tool for self-Efficacy|Assess patient self-efficacy for symptom management 12 weeks after educational program (MPI) in MM patients using the PROMIS assessment tool for self-Efficacy|Assess patient self-efficacy for symptom management 24 weeks after educational program (MPI) in MM patients using the PROMIS assessment tool for self-Efficacy|Assess baseline patient adherence to myeloma specific medication and treatment schedules in MM patients using the CASE Medication Adherence Index|Assess patient improvement in adherence to myeloma specific medication and treatment schedules 12 weeks after educational program (MPI) in MM patients using the CASE Medication Adherence Index|Assess patient improvement in adherence to myeloma specific medication and treatment schedules 24 weeks after educational program (MPI) in MM patients using the CASE Medication Adherence Index\",\"Active, not recruiting\",\"Not Applicable\"\n",
      "950,\"A Study of CC-98633, BCMA-targeted Chimeric Antigen Receptor (CAR) T Cells, in Participants With Relapsed and/or Refractory Multiple Myeloma\",\"Adverse Events (AEs)\",\"From the time of informed consent and follow up to 2 years after infusion of CC-98633:\",\"Overall Response Rate (ORR)|Complete Response (CR) Rate|Duration of response (DOR)|Time to response (TTR)|Time to complete response (TTCR)|Progression free survival (PFS)|Overall survival (OS)|Pharmacokinetics - maximum serum concentration (Cmax)|Pharmacokinetics -time to peak serum concentration (tmax)|Pharmacokinetics - Area under curve (AUC)|Very good partial response (VGPR) or better\",\"Active, not recruiting\",\"Phase 1\"\n",
      "951,\"Expanded Access Program:Lenalidomide With or Without Dexamethasone In Previously Treated Subjects With Multiple Myeloma\",\"Incidence of Adverse Events Summarized by System Organ Class, Preferred Term, Severity, Seriousness, and Relationship to Treatment.|Overall Incidence of Adverse Events\",\"Median time-on-study=18.3 weeks|Median time-on-study=18.3 weeks\",,\"Completed\",\"Phase 3\"\n",
      "952,\"Study Association of Lenalidomide, Ixazomib, Dexamethasone and Daratumumab in Newly Diagnosed Standard Risk Multiple Myeloma\",\"minimal residual disease-negativity rate\",\"22 months\",\"Adverse events|Response rates|Progression free survival|Overall survival\",\"Recruiting\",\"Phase 2\"\n",
      "953,\"A Study of Cobimetinib Administered as Single Agent and in Combination With Venetoclax, With or Without Atezolizumab, in Participants With Relapsed and Refractory Multiple Myeloma\",\"Percentage of Participants With Adverse Events (AEs)|Percentage of Participants With Overall Response Rate (ORR) as Determined by the Investigator Using International Myeloma Working Group (IMWG) Response Criteria\",\"Randomization up to end of study (up to approximately 3 years, 7 months)|From randomization to the first occurrence of a response as defined above (up to approximately 3 years, 7 months)\",\"Percentage of Participants With Clinical Benefit as Determined by the Investigator Using IMWG Response Criteria|Progression-Free Survival (PFS) as Determined by the Investigator Using IMWG Response Criteria|Duration of Response (DOR) as Determined by the Investigator Using IMWG Response Criteria|Overall Survival (OS)|Area Under the Plasma Concentration Versus Time Curve (AUC) of Cobimetinib|Maximum Observed Plasma Concentration (Cmax) of Cobimetinib|Time to Reach Cmax (Tmax) of Cobimetinib|AUClast of Venetoclax|Cmax of Venetoclax|Tmax of Venetoclax|Percentage of Participants With Anti-Drug Antibody (ADA) to Atezolizumab\",\"Completed\",\"Phase 1|Phase 2\"\n",
      "954,\"MTD, Safety, and Efficacy of Pomalidomide (CC-4047) Alone or With Low-dose Dexamethasone in Patients With Relapsed and Refractory Multiple Myeloma\",\"Phase 1: Participants With Dose-Limiting Toxicities (DLT) in Cycle 1|Phase 2: Kaplan-Meier Estimates of Progression-free Survival (PFS) as of the 01 April 2011 Cut-off|Phase 2: Percentage of Participants With Progression-Free Survival (PFS) Events as of the 01 April 2011 Cut-off\",\"Up to Day 28 (Cycle 1)|up to 67 weeks|up to 67 weeks\",\"Phase 1: Percentage of Participants With Treatment-Emergent Adverse Events (TEAEs) While on Single-Agent Pomalidomide as of the 01 April 2011 Cut-off|Phase 1: Percentage of Participants With Treatment-Emergent Adverse Events (TEAEs) While on Both Pomalidomide and Dexamethasone as of the 01 April 2011 Cut-off|Phase 2: Percentage of Participants With Treatment-Emergent Adverse Events (TEAEs) as of the 01 April 2011 Cut-off|Phase 2: Summary of Best Myeloma Response As Assessed by Independent Response Adjudication Committee (IRAC) Using European Group for Blood and Bone Marrow Transplant (EBMT) Criteria as of the 01 April 2011 Cut-off|Phase 2: Kaplan-Meier Estimates of Duration of Response as of the 01 April 2011 Cut-off|Phase 2: Time to Response as of the 01 April 2011 Cut-off|Phase 2: Kaplan-Meier Estimates of Overall Survival as of the 01 April 2011 Cut-off\",\"Completed\",\"Phase 1|Phase 2\"\n",
      "955,\"Velcade, Thalidomide, Dexamethasone and Panobinostat Treatment and Panobinostat Maintenance in Multiple Myeloma\",\"Dose limiting toxicities (DLTs)|Proportion o f participants achieving at least partial response\",\"From cycle 1 day 1 up to the administration of cycle 2 day 1 (up to 22 days)|within 16 cycles of therapy (an expected average of 48 weeks)\",\"Safety and toxicity|Proportion of patients with each maximum response category|Time to maximum response to therapy|Progression free survival|Compliance to therapy|Feasibility of panobinostat maintenance|Overall survival|The proportion of participants mobilising sufficient stem cells for transplant(out of those undergoing mobilisation)\",\"Unknown status\",\"Phase 1|Phase 2\"\n",
      "956,\"KRDI in Transplant-Eligible MM\",\"Complete Response (CR + stringent CR) rate\",\"112 Days\",\"Overall Response Rate|Minimal residual disease (MRD) Rate|Minimal residual disease (MRD) Rate|Minimal residual disease (MRD) Rate|Minimal residual disease (MRD) Rate|Progression Free Survival|Overall Survival|Number of Participants with Treatment-Related Adverse Events as NCI CTCAE Version 5.0 severity grades.|Complete Response rate (Transplant)|Complete Response rate (Transplant Deferred)|Complete Response rate (All )\",\"Recruiting\",\"Phase 2\"\n",
      "957,\"Global Response Assessment by Advanced Imaging and Myeloma Lesion Biopsies During Induction Therapy of Multiple Myeloma With Carfilzomib Lenalidomide Dexamethasone\",\"Detection rate of residual/refractory\",\"4 months\",\"Myeloma lesion response rate|Overall clinical response rate\",\"Completed\",\"Not Applicable\"\n",
      "958,\"Vaccination With PD-L1 Peptide Against Multiple Myeloma\",\"Incidence of toxicity\",\"12 months\",\"Evaluation of immunological responses\",\"Completed\",\"Phase 1\"\n",
      "959,\"Study of DNA Samples From Patients With Multiple Myeloma\",\"Increased frequency of ≥1 polymorphic alleles associated with clinical endpoints using custom myeloma SNP chip analysis of banked DNA samples from patients with multiple myeloma|SNPs associated with toxicities caused by individual genetic variations affecting drug activation, distribution, metabolism, and export (ADME)|SNPs associated with response|SNPs associated with bone disease|SNPs associated with epidemiology (i.e., risk factors for the development of multiple myeloma)\",\"1 month|1 month|1 month|1 month|1 month\",,\"Completed\",\n",
      "960,\"Multicenter Open Label Phase 2 Study of Isatuximab Plus Pomalidomide and Dexamethasone With Carfilzomib in Relapsed or Refractory Multiple Myeloma\",\"Efficacy of trial treatment\",\"Up to 5 years\",\"Safety of trial treatment|Depth of response to the trial treatment|Progression Free survival\",\"Active, not recruiting\",\"Phase 2\"\n",
      "961,\"Clinical Trial of Clarithromycin, Lenalidomide and Dexamethasone in the Treatment of the First Relapsed Multiple Myeloma\",\"Objective response rate (ORR)\",\"Every 2 months until disease progression or study completion，an average of 2 year\",\"Number of participants with treatment-related adverse events as assessed by NCI-CTCAE v4.03|Progression-Free Survival (PFS)|Overall Survival (OS)|Duration of Response (DOR)\",\"Unknown status\",\"Phase 2\"\n",
      "962,\"A Study of Tanespimycin (KOS-953) in Patients With Relapsed-refractory Multiple Myeloma\",\"Objective Response Rate\",\"approximately 3 months\",\"Response rate between treatment arms and time-to-event endpoints.\",\"Completed\",\"Phase 2|Phase 3\"\n",
      "963,\"Study of XL999 in Patients With Multiple Myeloma\",\"Response rate|Safety and tolerability\",\"Inclusion of subject until disease progression|Inclusion until 30 days post last treatment\",\"Duration of response|Progression-free survival|Overall survival\",\"Terminated\",\"Phase 2\"\n",
      "964,\"A Study of People With Multiple Myeloma (MM) in Portugal (CharisMMa-Portugal)\",\"Number of MM Participants Categorized by Sociodemographic Variables|Number of MM Participants Categorized by Clinical Variables on Diagnosis and During Previous Relapses|Number of MM Participants Categorized by Clinical Variables at Last R/R Episode|Number of Participants Categorized by Current Treatment\",\"Day 1|Day 1|Day 1|Day 1\",\"Number of Participants Categorized by Sociodemographic Characteristics at the Latest Symptomatic R/R Episode per Type of Treatment|Number of MM Participants Categorized by Clinical Variables at Latest Symptomatic R/R Episode per Type of MM|Number of Participants Categorized by Relevant Variables that are not Currently Collected in Clinical Record and Could Influence in the Disease Management at Relapse\",\"Completed\",\n",
      "965,\"Elotuzumab Safety Surveillance In Japanese Patients With Relapse Or Refractory Multiple Myeloma\",\"Incidence of all adverse events(AE) to elotuzumab in real-world practice in Japan|Incidence of immune-related (IR) adverse events to elotuzumab in real-world practice in Japan|Number of patients who achieve a Stringent complete response (sCR) as measured by International Myeloma Working Group (IMWG) criteria|Number of patients who achieve a Complete response (CR) as measured by International Myeloma Working Group (IMWG) criteria|Number of patients who achieve a Very good partial response (VGPR) as measured by International Myeloma Working Group (IMWG) criteria|Number of patients who achieve a Partial response (PR) as measured by International Myeloma Working Group (IMWG) criteria|Number of patients who achieve a Progressive Disease (PD) as measured by International Myeloma Working Group (IMWG) criteria|Number of patients who achieve a Relapse from complete response as measured by International Myeloma Working Group (IMWG) criteria\",\"Up to 72 weeks|Up to 72 weeks|Up to 72 weeks|Up to 72 weeks|Up to 72 weeks|Up to 72 weeks|Up to 72 weeks|Up to 72 weeks\",,\"Completed\",\n",
      "966,\"TCD Followed by autoSCT for Newly Diagnosed MM Patients\",\"Response rate of TCD induction Therapy\",,\"Progression free survival and Overall survival of TCD, followed by high dose chemotherapy and autoPBSCT and TD maintenance|To evaluate toxicities of TCD, followed by high dose chemotherapy and autoPBSCT and TD maintenance.\",\"Unknown status\",\"Phase 2\"\n",
      "967,\"Study of Single Agent Belantamab Mafodotin Versus Pomalidomide Plus Low-dose Dexamethasone (Pom/Dex) in Participants With Relapsed/Refractory Multiple Myeloma (RRMM)\",\"Progression-free survival (PFS)\",\"Up to 25 months\",\"Overall survival (OS)|Overall response rate (ORR)|Clinical benefit rate (CBR)|Duration of response (DoR)|Time to response (TTR)|Time to progression (TTP)|Number of participants with adverse events (AEs)|Change from Baseline in hematology parameters: absolute white blood cell count (WBC), basophils,eosinophils, lymphocytes, monocytes, platelet count, and neutrophils (Giga cells per liter)|Change from Baseline in hematology parameters: Red Blood Cell (RBC) count and reticulocyte count (Trillion cells per liter)|Change from Baseline in hematology parameters: Mean Corpuscular Hemoglobin concentration (MCHC) and hemoglobin (Grams per Liter)|Change from Baseline in hematology parameters: Hematocrit (Proportion of red blood cells in blood)|Change from Baseline in hematology parameters: Mean Corpuscular Volume (MCV) [Femtoliter]|Change from Baseline in hematology parameters: Mean Corpuscular Hemoglobin (MCH) [Picograms]|Change from Baseline in clinical chemistry parameters: Alanine Amino Transferase (ALT), Alkaline Phosphatase (ALP), Aspartate Amino Transferase (AST), Creatine kinase (CK), Gamma Glutamyl Transferase (GGT), and lactate dehydrogenase (LDH)|Change from Baseline in clinical chemistry parameters: Calcium, chloride, glucose, potassium, sodium, magnesium, blood urea nitrogen (BUN), and phosphorous (Millimoles per Liter)|Change from Baseline in clinical chemistry parameters: Creatinine, direct bilirubin, total bilirubin, uric acid (Micromoles per liter)|Change from Baseline in clinical chemistry parameters: Albumin and total protein (Grams per Liter)|Change from Baseline in Urinalysis Parameter: Specific Gravity (Ratio)|Change from Baseline in Urinalysis Parameters- Urine potential of hydrogen (pH) (Points on a scale)|Change from Baseline in urinalysis parameter: Glucose (Millimole per liter)|Change from Baseline in urinalysis parameter: Protein (Grams per liter)|Change from Baseline in urinalysis parameter: Ketones (Millimoles per liter)|Change from Baseline in urinalysis parameter: blood (10^9 cells per liter)|Change from Baseline in urinalysis parameter: creatinine/albumin ratio (ratio)|Number of participants with abnormal ocular findings|Plasma concentrations of belantamab mafodotin|Plasma concentrations of total monoclonal antibody (mAb)|Plasma concentrations of cys-mc Microtubular inhibitor monomethyl auristatin-F (MMAF)|Number of participants with Anti-drug antibody (ADAs) against belantamab mafodotin|Titer of ADAs against belantamab mafodotin|Number of participants with symptomatic adverse effects measured by Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE)|Number of participants with symptomatic adverse effects measured by Ocular Surface Disease Index (OSDI)|European Organization for Research and Treatment of Cancer Quality of Life Questionnaire 30-item Core module (EORTC QLQC30) score|European Organization for Research and Treatment of Cancer IL52 (EORTC IL52) score|EORTC Quality of Life Questionnaire 20-item Multiple Myeloma module (QLQMY20) Score|Rate of Minimal Residual Disease (MRD)\",\"Active, not recruiting\",\"Phase 3\"\n",
      "968,\"Velcade (Bortezomib), Adriamycin Dexamethasone (PAD) or Vincristine Adriamycin Dexamethasone in Second Line Treatment of Multiple Myeloma\",\"Best Confirmed Disease Response|Best Reported Disease Response\",\"every 28 days during treatment period for up to 6 to 8 cycles|every 28 days during treatment period for up to 6 to 8 cycles\",\"Duration of Response (DOR)\",\"Terminated\",\"Phase 2\"\n",
      "969,\"Stem Cell Translpantation in Multiple Myeloma\",\"Progression free survival\",\"5 years\",\"Transplant related mortality|Complete hematological and molecular remission rate|Relapse rate|Survival\",\"Completed\",\"Phase 2\"\n",
      "970,\"Study With Elranatamab Versus Lenalidomide in Patients With Newly Diagnosed Multiple Myeloma After Transplant\",\"Progression Free Survival\",\"Assessed for up to approximately 5 years\",\"Overall Survival|Minimal Residual Disease negativity rate|Sustained MRD negativity rate|Progression Free Survival|Overall minimal residual disease negativity rate|Duration of minimal residual disease negativity|Sustained minimal residual disease negativity rate|Complete response rate|Duration of complete response|Frequency of adverse events|Frequency of laboratory abnormalities|Pre-dose concentrations of elranatamab|Post-dose concentrations of elranatamab|Incidence and titers of Anti-Drug Antibody and Neutralizing Antibody against elranatamab|Health-related quality of life by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire - Core 30|Health-related quality of life by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire - Myeloma 20|Progression Free Survival 2\",\"Recruiting\",\"Phase 3\"\n",
      "971,\"Comparing Treatments for Multiple Myeloma\",,,,\"Completed\",\"Phase 2\"\n",
      "972,\"Prevalence of Asymptomatic Thrombosis in Multiple Myeloma\",\"Analysis of the occurrence of venous thromboembolic events via transverse Doppler echo\",\"1 day\",,\"Withdrawn\",\"Not Applicable\"\n",
      "973,\"Phase 3 Study of Carfilzomib, Melphalan, Prednisone vs Bortezomib, Melphalan, Prednisone in Newly Diagnosed Multiple Myeloma\",\"Progression-Free Survival (PFS)\",\"From randomization until the data cut-off date of 15 July 2016; median follow-up time for PFS was 21.6.and 22.2 months in the bortezomib and carfilzomib arms respectively.\",\"Overall Survival (OS)|Overall Response Rate|Complete Response Rate|Percentage of Participants With ≥ Grade 2 Peripheral Neuropathy|European Organisation for Research and Treatment of Cancer Quality of Life Core Module (EORTC QLQ-C30) Global Health Status/Quality of Life (QOL) Scores|Number of Participants With Adverse Events\",\"Completed\",\"Phase 3\"\n",
      "974,\"A Study to Evaluate Subcutaneous Daratumumab in Combination With Standard Multiple Myeloma Treatment Regimens\",\"D-VMP, D-Rd, and D-Kd Cohorts: Overall Response Rate (ORR)|D-VRd Cohort: Percentage of Participants With Very Good Partial Response (VGPR) or Better Response\",\"Up to 2 years 3 months|Up to 2 years and 3 months\",\"Maximum Observed Serum Concentration (Cmax) of Daratumumab|Percentage of Participants With Infusion-Related Reactions (IRRs)|D-VMP, D-Rd, and D-Kd Cohorts: Percentage of Participants With VGPR or Better Response|D-VRd Cohort: Overall Response Rate (ORR)|Percentage of Participants With CR or Better Response|D-VMP, D-Rd and D-Kd Cohorts: Duration of Response (DOR)|Percentage of Participants With Anti-Daratumumab Antibodies|Percentage of Participants With Anti-rHuPH20 Antibodies|D-VMP, D-Rd, and D-Kd Cohorts: Percentage of Participants With Minimal Residual Disease (MRD) Negative Rate\",\"Active, not recruiting\",\"Phase 2\"\n",
      "975,\"Pomalidomide, Dexamethasone and Pegylated Liposomal Doxorubicin for Relapsed/Refractory Multiple Myeloma\",\"MTD of Pomalidomide|Overall Response Rate\",\"12 months|24 months\",\"Number of Patients with Adverse Events|Time to Progression|Progression-free Survival|Time to First Response|Duration of Response|Overall Survival\",\"Unknown status\",\"Phase 1|Phase 2\"\n",
      "976,\"A Window of Opportunity Trial to Learn if Linvoseltamab is Safe and Well Tolerated, and How Well it Works in Participants With Recently Diagnosed Multiple Myeloma Who Have Not Already Received Treatment.\",\"Incidence of dose-limiting toxicities (DLTs)|Incidence of treatment-emergent adverse events (TEAEs)|Severity of treatment-emergent adverse events (TEAEs)|Incidence of adverse events of special interest (AESIs)|Severity of adverse events of special interest (AESIs)|Proportion of participants with a very good partial response (VGPR) or better using the International Myeloma Working Group (IMWG) response criteria|Proportion of participants achieving Minimal Residual Disease (MRD) negative status (at 10^-5) after induction with consolidation therapy|Proportion of participants achieving MRD-negative status (at 10^-5) after induction without consolidation therapy|Proportion of participants achieving MRD-negative status as their best response after treatment period I with continuing to treatment period II|Proportion of participants achieving MRD-negative status as their best response after treatment period I without continuing to treatment period II\",\"End of the Observation period; up to day 28|Post-Last Linvoseltamab Dose, up to 90 days|Post-Last Linvoseltamab Dose, up to 90 days|Post-Last Linvoseltamab Dose, up to 90 days|Post-Last Linvoseltamab Dose, up to 90 days|Up to 5 years|Up to 5 years|Up to 5 years|Up to 5 years|Up to 5 years\",\"Concentrations of Linvoseltamab in serum|Concentrations of total soluble B-cell maturation antigen (BCMA)|Incidence of anti-drug antibodies (ADAs) to Linvoseltamab|Titer of ADAs to Linvoseltamab|Objective response rate (ORR) measured using the IMWG criteria|Duration of Response (DOR) measured using the IMWG criteria|Progression-free survival (PFS) measured using the IMWG criteria|Proportion of participants achieving MRD-negative status (at 10^-5) in participants with NDMM measured using the IMWG criteria|Incidence of treatment-emergent adverse events (TEAEs)|Severity of TEAEs|Incidence of adverse events of special interest (AESIs)|Severity of AESIs|ORR of participants deemed transplant-eligible and transplant-ineligible by the treating physician|MRD-negative status of participants deemed transplant-eligible and transplant-ineligible by the treating physician|DOR of participants deemed transplant-eligible and transplant-ineligible by the treating physician|PFS of participants deemed transplant-eligible and transplant-ineligible by the treating physician|Overall Survival (OS) of participants deemed transplant-eligible and transplant-ineligible by the treating physician|Time to response (TTR) as measured using the IMWG criteria|ORR by risk levels|MRD-negative rstatus by risk levels|DOR by risk levels|TTR by risk levels|PFS by risk levels|Incidence of MRD-negative status|Cluster of differentiation 34+ (CD34+) stem cell yield|Time to neutrophil engraftment|Time to platelet engraftment|PFS after ASCT followed by 3 cycles of linvoseltamab\",\"Not yet recruiting\",\"Phase 1|Phase 2\"\n",
      "977,\"Vorinostat, Bortezomib and Dexamethasone in Multiple Myeloma (MUKFour)\",\"Overall response rate to vorinostat, bortezomib and dexamethasone.\",\"up to 24 weeks\",\"Number of dose reductions during treatment with vorinostat, bortezomib and dexamethasone.|Overall numbers and rates of adverse events|Progression free survival|Maximum response to treatment|Time to maximum response\",\"Completed\",\"Phase 2\"\n",
      "978,\"Bortezomib and Dexamethasone as Treatment and Maintenance for Multiple Myeloma Relapse\",\"Overall Response Rate, defined as the best response on treatment assessed using the EBMT criteria\",\"2 years\",\"Time To Progression, defined as the time from commencement of treatment to the date of first evidence of progressive disease.|Overall survival, defined as the time from commencement of treatment to the date of death from any cause.\",\"Completed\",\"Phase 2\"\n",
      "979,\"Efficacy and Safety Study of Pembrolizumab (MK-3475) in Combination With Daratumumab in Participants With Relapsed Refractory Multiple Myeloma (MK-3475-668/KEYNOTE-668)\",\"Objective Response Rate (ORR)\",\"Up to approximately 2 years\",\"Disease Control Rate (DCR)|Duration of Response (DOR)|Adverse Events (AEs)|Study Treatment Discontinuations Due to AEs\",\"Withdrawn\",\"Phase 2\"\n",
      "980,\"Patients With Newly Diagnosed Multiple Myeloma Comparing KTd vs. KRd Induction Therapy and Investigating a K-mono Maintenance Strategy\",\"Response Rates\",\"36 weeks after start of induction treatment (9 cycles, each cycle is 28 days)\",\"Feasibility of a carfilzomib monotherapy maintenance|Safety (adverse events) of a carfilzomib monotherapy maintenance|Overall response rate (efficacy) of a carfilzomib monotherapy maintenance|Response|Overall survival (OS)|Progression free survival (PFS)|Safety and tolerability (adverse events) of induction and maintenance treatment|Changes in quality of life (QoL)|Changes in quality of life (QoL) using multiple myeloma specific questionnaire|Changes of general health status\",\"Active, not recruiting\",\"Phase 2\"\n",
      "981,\"A Study of JNJ-54767414 (HuMax CD38) (Anti-CD38 Monoclonal Antibody) in Combination With Backbone Treatments for the Treatment of Patients With Multiple Myeloma\",\"Number of participants affected by adverse events by MedDRA system organ class (SOC) and Preferred term (PT)|Number of participants affected by dose-limiting toxicities\",\"Up to 30 days after the last dose of study medication|Up to 30 days after the last dose of study medication\",\"Maximum observed concentration of daratumumab|Number of participants with generation of antibodies to daratumumab|Complete response rate|Overall response rate|Duration of response\",\"Active, not recruiting\",\"Phase 1\"\n",
      "982,\"A Study of Tabalumab (LY2127399) in Participants With Previously Treated Multiple Myeloma (MM)\",\"Progression Free Survival (PFS)\",\"Baseline up to Objective Disease Progression or Death From Any Cause (assessed up to 9 months)\",\"Overall Survival|Time to First Skeletal-Related Event (SRE)|Number of Participants With >30% Reduction in Brief Pain Inventory (BPI) - Worst Pain Score|Time to Progression (TTP)|Duration of Response (DoR)|Time to Next Treatment (TNT)|Pharmacokinetics (PK): Maximum Concentration (Cmax) of Tabalumab|PK: Time to Maximum Plasma Concentration (Tmax) of Tabalumab|PK: Area Under the Curve Over the Dosing Interval (AUC-T) for Tabalumab|Number of Participants Developing Anti-tabalumab Antibodies|Participants With Best Overall Response (BOR) in Each Category|Number of Participants With a Given Best Objective Myeloma Response (Quality of Response [QoR])|Overall Response Rate (ORR)\",\"Completed\",\"Phase 2\"\n",
      "983,\"Phase Ib Study of SAR650984 in Combination With Carfilzomib for Treatment of Relapsed or Refractory Multiple Myeloma\",\"ARM I: Incidence of Dose-Limiting Toxicities (DLT)|ARM I: Maximum tolerated dose (MTD) of isatuximab|ARM II: Overall Response Rate (ORR)\",\"Up to 60 days of the last dose of study drug|At the end of Cycle 1 (each cycle is 28 days)|Up to 60 days of the last dose of study drug\",\"ARM I: Pharmacokinetic (PK) profile of isatuximab|ARM I: Overall Response Rate (ORR)|ARM I: Clinical benefit response (CBR)|ARM I: Incidence of isatuximab-specific antidrug antibodies (ADA)|ARM I: Percentage of bone marrow cells expressing cell surface determinant, CD38 and receptor density|Overall survival (OS)|Progression Free Survival (PFS)|Time To Progression (TTP)|Duration of Response (DOR)|Changes in pharmacodynamics variables as they relate to dose, response, and toxicity of carfilzomib in combination with isatuximab\",\"Recruiting\",\"Phase 1\"\n",
      "984,\"Once-weekly Versus Twice-weekly Carfilzomib in Combination With Dexamethasone in Adults With Relapsed and Refractory Multiple Myeloma\",\"Progression Free Survival\",\"From randomization until the data cut-off date of 15 June 2017; median (minimum, maximum) follow-up time for PFS was 12.0 (0, 20) and 12.6 (0, 19) months in each treatment group respectively.\",\"Overall Response Rate|Overall Survival|Number of Participants With Adverse Events (AEs)|Plasma Carfilzomib Concentration During Cycle 2\",\"Completed\",\"Phase 3\"\n",
      "985,\"Selinexor and Backbone Treatments of Multiple Myeloma Patients\",\"Phase 1 (Dose-escalation): Maximum Tolerated Dose (MTD)|Phase 1 (Dose-escalation): Recommended Phase-2 dose (RP2D)|Phase 1 (Dose-escalation): Maximum Plasma Concentration (Cmax) of Selinexor|Phase 1 (Dose-escalation): Area Under the Concentration-time Curve From Time Zero to the Last Non-zero Concentration (AUC0-t) of Selinexor|Phase 1 (Dose-escalation): Area Under the Concentration-time Curve From Time Zero to Infinity (Extrapolated) (AUC0-inf)|Phase 2 (Expansion): Overall response rate (ORR)|Phase 2 (Expansion): Duration of response (DOR)|Phase 2 (Expansion): Clinical Benefit Rate (CBR)\",\"12 months|12 months|Pre-dose, 1 hour, 1.5, 2, 3, 4, 5, 6, 8, and 24 hours post-dose on Day 1 (without clarithromycin) and Day 8 (with clarithromycin)|Pre-dose, 1, 1.5, 2, 3, 4, 5, 6, 8, and 24 hours post-dose on Day 1 (without clarithromycin) and Day 8 (with clarithromycin)|Pre-dose, 1, 1.5, 2, 3, 4, 5, 6, 8, and 24 hours post-dose on Day 1 (without clarithromycin) and Day 8 (with clarithromycin)|12 months|12 months|12 months\",,\"Active, not recruiting\",\"Phase 1|Phase 2\"\n",
      "986,\"Treatment With AMD3100 (Plerixafor) in Non-Hodgkin's Lymphoma and Multiple Myeloma Patients\",\"Number of Participants in Overall Safety Summary of Treatment Emergent Adverse Events (TEAE)\",\"Day 1 to approximately Day 38 (before start of chemotherapy)\",\"Fold (i.e., Relative) Increase in Peripheral Blood (PB) CD34+ Cells/µL After First Dose of Plerixafor|Number of Transplants in Which Participants Achieved Polymorphonuclear Leukocyte (PMN) Engraftment by Day 12 But No Later Than Day 21 Post Peripheral Blood Stem Cell (PBSC) Transplant|Increase in Peripheral Blood (PB) CD34+ Cells From Steady-state Hematopoiesis to Pre-leukapheresis in G-CSF+Plerixafor Treated Participants Compared to Historical Controls Treated With G-CSF Alone or Chemotherapy and G-CSF\",\"Completed\",\"Phase 2\"\n",
      "987,\"Melphalan Followed by Peripheral Stem Cell Transplantation in Treating Patients With Multiple Myeloma\",,,,\"Completed\",\"Phase 3\"\n",
      "988,\"Study of AO-176 as Monotherapy and in Combination With Bortezomib/Dexamethasone in Relapsed/Refractory Multiple Myeloma\",\"Phase 1: MTD / RP2D of AO-176 assessed by incidence of dose-limiting toxicities and incidence of treatment-related adverse events (TEAEs) as assessed by CTCAE v5.0|Phase 2: Objective response rate (ORR) of AO-176 + DEX + BORT\",\"12 months|12 months\",\"Phase 1: ORR of single agent AO-176|Phase 1: Duration of response (DOR) of single agent AO-176|Phase 1: Disease control rate (DCR) of single agent AO-176|Phase 1: Progression-free survival (PFS) of single agent AO-176|Phase 1: Overall survival (OS) of single agent AO-176|Phase 2: DOR of AO-176 + DEX + BORT|Phase 2: DCR of AO-176 + DEX + BORT|Phase 2: PFS of AO-176 + DEX + BORT|Phase 2: OS of AO-176 + DEX + BORT\",\"Active, not recruiting\",\"Phase 1|Phase 2\"\n",
      "989,\"Study to Investigate Alternative Dosing Regimens of Belantamab Mafodotin in Participants With Relapsed or Refractory Multiple Myeloma\",\"Incidence rate of Grade ≥2 Corneal events according to the keratopathy visual acuity (KVA) scale\",\"Up to 12 months\",\"Cumulative event rate of corneal events to Week 16 (KVA scale)|Incidence rate of corneal events by grade (KVA scale)|Exposure adjusted incidence rate of corneal events by grade (KVA scale)|Median duration of dose delay|Percentage of participants requiring dose reductions, dose delays, and study treatment discontinuation due to corneal events|Cumulative incidence of corneal events by grade|Toxicity Index score by assessment/visit|Duration of corneal events|Percentage of time on study with corneal events|Change in best corrected visual acuity (BCVA)|Overall response rate (ORR)|Percentage of participants with very good partial response (VGPR) or better|Time to response (TTR)|Duration of response (DoR)|Time to progression (TTP)|Progression-free survival (PFS)|Overall survival (OS)|Number of participants with AEs and serious AEs (SAEs)|Number of participants with clinically significant changes in hematology, clinical chemistry and urinalysis laboratory parameters|Percentage of participants requiring dose reductions, dose delays, and study treatment discontinuation due to any AEs|Maximum concentration (Cmax) of belantamab mafodotin|Time taken to reach Cmax (Tmax) of belantamab mafodotin|Area under the concentration time-curve (AUC) of belantamab mafodotin|Number of participants with positive anti-drug antibodies (ADAs) against belantamab mafodotin|Titers of ADAs against belantamab mafodotin\",\"Recruiting\",\"Phase 2\"\n",
      "990,\"Study of Iberdomide, Bortezomib, and Dexamethasone for ND-NTE MM Patients\",\"Evaluate Rate of Stringent Complete Response (sCR) transplant ineligible multiple myeloma patients.\",\"After 4 cycles of therapy (each cycle is 28 days)\",\"Evaluate Objective Response\",\"Not yet recruiting\",\"Phase 2\"\n",
      "991,\"Abatacept, Ixazomib Citrate, and Dexamethasone in Treating Patients With Multiple Myeloma Resistant to Chemotherapy\",\"Response rate of abatacept + ixazomib citrate + dexamethasone in multiple myeloma patients\",\"Up to 1.5 years\",\"Incidence of adverse events assessed using National Cancer Institute Common Terminology Criteria for Adverse Events version 4.0|Overall survival|Progression-free survival\",\"Active, not recruiting\",\"Phase 2\"\n",
      "992,\"A Study of JNJ-68284528, a Chimeric Antigen Receptor T Cell (CAR-T) Therapy Directed Against B-cell Maturation Antigen (BCMA) in Participants With Multiple Myeloma\",\"Percentage of Participants with Negative Minimal Residual Disease (MRD)\",\"At least 1 year after JNJ-68284528 infusion on Day 1\",\"Overall Response Rate (ORR)|VGPR or Better Rate|Clinical Benefit Rate (CBR)|Duration of Response (DOR)|Time to Response (TTR)|MRD Negative Rate at 12 Months for Participants who Achieve a Complete Response (CR)|Time to MRD Negativity|Duration of MRD Negativity|MRD Negative Rate Across Clinical Response|Number of Participants with Adverse Events by Severity|Number of Participants with Adverse Events (AE) as a Measure of Safety and Tolerability|Number of Participants with Laboratory Abnormalities|Number of Participants with Vital Sign Abnormalities|Levels of B-Cell Maturation Antigen (BCMA) Expressing Cells and Soluble BCMA|Systemic Inflammatory Cytokine Concentrations|Levels of JNJ-68284528 T Cell Expansion (proliferation), and Persistence|Number of Participants with Anti-JNJ-68284528 Antibodies\",\"Recruiting\",\"Phase 2\"\n",
      "993,\"Geriatric Assessments in Senior Adults With Multiple Myeloma\",\"The relationship between initial treatment recommendation and baseline questionnaires assessment\",\"At baseline visit\",\"Changes in questionnaires from baseline to 6 months|Completion of the questionnaires at baseline, 3 months and 6 months.\",\"Completed\",\n",
      "994,\"A Randomized Study With Oral Melphalan + Prednisone (MP) Versus Melphalan, + Prednisone + Thalidomide (MPT) for Newly Diagnosesd Elderly Patients With Multiple Myeloma\",\"To assess the efficacy|To assess the toxicity\",\"from 8 to 12 months|From 1 to 12 months\",\"To evaluate the Overall Survival (OS) in the 2 arms of treatment|To evaluate the Duration of Remission (DR) in the 2 arms of treatment\",\"Completed\",\"Phase 2\"\n",
      "995,\"Pembrolizumab Cyclophosphamide and Lenalidomide for Patients With Relapsed Multiple Myeloma\",\"Dose Limiting Toxicities (DLT) in dose finding phase|Response rate\",\"End of cycle 1 of treatment, 4 weeks|From registration until disease progression, 2 years\",\"Safety of trial treatment|Progression free survival (PFS)|Maximum response|Duration of response|Compliance to therapy|Toxicity of trial treatment\",\"Withdrawn\",\"Phase 1|Phase 2\"\n",
      "996,\"Lenalidomide, Thalidomide and Dexamethasone in Treating Participants With Relapsed or Refractory Multiple Myeloma\",\"Number of Participants With Dose Limitations Toxicities of the Combination of Lenalidomide and Thalidomide and Dexamethasone (LTD) in Patients With Relapsed/Refractory Multiple Myeloma (RRMM)|Complete Response(CR) and Very Good Partial Response(VGPR)\",\"After one 28-day cycle|Evaluated each 28-day cycle and nadir of criteria is considered best overall response (median time to best response for this study was 2 cycles (range for best overall response was 1-21 cycles).\",\"Time to Progression|Progression Free Survival|Time to Best Response|Incidence of Adverse Events|Time to Next Therapy\",\"Completed\",\"Phase 1|Phase 2\"\n",
      "997,\"Carfilzomib in Treating Patients With Multiple Myeloma in First Relapse or Refractory to First-Line Therapy\",\"Overall Response Rate (ORR) After 8 Courses of Treatment\",\"At 32 weeks\",\"Overall Response Rate (ORR) After 4 Courses of Treatment|Progression-free Survival (PFS)|Time to Progression (TTP)|Duration of Response (DOR)|Treatment Related Adverse Events Grade 3 or Higher\",\"Terminated\",\"Phase 2\"\n",
      "998,\"Study of Carfilzomib Weekly Plus Melphalan and Prednisone in Untreated Symptomatic Elderly Multiple Myeloma\",\"Dose Maximum Tolerate of Carfilzomib Weekly\",\"35 days\",\"number of patients who reach Very Good Partial Response and Complete\",\"Unknown status\",\"Phase 2\"\n",
      "999,\"A Safety, PK and Efficacy Study of CC-92480 Monotherapy and in Combination With Dexamethasone in Subjects With Relapsed and Refractory Multiple Myeloma (RRMM)\",\"Adverse Events (AEs)|Pharmacokinetics- AUC|Pharmacokinetics- Cmax|Pharmacokinetics- Tmax|Pharmacokinetics- t1/2|Pharmacokinetics- CL/F|Pharmacokinetics- Vz/F|Maximum tolerated dose (MTD)|Overall Response Rate (ORR)\",\"From enrollment until at least 28 days after completion of study treatment|Up to approximately 28 days|Up to approximately 28 days|Up to approximately 28 days|Up to approximately 28 days|Up to approximately 28 days|Up to approximately 28 days|Up to approximately 28 days|Up to approximately 3 years\",\"Overall response rate (ORR)|Time to response (TTR)|Duration of response (DOR)|Progression free survival|Overall survival (OS)|Adverse Events (AEs)\",\"Recruiting\",\"Phase 1|Phase 2\"\n",
      "\n"
     ]
    }
   ],
   "source": [
    "# FETCH THE CSV DATA FROM THE API\n",
    "\n",
    "from requests import get\n",
    "import pandas as pd\n",
    "\n",
    "base_url = \"https://clinicaltrials.gov/api/query/study_fields?\" # base url for our endpoint\n",
    "\n",
    "expr = \"multiple myeloma\" # basic search term\n",
    "actual_expr = expr.replace(' ', '+') # replace spaces in expr with '+'\n",
    "\n",
    "fields = [\"BriefTitle\", \"PrimaryOutcomeMeasure\", \"PrimaryOutcomeTimeFrame\", \"SecondaryOutcomeMeasure\", \"OverallStatus\", \"Phase\"] # fields we want to get\n",
    "actual_fields = \",\".join(fields) # join fields with commas\n",
    "\n",
    "fmt = \"csv\" # get in csv format\n",
    "\n",
    "num_results = 999 # number of results we want – 1000 is maximum\n",
    "\n",
    "params = {\n",
    "    \"expr\": actual_expr,\n",
    "    \"fields\": actual_fields,\n",
    "    \"min_rnk\": \"1\",\n",
    "    \"max_rnk\": str(num_results),\n",
    "    \"fmt\": fmt\n",
    "}\n",
    "\n",
    "response = get(base_url, params=params)\n",
    "\n",
    "if response.ok:\n",
    "    print(\"Request successful!\")\n",
    "else:\n",
    "    print(\"Request failed!\")\n",
    "print(\"\\n\\n\" + response.text)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 780,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "File written successfully!\n"
     ]
    }
   ],
   "source": [
    "# WRITE THE CSV DATA TO A FILE\n",
    "\n",
    "import csv\n",
    "lines = response.text.split('\\n') # split by newlines\n",
    "\n",
    "with open('output.csv', mode='w', newline='') as file: # open a file to write to\n",
    "    writer = csv.writer(file, delimiter=';') # create a csv writer\n",
    "    headers = ['Rank'] + fields # create headers\n",
    "    writer.writerow(headers) # write headers\n",
    "\n",
    "    for line in lines[11:]: # skip first 11 lines\n",
    "        row = [txt for txt in line.split(',\\\"') if txt != \"\"] # split by commas followed by a quote, remove anything empty\n",
    "        \n",
    "        split_count = 0\n",
    "        for i,text in enumerate(row):\n",
    "            if split_count == 0 and row[i].count('|') >= 1: # if there are vertical bars\n",
    "                split_count = row[i].count('|')+1 # count the number of copies of other fields we will need to make\n",
    "            row[i] = text.replace('\\\"', '') # remove quotes\n",
    "             \n",
    "        if split_count: # we need to split by the primary outcome measures\n",
    "            for i,text in enumerate(row):\n",
    "                if row[i].count('|') >= 1:\n",
    "                    row[i] = row[i].split('|') # split by vertical bars\n",
    "                else:\n",
    "                    row[i] = [row[i]]*split_count # make it a list\n",
    "            # fetch each new row and write to file\n",
    "            for r in zip(*row):\n",
    "                writer.writerow(r)\n",
    "        else:\n",
    "            writer.writerow(row) # write row as it is\n",
    "    print(\"File written successfully!\")"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 781,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>Rank</th>\n",
       "      <th>BriefTitle</th>\n",
       "      <th>PrimaryOutcomeMeasure</th>\n",
       "      <th>PrimaryOutcomeTimeFrame</th>\n",
       "      <th>SecondaryOutcomeMeasure</th>\n",
       "      <th>OverallStatus</th>\n",
       "      <th>Phase</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>0</th>\n",
       "      <td>1</td>\n",
       "      <td>Early Detection of Multiple Myeloma to Fight C...</td>\n",
       "      <td>To conduct and evaluate a study that incorpora...</td>\n",
       "      <td>12 months</td>\n",
       "      <td>Not yet recruiting</td>\n",
       "      <td>Not Applicable</td>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1</th>\n",
       "      <td>1</td>\n",
       "      <td>Early Detection of Multiple Myeloma to Fight C...</td>\n",
       "      <td>To conduct and evaluate a study that incorpora...</td>\n",
       "      <td>12 months</td>\n",
       "      <td>Not yet recruiting</td>\n",
       "      <td>Not Applicable</td>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2</th>\n",
       "      <td>1</td>\n",
       "      <td>Early Detection of Multiple Myeloma to Fight C...</td>\n",
       "      <td>To study participant knowledge of Multiple Mye...</td>\n",
       "      <td>12 months,</td>\n",
       "      <td>Not yet recruiting</td>\n",
       "      <td>Not Applicable</td>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3</th>\n",
       "      <td>2</td>\n",
       "      <td>Multiple Myeloma (MM) Profile in Brazil: A Ret...</td>\n",
       "      <td>Number of Multiple Myeloma (MM) Participants C...</td>\n",
       "      <td>From initial diagnosis up to end of follow up ...</td>\n",
       "      <td>Overall Survival (OS)</td>\n",
       "      <td>Completed,</td>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4</th>\n",
       "      <td>2</td>\n",
       "      <td>Multiple Myeloma (MM) Profile in Brazil: A Ret...</td>\n",
       "      <td>Number of Multiple Myeloma (MM) Participants C...</td>\n",
       "      <td>From initial diagnosis up to end of follow up ...</td>\n",
       "      <td>Duration of Treatment</td>\n",
       "      <td>Completed,</td>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>...</th>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3711</th>\n",
       "      <td>997</td>\n",
       "      <td>Carfilzomib in Treating Patients With Multiple...</td>\n",
       "      <td>Overall Response Rate (ORR) After 8 Courses of...</td>\n",
       "      <td>At 32 weeks</td>\n",
       "      <td>Duration of Response (DOR)</td>\n",
       "      <td>Terminated</td>\n",
       "      <td>Phase 2</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3712</th>\n",
       "      <td>997</td>\n",
       "      <td>Carfilzomib in Treating Patients With Multiple...</td>\n",
       "      <td>Overall Response Rate (ORR) After 8 Courses of...</td>\n",
       "      <td>At 32 weeks</td>\n",
       "      <td>Treatment Related Adverse Events Grade 3 or Hi...</td>\n",
       "      <td>Terminated</td>\n",
       "      <td>Phase 2</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3713</th>\n",
       "      <td>998</td>\n",
       "      <td>Study of Carfilzomib Weekly Plus Melphalan and...</td>\n",
       "      <td>Dose Maximum Tolerate of Carfilzomib Weekly</td>\n",
       "      <td>35 days</td>\n",
       "      <td>number of patients who reach Very Good Partial...</td>\n",
       "      <td>Unknown status</td>\n",
       "      <td>Phase 2</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3714</th>\n",
       "      <td>999</td>\n",
       "      <td>A Safety, PK and Efficacy Study of CC-92480 Mo...</td>\n",
       "      <td>Adverse Events (AEs)</td>\n",
       "      <td>From enrollment until at least 28 days after c...</td>\n",
       "      <td>Overall response rate (ORR)</td>\n",
       "      <td>Recruiting</td>\n",
       "      <td>Phase 1</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3715</th>\n",
       "      <td>999</td>\n",
       "      <td>A Safety, PK and Efficacy Study of CC-92480 Mo...</td>\n",
       "      <td>Pharmacokinetics- AUC</td>\n",
       "      <td>Up to approximately 28 days</td>\n",
       "      <td>Time to response (TTR)</td>\n",
       "      <td>Recruiting</td>\n",
       "      <td>Phase 2</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "<p>3716 rows × 7 columns</p>\n",
       "</div>"
      ],
      "text/plain": [
       "      Rank                                         BriefTitle  \\\n",
       "0        1  Early Detection of Multiple Myeloma to Fight C...   \n",
       "1        1  Early Detection of Multiple Myeloma to Fight C...   \n",
       "2        1  Early Detection of Multiple Myeloma to Fight C...   \n",
       "3        2  Multiple Myeloma (MM) Profile in Brazil: A Ret...   \n",
       "4        2  Multiple Myeloma (MM) Profile in Brazil: A Ret...   \n",
       "...    ...                                                ...   \n",
       "3711   997  Carfilzomib in Treating Patients With Multiple...   \n",
       "3712   997  Carfilzomib in Treating Patients With Multiple...   \n",
       "3713   998  Study of Carfilzomib Weekly Plus Melphalan and...   \n",
       "3714   999  A Safety, PK and Efficacy Study of CC-92480 Mo...   \n",
       "3715   999  A Safety, PK and Efficacy Study of CC-92480 Mo...   \n",
       "\n",
       "                                  PrimaryOutcomeMeasure  \\\n",
       "0     To conduct and evaluate a study that incorpora...   \n",
       "1     To conduct and evaluate a study that incorpora...   \n",
       "2     To study participant knowledge of Multiple Mye...   \n",
       "3     Number of Multiple Myeloma (MM) Participants C...   \n",
       "4     Number of Multiple Myeloma (MM) Participants C...   \n",
       "...                                                 ...   \n",
       "3711  Overall Response Rate (ORR) After 8 Courses of...   \n",
       "3712  Overall Response Rate (ORR) After 8 Courses of...   \n",
       "3713        Dose Maximum Tolerate of Carfilzomib Weekly   \n",
       "3714                               Adverse Events (AEs)   \n",
       "3715                              Pharmacokinetics- AUC   \n",
       "\n",
       "                                PrimaryOutcomeTimeFrame  \\\n",
       "0                                             12 months   \n",
       "1                                             12 months   \n",
       "2                                            12 months,   \n",
       "3     From initial diagnosis up to end of follow up ...   \n",
       "4     From initial diagnosis up to end of follow up ...   \n",
       "...                                                 ...   \n",
       "3711                                        At 32 weeks   \n",
       "3712                                        At 32 weeks   \n",
       "3713                                            35 days   \n",
       "3714  From enrollment until at least 28 days after c...   \n",
       "3715                        Up to approximately 28 days   \n",
       "\n",
       "                                SecondaryOutcomeMeasure   OverallStatus  \\\n",
       "0                                    Not yet recruiting  Not Applicable   \n",
       "1                                    Not yet recruiting  Not Applicable   \n",
       "2                                    Not yet recruiting  Not Applicable   \n",
       "3                                 Overall Survival (OS)      Completed,   \n",
       "4                                 Duration of Treatment      Completed,   \n",
       "...                                                 ...             ...   \n",
       "3711                         Duration of Response (DOR)      Terminated   \n",
       "3712  Treatment Related Adverse Events Grade 3 or Hi...      Terminated   \n",
       "3713  number of patients who reach Very Good Partial...  Unknown status   \n",
       "3714                        Overall response rate (ORR)      Recruiting   \n",
       "3715                             Time to response (TTR)      Recruiting   \n",
       "\n",
       "        Phase  \n",
       "0         NaN  \n",
       "1         NaN  \n",
       "2         NaN  \n",
       "3         NaN  \n",
       "4         NaN  \n",
       "...       ...  \n",
       "3711  Phase 2  \n",
       "3712  Phase 2  \n",
       "3713  Phase 2  \n",
       "3714  Phase 1  \n",
       "3715  Phase 2  \n",
       "\n",
       "[3716 rows x 7 columns]"
      ]
     },
     "execution_count": 781,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "# READ INTO A PANDAS DATAFRAME\n",
    "df = pd.read_csv(\"output.csv\", delimiter=';')\n",
    "numtrials = df[\"BriefTitle\"].unique().shape[0]\n",
    "df"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 782,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "2 years                                                                                                           106\n",
       "6 months                                                                                                           70\n",
       "1 year                                                                                                             66\n",
       "3 years                                                                                                            51\n",
       "28 days                                                                                                            42\n",
       "                                                                                                                 ... \n",
       "every 3 weeks up to 48 weeks                                                                                        1\n",
       "every 3 weeks up to 48 weeks, then every 3 months thereafter up to 3 years from initiation of study treatment.      1\n",
       "Skeletal related event (time to first SRE)                                                                          1\n",
       "Cost-utility analysis                                                                                               1\n",
       "Up to approximately 28 days                                                                                         1\n",
       "Name: PrimaryOutcomeTimeFrame, Length: 966, dtype: int64"
      ]
     },
     "execution_count": 782,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "df.PrimaryOutcomeTimeFrame.value_counts()\n",
    "# THIS IS GOING TO BE VERY TOUGH TO DEAL WITH..."
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 783,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "Completed                   1131\n",
       "Recruiting                   612\n",
       "Active, not recruiting       487\n",
       "Terminated                   339\n",
       "Unknown status               152\n",
       "Phase 2                      141\n",
       "Completed,                   122\n",
       "Withdrawn                    110\n",
       "Not yet recruiting           107\n",
       "Recruiting,                   96\n",
       "Phase 3                       67\n",
       "Active, not recruiting,       50\n",
       "Phase 1                       47\n",
       "Not Applicable                22\n",
       "Terminated,                   22\n",
       "Unknown status,               21\n",
       "Not yet recruiting,           10\n",
       "Phase 4                        9\n",
       "Suspended                      7\n",
       "Enrolling by invitation        4\n",
       "Early Phase 1                  4\n",
       "Enrolling by invitation,       2\n",
       "Name: OverallStatus, dtype: int64"
      ]
     },
     "execution_count": 783,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "df.OverallStatus.value_counts()\n",
    "# We probably should remove everything that is \"Unknown Status\" or random dates or other nonsense"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 784,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "Completed                  1131\n",
       "Recruiting                  612\n",
       "Terminated                  339\n",
       "Withdrawn                   110\n",
       "Not yet recruiting          107\n",
       "Suspended                     7\n",
       "Enrolling by invitation       4\n",
       "Name: OverallStatus, dtype: int64"
      ]
     },
     "execution_count": 784,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "# Clean up by the overallstatus column\n",
    "df = df[df['OverallStatus'].isin(['Completed', 'Terminated', 'Withdrawn', 'Active not recruiting', 'Recruiting', 'Enrolling by invitation', 'Suspended', 'Not yet recruiting'])]\n",
    "df.OverallStatus.value_counts()\n",
    "# So much better"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 785,
   "metadata": {},
   "outputs": [],
   "source": [
    "# # CONVERT THE LastUpdatePostDate COLUMN TO A DATETIME\n",
    "# df['LastUpdatePostDate'] = pd.to_datetime(df['LastUpdatePostDate'])\n",
    "# df"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 786,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>Rank</th>\n",
       "      <th>BriefTitle</th>\n",
       "      <th>PrimaryOutcomeMeasure</th>\n",
       "      <th>PrimaryOutcomeTimeFrame</th>\n",
       "      <th>SecondaryOutcomeMeasure</th>\n",
       "      <th>OverallStatus</th>\n",
       "      <th>Phase</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>5</th>\n",
       "      <td>3</td>\n",
       "      <td>CAR-T Cells Therapy in Relapsed/Refractory Mul...</td>\n",
       "      <td>Adverse events that Are related to treatment</td>\n",
       "      <td>2 years</td>\n",
       "      <td>Estimate 2 year overall survival(OS) after inf...</td>\n",
       "      <td>Terminated</td>\n",
       "      <td>Not Applicable</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>23</th>\n",
       "      <td>7</td>\n",
       "      <td>Impact of Paramedical Consultations in Oncolog...</td>\n",
       "      <td>Comparison of quality of life evolution in out...</td>\n",
       "      <td>6 months</td>\n",
       "      <td>Qualitative evaluation of quality of life</td>\n",
       "      <td>Recruiting</td>\n",
       "      <td>Not Applicable</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>29</th>\n",
       "      <td>9</td>\n",
       "      <td>Comparison of F-18 FDG and C-11 Acetate PET in...</td>\n",
       "      <td>Mean Multiple Myeloma Lesions Detected</td>\n",
       "      <td>Day 1, Day 2</td>\n",
       "      <td>Visual Image Analysis of Detected Multiple Mye...</td>\n",
       "      <td>Completed</td>\n",
       "      <td>Phase 2</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>31</th>\n",
       "      <td>11</td>\n",
       "      <td>A Study of Siltuximab (Anti- IL 6 Monoclonal A...</td>\n",
       "      <td>One-Year Progression-Free Survival (PFS) Rate</td>\n",
       "      <td>Up to 1 Year</td>\n",
       "      <td>Progressive Disease Indicator Rate (PDIR) at 6...</td>\n",
       "      <td>Completed</td>\n",
       "      <td>Phase 2</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>40</th>\n",
       "      <td>13</td>\n",
       "      <td>Phase II Study of Thalidomide, Clarithromycin,...</td>\n",
       "      <td>Effect of Drug Combination on Multiple Myeloma</td>\n",
       "      <td>This was collected from patients for their dur...</td>\n",
       "      <td>Median Time to Maximum Response</td>\n",
       "      <td>Completed</td>\n",
       "      <td>Phase 2</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>...</th>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3702</th>\n",
       "      <td>994</td>\n",
       "      <td>A Randomized Study With Oral Melphalan + Predn...</td>\n",
       "      <td>To assess the efficacy</td>\n",
       "      <td>from 8 to 12 months</td>\n",
       "      <td>To evaluate the Overall Survival (OS) in the 2...</td>\n",
       "      <td>Completed</td>\n",
       "      <td>Phase 2</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3704</th>\n",
       "      <td>995</td>\n",
       "      <td>Pembrolizumab Cyclophosphamide and Lenalidomid...</td>\n",
       "      <td>Dose Limiting Toxicities (DLT) in dose finding...</td>\n",
       "      <td>End of cycle 1 of treatment, 4 weeks</td>\n",
       "      <td>Safety of trial treatment</td>\n",
       "      <td>Withdrawn</td>\n",
       "      <td>Phase 1</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3706</th>\n",
       "      <td>996</td>\n",
       "      <td>Lenalidomide, Thalidomide and Dexamethasone in...</td>\n",
       "      <td>Number of Participants With Dose Limitations T...</td>\n",
       "      <td>After one 28-day cycle</td>\n",
       "      <td>Time to Progression</td>\n",
       "      <td>Completed</td>\n",
       "      <td>Phase 1</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3708</th>\n",
       "      <td>997</td>\n",
       "      <td>Carfilzomib in Treating Patients With Multiple...</td>\n",
       "      <td>Overall Response Rate (ORR) After 8 Courses of...</td>\n",
       "      <td>At 32 weeks</td>\n",
       "      <td>Overall Response Rate (ORR) After 4 Courses of...</td>\n",
       "      <td>Terminated</td>\n",
       "      <td>Phase 2</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3714</th>\n",
       "      <td>999</td>\n",
       "      <td>A Safety, PK and Efficacy Study of CC-92480 Mo...</td>\n",
       "      <td>Adverse Events (AEs)</td>\n",
       "      <td>From enrollment until at least 28 days after c...</td>\n",
       "      <td>Overall response rate (ORR)</td>\n",
       "      <td>Recruiting</td>\n",
       "      <td>Phase 1</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "<p>551 rows × 7 columns</p>\n",
       "</div>"
      ],
      "text/plain": [
       "      Rank                                         BriefTitle  \\\n",
       "5        3  CAR-T Cells Therapy in Relapsed/Refractory Mul...   \n",
       "23       7  Impact of Paramedical Consultations in Oncolog...   \n",
       "29       9  Comparison of F-18 FDG and C-11 Acetate PET in...   \n",
       "31      11  A Study of Siltuximab (Anti- IL 6 Monoclonal A...   \n",
       "40      13  Phase II Study of Thalidomide, Clarithromycin,...   \n",
       "...    ...                                                ...   \n",
       "3702   994  A Randomized Study With Oral Melphalan + Predn...   \n",
       "3704   995  Pembrolizumab Cyclophosphamide and Lenalidomid...   \n",
       "3706   996  Lenalidomide, Thalidomide and Dexamethasone in...   \n",
       "3708   997  Carfilzomib in Treating Patients With Multiple...   \n",
       "3714   999  A Safety, PK and Efficacy Study of CC-92480 Mo...   \n",
       "\n",
       "                                  PrimaryOutcomeMeasure  \\\n",
       "5          Adverse events that Are related to treatment   \n",
       "23    Comparison of quality of life evolution in out...   \n",
       "29               Mean Multiple Myeloma Lesions Detected   \n",
       "31        One-Year Progression-Free Survival (PFS) Rate   \n",
       "40       Effect of Drug Combination on Multiple Myeloma   \n",
       "...                                                 ...   \n",
       "3702                             To assess the efficacy   \n",
       "3704  Dose Limiting Toxicities (DLT) in dose finding...   \n",
       "3706  Number of Participants With Dose Limitations T...   \n",
       "3708  Overall Response Rate (ORR) After 8 Courses of...   \n",
       "3714                               Adverse Events (AEs)   \n",
       "\n",
       "                                PrimaryOutcomeTimeFrame  \\\n",
       "5                                               2 years   \n",
       "23                                             6 months   \n",
       "29                                         Day 1, Day 2   \n",
       "31                                         Up to 1 Year   \n",
       "40    This was collected from patients for their dur...   \n",
       "...                                                 ...   \n",
       "3702                                from 8 to 12 months   \n",
       "3704               End of cycle 1 of treatment, 4 weeks   \n",
       "3706                             After one 28-day cycle   \n",
       "3708                                        At 32 weeks   \n",
       "3714  From enrollment until at least 28 days after c...   \n",
       "\n",
       "                                SecondaryOutcomeMeasure OverallStatus  \\\n",
       "5     Estimate 2 year overall survival(OS) after inf...    Terminated   \n",
       "23            Qualitative evaluation of quality of life    Recruiting   \n",
       "29    Visual Image Analysis of Detected Multiple Mye...     Completed   \n",
       "31    Progressive Disease Indicator Rate (PDIR) at 6...     Completed   \n",
       "40                      Median Time to Maximum Response     Completed   \n",
       "...                                                 ...           ...   \n",
       "3702  To evaluate the Overall Survival (OS) in the 2...     Completed   \n",
       "3704                          Safety of trial treatment     Withdrawn   \n",
       "3706                                Time to Progression     Completed   \n",
       "3708  Overall Response Rate (ORR) After 4 Courses of...    Terminated   \n",
       "3714                        Overall response rate (ORR)    Recruiting   \n",
       "\n",
       "               Phase  \n",
       "5     Not Applicable  \n",
       "23    Not Applicable  \n",
       "29           Phase 2  \n",
       "31           Phase 2  \n",
       "40           Phase 2  \n",
       "...              ...  \n",
       "3702         Phase 2  \n",
       "3704         Phase 1  \n",
       "3706         Phase 1  \n",
       "3708         Phase 2  \n",
       "3714         Phase 1  \n",
       "\n",
       "[551 rows x 7 columns]"
      ]
     },
     "execution_count": 786,
     "metadata": {},
     "output_type": "execute_result"
    },
    {
     "data": {
      "image/png": "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",
      "text/plain": [
       "<Figure size 640x480 with 1 Axes>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    }
   ],
   "source": [
    "# Sample plot\n",
    "per_study = df.drop_duplicates(subset='BriefTitle', keep='first') # remove duplicates from BriefTitle column to get a count of unique studies\n",
    "per_study.OverallStatus.value_counts().plot(kind='bar', title='Number of studies by status', xlabel='Status', ylabel='Number of studies')\n",
    "per_study"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 787,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "2 years                                                                                                                                                                                                                                               61\n",
       "6 months                                                                                                                                                                                                                                              61\n",
       "1 year                                                                                                                                                                                                                                                40\n",
       "28 days                                                                                                                                                                                                                                               38\n",
       "24 Months                                                                                                                                                                                                                                             32\n",
       "Up to 12 months                                                                                                                                                                                                                                       31\n",
       "Up to approximatively 5 years                                                                                                                                                                                                                         31\n",
       "Baseline visit and 3 days after the Autologous Stem Cell Transplant                                                                                                                                                                                   29\n",
       "up to 165 weeks                                                                                                                                                                                                                                       27\n",
       "Up to 84 months                                                                                                                                                                                                                                       24\n",
       "3 years                                                                                                                                                                                                                                               24\n",
       "up to 123 weeks                                                                                                                                                                                                                                       23\n",
       "Up to 4 years and 5 months                                                                                                                                                                                                                            20\n",
       "84 days                                                                                                                                                                                                                                               20\n",
       "Up to data cut off: 2 December 2019 (Up to approximately 79 months)                                                                                                                                                                                   19\n",
       "at 5 years after randomization                                                                                                                                                                                                                        19\n",
       "Time interval between the date of the first dose administration in Cycle 1 (each cycle is 28 days) and the date of the first dose administration in Cycle 2 which is expected to be 28 days or up to 42 days in case of dose delay due to toxicity    19\n",
       "Up to 2 years and 10 months                                                                                                                                                                                                                           18\n",
       "Up to approximately 5 years                                                                                                                                                                                                                           17\n",
       "Up to 36 weeks                                                                                                                                                                                                                                        17\n",
       "Assessed for up to approximately 5 years                                                                                                                                                                                                              17\n",
       "12 months                                                                                                                                                                                                                                             17\n",
       "Up to 1 year                                                                                                                                                                                                                                          17\n",
       "Up to 6 years                                                                                                                                                                                                                                         17\n",
       "Name: PrimaryOutcomeTimeFrame, dtype: int64"
      ]
     },
     "execution_count": 787,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "df[\"PrimaryOutcomeTimeFrame\"].value_counts()[-600:-540]\n",
    "# messing around with the timeframes"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 788,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "1.3339382940108893"
      ]
     },
     "execution_count": 788,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "df[\"PrimaryOutcomeMeasure\"].unique().size / df[\"Rank\"].unique().size\n",
    "# 1.33 primary outcome measures per trial"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 789,
   "metadata": {},
   "outputs": [],
   "source": [
    "# completed_studies = per_study[per_study[\"OverallStatus\"] == \"Completed\"]\n",
    "# completed_studies.sort_values(by=\"LastUpdatePostDate\", ascending=False)\n",
    "# # completed_studies[:1][\"BriefTitle\"].values[0]\n",
    "# completed_studies[-1:]"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 790,
   "metadata": {},
   "outputs": [],
   "source": [
    "# CLASSIFYING THE OUTCOME MEASURES\n",
    "\n",
    "# Define the category lists\n",
    "orr_keywords = set(['orr', 'objective response', 'overall response', 'response rate'])\n",
    "cr_keywords = set(['complete response', 'cr', 'complete-response'])\n",
    "pr_keywords = set(['partial response', 'pr', 'partial-response'])\n",
    "ae_keywords = set(['AE', 'adverse events', 'side effects'])\n",
    "it_keywords = set(['infusion time', 'administration time'])\n",
    "mtd_keywords = set(['maximum tolerated dose', 'mtd', 'tolerance'])\n",
    "s_keywords = set(['severity', 'grading'])\n",
    "dlt_keywords = set(['dose limiting', 'dose-limiting', 'dlt', 'toxicity', 'dose limit', 'dose-limit'])\n",
    "pfs_keywords = set(['progression-free', 'pfs', 'progression free'])\n",
    "dur_keywords = set(['duration of response', 'dor'])\n",
    "cmax_keywords = set(['cmax'])\n",
    "tmax_keywords = set(['tmax'])\n",
    "auc_keywords = set(['auc'])\n",
    "pharmaco_keywords = set(['pharmacokinetics', 'pharmacodynamics'])\n",
    "death_keywords = set(['death', 'dead', 'die', 'mortal'])\n",
    "imwg_keywords = set(['imwg', 'international myeloma working group'])\n",
    "mrd_keywords = set(['mrd', 'minimal residual', 'residual', 'minimal disease', 'minimum residual'])\n",
    "\n",
    "# Function to classify outcome measures into categories\n",
    "def classify_outcome_measure(outcome_measure):\n",
    "    for keyword in orr_keywords:\n",
    "        if keyword in outcome_measure.lower():\n",
    "            return 'ORR'\n",
    "    for keyword in ae_keywords:\n",
    "        if keyword in outcome_measure.lower():\n",
    "            return 'AE'\n",
    "    for keyword in it_keywords:\n",
    "        if keyword in outcome_measure.lower():\n",
    "            return 'IT'\n",
    "    for keyword in mtd_keywords:\n",
    "        if keyword in outcome_measure.lower():\n",
    "            return 'MTD'\n",
    "    for keyword in s_keywords:\n",
    "        if keyword in outcome_measure.lower():\n",
    "            return 'Severity'\n",
    "    for keyword in dlt_keywords:\n",
    "        if keyword in outcome_measure.lower():\n",
    "            return 'DLT'\n",
    "    for keyword in pfs_keywords:\n",
    "        if keyword in outcome_measure.lower():\n",
    "            return 'PFS'\n",
    "    for keyword in dur_keywords:\n",
    "        if keyword in outcome_measure.lower():\n",
    "            return 'DOR'\n",
    "    for keyword in cr_keywords:\n",
    "        if keyword in outcome_measure.lower():\n",
    "            return 'CR'\n",
    "    for keyword in pr_keywords:\n",
    "        if keyword in outcome_measure.lower():\n",
    "            return 'PR'\n",
    "    for keyword in pharmaco_keywords:\n",
    "        if keyword in outcome_measure.lower():\n",
    "            return 'Pharmacokinetics'\n",
    "    # if \"pharmaco\" in outcome_measure.lower():\n",
    "    #     for keyword in cmax_keywords:\n",
    "    #         if keyword in outcome_measure.lower():\n",
    "    #             return 'Cmax'\n",
    "    #     for keyword in tmax_keywords:\n",
    "    #         if keyword in outcome_measure.lower():\n",
    "    #             return 'Tmax'\n",
    "    #     for keyword in auc_keywords:\n",
    "    #         if keyword in outcome_measure.lower():\n",
    "    #             return 'AUC'\n",
    "    for keyword in death_keywords:\n",
    "        if keyword in outcome_measure.lower():\n",
    "            return 'Mortality'\n",
    "    for keyword in mrd_keywords:\n",
    "        if keyword in outcome_measure.lower():\n",
    "            return 'MRD'\n",
    "    for keyword in imwg_keywords:\n",
    "        if keyword in outcome_measure.lower():\n",
    "            return 'IMWG'\n",
    "    return 'Unclassified'"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 791,
   "metadata": {},
   "outputs": [
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "/var/folders/f1/87whmjt97m90gfstrm2p61d80000gn/T/ipykernel_58017/246251396.py:2: SettingWithCopyWarning: \n",
      "A value is trying to be set on a copy of a slice from a DataFrame.\n",
      "Try using .loc[row_indexer,col_indexer] = value instead\n",
      "\n",
      "See the caveats in the documentation: https://pandas.pydata.org/pandas-docs/stable/user_guide/indexing.html#returning-a-view-versus-a-copy\n",
      "  df['PrimaryCat'] = df['PrimaryOutcomeMeasure'].apply(classify_outcome_measure)\n"
     ]
    }
   ],
   "source": [
    "# Apply the function to the dataframe\n",
    "df['PrimaryCat'] = df['PrimaryOutcomeMeasure'].apply(classify_outcome_measure)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 792,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "<AxesSubplot:title={'center':'Number of studies by outcome measure category'}, xlabel='Category', ylabel='Number of studies'>"
      ]
     },
     "execution_count": 792,
     "metadata": {},
     "output_type": "execute_result"
    },
    {
     "data": {
      "image/png": "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",
      "text/plain": [
       "<Figure size 1400x500 with 1 Axes>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    }
   ],
   "source": [
    "import matplotlib.pyplot as plt\n",
    "\n",
    "plt.figure(figsize=(14,5))\n",
    "classifiedcounts = df[df['PrimaryCat'] != 'Unclassified']['PrimaryCat'].value_counts()\n",
    "classifiedcounts.plot(kind='bar', title='Number of studies by outcome measure category', xlabel='Category', ylabel='Number of studies')\n",
    "# NOT PER PHASE"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 793,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "array(['Comparison of quality of life evolution in outpatients with multiple myeloma between the two groups',\n",
       "       'Mean Multiple Myeloma Lesions Detected',\n",
       "       'Effect of Drug Combination on Multiple Myeloma',\n",
       "       'Determine antitumor activity of ultrahigh dose dexamethasone (UHDD) as monotherapy in relapsed multiple myeloma.',\n",
       "       'User average weekly log-in rates over the duration of follow-up from patients with MM and HCPs',\n",
       "       'Recommended phase II dose (RPTD)', 'number of myeloma lesions',\n",
       "       'Rate of Response in Participants Receiving Fenofibrate Therapy',\n",
       "       'Number of Patients Who Develop Immunologic Response to Nivolumab and the DC/MM Fusion Vaccine',\n",
       "       'Response of relapsed refractory multiple myeloma (RRMM) patient to elotuzumab, selinexor, and dexamethasone (ESd).',\n",
       "       'Response', 'Number of whole-body bone lesions',\n",
       "       'Number of bone lesions within defined skeletal areas',\n",
       "       'Remission status of multiple myeloma',\n",
       "       'Incidence of venous thromboembolic (VTE) and/or arterial thromboembolic (ATE) events in patients with Multiple Myeloma placed on the Rivaroxaban vs Aspirin after starting with Len-Dex therapy',\n",
       "       'Achievement of a target of ≥ 2*10^6 CD34+ cells/kg collected during apheresis period in patients with multiple myeloma.',\n",
       "       'Percent enrichment of 13-Carbon in the tricarboxylic acid (TCA) cycle intermediates within bone marrow plasma cells from patients with monoclonal gammopathy of undetermined significance (MGUS) and multiple myeloma',\n",
       "       'Safety and Efficacy', 'Event-free Survival',\n",
       "       'Safety of Maintenance Rituximab Following High Dose Cyclophosphamide',\n",
       "       'Level of thrombin generation in newly diagnosed and untreated MM',\n",
       "       'Level of factor VIII in newly diagnosed and untreated MM',\n",
       "       'Level of D-Dimers in newly diagnosed and untreated MM',\n",
       "       'Feasibility, usability, and acceptability of a tablet-based modified geriatric assessment using online questionnaires.',\n",
       "       'Physician use and perceived utility of the modified geriatric assessment',\n",
       "       'Feasibility to Mobilize and Infuse Autologous Lymphocytes (ALI) After Immunomodulatory Therapy and After Stem Cell Transplant Engraftment',\n",
       "       'Number of Patients Without Symptomatic Myeloma',\n",
       "       'effect of BHQ880 compared with placebo on time to first Skeletal Related Event (SRE) in patients with untreated multiple myeloma and renal insufficiency in combination with bortezomib and dexamethasone',\n",
       "       'Establish a maximum-tolerated dose of Palbociclib, lenalidomide, and dexamethasone for patients with relapsed or refractory multiple myeloma',\n",
       "       'Time to next need treatment',\n",
       "       'Number of Patients With an Adverse Event Attributable to the Investigational Therapy',\n",
       "       'Clinical Response to Treatment',\n",
       "       'Phase I: Determine the safety and feasibility of administering BI-505 in conjunction with HDM+ASCT in multiple myeloma patients',\n",
       "       'Safety measured by occurrence of study related adverse effects defined by NCI CTCAE 5.0',\n",
       "       'Event Free Survival',\n",
       "       'Number of Participants With a Treatment-emergent Adverse Event (TEAE)',\n",
       "       'Persistence of CAR-T cells (cell counts and cell percentage in peripheral blood and bone marrow )',\n",
       "       'Safety of the combination of G-CSF and bortezomib-, carfilzomib-, or IMID-based treatment regimens in patients with refractory multiple myeloma.',\n",
       "       'Phase I - Maximum Planned Dose (MPD) Level',\n",
       "       'sensitivity and specificity per patient analysis',\n",
       "       'Recommended Dose of Plitidepsin in Combination With Bortezomib and Dexamethasone',\n",
       "       'Recommended Dose of Bortezomib in Combination With Plitidepsin and Dexamethasone',\n",
       "       'Recommended Dose of Dexamethasone in Combination With Plitidepsin and Bortezomib',\n",
       "       'The Percentage of Patients That Achieve a Response to Treatment',\n",
       "       'safety and tolerability of hLL1 administered twice weekly for 4 consecutive weeks',\n",
       "       'Safety and tolerability of ciforadenant in combination with daratumumab relapsed / refractory multiple myeloma.',\n",
       "       'Longitudinal Assessment of T Cell (Cluster of Differentiation 4 (CD4), Cluster of Differentiation 8 (CD8), Natural Killer T-cell (NKT) and Natural Killer (NK) Cell Counts',\n",
       "       'Number of Participants With a Positive Response to Bortezomib Measured by the Bone Marker Parathyroid Hormone',\n",
       "       'Number of Participants With a Positive Response to Bortezomib Measured by Bone Markers Like Calcium',\n",
       "       'Number of Participants With a Positive Response to Bortezomib Measured by Bone Marker Alkaline Phosphatase',\n",
       "       'Number of Participants With a Positive Response to Bortezomib Measured by Bone Markers Like Magnesium',\n",
       "       'Number of Participants With a Positive Response to Bortezomib Measured by Bone Markers Like Phosphate.',\n",
       "       'To evaluate the clinical efficacy of AT7519M alone or in combination with bortezomib',\n",
       "       'Number of patients with relapsing/refractory multiple myeloma with TEAE, included serious AE',\n",
       "       \"The patient's best response to treatment with CEP-18770 in combination with lenalidomide and dexamethasone\",\n",
       "       'Part 1, 2 and 3: Number of Participants with any Adverse Event',\n",
       "       'Metabolic parameter',\n",
       "       'PET-positive diffuse bone marrow involvement',\n",
       "       'PET-positive focal bone marrow lesions',\n",
       "       'PET-positive extramedullary lesions',\n",
       "       'Maximum plasma concentration (Cmax) of ABBV-838',\n",
       "       'Phase 1: Maximum Observed Plasma Concentration (Cmax) of Venetoclax',\n",
       "       'Number of patients with changes in laboratory parameters from baseline',\n",
       "       'Number of patients with changes in vital signs from baseline',\n",
       "       'Number of patients with changes in elctrocardiogram (ECG) results from baseline',\n",
       "       'Efficacy in terms of response and survival',\n",
       "       'Number of patients with changes in laboratory test results',\n",
       "       'Hematopoietic Engraftment', 'Disease Response',\n",
       "       'Event Free Survival (ESF)',\n",
       "       'Differences of quality of life in cancer patients between each group',\n",
       "       'Differences of quality of life in myeloma patients between each group',\n",
       "       'Safety of STI-1492',\n",
       "       'Sub-Study B Phase 1 Expansion: Frequency of Laboratory Abnormalities',\n",
       "       'Clonotypic B cells', 'Overall Rate of Response (Efficacy)',\n",
       "       '· To examine the effect of intravenous zoledronic acid at the dose of 4 mg given every three months compared with observation, on percent change in bone mineral density of the spine at one year in patients with asymptomatic, smoldering and stage I MM.',\n",
       "       'To determine the sensitivity of [68Ga]Ga-PentixaFor-PET to detect Multiple Myeloma (MM) lesions [Bone marrow (BM) lesions and/or extra-medullary disease (EMD) ] at the time of initial diagnosis.',\n",
       "       'Overall Survival (OS)', 'Incidence of laboratory abnormalities',\n",
       "       'Bone Formation Markers Measurement',\n",
       "       'Tumor-specific immune response', 'Serum free light chain (FLC)',\n",
       "       'Percentage of Participants With Overall Disease Response at Month 6',\n",
       "       'Incidence of analytical alterations',\n",
       "       'Incidence of ocular events',\n",
       "       'Maximal tolerable dose of lenalidomide after allogeneic stem cell transplantation in patients with multiple myeloma',\n",
       "       'The Clinical Benefit Response (CBR)', 'overall survival',\n",
       "       'Determination of optimal dose of BT062 (Phase I part)',\n",
       "       'Evaluation of response (Phase IIa part)', 'Clinical Benefit Rate',\n",
       "       'All patients administered any dose of study drug will be included in the evaluation of safety',\n",
       "       'overall Survival',\n",
       "       'Maximal percentage of bone marrow measurement on last WB DCE MRI',\n",
       "       'Establish the RP2D of the investigational agent',\n",
       "       'Tolerability as assessed by CTCAE v3.0 (Phase I)',\n",
       "       'Dose Timing After Autologous Stem Cell Transplant',\n",
       "       'Phase 1: Number of Participants With Any Treatment-emergent Adverse Event (TEAE)',\n",
       "       'Number of Participants With a Grade 3 and 4 Adverse Event (Phase I)',\n",
       "       'Number of Participants With Clinically Significant Abnormalities Reported as TEAEs',\n",
       "       'Number of Participants With a TEAE of Peripheral Neuropathy',\n",
       "       'Number of Participants With Clinically Significant Changes in Vital Signs Reported as TEAEs',\n",
       "       'Recommended Phase 2 Dose (RP2D) of Ixazomib',\n",
       "       'Assessment of Safety of recMAGE-A3 + AS15',\n",
       "       'Best Response to Combination Treatment', 'Overall Survival',\n",
       "       'Rate of Participant Enrollment', 'Assessment Completion Rate',\n",
       "       'Number of participants with significant laboratory abnormalities',\n",
       "       'Recommended Phase 2 Dose (RP2D)',\n",
       "       'Overall survival at five years after randomization',\n",
       "       'event-free survival',\n",
       "       'The recommended Phase II dose (RP2D) and schedule of GSK2110183, bortezomib and dexamethasone dosed in combination.',\n",
       "       'Best response',\n",
       "       'Recommended Phase II Dose (RP2D) of PD-0332991: Phase 1',\n",
       "       'Safety and tolerability of rhMBL', 'Safety of Cabozantinib',\n",
       "       'Determination of peak concentration (Cmax) of ABT-199',\n",
       "       'Average duration of absolute neutropenia',\n",
       "       'Feasibility of imaging MM patients with 64Cu-LLP2A-PET/MR as measured by average organ activity concentration of 64Cu-LLP2A',\n",
       "       'Feasibility of imaging MM patients with 64Cu-LLP2A-PET/MR as measured by the number of participants who experience an adverse event related to 64Cu-LLP2A',\n",
       "       'Feasibility of imaging MM patients with 64Cu-LLP2A-PET/MR as measured by the optimal image time after injection of 64Cu-LLP2A',\n",
       "       'Number of Participants For Whom 2.0 x 10e6 CD34+ HSC Cells/kg Could be Collected in 1 or 2 Apheresis Harvests',\n",
       "       'Establish Recommended Phase 2 doses (RP2Ds) of CC-220 as monotherapy and in combination with other treatment',\n",
       "       'Recommended Phase II dose for every-3-week or weekly administration of DFRF4539A',\n",
       "       'Change from Blood routine in plasma at Week 18',\n",
       "       'Change from liver and kidney function at Week 18',\n",
       "       'Adverse event:', 'Adverse event: Difficulty breathing',\n",
       "       'Adverse event: Numbness',\n",
       "       'Best Confirmed Response to Bortezomib Re-Treatment',\n",
       "       'Patients With Overall Confirmed Response', 'efficacy',\n",
       "       'incidence of drop-out or dose reduction',\n",
       "       'Phase 1: Laboratoty tests', 'Changes in Urinary Melatonin',\n",
       "       'Incidence of Treatment-emergent Peripheral Neuropathy',\n",
       "       'Myeloma response',\n",
       "       'Percentage of Participants With ≥1 SRE at the End of 1 Year on Study',\n",
       "       'Safety and tolerability of NOX A12 alone and in combination with VD',\n",
       "       'Safety and Efficacy of High Dose Carfilzomib',\n",
       "       'Number of participants with laboratory abnormalities',\n",
       "       'Incidence of completion of treatment',\n",
       "       'safety and efficacy of Daratumumab assessed by free survival',\n",
       "       'Joint positive adjudication of safety summary in Phase 1b by steering committee, investigator and sponsor (Yes/No)',\n",
       "       'Initial Response to Therapy',\n",
       "       'Number of participants who experience one or more treatment-related TEAEs',\n",
       "       'Number of participants with abnormal changes in vital signs',\n",
       "       'Number of participants with abnormal changes in electrocardiograms (ECGs) findings',\n",
       "       'Number of participants with abnormal changes in clinical laboratory tests',\n",
       "       'Sensitivity',\n",
       "       'Percentage of Participants Experiencing Treatment-emergent Laboratory Abnormalities According to the NCI CTCAE Version 5.0 (Safety Run-in Cohorts)',\n",
       "       'Non-Tolerated Dose (NTD)',\n",
       "       'The number of patients who experience a treatment-related adverse event after being treated with a single dose of single agent CJM112, or two doses of PDR001 in combination with CJM112 or LCL161',\n",
       "       'The number of patients requiring interruptions after a single dose of single agent CJM112, or two doses of PDR001 in combination with CJM112 or LCL161',\n",
       "       'The number of patients treated with single agent CJM112, or PDR001 in combination with either CJM112 or LCL161, who discontinued treatment',\n",
       "       'The number of patients requiring a dose reduction after a single dose of single agent CJM112, or two doses of PDR001 in combination with CJM112 or LCL161',\n",
       "       'Safety of patients receiving SAHA and lenalidomide following autologous PBSCT',\n",
       "       'Determine the RP2D which will be based on the overall safety and anti-tumor activity among the dose escalation and dose expansion cohorts',\n",
       "       'Phase I: Determine a safe dose of ATN-224 and bortezomib to be used in the phase II portion of the study',\n",
       "       'Phase II: Efficacy', 'Quality of life',\n",
       "       'Rate of grade 3 or 4 treatment related adverse effect',\n",
       "       'Tolerability: Dose interruptions',\n",
       "       'Tolerability: Dose reductions', 'Tolerability: Dose intensity',\n",
       "       'The difference in event-free survival time will be compared between both arms',\n",
       "       \"Change in Patient's Qualitative Assessment of Treatment Real World version (PQAT-RW)\",\n",
       "       'Qualitative Interview',\n",
       "       'The safe dose of AUY922 when administered once a week.',\n",
       "       'Change From Baseline in Hemoglobin Levels',\n",
       "       'Change From Baseline in Platelet Count',\n",
       "       'Change From Baseline in Neutrophil Count',\n",
       "       'Change From Baseline in Bilirubin',\n",
       "       'Phase 1: Assess the Safety of P-BCMA-101',\n",
       "       'Safety and tolerability',\n",
       "       'Evaluation of the best response after consolidation',\n",
       "       'Part 2: Assess the safety and tolerability of P-BCMA-ALLO1 when administered as a fixed dose of cells.',\n",
       "       'To evaluate whether high-dose density treatment during the initial seven months, including tandem transplants within six months after starting therapy, results in superior event-free and overall survival rates as compared to historical controls.',\n",
       "       'Relative Dose Intensity (RDI) Per Cohort',\n",
       "       'Evaluate the change of neuropathy in actively treated multiple myeloma subjects diagnosed with CIPN who received acupuncture vs standard of care management.',\n",
       "       'Daratumumab Related Infusion Reactions',\n",
       "       'Part 1 and Part 2: Maximum observed plasma concentration (Cmax) of GSK2857916',\n",
       "       'Part 1 and Part 2: Time to Cmax (Tmax) of GSK2857916',\n",
       "       'Part 1 and Part 2: Concentration at the end of infusion (C-EOI)',\n",
       "       'Part 1 and Part 2: Area under the plasma concentration-time curve (from zero to the end of dosing interval)',\n",
       "       'Part 1 and Part 2 : AUC over the dosing interval (AUC[0-tau]) of GSK2857916',\n",
       "       'Part 1 and Part 2: Last time point where the concentration is above the limit of quantification (Tlast) of GSK2857916',\n",
       "       'Number of Participants Who Completed 12 Cycles of Treatment',\n",
       "       'Percentage of Expected Dose of Carfilzomib Received in Cycles 1 to 12',\n",
       "       'Relative Dose Intensity of Carfilzomib in Cycles 1 to 12',\n",
       "       'Number of Participants With Carfilzomib Dose Modifications During Cycles 1 to 12',\n",
       "       'Randomisation 1: Number of participants with early treatment cessation',\n",
       "       'Overall survival',\n",
       "       '90% confidence interval of the relative mean Cmax, AUC0-t, AUC0-∞, of the test and reference',\n",
       "       'Maximum Tolerated Dosage', 'Recommended Dosage',\n",
       "       'To determine the highest and safest dose of LBH589 when it is administered in combination with lenalidomide & dexamethasone',\n",
       "       'White blood cell (WBC) count',\n",
       "       'Determine if there is grade 3 to 5 cytokine release syndrome',\n",
       "       'Fluorine F18 sodium fluoride positron emission tomography (NaF-PET/CT) standard uptake value (SUV)',\n",
       "       'Fluorine F18 sodium fluoride positron emission tomography (NaF-PET/CT) influx constant (Ki)',\n",
       "       'F18 fluorodeoxyglucose positron emission tomography (FDG-PET/CT) standard uptake value (SUV)',\n",
       "       'Safety of UCARTCS1A', 'Best Confirmed Disease Response',\n",
       "       'Best Reported Disease Response',\n",
       "       'Incidence rate of Grade ≥2 Corneal events according to the keratopathy visual acuity (KVA) scale',\n",
       "       'To assess the efficacy'], dtype=object)"
      ]
     },
     "execution_count": 793,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "# looking at all the unclassified ones\n",
    "df[df[\"PrimaryCat\"] == \"Unclassified\"]['PrimaryOutcomeMeasure'].unique()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 794,
   "metadata": {},
   "outputs": [],
   "source": [
    "def which_phase(phase):\n",
    "    if \"1\" in phase:\n",
    "        return \"Phase 1\"\n",
    "    elif \"2\" in phase:\n",
    "        return \"Phase 2\"\n",
    "    elif \"3\" in phase:\n",
    "        return \"Phase 3\"\n",
    "    elif \"4\" in phase:\n",
    "        return \"Phase 4\"\n",
    "    else:\n",
    "        return \"Unknown\"\n",
    "\n",
    "\n",
    "def get_phase(rows):\n",
    "    compressed_row = rows.iloc[0]  # take the first row as a starting point\n",
    "    compressed_row[\"Phase\"] = which_phase(rows[\"Phase\"].values[0])\n",
    "    return compressed_row\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 795,
   "metadata": {},
   "outputs": [],
   "source": [
    "# count how many studies are in each phase (matters since phase 1 also has \"early phase 1\")\n",
    "phase_counts = {}\n",
    "for i in range(1, 5):\n",
    "    phase_counts[\"Phase \" + str(i)] = per_study[per_study[\"Phase\"].str.contains(str(i))].shape[0]"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 796,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "<AxesSubplot:title={'center':'Relative Frequency of Primary Outcome Measures for 243 Phase 1 Trials'}, xlabel='Primary Outcome Measure', ylabel='Relative Frequency'>"
      ]
     },
     "execution_count": 796,
     "metadata": {},
     "output_type": "execute_result"
    },
    {
     "data": {
      "image/png": "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",
      "text/plain": [
       "<Figure size 1400x500 with 1 Axes>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    }
   ],
   "source": [
    "plt.figure(figsize=(14,5))\n",
    "classifiedcounts = df[(df['PrimaryCat'] != 'Unclassified') & (df['Phase'] == 'Phase 1')]['PrimaryCat'].value_counts()\n",
    "classifiedcounts /= classifiedcounts.sum()\n",
    "classifiedcounts.plot(kind='bar', title=f'Relative Frequency of Primary Outcome Measures for {phase_counts[\"Phase 1\"]} Phase 1 Trials', xlabel='Primary Outcome Measure', ylabel='Relative Frequency')"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 797,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "<AxesSubplot:title={'center':'Relative Frequency of Primary Outcome Measures for 216 Phase 2 Trials'}, xlabel='Primary Outcome Measure', ylabel='Relative Frequency'>"
      ]
     },
     "execution_count": 797,
     "metadata": {},
     "output_type": "execute_result"
    },
    {
     "data": {
      "image/png": "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",
      "text/plain": [
       "<Figure size 1400x500 with 1 Axes>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    }
   ],
   "source": [
    "plt.figure(figsize=(14,5))\n",
    "classifiedcounts = df[(df['PrimaryCat'] != 'Unclassified') & (df['Phase'] == 'Phase 2')]['PrimaryCat'].value_counts()\n",
    "classifiedcounts /= classifiedcounts.sum()\n",
    "classifiedcounts.plot(kind='bar', title=f'Relative Frequency of Primary Outcome Measures for {phase_counts[\"Phase 2\"]} Phase 2 Trials', xlabel='Primary Outcome Measure', ylabel='Relative Frequency')"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 798,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "<AxesSubplot:title={'center':'Relative Frequency of Primary Outcome Measures for 61 Phase 3 Trials'}, xlabel='Primary Outcome Measure', ylabel='Relative Frequency'>"
      ]
     },
     "execution_count": 798,
     "metadata": {},
     "output_type": "execute_result"
    },
    {
     "data": {
      "image/png": "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",
      "text/plain": [
       "<Figure size 1400x500 with 1 Axes>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    }
   ],
   "source": [
    "plt.figure(figsize=(14,5))\n",
    "classifiedcounts = df[(df['PrimaryCat'] != 'Unclassified') & (df['Phase'] == 'Phase 3')]['PrimaryCat'].value_counts()\n",
    "classifiedcounts /= classifiedcounts.sum()\n",
    "classifiedcounts.plot(kind='bar', title=f'Relative Frequency of Primary Outcome Measures for {phase_counts[\"Phase 3\"]} Phase 3 Trials', xlabel='Primary Outcome Measure', ylabel='Relative Frequency')"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 799,
   "metadata": {},
   "outputs": [
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "/var/folders/f1/87whmjt97m90gfstrm2p61d80000gn/T/ipykernel_58017/1520065185.py:2: SettingWithCopyWarning: \n",
      "A value is trying to be set on a copy of a slice from a DataFrame.\n",
      "Try using .loc[row_indexer,col_indexer] = value instead\n",
      "\n",
      "See the caveats in the documentation: https://pandas.pydata.org/pandas-docs/stable/user_guide/indexing.html#returning-a-view-versus-a-copy\n",
      "  df['SecondCat'] = df['SecondaryOutcomeMeasure'].apply(classify_outcome_measure)\n"
     ]
    }
   ],
   "source": [
    "# Apply the function to the dataframe\n",
    "df['SecondCat'] = df['SecondaryOutcomeMeasure'].apply(classify_outcome_measure)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 800,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "<AxesSubplot:title={'center':'Relative Frequency of Secondary Outcome Measures for 243 Phase 1 Trials'}, xlabel='Secondary Outcome Measure', ylabel='Relative Frequency'>"
      ]
     },
     "execution_count": 800,
     "metadata": {},
     "output_type": "execute_result"
    },
    {
     "data": {
      "image/png": "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",
      "text/plain": [
       "<Figure size 1400x500 with 1 Axes>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    }
   ],
   "source": [
    "plt.figure(figsize=(14,5))\n",
    "classifiedcounts = df[(df['SecondCat'] != 'Unclassified') & (df['Phase'] == 'Phase 1')]['SecondCat'].value_counts()\n",
    "classifiedcounts /= classifiedcounts.sum()\n",
    "classifiedcounts.plot(kind='bar', title=f'Relative Frequency of Secondary Outcome Measures for {phase_counts[\"Phase 1\"]} Phase 1 Trials', xlabel='Secondary Outcome Measure', ylabel='Relative Frequency')"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 801,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "<AxesSubplot:title={'center':'Relative Frequency of Secondary Outcome Measures for 216 Phase 2 Trials'}, xlabel='Secondary Outcome Measure', ylabel='Relative Frequency'>"
      ]
     },
     "execution_count": 801,
     "metadata": {},
     "output_type": "execute_result"
    },
    {
     "data": {
      "image/png": "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",
      "text/plain": [
       "<Figure size 1400x500 with 1 Axes>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    }
   ],
   "source": [
    "plt.figure(figsize=(14,5))\n",
    "classifiedcounts = df[(df['SecondCat'] != 'Unclassified') & (df['Phase'] == 'Phase 2')]['SecondCat'].value_counts()\n",
    "classifiedcounts /= classifiedcounts.sum()\n",
    "classifiedcounts.plot(kind='bar', title=f'Relative Frequency of Secondary Outcome Measures for {phase_counts[\"Phase 2\"]} Phase 2 Trials', xlabel='Secondary Outcome Measure', ylabel='Relative Frequency')"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 802,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "<AxesSubplot:title={'center':'Relative Frequency of Secondary Outcome Measures for 61 Phase 3 Trials'}, xlabel='S Outcome Measure', ylabel='Relative Frequency'>"
      ]
     },
     "execution_count": 802,
     "metadata": {},
     "output_type": "execute_result"
    },
    {
     "data": {
      "image/png": "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",
      "text/plain": [
       "<Figure size 1400x500 with 1 Axes>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    }
   ],
   "source": [
    "plt.figure(figsize=(14,5))\n",
    "classifiedcounts = df[(df['SecondCat'] != 'Unclassified') & (df['Phase'] == 'Phase 3')]['SecondCat'].value_counts()\n",
    "classifiedcounts /= classifiedcounts.sum()\n",
    "classifiedcounts.plot(kind='bar', title=f'Relative Frequency of Secondary Outcome Measures for {phase_counts[\"Phase 3\"]} Phase 3 Trials', xlabel='S Outcome Measure', ylabel='Relative Frequency')\n",
    "\n",
    "# NEED TO FIGURE OUT HOW MANY OF THESE THINGS WE HAVE"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [],
   "source": []
  }
 ],
 "metadata": {
  "kernelspec": {
   "display_name": "base",
   "language": "python",
   "name": "python3"
  },
  "language_info": {
   "codemirror_mode": {
    "name": "ipython",
    "version": 3
   },
   "file_extension": ".py",
   "mimetype": "text/x-python",
   "name": "python",
   "nbconvert_exporter": "python",
   "pygments_lexer": "ipython3",
   "version": "3.9.13"
  },
  "orig_nbformat": 4
 },
 "nbformat": 4,
 "nbformat_minor": 2
}
